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Over the past decade, antiretroviral therapy (ART) programmes have rapidly expanded 
in resource-limited settings.  Access to ART has been accelerated through a public 
health approach to reduce morbidity and mortality, thereby transforming HIV from a 
humanitarian crisis to a chronic disease.  However, the benefits of ART to patients and 
communities are dependent on patients being retained in care. This thesis investigates 
loss to follow-up (LTFU) after ART initiation, in the context of scale-up and limited 
resources and evaluates models of ART delivery to improve retention. 
After a brief introduction that offers orientation to the key issues and concepts in the 
field, Chapter 2 provides a comprehensive literature review discussing the public 
health concerns related to LTFU in ART programmes, as well as the methodological 
concerns encountered in studying LTFU. Six results chapters (Chapters 3-8) are 
presented using complementary cohort data from two collaborative datasets (one from 
programmes in resource-limited settings and one including only South African cohorts) 
and from a single ART programme at a community health centre. How to define LTFU is 
the focus of Chapter 3, demonstrating that definitions can have an appreciable impact 
on estimates of LTFU. In Chapter 4, temporal factors related to the expansion of ART 
programmes are investigated, with evidence that the risk of patient LTFU increases 
with each successive calendar year of ART initiation, and that the rate of programme 
expansion has a stronger association with the risk of LTFU than absolute programme 
size.  Analyses in Chapter 5 suggest that patients initiating ART at higher CD4 cell 
counts, above 300 cells/l, may have an increased risk of LTFU compared to patients 
initiating ART with lower CD4 cell counts.  Taken together, these findings underscore 
the notion that LTFU is a burgeoning threat to the long-term successes of ART 
programmes in South Africa and other resource-limited settings. Chapters 6-8 report 
on the implementation and outcomes from innovative models of ART delivery for 
stable ART patients.  Patient outcomes from (i) a nurse-managed ART service and then 
(ii) community-based ‘Adherence Clubs’ highlight that comparable and, in some cases,
favourable patient outcomes may be achieved when ART delivery is decentralised.  
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This thesis concludes that LTFU is a significant challenge faced by ART programmes. In 
the context of ambitious targets and evidence of the potential benefits of ART for 
individuals and communities, concurrent changes to the health system are necessary to 
support retention in care.  The successes of ART programmes in treating a chronic 
condition in resource-limited settings can be built upon by expanding community-
based ART provision and potentially integrating management of other adulthood 
illnesses.   
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Chapter 1. Introduction 
1.1 INTRODUCTION & BACKGROUND 
Background 
The first case of Acquired Immune Deficiency Syndrome (AIDS) was reported more 
than 30 years ago in 1981 [1].  Soon after, the human immunodeficiency virus (HIV), 
the virus that causes of AIDS, was identified and named [2].  Today, HIV is a global 
epidemic with an estimated 35 million people living with HIV (PLWHIV) worldwide 
and 2.1 million new infections annually [3].  
HIV has disproportionately affected Africa.  The continent is home to 69% of PLWHIV, 
but only makes up 12% of the overall global population [3].  South Africa has the 
largest HIV epidemic, with an estimated 6.4 million cases [4].  The adult prevalence in 
South Africa is 18% and the majority of transmission is through heterosexual sex [4, 5].  
Substantial progress has been made in the development of antiretroviral drugs (ARVs) 
to treat HIV and slow the progression to AIDS.  In 1996, the first triple therapy 
combination antiretroviral treatment was available in developed countries [2, 6].  
Adherence to a highly active combination ARV regimen, commonly referred to as 
antiretroviral therapy or ART, has transformed HIV from an infectious to a chronic 
disease [7, 8].  ART has dramatically increased the life expectancy of PLWHIV [9] and 
recent data from South Africa highlights that if patients access ART early, they can have 
a near normal life expectancy [10, 11].   
Scaling up ART in resource-limited settings 
Initially there was a slow response to providing ART in resource-limited settings [12].  
The reluctance for scaling up ART was argued on the basis that ART was too expensive 
and the regimens too complicated to expand access [13]. Concerns were raised around 
the potential transmission of drug-resistant HIV and the case made to prioritize 
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prevention efforts instead of scaling up ART [6].  However, as a result of considerable 
advocacy by patients, activists, scientists and academics, ART became increasingly 
available in resource-limited countries from the early 2000s [14, 15].  Data from early 
cohorts highlighted that patients in resource-limited settings could have comparable 
outcomes, including rates of retention and loss to follow-up (LTFU), to patients in 
developed countries [12, 16-19]. 
 
In South Africa, treatment access lagged behind other low- and middle-income 
countries [15, 20]. The government denied that HIV caused AIDS and only after 
litigation in court and uprising by civil society was ART finally made available in the 
public sector [21].  After a slow start of public sector ART roll-out beginning in April 
2004, there has been exceptional scale-up over the past decade [15, 22].  By mid-2013, 
South Africa had the largest ART programme in the world with more than 2 million 
patients on ART [4], and was acclaimed for its progressive HIV policies [23]. 
 
The unprecedented scale-up of ART has increased the size of the ART cohort in low- 
and middle-income countries from just 300,000 patients in 2002 to 9.7 million patients 
by the end of 2012 [24, 25].  The number of people in low- and middle-income 
countries on ART has tripled over 5 years, including 1.6 million new ART patients in 
2012 alone [24]. The most rapid scale-up has been in Africa.  In 2012, 4 out of every 5 
new ART patients in 2012 were in the region [24].  This trend is most evident in South 
Africa, making up a third of all new ART patients globally between 2010 and 2013 [26, 
27].  
 
The evolution of ART programmes in resource-limited settings 
The scale-up of ART has resulted in an estimated 4.2 million deaths averted [24] and 
been heralded as the fastest implementation of a life-saving public health 
intervention [28].  Over time and with improvements to the ARVs and regimens, ART 
was shown not only to extend life, but also to reduce morbidity.  Most recently, with the 
results of the HIV Prevention Trials Network 052 trial, ART has also been shown to 
reduce new infections by lowering viral loads [29].  Modelling studies have shown the 
potential for ART to act as prevention, through test and treat strategies where 
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community viral load is decreased thus reducing transmission [30, 31]. Emerging data 
from pilot projects suggest very low rates of new infections can be achieved with 
universal testing and treatment and community viral load suppression [32].  ART is 
therefore no longer recommended only to reduce the risk of mortality and morbidity in 
HIV-positive individuals, but also to prevent transmission (Figure 1.1).  However, the 
benefits of ART are dependent on patients being both retained and adherent to 
ART [33].   
 
 




With improvements in ARVs and increasing evidence of the potential benefits of ART, 
guidelines around the provision of ART have been updated [28, 34].  The World Health 
Organization (WHO) recommendations on use of ARVs have recently been revised in 
favour of earlier initiation of ART both to benefit patients, but also to reduce 
transmission to uninfected partners. As guidelines have expanded eligibility, patients 
are accessing treatment earlier in their HIV disease progression.  In all regions of the 
world, median CD4 cell count at ART initiation is increasing [24].  In light of the 
potential benefits to individuals and communities, there is renewed pressure for ART 
programmes to expand and accelerate access [3]. 
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Changes have also been made to recommended first-line regimens.  These 
recommendations have been adapted as new drugs and combinations have been 
developed and as generic versions of more expensive drugs have become available.  
Early regimens were complicated with multiple pills at multiple times of day and 
serious side effects and toxicities.  The 2013 WHO guidelines recommend a single-pill 
once a day fixed-dose combination [28].  For the first time since WHO began providing 
recommendations for ART, the first-line therapy recommended in resource-limited 
settings is the same as that utilised in resource-rich settings.   
 
The challenge of loss to follow-up 
The initial focus of ART programmes in resource-limited settings was on accelerating 
scale-up and expanding ART coverage to save lives.  The achievement of providing ART 
to such a high volume of patients in resource-limited settings cannot be understated. 
However, the benefits of ART are dependent on patients being retained in care and 
adherent to treatment.  Reducing LTFU and improving the proportion of patients 
retained in care is thus crucial, given that ART is a life-long therapy.  Increasingly, 
retention, and in turn LTFU, are acknowledged as key measures of ART programme 
effectiveness [35, 36].   
 
Loss to follow-up represents a growing and pervasive problem to ART programmes.  A 
patient who is LTFU is at risk of HIV-related morbidity and mortality, as well as 
developing drug-resistant HIV.  Systematic reviews suggest that approximately a third 
of patients are lost to the ART programme within the first two years on treatment [37-
39]. A 2007 systematic review from sub-Saharan Africa estimated retention to be 79%, 
75% and 62% at 6, 12, and 24 months, respectively [37].  In a 2010 updated review  of 
more than 200,000 patients, programme retention was 86%, 80, 77% and 72% at 6, 12, 
24, and 36 months, respectively [38]. Therefore, the key challenge in the provision of 
ART in resource-limited settings is no longer merely scaling up access to ART, but 
simultaneously ensuring patients are not LTFU (Figure 1.1).  Further research is 
warranted to understand how temporal effects of scale-up are related to the challenge 
of LTFU and retention in care.  
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The public-health approach to ART provision  
When ART was first made available, its provision was an emergency response to a 
humanitarian crisis.  The health systems that initially provided ART were for an acute 
condition and have since evolved to support life-long chronic management of HIV [40].  
Today, HIV is considered a manageable chronic condition. ART programmes in 
resource-limited settings have adapted to the huge demand for services, despite 
considerable health systems and human resource challenges.  Expansion of ART in 
resource-limited settings has been through a public health approach, based on the 
principles of simplification, standardisation, decentralisation, equity and patient and 
community participation [41].  
 
Models of ART delivery were originally based on the model from resource-intensive 
settings with doctor-led provision in hospitals providing highly specialised and 
individualised care [42].  In high-prevalence resource-limited settings, including South 
Africa, the response to the sheer volume of HIV patients and limited capacity of the 
health care system led to model adaptation.  ART delivery has become increasingly 
decentralised with programmes moving out of hospitals and into primary health care 
clinics, or community health centres.  Along with decentralisation, tasks have been 
shifted from doctors to nurses and community health workers (CHWs), often PLWHIV, 
have been engaged to provide counselling and support to ART patients.  Decentralised 
models of ART delivery with elements of task shifting were implemented not simply 
out of necessity but also because they can increase programme efficiency and 
effectiveness [43].  Figure 1.1 highlights the evolution to ART over the first decade of 
ART provision in sub-Saharan Africa, including the key challenges, utility of ART and 
adaptations to ART models of care delivery.     
 
The early responses to HIV aimed to initiate as many people onto ART as quickly as 
possible to avert mortality and perinatal transmission; decisions were often made 
without data or as data was being collected. The most ethical and sensible approach for 
the context of the period was not to wait for results before implementing adapted 
delivery models.  Operational research of the effectiveness of adaptations was often 
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conducted in parallel to providing care [42].  For example, in South Africa, the practice 
of nurses prescribing ART was implemented while randomised control trials were 
being conducted on the effectiveness of this task shifting [6, 44, 45].  Given the 
ambitious treatment targets and the high rates of LTFU, further adaptation of models of 
care delivery is needed to support patients and health systems.   
 
Extending ART programmes in resource-limited settings 
In many resource-limited settings, ART programmes were the first large-scale chronic 
disease programmes [46].  There is growing recognition of interfaces between HIV and 
other chronic conditions [46-48].  Given the successes of the ART programmes and the 
acknowledgment of the burden of other chronic conditions in resource-limited settings, 
there are calls for integration of previously fragmented, disease-specific 
programmes [40, 46, 47, 49].    
 
While the implementation of effective ART programmes can be built upon and 
leveraged for other chronic conditions, the issue of LTFU remains.  This thesis provides 
insight into the pervasive challenge of LTFU from ART programmes in resource-limited 
settings over the past decade with the view to offering insight into how further 
programme adaptation can support long-term retention in care. 
 
 
1.2 PROBLEM STATEMENT AND RATIONALE 
LTFU from ART programmes in resource-limited settings such as South Africa presents 
a significant challenge to programme effectiveness.  Without being retained in care, 
ART patients are susceptible to HIV-related morbidity and mortality as well as at risk of 
transmitting drug-resistant strains of the virus.  Given the high rates of LTFU, more 
data on risk factors for LTFU in the context of scale-up are needed.  Temporal factors 
relating to programme expansion, higher CD4 cell counts at ART initiation and year of 
ART initiation require further investigation as they may relate to LTFU.  In addition, the 
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role of innovative models of ART delivery to support the expanding ART cohort and 
improve patient LTFU needs to be explored.   
1.3 AIM AND OBJECTIVES 
The aim of this thesis is to address the challenge of defining LTFU and describe 
temporal factors contributing to loss to follow-up during scale-up of ART in resource-
limited settings to inform strategies for improving the retention of South Africa’s ART 
program. 
Specific objectives are: 
1. To examine the impact of the analytic approach to defining loss to follow-up on
estimates of programme outcomes.
2. To elucidate temporal factors contributing to loss to follow-up during scale-up
of ART programmes in resource-limited settings, specifically:
a. To determine if the temporal trend of increasing loss to follow-up is
observed across resource-limited settings,
b. To determine if the temporal trend of increasing loss to follow-up can be
attributed to programme expansion,
c. To determine if ART initiation at higher CD4 cell counts is associated
with an increase risk of loss to follow-up.
3. To evaluate the effectiveness of decentralised models of care with task shifting
for stable ART patients, specifically:
a. To examine and compare outcomes of stable ART patients down-referred
to innovative models of care with patients in a community health centre,
b. To investigate if innovative models of care are more appropriate for
different sub-groups of patients.
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1.4 OVERVIEW, CONTEXT AND STRUCTURE OF THIS 
THESIS  
When this thesis was conceptualised in 2009, the public sector ART programme in 
South Africa was only five years old. Data were emerging to suggest that patients 
initiating ART in more recent years were at an increased risk of LTFU. Models of care to 
support ART delivery were evolving with decentralisation to community health centres 
and task shifting to nurses and CHWs. The relationship of temporal factors with LTFU 
and how models of ART delivery could adapt to face the challenge of expanding access 
while improving retention became evident.  It is within this context that this thesis was 
conceived.  This thesis includes a literature review, six results chapters and a 
discussion chapter summarizing the contributions of this thesis.    
 
The literature review introduces the treatment cascade, highlighting how HIV patients 
may be lost at each step from HIV testing and diagnosis, through to ART initiation and 
viral suppression.  The challenges in defining LTFU are presented and the relationship 
between LTFU, retention and adherence are clarified.  Temporal factors for LTFU are 
described and classified at the levels of the health system, the disease and its treatment 
(HIV and ART) and the individual, in order to inform discussions on how to improve 
ART delivery.  Models of care for ART delivery, which incorporate decentralisation and 
task shifting interventions to improve LTFU, are reviewed.   
 
Six results chapters, in the form of published papers or those submitted or prepared for 
publication, are presented.  Chapters 3-5 focus on challenges in LTFU from ART 
programmes in resource-limited settings over the past decade of expansion.  Chapter 3 
addresses Objective 1 of the thesis and concludes that analytic definitions in LTFU can 
appreciably impact on estimates of LTFU.  In all of the analyses presented in this thesis, 
the most conservative definition of LTFU is used, per the recommendation resulting 
from Chapter 3.   
 
Objective 2a, determining the temporal relationship between year of ART initiation and 
risk of LTFU, is explored in Chapter 4. To investigate if the observed association 
between year of ART initiation and increasing risk of LTFU that was observed in South 
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Africa extended to other countries, data from a multicentre cohort in other resource-
limited settings was used.  An increased risk of LTFU was observed for each successive 
calendar year of ART initiation in both early (0-12 months) and late (12-72 months) 
LTFU.  Given the association between LTFU and year of ART initiation, year of ART 
initiation was adjusted for in all subsequent thesis chapters reporting on programme 
outcomes.  Risk of LTFU in Chapter 4 was also adjusted for two measures of 
programme expansion, programme size and rate of scale-up. Adjusting for programme 
expansion relates to Objective 2b, and assessing the role of expansion on outcomes.  In 
the findings from Chapter 4, the association between rate of expansion and LTFU was 
more important that programme size.  Measures of programme expansion were 
therefore included in the multicentre analysis in Chapter 5.   
 
Chapter 5 addresses Objective 2c and describes the association with higher CD4 cell 
counts at ART initiation and risk of LTFU.  The temporal trend of higher CD4 cell counts 
at ART initiation, combined with the continued increase in CD4 threshold 
recommended for ART initiation, was the rationale for this analysis.  Final models 
adjusted for year of ART initiation and programme expansion as well as correcting for 
unascertained deaths through linkage with the National Population Register.  Results 
conclude that patients initiating ART at higher CD4 cell counts may have an increased 
risk of LTFU in the first year on ART.   
 
Chapters 6-8 present two models of care delivery for stable ART patients implemented 
at the Gugulethu Community Health Centre (CHC) and address Objective 3.  
Implementation and outcomes from the Green Clinic, a nurse-managed down-referral 
programme (Chapter 6), and community-based Adherence Clubs (CACs) (Chapters 7 
and 8) address Objective 3a, comparing outcomes with the CHC.  The risk of mortality 
and viral rebound were comparable in the Green Clinic and the CHC, with a slight 
increase in the risk of LTFU in patients down-referred.  CACs offered improved LTFU 
compared to the CHC. Details of the outcomes of different sub-groups of patients 
(Objective 3b) are included in Chapter 6 for the Green Clinic and Chapter 8 for the 
CACs. In the Green Clinic, the increased risk of LTFU was the result of higher LTFU 
among men, patients 25-34 years of age, and those who accessed ART with advanced 
HIV disease or in early years of the programme.  Rates of LTFU were preferable in the 
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Green Clinic for patients with CD4 cell counts ≥200 cells/l and those who recently 
initiated ART. Chapter 8 highlights the outcomes of CACs and suggests that all patients 
in CACs had a significant reduction in the risk of LTFU.  The exception was youth, 
patients 16-24 years of age, who had a not significant difference in LTFU between the 
two models of care.  Of note, men and women in CACs had comparable LTFU.  This 
suggests that community-based models of care may offer significant benefits for men 
for whom outcomes on ART are generally worse than for women.  
 
The results chapters 3-8 are directly from manuscripts published, submitted or 
prepared for publication.  Minor revisions to the published versions of results chapters 
have been made to ensure consistency and continuity of terms throughout the thesis.   
 
The discussion in Chapter 9 synthesises key findings from the thesis as a combined 
body of work.  Recommendations are made for future research, policy and programmes 
and services.  The conclusion summarises the novel contributions of this thesis.  
 
 
1.5 DATA SOURCES 
Data for this thesis came from three complementary cohort data sources: two data 
collaborations and an ART programme within a community health centre (Table 1.1). 
Details of each data source are described in detail below drawing attention to why they 
were drawn upon and their unique contributions.  
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Chapter Objective Publication title Data 
Source 
1 3 1 Impact of definitions of loss to follow-up in 
antiretroviral therapy program evaluation: 
variation in the definition can have an 
appreciable impact on estimated proportions of 
LTFU 
IeDEA-SA 
2 4 2a & 2b Outcomes of antiretroviral therapy over a 10-
year period of expansion: a multicohort analysis 
of African and Asian HIV programmes  
MSF 
1 5 2c CD4 cell count at antiretroviral therapy initiation 
and the risk of loss to follow-up: results from a 
multicentre study 
IeDEA-SA 
3 6 3a & 3b Outcomes of a nurse-managed service for stable 
HIV-positive patients in a large South African 
public sector antiretroviral therapy program 
Gugulethu 
CHC 
3 7 3a Implementation of community-based Adherence 
Clubs for stable antiretroviral therapy patients  
Gugulethu 
CHC 
3 8 3a & 3b Community-based Adherence Clubs for stable 
antiretroviral therapy patients: Outcomes from 




1.5.1 International Epidemiological Databases to Evaluate 
AIDS- Southern Africa (IeDEA-SA) collaboration 
Background 
The International Epidemiological Databases to Evaluate AIDS (IeDEA) is a 
collaboration of seven global regions initiated by the National Institutes of Allergy and 
Infectious Diseases (NIAID) in 2005.  The purpose is to combine regional ART 
databases to answer questions that are unable to be assessed within single 
cohorts [50].  To date, the global cohorts contribute data on 750,000 patients on 
ART [51].  
 
The Centre for Infectious Disease Epidemiology and Research at the University of Cape 
Town, in conjunction with the University of Bern in Switzerland, is the data centre for 
the IeDEA-Southern African regional collaboration (IeDEA-SA).  Data are contributed 
from cohorts in Botswana, Lesotho, Malawi, Mozambique, South Africa, Zambia and 
Zimbabwe (Figure 1.2). Within South Africa, 10 ART sites have contributed data to the 
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collaboration, including eight adult sites.  In 2010, the IeDEA-SA database included 
approximately 10% of all adults on treatment in South Africa [52].  The sites are in 
urban and peri-urban areas and located within four provinces: the Western Cape, 
Gauteng, Kwa-Zulu Natal and the Free State.  Recently, efforts have been made to link 
the IeDEA-SA data with the National Population Register to ascertain the mortality 
status of patients in the collaboration [53, 54].   
1.5.2 Contribution of IeDEA-SA data to the thesis 
The IeDEA-SA data was included as it represents the largest cohort data set available in 
South Africa to evaluate the impact of definitions of LTFU and the relationship between 
CD4 cell count at ART initiation and LTFU. Two of the chapters (Chapters 3 and 5) 
utilised data from the South African adult cohorts in the IeDEA-SA collaboration.  In 
Chapter 5, the primary results were further restricted to include only patients with 
recorded South African National Identification numbers.  This further restriction was 
done so that estimates of LTFU could be corrected for unascertained mortality through 
linkage, based on National Identification numbers with the National Population 
Registry.  The contribution of the IeDEA-SA data are unique in that it represents such a 
large proportion of the South African adult ART cohort, with data from multiple cohorts 
in multiple provinces.  In relation to Chapter 5, the IeDEA-SA dataset had outcome data 
on a significant number of patients initiating ART at higher CD4 cell counts, thus 
allowing for sufficient sample size to investigate the association with higher CD4 cell 
counts and LTFU. The linkage with the National Population Registry further 
strengthens the IeDEA-SA contribution, allowing for analysis to correct for 
unascertained deaths and thus draw out associations between corrected LTFU and risk 
factors.   
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Figure 1.2 Map of IeDEA-SA contributing cohorts* 
 




Ethical approval for the collaboration is obtained from the Human Research Ethics 
Committee at the Faculty of Health Sciences at the University of Cape Town and 
renewed annually (Ethics documents 1.1 and 1.2).  Institutional ethical approval is 
obtained from each contributing cohort for participation in the collaboration.  
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1.5.3 Médecins Sans Frontières (MSF) supported HIV 
programmes  
Background 
Médecins Sans Frontières (MSF) is involved in HIV programmes in 32 resource-limited 
countries primarily in sub-Saharan Africa and Asia, as well as Latin America and 
Eastern Europe.  At the end of 2013, MSF-supported programmes were supporting 
over 340,000 HIV patients [55].  Programmatic data are collected, anonymised and 
stored centrally at Epicentre in Paris, France.  Chapter 4 of this thesis is based on MSF 
data from projects in eight resource-limited countries (Figure 1.3). 
 
Contribution of MSF data to the thesis 
The MSF dataset was utilised to investigate if the association between increasing LTFU 
and each successive calendar year of ART initiation, that was observed within an 
IeDEA-SA analysis of South African cohorts, extended to other resource-limited 
settings [56].  It offered a large cohort of patients from a number of resource-limited 
settings outside of South Africa and had sufficient data quality to assess multiple 
temporal risk factors.  The cohorts within the dataset were also sufficiently 
heterogeneous, allowing for investigation into how measures of scale-up, including 
programme size and rate of scale-up, were associated with the outcomes of mortality 
and LTFU.   
 
Ethics 
Ethical approval for the analysis of data in Chapter 4 was obtained from the Human 
Research Ethics Committee at the Faculty of Health Sciences at the University of Cape 
Town (Ethics document 1.3).  The analysis plan was submitted to the Ethical Review 
Board of MSF and satisfied the criteria for analysis of routinely collected programme 
data (Ethics document 1.4).  A data transfer agreement for the analysis was signed 
between the University of Cape Town, the four operational centres of MSF contributing 
 27 
data and Epicentre. The data transfer agreement specified that results of the analysis 
would be included within this thesis.   
 
Figure 1.3 Map of MSF contributing cohorts to data in Chapter 4 
 
 
1.5.4 Hannan Crusaid Treatment Centre at the Gugulethu 
Community Health Centre 
Background 
The Hannan Crusaid Treatment Centre (HCTC) is a public sector antiretroviral clinic 
located within the Gugulethu Community Health Centre (CHC) in the Cape Town 
suburb of Gugulethu.  Gugulethu, in the Nyanga district of Cape Town, is a peri-urban 
area with a high prevalence of HIV and the majority of residents are of low 
socioeconomic status. In September 2002, the Desmond Tutu HIV Foundation (DTHF) 
began providing ART free of charge at the HCTC [16].  ART patients received 
counselling and support from the Sizophila programme, a group of HIV-positive 
patients educated in ART side effects and adherence [16, 57].  Collaboration with the 
Desmond Tutu HIV Foundation has continued since handover of the ART programme to 
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the Provincial Government of the Western Cape in the mid-2000s.  Details of the site 
have been described previously [16, 58-65].  Routine patient data are collected at the 
site and merged with data from laboratory services and the pharmacy.   
 
In Chapter 6, outcomes from the Green Clinic programme at the Gugulethu CHC are 
described. The Green Clinic was a nurse-managed programme where stable ART 
patients were down-referred for ART maintenance.  It was started in 2006 in response 
to the growing patient numbers at the CHC and continued until the end of 2012.  From 
June 2012, Adherence Clubs were started at the facility.  The implementation and 
outcomes of the community-based Adherence Clubs at the Gugulethu CHC are 
presented in Chapters 7 and 8.  
 
Contribution of the Gugulethu CHC data to the thesis 
The Gugulethu cohort was uniquely positioned to compare ART delivery models with 
experience delivering ART within a facility-based CHC, a down-referral programme 
managed by nurses and a community-based model of care facilitated by community 
health workers. The Gugulethu cohort is a well-established research cohort with a large 
number of patients and follow-up from more than a decade of ART provision.  The 
resources support good quality outcome ascertainment and the site also has access to 
the laboratory results of patients through the National Health Laboratory Service.   This 
allowed for adjustment of time-updated measures of CD4 cell count and viral load 
within the models.   
 
The Gugulethu CHC also contributes data to the IeDEA-SA collaboration.  Data from the 
Gugulethu CHC was thus also part of Chapter 3 and in some of the sensitivity analyses 
in Chapter 5.   
 
Ethics 
Ethical approval was received from the Human Research Ethics Committee at the 
Faculty of Health Sciences at the University of Cape Town for the ongoing collection of 
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routine patient data and for the collection of data of the Green Clinic and Adherence 
Clubs (Ethics document 1.5).  
1.5.5 Role of the candidate 
The candidate conceptualised all of the primary research presented in the six results 
chapters and her original thinking compelled their development.  Further, the 
candidate was the lead and corresponding author for each results chapter, prepared all 
the data for the analyses, conceptualised, conducted all analyses and drafted all 
versions of the manuscripts.  
 
IeDEA-SA 
For the two IeDEA-SA analyses in this thesis (Chapters 3 and 5), the candidate 
submitted concept sheets to the site investigators and data centres for approval. The 
concept sheets outlined the analyses and outputs and gave each cohort the opportunity 
for their data to be included or excluded. Both analyses were approved by the 
collaboration.  Final papers were reviewed by co-authors, including representatives 
from sites contributing data, and the collaboration steering committee.  
 
MSF 
A concept sheet outlining the data required and analysis plan for Chapter 4 of the thesis 
was submitted to the HIV reference groups within MSF’s five operational centers and 
Epicentre.  The concept sheet was developed and drafted by the PhD candidate.  Four of 




The candidate was responsible for designing and conducting the evaluation of the 
Green Clinic and the community-based Adherence Clubs.  The Green Clinic programme 
started in 2006, in advance of the candidate’s involvement at the site. The dataset for 
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analysis was merged by the candidate and incorporated data from the clinical database, 
laboratory database and review of Green Clinic source data. 
The candidate supported implementation of the community-based Adherence Club 
model at the Gugulethu CHC.  The candidate oversaw data collection from the CACs 
model and managed the CAC database.  The dataset for analysis was created by the 
candidate, merging data from the CACs, the CHC and the laboratory.  
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Chapter 2. Literature Review 
Overview 
This literature review establishes the conceptual background for the thesis.  It provides 
orientation to the topic of LTFU and retention from ART programmes and summarises 
key features of existing knowledge that are most relevant to the focus of the thesis. 
LTFU is presented as a key programme outcome with significant methodological 
challenges.  The review is organised around the thesis objectives and addresses themes 
relevant to the following results chapters.  
 
This review is not intended to be systematic but rather to represent key points in the 
literature on LTFU, in the context of rapid scale-up of ART in resource-limited settings.  
This is in accordance with the scope of the thesis, which addresses LTFU after ART 
initiation and how to support retention in care in the context of rapid expansion and 
limited resources.  The review focuses on drawing specific attention to where there are 
gaps or ambiguity in our understanding and is divided into five sections.   
 
Section 2.1 presents LTFU within the paradigm of the HIV “treatment cascade”.  While 
significant losses occur throughout the stages of the HIV treatment cascade, the scope 
of the thesis is on losses after ART initiation.  Sections 2.2 to 2.4 review the literature to 
give context to the objectives of the thesis.  The complexity of, and challenges in, 
defining the outcome LTFU is discussed at length in Section 2.2 and provides the 
background for Objective 1 and the content of Chapter 3.  Given that the focus of thesis 
is on LTFU and retention, how these outcomes relate to each other is defined.  
 
To address Objective 2 and provide background for Chapters 4 and 5, factors 
associated with LTFU are reviewed using a three-tiered multilevel framework in 
Section 2.3.  The focus is on temporal factors related to the expansion of ART 
programmes: health systems level factors, given the demands of growing and maturing 
ART programmes; HIV and ART-related factors that have changed over the past 
decade; and individual level factors that should be considered when adapting ART 
delivery systems. Reviewing risk factors for LTFU (Section 2.3) is critical to informing 
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discussions on interventions to improve retention (Section 2.4).  Frequently, the focus 
is on individual level risk factors and identifying specific at-risk groups for LTFU.  
However, given the size of the HIV epidemic and the challenge of retaining patients in 
ART programmes, there has been a burgeoning interest in operational research to 
assess the effectiveness of models of ART delivery.  
 
The focus of Section 2.4 is on health systems interventions reviewing models of care for 
ART provision with elements of decentralisation and task shifting to address Objective 
3.  This section presents the background for Chapters 6-8.  Findings from recent 
systematic reviews on decentralisation and task shifting are summarised. Models of 
care delivery that contributed to the systematic reviews are discussed, summarising 
the quality of the evidence and agenda for future research.  
 
The concluding Section 2.5 summarises the key gaps identified from the literature 
review and outlines how the results chapters of this thesis contribute to these gaps.   
 
Methodology of the literature review 
The literature reviews aims to provide an overview on LTFU and retention in care in 
the context of rapid expansion of ART programmes in resource-limited settings and 
sub-Saharan Africa in particular.  To assess temporal factors in this context and models 
of care to support retention, published work from 2004 to June 2014 was reviewed. 
PUBMED was searched limiting results to studies on adults (≥15 years of age) that 
described LTFU or programme retention after ART initiation.   The search terms 
included “HIV” or “AIDS” AND “sub-Saharan Africa” or “Africa” or Southern Africa” AND 
“antiretroviral therapy” or “ART” or “HAART” AND “risk factors” or “task shifting” or 
“decentralisation” or “ART delivery” or “model of care” or “intervention”.  We also 
identified included literature from the WHO and UNAIDS that addressed LTFU, 
retention and support for scale-up.  Reference lists in sources were also checked for 
publications to include.  The intention of the review is to represent key points in the 
literature review and is not systematic or exhaustive.    
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2.1 LTFU AND THE TREATMENT CASCADE 
The stages of an HIV programme – from testing, to care, treatment and suppression – 
are commonly referred to as the HIV “treatment cascade”.  In sub-Saharan Africa [66], it 
is estimated that less than half of adults with HIV know their status (45%) and a third 
(31%) of people living with HIV are on ART [4].   Overall, 29% of people living with HIV 
have a supressed viral load [67, 68].    
 
The reality of losing patients at each stage of the treatment cascade is not unique to 
sub-Saharan Africa ART programmes or to the management of HIV infection.  In the 
United States, an estimated 82% of PLWHIV are diagnosed, 66% are linked to care, 
37% are retained in care, with 33% prescribed ART and 25% with a supressed viral 
load [69]. The magnitude of these losses along the cascade is similar to those described 
in sub-Saharan Africa. 
 
The notion of a cascade or continuum to describe patients being lost has been 
described previously for other chronic conditions.  In 1972, the “rule of halves” was 
termed in regards to the management of hypertension where only half of hypertensive 
patients were diagnosed, of those diagnosed only half were treated and of those 
treated, only half were well controlled [70].  This cascade has since been applied to a 
number of additional chronic diseases including diabetes, asthma and 
osteoarthritis [71, 72] and more recently, to HIV.    
 
The notion of a “treatment cascade” within HIV was first depicted in reference to 
mother-to-child transmission (MTCT), describing the steps in preventing vertical 
transmission [73-75].  Recently, the treatment cascade concept has been expanded to 
describe the challenge of LTFU across the HIV epidemic, not only in relation to 
MTCT [76-84]. Stages of the cascade vary in different representations: some represent 
the proportion of patients eligible for ART after a positive HIV test, while others 
highlight the cyclical nature of LTFU and how patients can re-engage with care at a 
later stage. Four depictions of HIV treatment cascade from the literature are reprinted 
in Figure 2.1 to highlight the proliferation of the concept and the differences in what 
constitutes a stage in the cascade.  
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Figure 2.1 Different representations of the HIV treatment cascade 
Four depictions of the HIV treatment cascade are reprinted to highlight the proliferation of the concept 
and differences in presentation. 
From top to bottom: Kranzer et al. [76], WHO [77], Mills et al. [79], and the Centres for Disease 
Control [80] 
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There are significant losses within the HIV treatment cascade prior to ART initiation 
(pre-ART). Two systematic reviews focussing on pre-ART retention in sub-Saharan 
Africa have been published [85, 86].  The 2011 review included 20 articles and eight 
conference abstracts and reported that 59% of patients who tested positive for HIV 
received information on their CD4 cell count or clinical staging, 46% received 
information on their eligibility to initiate ART, and 68% initiated ART [85].  The 2012 
review included 29 studies of which data from 25 contributed to the meta-analysis.  It 
found that 72% of patients with a positive HIV test result received a CD4 cell count, 
with 40% eligible for ART and 25% starting ART [86].  Ten articles were included in 
both reviews.  In addition, both reviews conceded that there was substantial 
heterogeneity between cohorts and in definitions of the stages in the cascade.  While 
acknowledging the substantial contribution of LTFU in pre-ART care, the focus of this 
thesis is limited to loss to follow-up after initiation onto ART.  Furthermore, this 
literature review and thesis is focussed on LTFU among adults in ART programmes in 
resource-limited settings.  
 
 
2.2 THE CHALLENGES IN DEFINING LTFU   
Loss to follow-up (LTFU) from ART programmes describes all patients who are no 
longer in care and have an unknown outcome.  It has been explained as a generic or 
“catch-all” term that refers to all patients who have not returned to the clinic following 
ART initiation [39, 87].  Therefore, the most accurate definition of LTFU is patients with 
an unknown outcome [77]. Figure 2.2 depicts patient outcomes dividing patients into 
those with known and unknown (LTFU) outcomes.  
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Figure 2.2 Patients with known and unknown (LTFU) outcomes* 
 
*Adapted from Figure 2 in WHO, 2012. [77] 
 
 
Patients who are defined as LTFU are heterogeneous and comprise of patients with 
three distinct outcomes: unascertained deaths, unascertained transfers and patients 
who are currently disengaged from care (boxes on the left, Figure 2.2) [87, 88].  The 
terminology used to describe these three patient groups is further confused due to the 
many different terms used to describe these three outcomes (Table 2.1). Those who are 
unascertained deaths (dark grey boxes on the right of Figure 2.2) are also called 
patients who have died, unreported deaths [87], and unknown death.  Patients who are 
unascertained transfers are also referred to as unknown transfers [87], ‘silent’ 
transfers [89], undocumented transfers [90], receiving ART at another facility, and self-
transferred care [91] (grey boxes with horizontal lines on the left, Figure 2.2). There is 
also a third group of patients with unknown outcomes referred to as disengaged from 
care [87], meaning they are not presently on treatment.  They are also defined as 






Table 2.1 Summary of terms used to describe the three categories of patients 
who are LTFU 
Patients who are LTFU 
Outcome 1:  
Unascertained transfer 
Outcome 2:  
Unascertained death 
Outcome 3:  
Currently disengaged from 
care 
 Patients receiving ART at 
another facility 
 Self-transferred 
 Unknown transfers 
 Silent transfers 
 Undocumented transfers 
 
 Patients who have died 
 Unknown death 
 Unreported death 
 Patients who are 
currently not on ART 
 Discontinued treatment 
 “True” LTFU 
 Unstructured treatment 
interruption (if they 
return to care)  
 Not currently accessing 
treatment  
 Permanently LTFU 
 
2.2.1 Loss to follow-up as a programme outcome 
Traditionally within cohort analyses, the outcome of interest is the proportion of 
patients who survive.  Patients who are LTFU are accordingly censored and this 
censoring is presumed to be uninformative and random [93, 94].  However, within the 
context of ART programmes and other chronic disease programmes, the proportion of 
patients LTFU is an outcome of interest independent of the survival proportion [95].  
Given that LTFU reflects patients who are not retained in the programme, it is 
increasingly recognised as a key measure of programme effectiveness within chronic 
disease programmes [35, 36, 39, 96-98]. 
 
2.2.2 Differences in how LTFU is operationalised  
As outlined above and depicted in Figure 2.2, LTFU is the absence of a known outcome, 
including patients who are dead, in care at another facility, and not currently on ART.  
LTFU is operationalised as the proportion of patients who are not in care and how this 
is defined varies.  At the level of the individual, LTFU is commonly defined as a period 
of no visit, a missed appointment, or a number of days late for an appointment.   
Systematic reviews of retention in ART programmes in sub-Saharan Africa report 
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differences in definitions of LTFU in contributing cohorts [37, 38]. Among the cohorts 
in the Fox and Rosen 2010 review of patient retention, eight different LTFU definitions 
were reported including being late for appointments, not having contact for periods of 
time, and being untraceable [38].  Also of concern is that 14 of the 33 sources included 
did not report on how LTFU was defined. It is clear that there is no standardised 
definition of LTFU. Given both the uncertainty and heterogeneity in how LTFU was 
defined in the contributing cohorts, the appropriateness of deriving a summary 
estimate and then comparing retention after two years on ART between the 2007 and 
2010 review has been questioned [99]. 
 
Additional concerns have been raised about the validity of the two systematic 
reviews [37, 38] that combined outcome data from multiple cohorts [99-101]. Access to 
ART varies by site with different criteria for starting ART, relating to disease status or 
social support networks.  For example, some contributing cohorts required patients to 
nominate an adherence supporter and disclose to a family member [100, 101].  
Differences in eligibility criteria could also impact the risk of mortality and 
unascertained mortality if ART was restricted to, or excluded, the sickest patients. 
Moreover, LTFU occurs at a different rate over time with higher rates immediately 
following treatment initiation and thus presuming a constant rate would be 
problematic.  Some cohorts also had tracing programmes, which would lead to 
differential reporting of the outcome LTFU. Resources vary by cohorts as well, and 
those with additional resources for adherence support programmes may have greater 
retention in care [102]. 
 
2.2.3 Definitions of and the analytic approach to LTFU may 
also impact on outcomes 
When this thesis was conceptualised, no work on definitions of LTFU had been 
published.  Since then, Chi et al. has assessed what window period of no visit should be 
used to generate the outcome LTFU [103, 104] and Shepherd et al. has considered 
other components of how the analytic approach impacts the outcome LTFU [95].  Chi’s 
work concluded that a period of 180 days since contact with the clinic has been 
recommended to minimise the number of misclassifications [103, 104].   Shepherd et 
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al. assessed the window period, as well as whether the last contact was from a 
laboratory or clinic visit, if patient loss was retrospective or prospective and if time 
was premeasured from last or missed visit.  Estimates of LTFU varied depending on the 
components used to define LTFU and the authors concluded that how LTFU was 
operationalised could affect estimates of programme outcomes [95]. While Chi and 
Shepherd investigated the LTFU window period and some components of LTFU 
definitions, additional aspects of defining LTFU and how to approach LTFU as an 
outcome within analysis require attention.  Potentially, the improvement cited by Fox 
and Rosen in 24-month retention between the 2007 and 2010 reviews was a spurious 
difference resulting from differences in LTFU definitions by the contributing 
cohorts [105].       
There are three components of how LTFU is approached in an analysis that will 
determine who is defined as being LTFU: 1) the date assigned to the outcome LTFU 
(e.g. the last date of contact or the date the patient was expected to return); 2) the 
interval without contact (e.g. 60, 90 or 180 days); and 3) who is eligible for analysis 
(e.g. restricting to patients with 180 days of potential follow-up, adding a day of 
survival time to patients who initiate ART but never return).  Given that all of these 
components will change estimates of LTFU, further assessment of the impact of 
different analytic definitions of LTFU on estimates of programme outcomes is needed.  
2.2.4 LTFU, retention and adherence 
The concepts of LTFU, retention and adherence are related and it is important to clarify 
the associations and differences between them.  It is also fundamental to defining the 
scope of this thesis, which is limited to LTFU and retention after ART initiation.   
Programme retention refers to all patients retained in the programme, depicted by the 
white boxes on the right of Figure 2.2.   Patients who are no longer retained in care 
with unknown outcomes will be classified as LTFU, and therefore how LTFU is defined 
will impact on estimates of programme retention.  The objective of improving or 
reducing LTFU is thus closely related to improving programme retention.   
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A patient who is adherent to treatment is a patient who is taking their prescribed dose 
of ART at the correct times and frequencies [106]. In order to be adherent, a patient 
needs an uninterrupted supply of ART and must consequently be retained within an 
ART programme.  However, being retained in care does not equate to being adherent to 
treatment [107].  A patient can be attending their clinic visits and collecting their ART 
(retained) but not taking their ART as prescribed (not adherent). A measure of 
programme retention or LTFU does not, therefore, define adherence or the extent of 
viral suppression.  It is incorrect to presume that patients retained in care are by 
default adhering to treatment. 
 
Adherence is beyond the scope of this thesis, which focuses on LTFU and retention in 
care.  While it is recognised that adherence is necessary for ART to be beneficial, this 
thesis does not specifically address the challenges of adherence.  
2.2.5 Loss to follow-up threatens the effectiveness of ART 
Systematic reviews of retention in ART programmes in sub-Saharan 
Africa 
Three systematic reviews by Fox and Rosen have assessed ART retention, two in sub-
Saharan Africa and one globally.  The first, published in 2007, summarised retention in 
the first two years on ART from 33 cohorts.  At 6, 12 and 24 months, the weighted 
mean retention rates were 79%, 75% and 62%, respectively [37].  In 2010, an updated 
version was published, with retention rates through to three years on treatment from 
39 cohorts in the region.  Estimates of retention were 86%, 80%, 77%, and 72% at 6, 
12, 24, and 36, respectively [38].  Data from the 2013 review on patients in Africa 
estimated LTFU to be 82%, 76%, 68% and 65% at months 6, 12, 24, and 36, 
respectively [39].  While there is some variation in the estimates of programme 
retention, it is clear that retention is a substantial threat to ART programme 
effectiveness.   
Increases in programme attrition are due to increases in LTFU 
The contribution of LTFU within programme attrition is substantial and 
increasing [38].  A growing body of literature highlights that as programmes expand 
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and retention increases, that it is LTFU and not mortality that is increasingly 
responsible for losses to the programme [38, 53, 56].  A systematic review of tracing 
studies found an inverse relationship between mortality and LTFU; as LTFU increased 
the contribution of unascertained mortality decreased [88].  In other words, as the 
proportion of patients LTFU increases, it is not due to increases in unascertained 
mortality but rather from an increase in the number of patients who are receiving care 
at another facility (unascertained transfers) and/or patients who are not currently 
engaged in care.  The systematic review also found that with each additional year on 
ART, the proportion of programme attrition due to LTFU increases [56]. 
With estimates of programme attrition at 20-40% after three years, LTFU is a 
considerable challenge to the long-term success of ART programmes.  Improving 
retention by decreasing LTFU is essential to the effective provision of ART. Therefore 
temporal factors associated to LTFU during scale-up of ART in resource-limited 
settings are reviewed below.  
2.2.6 Summary 
Considerable methodological challenges exist in the measurement of LTFU.  This thesis 
focuses on LTFU after ART initiation, defining LTFU as patients without a clinic visit in 
the period between analysis and database closure. Challenges exist in how to define 
LTFU and additional research is warranted to determine how analytic approaches to 
defining LTFU impact outcomes.  Estimates of LTFU highlight that a significant portion 
of ART patients are not being retained in care.  The growing contribution of LTFU to 
programme attrition warrants further research into factors associated with LTFU.  
Determining temporal factors for LTFU is also necessary to inform models of care 
delivery that support the large and maturing ART programmes in resource-limited 
settings.   
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2.3 TEMPORAL FACTORS CONTRIBUTING TO LTFU 
DURING SCALE-UP  
2.3.1 Challenges in determining risk factors for LTFU 
Given that LTFU refers to patients with three distinct outcomes (Figure 2.2 and Table 
2.1), it is difficult disentangle which of the observed associations with LTFU are driven 
by associations with unascertained morality, unascertained transfers and/or 
disengagement from care.  Evidence of associations with LTFU is primarily from 
observational cohorts.  Data from studies that utilise linkage to death registries is 
adjusted for unascertained deaths and thus presents risk factors for unascertained 
transfers and currently disengaged from care (Table 2.1).  Tracing studies divide LTFU 
into its three components and therefore report on risk factors for patients currently 
disengaged from care.   In this section, factors from observational  cohorts, studies with 
linkage and tracing students are presented.  
2.3.2 A framework for assessing risk factors for LTFU 
Risk factors for LTFU may be defined at the level of health system, HIV and ART (the 
disease and its treatment) and the individual [108].  This review of the literature 
provides an overview of commonly cited and recurring factors highlighted in the 
literature, focussing on temporal factors that have changed with the rapid expansion of 
ART. For the purposes of this review, risk factors for LTFU will be placed within a 
three-tiered, multilevel framework (Figure 2.3).  The distal components are comprised 
of health system and social/economic factors and reviewed given the interest in 
modifying ART delivery systems to improve programme retention.  HIV and ART 
factors are presented as they have evolved during ART expansion.  Individual level 
factors are summarised to inform targeted strategies and to understand how the 
composition of ART cohorts may affect programme outcomes.   
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2.3.3 Health systems & social/economic factors 
The Commission on Social Determinants of Health define the socioeconomic and 
political context as the overarching structural determinant of health inequities [109].  
Their framework further recognises the role of the health system and conceptualises 
the health system as a social determinant in its own right.  These structural 
determinants are fundamental determinants of health outcomes. Eight reasons for 
decreased retention related to the health system and social/economic factors are listed 
in the 2013 WHO guidelines: i) High direct and indirect costs of receiving care, ii) 
Stock-outs of ARV drugs, iii) Lack of a system for monitoring retention in care, iv) Lack 
of a system for transferring people across different points of care, v) Lack of accurate 
information for patients and their families and peer support, vi) Adherence support, 
vii) Poor relationship between patient and care provider, and viii) Lack of time for 
educating people in HIV care [28].  
 
Cost can be either direct, such as having to pay for ART, or indirect, such as the time 
away from childcare responsibilities in order to receive ART.  Many studies have shown 
that paying for ART or ART services is directly related to an increased risk of 
Health system & social/economic 
factors 
e.g. cost, drug stock-outs, 
supportDecentralisation 
HIV & ART related factors 
e.g. CD4 level, ART side effects 
 
Individual level factors 
e.g. Age, gender, education 
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LTFU [110-112].  Brinkhof et al. investigated data from the first 12 months after 
treatment initiation in resource limited settings and found follow-up to be associated 
with advanced disease at baseline and services that charged a fee, as opposed to those 
that were freely offered [97].  Treatment costs were also reported as reasons 
responsible for treatment interruptions [92]. Drug shortages and stock-outs have been 
reported to increase LTFU and treatment interruptions [92, 110, 113, 114].  Issues with 
transportation and distance to the facility [115-117] and long queues and waiting 
times [118-120] are also commonly cited reasons for LTFU.  
 
Data from tracing studies, where patients who are LTFU are found and interviewed, 
found similar health systems factors associated with LTFU, as did observational 
studies  [121-125].  In the 2009 systematic review of tracing studies, the most 
commonly cited reasons were the cost of transport, followed by either an improvement 
or decline in health and then stigma [126]. In addition, competing commitments (work 
and childcare responsibilities) [122], social problems, use of traditional medication and 
side effects were also reported as reasons for disengaging from care [123]. Of patients 
traced in a Malawian cohort, men were more likely to report travelling away, while 
women were more likely to report transport costs as reasons for discontinuing 
ART [124].  A programme that has a tracing programme is also more likely to have 
improved retention compared to cohorts without tracing [87].  In summary, the 
structure of the health system as well as social and economic factors impact patient 
retention on ART. 
Temporal trends in LTFU and year of ART initiation  
When this thesis was conceived, there was conflicting evidence of how LTFU was 
changing as ART programmes expanded.  Reporting an improvement in programme 
retention at 2 years between the 2007 and 2010 systematic reviews of retention in 
sub-Saharan Africa, authors Fox and Rosen concluded that retention in care was 
improving in the region [37, 38].  They suggested the improvement was due to 
programmes growing in experience, being better able to track patients and investing in 
interventions to trace patients and have them return to care.   
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While Fox and Rosen have suggested LTFU may be improving based on their estimates 
from meta-analyses, other cohorts have shown evidence of increasing LTFU with 
recent ART initiation [53, 56, 63, 90, 97, 127, 128].  There is also significant 
heterogeneity around estimates of LTFU from different cohorts.  Differences may be 
due to variations in definitions and analytic approaches to LTFU, heterogeneity in the 
profile of patients accessing ART and disparities in how patients are initiated and 
supported on treatment.  Alternatively, differences in LTFU could be related to the 
composition of the ART cohort.  Early treatment cohorts may be more likely to have a 
significant proportion of acutely ill patients at risk of early mortality.  Conversely, more 
mature cohorts may be more likely to have large numbers of unascertained transfers to 
programmes as the number of sites providing ART has expanded.  It has also been 
suggested that publication bias may be leading to overestimates of retention in care, 
especially among the first ART cohorts that were established in the region [39].  
Further research is necessary to determine the association between LTFU and year of 
initiation. 
Contribution of programme expansion to LTFU 
Health systems factors related to the high patient volume in HIV services are also 
related to LTFU.  For example, high patient volume and the considerable numbers of 
patients per staff member has also been investigated as a risk factor for LTFU.  In 
Mozambique, Lambdin et al. found high levels of attrition to be associated with medium 
and high burdens among pharmacy staff [129].  However, no association between 
clinical staff burden and patient attrition was found after adjusting for patient 
characteristics.   
With the rapid expansion of ART, some postulate that the scale-up and sheer volume of 
patients may be leading to a decrease in the quality of care. In 2008 Boulle et al. 
highlighted that LTFU at 6-months was higher in 2005 than in previous years [96]. This 
was significant; especially given that mortality in the first 6-months was decreasing 
with year of enrolment.  The authors attributed the increasing LTFU to the high volume 
of ART patients.   
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The relationship between LTFU and the size of ART programmes and rate of expansion 
has not received much attention in the literature.  Programmes have focussed on 
scaling up access and expanding the number of patients initiating ART, but not 
necessarily measuring how this expansion is related to quality of care and patient 
outcomes.  In previous analyses of ART cohorts, measures of size and scale-up have not 
been included, despite suggestions of their contributions to LTFU [56] and for limiting 
patient numbers to a manageable size [96]. Analyses adjusting for scale-up and 
expansion are required to ascertain how programme size and the rate of scale-up are 
related to LTFU.   
2.3.4 HIV and ART-related factors 
Factors related to HIV, and its treatment, ART, also affect LTFU.  Over the past decade 
as access to ART has increased and thresholds for ART initiation have expanded, 
median CD4 cell count at ART initiation has increased in all regions of the world [24].  
Concurrently, recommendations for first line ART have changed. The literature on the 
relationship between CD4 cell count at ART initiation and how ART affects LTFU is 
reviewed below. 
Increasing CD4 cell count at ART initiation 
With the median CD4 cell count increasing at ART initiation [24] and ART guidelines 
expanding to recommend initiation at higher CD4 cell counts [28], a growing body of 
literature describes the relationship between CD4 cell count at ART initiation and risk 
of LTFU. Some studies highlight a reduced risk of LTFU among patients initiating ART 
at higher CD4 cell counts. In a cohort from Lesotho and a South African cohort with 
linkage to the death registry [130], there was less LTFU among patients with CD4 cell 
counts >200 cells/l [131].  Conversely, higher CD4 cells counts of >200 cells/l [132, 
133],  >250 cells/l [134]  and ≥350 cells/l [135]  at ART initiation have been 
associated with an increased risk of LTFU in other observational studies. After 
adjusting for unascertained deaths through linkage to the death registry, a CD4>150 
cells/l had an increased risk of LTFU compared to patients with a lower CD4 cell 
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count at ART initiation [136]. Other cohorts have found no association between CD4 
cell count at ART initiation and LTFU [137-139]. 
 
There are also conflicting in the association between CD4 cell count at ART initiation 
and the risk of being disengaged from care. In a systematic review of unstructured 
treatment interruptions, five studies reported an increased risk of LTFU and three 
reported a decreased risk of LTFU among those with higher CD4 cell counts at ART 
initiation [92].  In a recent study of interruptions in a large hospital cohort, patients 
with a CD4 cell count of ≥250 cells/l were more likely to be LTFU, versus patients 
initiating ART < 250 cells/l [140]. 
 
Differences in findings on the association between CD4 cell count at ART initiation and 
LTFU may be the result of a number of methodological differences between the studies.  
The reference groups and CD4 categories (including what is defined as low and high 
CD4 cell count) varies between studies. Given that low CD4 cell count is highly related 
to early risk of mortality, programmes with poor outcome ascertainment may see a 
higher proportion of unascertained mortality within their estimates of LTFU.  In 
addition, some of the evidence was provided for studies where unascertained deaths 
were excluded from estimates of LTFU via linkage or tracing and therefore may be 
more accurately highlighting the association between CD4 cell count and LTFU. 
Conversely, patients with higher CD4 cell counts may be at increased risk of LTFU and 
early disengagement from care, as they may not have directly experienced the benefits 
of ART on their personal health.   
 
In summary, conflicting evidence is available on the association between CD4 cell count 
at ART initiation and risk of LTFU.  With ART eligibility expanding and supporting 
initiation at higher CD4 cell counts, additional analyses are needed to clarify the 
relationship between higher CD4 cell counts and risk of LTFU.    
 
Changes to ART and the impact on LTFU 
Considerable progress has been made in the development of antiretroviral drugs over 
the past decade.  From monotherapy regimens to triple therapy and now fixed-dose 
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combinations, ART has become considerably easier to take and with less side effects.  
In addition, the price of ART has decreased dramatically.  Data supports that drugs that 
are cheaper, with less side effects, and taken less frequently, support improved patient 
adherence [92, 110, 141]. A review by Kranzer et al. on the risk factors for treatment 
interruptions reported drug toxicity, adverse events and side effects as the most 
commonly reporting reasons for treatment interruptions [92].  ART regimens 
containing stavudine (d4T) have been increasingly phased out of preferred regimens 
and replaced with tenofovir (TDF) or zidovudine (AZT) due to the high rates of side 
effects and associated patient non-adherence.  Data from observational cohorts 
highlights an increased risk of LTFU among patients on d4T regimens [135].  
 
Fixed-dose combination (FDC) therapy is increasingly available in low- and middle-
income countries.  The 2013 WHO guidelines recommend a FDC option of TDF + 
lamivudine (3TC) (or emtricitabine [FTC]) + efavirenz [EFV] regimen to initiate 
ART [28]. A recent systematic review and meta-analysis on the patient and programme 
impacts of FDCs, concluded they were the preference in all of the 21 studies which 
were included [142]. Given the reduced volume of FDCs versus other regimens, they 
also offer benefits to decentralised models of care, by reducing the pre-packing burden 
and having simpler transportation [143]. 
 
2.3.5 Individual level factors 
LTFU is generally higher in men [132, 135, 138, 144-146], younger patients [131, 132, 
135, 147], patients with less education [132, 135, 146], and patients who are taking 
more complicated and toxic ART regimens.  Recent data also highlight time-updated 
laboratory values of lower CD4 cell count and detectable viral load as being associated  
with higher risk of LTFU [132].  While not all of these risk factors are observed in all 
studies, there are the common patient-level associations observed across sub-Saharan 
Africa.   
 
Tracing studies have found similar associations between individual level factors and 
LTFU.  An increased risk of LTFU has been found in patients who are younger, male or 
have less income [148].  Patients who were younger and had initiated treatment in 
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more recent years were less likely to be re-engaged in care (unascertained transfers 
and treatment interrupters), compared to patients not on treatment [124]. 
A limited number of cohorts have reported on risk factors when LTFU is corrected with 
linkage to death registries. In data from the Khayelitsha ART cohort in peri-urban 
South Africa, being male, a more recent year of initiation, young age, and lower weight 
were all associated with an increased risk of LTFU in multivariate analysis before 
correction for unascertained deaths [136].  After linkage, the associations with younger 
age and calendar year of ART initiation were strengthened.  In addition, women 
initiating ART while pregnant were at increased risk of being LTFU.  The association 
with low weight did not persist after correction and hence is a risk factor for 
unascertained mortality.  Males were also at an increased risk of LTFU after linkage in a 
study by Cornell et al. [149].  
2.3.6 Summary 
Data from cohorts, tracing studies and analyses with linkage to death registries to 
correct for unascertained deaths highlight multiple factors can affect retention in care.  
Temporal factors related to LTFU are present at the level of the health system, the 
disease and its treatment, and the individual.   
Risk factors for LTFU are often described at the level of the individual.  However, given 
the size of the ART programme and the scale of the challenge of retention in care, 
interventions at the level of the health system are needed.  These system level changes 
in how ART is delivered are necessary to support the public health approach to ART.  
The public health approach is based on equity and ensuring ART access to all those in 
need.  The key tenant is that it is based at the population and not individual level [41].  
In line with this, interventions to decrease LTFU must also be at the population level.   
The multilevel framework of risk factors (Figure 2.3) is useful when considering 
interventions.  Health system interventions can address risk factors at all levels and 
thus hold the greatest potential for impact.  Understanding of risk factors is thus crucial 
to discussions of health systems interventions, such as novel model of care. 
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This review of the challenges of LTFU and factors for LTFU in the context of rapid scale-
up of ART provides the background for why additional models of care to support 
retention in care are needed.  Over the first decade of ART delivery in resource-limited 
settings, substantial adaptations have been made to the models of care to provide ART.  
The adaptations have not been only out of necessity, but also because increased 
evidence supports different models of care, including models of decentralisation, with 
elements of task shifting.  Insights into the types of patients at risk for LTFU was 
provided to highlight that future modifications of the model need to acknowledge that 
the risk of LTFU is not constant or uniform across sub-groups.  
2.4 MODELS OF CARE TO SUPPORT PROGRAMME 
EXPANSION AND IMPROVE LTFU AND RETENTION 
Overview 
While many interventions have been suggested to improve LTFU and retention, it is 
increasingly acknowledged that health systems changes that are scalable and can 
increase the effectiveness of ART provision in the context of scale-up and regard HIV as 
a chronic condition, are essential to supporting long-term retention [150].  Recognising 
that health systems would need to adapt to implement the 2013 WHO guidelines, 
suggestions were also made for operations and service delivery [28].  These included 
specific recommendations for decentralisation and task shifting based on low- and 
moderate-quality evidence.  The burgeoning interest in and support for adaptations to 
models of care delivery is evidenced by the 2014 WHO supplement on community-
based models of care [151], a systematic review on improving ART effectiveness 
through decentralisation [152], and the recent Cochrane reviews on 
decentralisation [153] and task shifting [154].  The focus of this section is on models of 
care delivery with decentralisation and task shifting, given the potential impact on 
multiple factors for LTFU, as an intervention to improve retention and to inform 
Chapters 6-8 of this thesis.   
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Relationship between decentralisation, task shifting and models of 
care 
In this section, models of care delivery with components of decentralisation and task 
shifting are reviewed. Decentralisation of HIV care is defined as moving services from 
centralised sites (usually hospitals) to health centres or other venues closer to the 
patients’ home. This is done to increase the effectiveness of ART provision by 
decreasing costs and improving access for patients. With regards to the provision of 
ART, decentralisation can happen for ART initiation and/or maintenance.  The type of 
health care worker who conducts the tasks related to ART provision is the task shifting 
component, where task shifting refers to the redistribution of tasks from more 
clinically trained health staff to other cadres of employees.  Models of care are defined 
as the way in which ART services are provided including both where the services take 
place (decentralisation) and who conducts the tasks (task shifting).    
 
Structure of this section 
Models of care interventions are comprised of elements of both decentralisation and 
task shifting. It is consequently difficult to discuss decentralisation or task shifting in 
isolation, since that they are often implemented concurrently.  Therefore, this review of 
the literature presents evidence on decentralisation and task shifting from systematic 
reviews.  Subsequently, data from published models of care delivery are synthesised by 
the level of task shifting and type of decentralisation.  The impact of the intervention on 
LTFU and retention in care are presented alongside data on mortality and virological 
suppression when available.   
 
2.4.1 Recent systematic reviews on decentralisation and task 
shifting  
The recent publication of a number of systematic reviews on decentralisation and task 
shifting evidences the current interest in how models of care can support improving 
LTFU and programme retention.  Details of the systematic reviews reviewed here can 
be found in Supplementary Table 2.1.  Below, the recent reviews are summarized.  
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Decentralisation 
ART programmes in resource-limited settings were originally based on the traditional 
facility-based model in resource-rich settings where services were hospital-based and 
doctor-led and focussed on specialised and individualised care [6, 14, 42].  Given the 
prevalence of HIV and the capacity of health care systems in resource-limited settings, 
the scalability of this model was untenable. Programmes adapted implementing 
components of both decentralisation and task shifting to cope with the patient volume. 
The evidence regarding task shifting is discussed later in the chapter. First, the 
literature on decentralisation and patient outcomes is reviewed.   
Types of decentralisation 
There are four levels of decentralisation relating to when services are decentralised 
within the ART treatment cascade.  A framework for defining the types of 
decentralisation is provided in Table 2.2, adapted from the Cochrane systematic review 
of decentralisation [153].  Throughout this thesis, the primary care clinic or community 
health centre (CHC) is referred to as the CHC for the sake of consistency.  
Table 2.2 Levels of decentralisation for the provision of ART* 
Name Initiation Maintenance Description 
Standard hospital 
model 
Hospital Hospital Traditional model of ART care 
Partial 
decentralisation 
Hospital Community Health 
Centre (CHC) 
Starting ART in a hospital and 
being down-referred to a CHC 
Full decentralisation CHC CHC Both ART initiation and 





CHC & Community Facility-based ART initiation 
followed by down-referral for ART 
maintenance into the community  
* Adapted from Kredo et al. [153]
± Within CBART, one must consider where within the community the ART is provided (community
spaces, patient homes, etc.) and by whom (nurses, CHWs, PLWHIV, etc.).
The standard model of ART provision involves initiation and maintenance of ART 
within a hospital. “Partial decentralisation” describes the model whereby patients are 
initiated onto treatment at a hospital, but referred to a CHC for maintenance.  
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Increasingly, “full decentralisation” is occurring whereby patients are able to both 
initiate and be maintained on ART within their CHC.  There is a growing interest for the 
provision of ART to happen within communities and such models of care are defined as 
“community-based ART” (CBART).  Patients are initiated onto ART at a formal health 
facility, either hospital or CHC, and then down-referred for ART maintenance within 
the community.  Commonly within CBART models, regular clinical consultations occur 
back within formal health facilities. The furthest level of decentralisation occurs when 
patients receive ART within their homes.  
 
In all of these models, “down-referral” is the process whereby patients are 
decentralised to a level of care closer to home.  Conversely, “up-referral” is when 
patients are recommended to access care either at the CHC or hospital due to clinical 
complications or non-compliance with the model of ART.  In some models of care, 
patients are eligible to access decentralised models of care only once they are defined 
as stable.  The definition of “stable patient” varies, but generally includes an indicator 
or virologic suppression and a period of good adherence.   
 
Systematic reviews on decentralisation for the provision of ART 
Three recent systematic reviews have addressed decentralisation of ART provision 
(Supplementary Table 2.1) [152, 153, 155].  A 2013 Cochrane review by Kredo et al. 
assessed decentralised models of care and combined data on the impact of partial 
decentralisation, full decentralisation and CBART on the outcomes loss to follow-up, 
programme retention, and mortality.  A total of 16 studies were included; two cluster 
randomised control trials (RCTs) and 14 cohort studies (2 prospective, 12 
retrospective).  The review also included paediatric cohorts. Where possible, the 
results presented here are restricted to data on adults. Partial decentralisation led to a 
decreased risk of programme loss, loss to follow-up, and mortality at 12 months 
compared to traditional hospital-based models.  In models with full decentralisation, 
the risk of 12-month programme loss and loss to follow-up were reduced with a 
statistically insignificant increased risk of mortality compared to traditional hospital-
based, doctor-led models.   Data from CBARTs was limited to three models that 
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provided home-based ART delivery.  CBART models reported no difference in 
outcomes compared to facility care.   
Suthar et al. published a rapid systematic review in 2014, which was conducted to 
inform the WHO 2013 ART guidelines [28, 152].  A total of ten articles on 
decentralisation were included; 4 on partial decentralisation, 4 on full decentralisation 
and 2 on CBART.  All of the articles in the Suthar review were also included in the 
Cochrane review [153] (Supplementary Table 2.2).  Accordingly, findings were the 
same as the Cochrane review, with partial decentralisation having preferable retention 
and mortality, full decentralisation improving retention, and data from CBART models 
(all of which were in models with home-based ART provision) were limited, with no 
significant difference in retention compared to facility-based models.  
Decroo et al. conducted a review restricted to community-based models of ART [155].  
Six different programmes were included in the review.  Five of the programmes were 
CBART models with home-based ART delivery by CHWs, volunteers, or peer CHWs in 
Uganda or Kenya.  The sixth model reviewed was Community Adherence Groups 
(CAGs), a model of care designed and piloted by MSF, in rural Mozambique. No meta-
analysis was done, but the authors reported that all CBART models reported 
comparable attrition and virological outcomes to facility-based models.   
In summary, reviews of decentralisation suggest that outcomes from full and partial 
decentralisation can provide similar or favourable outcomes compared to hospital-
based models.  All of the reviews have considerable overlap in the studies included 
(Supplementary Table 2.2). Limited data from CBART models exists and are almost 
exclusively limited to models with home-based ART delivery.  With the data available, 
CBART outcomes are not significantly different from those in facility-based care.  
Details of the models included within these reviews are discussed later in this chapter 
as part of the review on models of care. 
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Task shifting 
Task shifting involves the allocation of tasks to lower cadres of staff; from doctors to 
nurses, and nurses to CHWs [156].  The WHO has described four types of task shifting 
(Table 2.3).  Task shifting I refers to tasks shifted from doctors to non-physician 
clinicians (NPCs)1, task shifting II from NPCs to nurses, task shifting III from clinicians 
to CHWs and task shifting IV is for patient self-management.  For continuity, other 
types of NPCs such as Clinical Officers have been referred to as NPCs, and all types of 
lay workers (counsellors, peer counsellors, etc.) are referred to as CHWs throughout 
this thesis.  
Table 2.3 Four types of task shifting* 
Name Summary Detailed definition 
Task shifting I Doctor to 
non-physician 
clinician 
“The extension of the scope of practice of non-physician 
clinicians in order to enable them to assume some tasks 
previously undertaken by more senior cadres (e.g. 
medical doctors).” [156] 




“The extension of the scope of practice of nurses and 
midwives in order to enable them to assume some tasks 
previously undertaken by senior cadres (e.g. non-





“The extension of the scope of practice of community 
health workers (often called non-professional health 
workers or lay providers), including people living with 
HIV/AIDS, in order to enable them to assume some tasks 
previously undertaken by senior cadres (e.g. nurses and 






“People living with HIV/AIDS, trained in self-
management, assume some tasks related to their own 
care that would previously have been undertaken by 
health workers.” [156] 
*From WHO’s Task shifting: rational redistribution of tasks among health workforce teams: global
recommendations and guidelines. [156]
1 Non-physician clinicians refer to a cadre of staff with less training than medical doctors who perform 
some functions of a medical doctor.  Specific types of NPCs include health officers, physician assistants 
and nurse clinicians.  A 2007 study reported that NPCs were involved in health care delivery in 25 of the 
47 countries in sub-Saharan Africa [157. Mullan F, Frehywot S. Non-physician clinicians in 47 sub-
Saharan African countries. Lancet. 2007 Dec 22;370(9605):2158-63. 
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In many resource-limited settings, task shifting in ART provision was done out of 
necessity in parallel to generating evidence of its effectiveness [42].  For example, the 
WHO recommended task shifting three years before the first randomised control trial 
on doctor- versus nurse-managed ART patients [44, 158].  In recent years, the 
published literature on the impact of task shifting on patient outcomes has grown.   
 
Systematic review on task shifting 
Five reviews of task shifting have been published since 2010 and are summarised in 
Supplementary Table 2.1 [154, 159-162]. The objectives and inclusion criteria of each 
review differed in the level of task shifting (Table 2.3), geographical location, study 
design, and where in the treatment cascade the task shifting was located.   
 
Callaghan et al. assessed task shifting in Africa across the treatment cascade, reviewing 
qualitative and quantitative data and including grey literature [159].  Emdin et al. 
conducted a meta-analysis comparing outcomes in physician versus NPC models of 
care, excluding CHW models [160].  ART maintenance by physicians, nurses or CHWs 
was compared by Mdege, but no meta-analysis was presented due to the high degree of 
heterogeneity between models of care [161].  Both qualitative and quantitate data was 
reviewed by Mwai et al. in their review on the outcomes of models of care utilising 
CHWs [162].  A 2014 Cochrane review and meta-analysis compared doctor versus 
nurse models for ART initiation and maintenance and outcomes of community 
maintenance models [154]. 
 
Task shifting from doctors to nurses for ART initiation 
In models comparing nurses and doctors for ART initiation, there was no difference in 
estimates of mortality from trial data [154]. Emdin et al. also reported no difference in 
mortality among almost 60,000 patients [160], while Kredo found a slight increased 
risk of mortality summarising cohort data [154].  LTFU was reduced for patients 
initiated in the nurse-led versus doctor-led models in the trial data in the Cochrane 
review and in the review by Emdin [154, 160]. 
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Task shifting from doctors to nurses for ART maintenance  
Mortality and LTFU when doctors initiated therapy and nurses provided follow-up also 
appeared to be comparable to doctor-led models.  Trial data in the Cochrane review 
found non-significant differences in the risk of death and LTFU comparing nurse-led 
versus doctor-led models for ART maintenance [154].  Cohort data suggested models 
with nurse-maintenance may provide better patient outcomes, with reduced mortality 
and LTFU compared to doctor-led models [154].  In Chapter 6, outcomes from a nurse-
managed programme for stable patients are presented contributing to the evidence on 
down referral to nurses for ART maintenance.  
Task shifting to CHWs for ART maintenance   
Less evidence is available on outcomes of patients who are maintained by CHWs.  No 
difference in mortality or LTFU was reported in the Cochrane review on community 
models [154] or in the systematic review by Mdege et al. [161].  The review by Mwai et 
al. on the role of CHWs found evidence of contributions by this cadre of workers 
throughout the treatment cascade and reported comparable outcomes and quality of 
care to other models [162].  While non-inferior patient outcomes do suggest CHWs can 
provide comparable support during ART maintenance, patient numbers are limited and 
authors recommend additional research for more conclusive evidence. 
Evidence from systematic reviews suggests patient outcomes of mortality and LTFU 
can be comparable or even slightly improved when ART initiation and maintenance is 
shifted from doctors to nurses.  None of the models reviewed have CHWs initiating ART 
and there is limited data on patients for who are maintained on ART by CHWs. None of 
the reviews included data on Task shifting IV, models with patient self-management.  
To that end, more data are necessary to increase the quality of evidence for task 
shifting to NPCs and nurses and to determine the effectiveness of task shifting to CHWs 
and patients.    In Chapters 7 and 8, the implementation and outcomes of a community-
based model of care facilitated by CHWs, with considerable patient, self-managed are 
presented.   
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2.4.2 Models of Care 
The level of decentralisation and task shifting involved defines each model of care. 
As discussed in the overview of this section, to review the literature on decentralisation 
or task shifting independently is difficult as models of care often in practice incorporate 
components of both. This section therefore looks to summarise the literature on 
models of care, programmes or interventions with components of both 
decentralisation and task shifting (Table 2.4).  The models presented here were 
included in the Cochrane reviews on decentralisation and task shifting [153, 154].  Also 
reviewed are two additional models of care with published outcomes.  
The level of decentralisation (Table 2.2) and type of task shifting (Table 2.3) are 
classified for each of the models included in this review (Table 2.4).  The systematic 
reviews of decentralisation and task shifting had differences and similarities in the 
publications that were reviewed, and this is denoted in Supplementary Table 2.2.  
Details of models of care are presented below, summarised by study design, type of 
decentralisation and level of task shifting, to highlight gaps in the literature. 
Trial data on nurses and decentralisation 
The role of nurses in the provision of ART has greatly expanded. Two large RCTs were 
designed to provide evidence that nurses could provide non-inferior care to ART 
patients compared to doctors.  The Comprehensive International Program for Research 
in AIDS in South Africa (CIPRA-SA) trial compared the management of ART patients by 
nurses and doctors within primary care clinics [44].  The trial concluded there to be 
non-inferiority nurse- and doctor-monitored ART.  Following on from CIPRA-SA, the 
STRETCH (Streamlining Tasks and Roles to Expand Treatment and Care for HIV) trial 
evaluated nurse versus doctor care for ART initiation and maintenance within primary 
care clinics  [45].  No difference was found in the proportion of deaths or time to death 
in the nurse-initiated versus doctor-initiated trial arms. 
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Observational data on nurses and decentralisation 
Increasingly, patients who are defined as stable are down-referred to models of care 
with further decentralisation and task shifting than the model where they initiated 
ART.  While definitions of stable varied from being adherent on first-line regimen for 
three to at least 11 months on treatment and virally supressed, outcomes were similar.  
This definition of stable may be difficult to apply outside of South Africa where access 
to viral load monitoring is limited.  Models down-referred stable patients for ART 
maintenance at nurse-managed sites and found comparable or lower mortality and 
LTFU compared to patients in hospital-based, doctor-led sites [163-165].  
Community-based models of ART delivery 
Community-based models of care offer a further level of decentralisation and often a 
further shifting of tasks to CHWs and the patient themselves.  CBART models in the 
Cochrane review of decentralisation included two studies in Uganda and one in 
Kenya [153].  All three of these models of care provide home-based ART delivery and 
reported comparable or favourable outcomes to facility-based models [166-175].   
An RCT in Jinja, Uganda evaluated the impact of a home-based ART delivery and 
support model with ART maintenance in the CHC where the primary outcome was 
virologic failure over 3 years of follow-up [168].  ART initiation was done in the CHC by 
NPCs.  In the intervention group, CHWs visited the homes of their patients every month 
delivery ART, screening for symptoms of toxicity and disease progression and 
providing adherence support. After 12 months on ART, no difference in mortality, LTFU 
or virological failure was observed between the two models of care.  In rural Uganda, 
Kipp et al. compared a community-based model linked to a CHC with a hospital-based 
cohort [171].  Volunteer CHWs made weekly visits to the homes of patients providing 
support and monthly ART delivery.  After two years, virological suppression was more 
than twice as likely in the CBART model patients versus those in the hospital-based 
model [172].  In the CBART model in Western Kenya, stable patients were randomised 
to receive either the standard of care within the clinic or a model where a CHW (who 
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was a PLWHIV) provided home-based ART delivery [175]. There were no differences in 
outcomes in the intervention and control arm after 12 months on ART [174].   
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Table 2.4 Publications on models of care with task shifting and/or decentralisation 
 
Publication Location Study design Objective Observation  
time 







Assefa 2012 Ethiopia Retrospective 
cohort 
Compare ART by doctors in 
hospitals to health 
officers/nurses in community 
health centers 
2006-2009 184,978 Type I & II Full vs. 
standard 
After 24-months, higher retention in care at 
CHCs (76% vs. 67%) due to less LTFU (13% 
vs. 25%) 
Balcha 2010 Ethiopia Retrospective 
cohort 
Compare ART outcomes 
between hospitals and CHCs 
2007-2009 1,709 Type II Full vs. 
standard 
After 24-months, higher retention in care at 
CHCs (83% vs. 57%) and lower LTFU (10% 
vs. 23%) 
Bedelu 2007 South Africa Prospective 
cohort 
Compare ART outcome from 
nurse-led CHC to doctor-led 
hospital 
2004-2006 1,025 Type I & II Full vs. 
standard 




South Africa Matched 
cohort 
analysis 
Compare outcomes of stable 
patients down-referred to a 
nurse-managed programme vs. 
doctor-managed site 
2008-2009 2,772 Type I & II Partial 
(stable) vs. 
standard 
After 12-months, down-referred patients had 
reduced LTFU (HR 0.3) and viral rebound (RR 
0.6) 
Chan 2010 Malawi Cohort study Compare outcomes of central 
hospital clinic to decentralised 
sites 
2004-2008 8,093 Type II Partial 
(stable) vs. 
standard 
Patients at CHC less likely to be LTFU (aOR 
0.48) 
Decroo 2014 Mozambique Cohort Describe outcomes of 
Community Adherence Group 
patients 
2008-2012 5,729 Type II & 
IV 
Full   Retention was 98% at 12 months and 96% at 
24 months.  Attrition associated with 
immunosuppression when joining a CAG and 
being male. 
Fairall 2012 South Africa Cluster RCT Compare nurse initiated and 
maintained patients vs. doctors 
2008-2010 15,483 Type II Full  No difference in 12-month mortality between 
patients initiated by nurses or doctors (HR 
0.94), no difference in12-month viral 
suppression between patients maintained by 
nurses vs. doctors (RD 1.1%) 
Fatti 2010 South Africa Retrospective 
cohort 
Compare outcomes between 
CHC and hospitals 
2004-2008 29,203 - Full vs. 
standard 
After 24 months, CHC had higher retention 
(80% vs. 72% & 69% at district and regional 





Compare outcomes of stable 
patients referred to CHC vs. 
hospital care 
2007 318 Type I & II Partial 
(stable) vs. 
standard 
No difference in LTFU, CHC patients less 
likely to miss an appointment (RR0.37) 
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Publication Location Study design Objective Observation  
time 







Jaffar 2009 Uganda Cluster RCT Compare home-based ART to 
facility-based care 
2005-2009 859 Type III CBART vs. 
standard 
After 12-months, no difference in mortality 
(11% vs. 11%), LTFU (1% vs. 2%), or 
virological failure (16% vs. 17%) between 
home-based and facility-based patients 
Kipp 2012 Uganda Prospective 
cohort 
Compare outcomes of home-
based ART to hospital-based 
program 




After 6-months, no difference in virological 
suppression (90% vs. 89%) or mortality 





South Africa Cohort Compare outcomes of stable 
patients in an Adherence Club to 
CHC 
2007-2011 2,829 Type II & 
III 
Full (stable) At 18-months, Adherence Club patients had 
higher retention in care (97% vs. 85%) and 





Compare outcomes of a 
decentralised programme to a 
centralised program 
2006-2007 4,074 - Full vs. 
standard 
CHCs had lower retention in care (aHR 1.18), 
similar attrition (aHR 1.17) with lower LTFU 






Compare outcomes of a 
decentralised programme to a 
centralised program 
2001-2008 15,412 Type III Full vs. 
standard 
After 24-months, lower attrition at the 
decentralised site (10/100 person years vs. 
21/100 person years) vs. the decentralised 
facility.  No difference in immunological 
success or suppression after 12-months. 
Sanne 2010 South Africa RCT Compare outcomes of nurse vs. 
doctor management models 
2005-2009 812 Type II Full  There were no differences in treatment 
failure, deaths, virologic failure, or 
programme losses between models 
Selke 2010 Kenya Cluster RCT Compare outcomes of stable 
patients managed by CHWs in 
HBC vs. clinic based care 
2006-2008 208 Type III CBART 
(stable) vs. 
full (stable) 
No differences in clinical outcomes, 
intervention patients made 1/2 as many clinic 
visits (p<0.001) 
Sherr 2010 Mozambique Retrospective 
cohort 
Compare outcomes of patients 
in NPC vs. physician models 
2004-2007 5,892 Type I Full 
decentralisa
tion 
NPC patients had more clinical visits 
(RR1.02), higher adherence in the first 6 
months (RR 1.05) and were less likely to be 
LTFU (RR 0.86, 95% CI 0.73-1.02) 
Abbreviations: aHR – adjusted Hazard Ratio, aOR – Adjusted Odds Ratio, ART – antiretroviral therapy, CBART – community-based ART, CHC – community health centre, HBC – home-based care, HR – 
hazard ratio, LTFU – loss to follow-up, NPC – non-physician clinician, RCT – Randomised control trial, RD – risk difference, RR – risk ratio 
*Types of task shifting denoted in Table 2.3, ± Levels of decentralisation denoted in Table 2
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Other models of care 
Médecins Sans Frontières (MSF) was one of the first non-governmental organisations 
to be involved with ART programmes in resource-limited settings.  In recent years, 
their HIV programmes in sub-Saharan Africa have piloted different models of ART 
delivery with increased decentralisation.  Published details of the Community 
Adherence Groups (CAGs) in Mozambique and Adherence Clubs, also referred to as 
peer educator-led ART refill groups, in South Africa are reviewed here. 
Community Adherence Groups 
CAGs were piloted in the Tete province in northern Mozambique starting in 2008 
(CBART, Task shifting III & IV) [176].  A CAG is a self-forming group of up to 6 stable 
ART patients.  Stable was defined as being clinically stable on ART for at least 6 months 
with a CD4 cell count of ≥200 cells/l.  CAGs members would rotate visiting the CHC 
and collect ART for all members. Pilot data found very low rates of LTFU and the 
programme expanded [176].  Retention among CAG members is 98%, 96% and 93% 
after 12, 24 and 36 months on ART [177].  Among CAG members, an increased risk of 
attrition was observed for men, patients with a CD4 cell count <200 cells/l or missing 
at CAG initiation and in patients from a district or rural clinic compared to a peri-urban 
clinic. The model has been implemented nationally in collaboration with the Ministry of 
Health in Mozambique and at the end of 2013, more than 17,000 patients were 
receiving ART in a CAG [43]. 
 
Adherence Clubs  
Adherence Clubs were piloted in Khayelitsha South Africa starting in 2007 [143].  
Stable patients, defined as being in ART for 18 months or more, two consecutive 
suppressed viral loads, no opportunistic infections and good adherence, were recruited 
to join an Adherence Clubs.  Adherence Clubs were comprised of approximately 30 
patients and met every 8 weeks with a CHW or nurse for group counselling, a brief 
symptom screen, and collection of pre-packed ART.  Data from the pilot found 97% of 
patients were retained in care, with club participation reducing the risk of LTFU by 
57% [178].  Subsequently, in collaboration with the Provincial Government of the 
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Western Cape (PGWC) and the City of Cape Town, the Adherence Clubs model has been 
implemented across the Cape Metro.  By June 2013, 19% of all ART patients in the Cape 
Metro were receiving ART in one of 776 Adherence Clubs [43]. 
2.4.3 Summary 
Data from randomised control trials, observational cohorts and pilot programmes 
suggest that models of care with elements of decentralisation and task shifting can 
provide comparable and sometimes improved LTFU and retention compared to 
traditional hospital-based, doctor-led models of care.  Data from two RCTs provides 
high-quality evidence that nurses can offer comparable ART initiation and maintenance 
to doctors [44, 45].  Observational cohorts confirm these findings and provide evidence 
for the decentralisation from hospitals to CHCs for both initiation and maintenance of 
ART.  Decentralisation of stable patients provided comparable or beneficial outcomes 
compared to the model of care where the patients was initiated on ART.  Comparative 
data from community-based models of care are limited to models with home-based 
ART delivery.  In these models, patient outcomes were comparable or favourable to 
facility-based models. Innovative pilot projects highlight that approaches to ART 
delivery can be further decentralised and task shifting further delineated towards 
patient self-management. The effectiveness of community-based models of care 
requires additional research and further evaluation outside of the traditional research 
settings.   
2.5 SUMMARY AND GAPS IN THE LITERATURE 
Loss to follow-up from ART programmes in resource-limited settings represents a key 
challenge in the effective provision of ART.  Challenges exist in defining LTFU, in 
understanding how LTFU is changing as ART programmes expand and in what 
adaptations can be made to the delivery of ART to support retention in care.  Given the 
context of rapid scale-up and limited resources, potential interventions also need to 
consider the public health approach to ART delivery and the multilevel framework of 
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health system and social/economic factors, HIV- and ART-related factors, and patient 
level factors that are associated with LTFU.  Key gaps identified in the literature review 
are summarised justifying the research focus of the subsequent chapters.    
 
2.5.1 Temporal changes over the first decade of ART 
provision in resource-limited settings  
Over the first decade of ART provision in resource-limited settings, a series of 
evolutions have occurred. As summarised in Figure 1.1, the key challenge of ART 
provision has shifted while the utility of ART has evolved from being a life-saving 
intervention to also a form of prevention.  Concurrently, decentralisation and task 
shifting of models of care have reshaped the systems in which ART is delivered.  These 
temporal changes underscore that the context is continually changing. Further research 
into the factors affecting LTFU and interventions to support retention is needed given 
the highly context-specific nature of the evidence.        
2.5.2 Challenges in defining LTFU  
LTFU is a key outcome to measure the effectiveness of ART programmes.  However, it 
has not previously received significant attention, traditionally considered a censoring 
event within time-to-event analyses.  LTFU, and in turn retention, are key to successful 
chronic care delivery.  As an outcome, LTFU is complex and includes patients with 
three distinct outcomes: unascertained mortality, unascertained transfers and patients 
currently disengaged from care.  This complexity leads to challenges in how to define 
LTFU and in assessment of factors related to LTFU. 
 
As discussed in section 2.1, substantial variation exists in how LTFU is defined.  Before 
investigating risk factors for LTFU, determining the impact of definitions of LTFU on 
outcomes is necessary.  Differences in definitions and analytic approaches pose a 
challenge when combining data and comparing outcomes between programmes. How 
these differences in approaches to LTFU impact estimates of LTFU is not well 
understood.  This thesis was conceived before any attention had been given to 
definitions of LTFU.  In recent years, a small body of research has appeared focusing on 
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the optimal window period for defining no contact and sources of data to generate the 
outcome LTFU [95, 103, 104].  However, critical public health questions remain on the 
impact of methodologies to define LTFU, and further research is required to inform 
recommendations on a standardised definition. Specific attention to the impact of 
definitions of LTFU on outcomes is examined in Chapter 3. 
 
2.5.3 Factors contributing to LTFU during scale-up of ART in 
resource-limited settings 
LTFU and successive calendar year of ART initiation 
As ART programmes have expanded and matured, there is conflicting evidence on how 
year of ART initiation is related to LTFU and programme retention.  It has been 
hypothesised that as programmes have developed and matured, the quality and 
outcomes have improved with experience [38].  Alternatively, it has been suggested 
that programme expansion has outpaced sufficient resources to adequately support 
patients resulting in poorer outcomes [53].  The question on how year of ART initiation 
is related to LTFU in resource-limited settings was postulated following an analysis of 
temporal trends in South Africa [56].  While data from South Africa highlighted a 
significant increase in LTFU among patients who had recently initiated ART, it is 
unclear if this association will be found in other resource-limited settings.  Therefore, 
data from MSF cohorts in other low- and middle-income countries and the association 
between year of ART initiation and LTFU is the focus of Chapter 4.   
 
LTFU and programme expansion 
Following from the ambiguity of the relationship between year of ART initiation and 
LTFU, limited data are available on how programme expansion relates to LTFU and 
retention in care.  As summarised in Section 2.2, observational studies and studies that 
trace patients who are LTFU identified health systems factors associated with LTFU.  
Factors relating to scale-up of ART including waiting times, long queues and patient 
volume have been found to increase the risk of LTFU.  However, it is less clear what 
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component of programme expansion relates to LTFU and if this association is 
independent of year of association.  Consequently, the analysis in Chapter 4 includes 
two measures of expansion in addition to year of ART association.  Both programme 
size and the rate of expansion are included in multivariate analyses to assess if 
temporal factors of scale-up are related to LTFU.    
 
LTFU and increasing CD4 cell count at ART initiation  
In all regions of the world, patients are accessing ART at progressively higher CD4 cell 
counts [24].  However, conflicting evidence exists on how initiation of ART at higher 
CD4 cell counts impacts patient outcomes.  Given the push towards earlier initiation, it 
is crucial for additional analyses to investigate the impact of higher CD4 cell counts at 
ART initiation on risk of LTFU and retention in care. Previous findings on the 
relationship between CD4 cell count and LTFU has been inconsistent with few patients 
accessing ART above a CD4 cell count <200 cells/l. Chapter 5 assesses the association 
between CD4 cell count and LTFU in the first two years on ART. The multivariate 
analyses in Chapter 5 adjust for health systems factors (year of ART initiation and 
programme expansion) and individual level factors (age and gender) given that LTFU is 
related to factors at multiple levels.  Linkage with the National Population Register in 
this chapter corrects for unascertained deaths.  This linkage is critical given that lower 
CD4 cell counts are related to mortality.   
 
Individual risk factors for LTFU 
Patient groups have disparate outcomes on ART.  Consistently higher LTFU was 
observed in men, young adults and other underserved groups.  As we expand ART 
eligibility criteria, the needs of these groups should be taken into consideration to 
ensure that all patients are supported as they endeavour to adhere to lifelong ART. 
Chapters 6-8 assess two novel models of care.  To understand how these models of ART 
delivery impact on outcomes for specific patient groups, both Chapter 6 and Chapter 8 
conduct sub-group analyses to address Objective 3b. 
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2.5.4 Models of care with decentralisation and task shifting 
There is considerable interest in the role of models of care with decentralisation and 
task shifting to support continued ART expansion and improve LTFU and retention. 
Adapting how ART is delivered can address multiple risk factors and provide scalable 
interventions to support retention in care. To date, the literature on decentralisation 
has focussed on partial and full decentralisation, whereby patients are initiated and or 
maintained at health facilities peripheral to hospitals.  WHO recommends 
decentralisation for ART initiation and maintenance to peripheral facilities on the basis 
of low quality evidence.  Further data are needed, given the low quality of evidence 
available and the importance of the context in implementing novel models of care.  To 
this end, Chapter 6 presents outcomes of the Green Clinic, a model of care with ART 
maintenance at a CHC. 
More data on community-models of care are needed 
Recently, community-based models of care have received increased attention.  
However, data from out-of-facility models are limited.  The CBART models included in 
both the Cochrane review on decentralisation and the review by Suthar et al. were 
limited to models with home-based ART delivery [28, 153].  Nevertheless, WHO 
recommends ART provision at the community level [28]. 
 
To date, the data from community-based models of care for ART delivery are limited to 
home-based models.  Home-based delivery is highly resource intensive and unlikely to 
be scalable in the contexts of generalised epidemics. Moreover, home-based delivery 
models do not encourage patient self-management.  Chapters 7 and 8 describe the 
implementation and outcomes of a community-based model of care to support ART 
retention of stable patients. 
 
Increased task shifting towards patient self-management 
The transition towards decentralisation of ART is happening in parallel with the 
progression towards further task shifting.  Overall, the WHO rates the quality of the 
evidence for task shifting as moderate [28]. The literature on task shifting is focused on 
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levels I-II, with tasks reallocated from doctors to NPCs and nurses.  Limited data on 
task shifting to CHWs and patient self-managed is available despite the shift to patient 
self-management being regarded as the most important task shifting transition [41]. 
Chapter 6 contributes data on how nurse-managed and CHW-supported models can 
support ART maintenance. Chapters 7 and 8 present the community-based Adherence 
Club model, which are CHW-managed and include substantial shifting of tasks to 
individual patients.   
 
Who do innovative models of care work for 
The other gap in the models of care literature is which patient sub-groups do 
innovative models of care provide comparable, favourable or poorer outcomes 
compared to the standard of care.  We do not know what profile of patients is best 
suited to these decentralised models.  To address this question, Chapters 6 and 8 assess 
outcomes by sub-groups and investigate how outcomes vary within the novel model of 
care compared to the standard of care. 
 
2.5.5 Conclusion 
Questions remain in our understanding of LTFU from ART programmes in the context 
of scale-up in resource-limited settings.  This thesis looks to contribute to some of the 
key areas where there is a paucity of evidence or conflicting findings.  Specifically, how 
definitions of LTFU affect estimates of retention will be elucidated.  Temporal factors 
related to LTFU in the context of scale-up including year of ART initiation, programme 
expansion and the role of higher CD4 cell counts at ART initiation will be investigated.  
Finally, models of care providing decentralised ART and utilising task shifting will be 
described and evaluated to inform how the health system can be reoriented to support 
expanding ART cohorts in resource-limited settings.  
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To examine the impact of different definitions of loss to follow-up (LTFU) on estimates 
of programme outcomes in cohort studies of patients on antiretroviral therapy (ART). 
Methods 
We examined the impact of different definitions of LTFU using data from the 
International Epidemiological Databases to Evaluate AIDS-Southern Africa. The 
reference approach, Definition A, was compared with five alternative scenarios that 
differed in eligibility for analysis and the date assigned to the LTFU outcome. Kaplan-
Meier estimates of LTFU were calculated up to two years after starting ART. 
 
Results 
Estimated cumulative LTFU were 14% and 22% at 12 and 24 months, respectively, 
using the reference approach. Differences in the proportion LTFU were reported in the 
alternative scenarios with 12-month estimates of LTFU varying by up to 39% 
compared with Definition A. Differences were largest when the date assigned to the 
LTFU outcome was 6 months after the date of last contact and when the site-specific 
definition of LTFU was used. 
Conclusion 
Variation in the definitions of LTFU within cohort analyses can have an appreciable 
impact on estimated proportions of LTFU over two years of follow-up. Use of a 
standardised definition of LTFU is needed to accurately measure programme 
effectiveness and comparability between programs. 
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3.2 INTRODUCTION 
In 2011, 30 years since the first cases of AIDS were reported, 34 million people 
worldwide were living with human immunodeficiency virus (HIV) [179].  More than 
two thirds of the global cases are located in sub-Saharan Africa.  Nearly six million 
people in the region were receiving antiretroviral therapy (ART) in 2011, up from only 
100,000 people in 2003 [179].  Across sub-Saharan Africa, the expansion of ART 
services represents one of the largest pharmacologic interventions to promote 
population health to date, and there is considerable interest in monitoring the impact 
of these programs [180].  Given the high mortality rate of untreated HIV infection, 
mortality and disease progression have been the major clinical outcomes of interest in 
ART programs. However more recently, loss to follow-up (LTFU) has emerged as a key 
indicator of ART programme effectiveness [97] and there is a growing emphasis on 
monitoring programs to improve long-term retention in care [98]. 
 
Conventionally within most cohort analyses, LTFU is considered an uninformative 
censoring event [181, 182] and in practice relatively little attention may be paid to the 
definition of LTFU compared to clinic outcomes of interest (such as mortality in the 
case of ART programs). However when LTFU becomes an outcome of interest, greater 
attention to the definition of this phenomenon may be warranted. Within ART 
programs, consideration of LTFU is of particular importance and is generally higher in 
settings where mortality ascertainment may be weak [183].  
 
Understanding the impact of varying definitions of LTFU on programme outcomes is a 
central consideration for other chronic disease programs that seek to retain patients in 
care over the long-term.  However there has been relatively little attention to how 
LTFU should be defined in cohort analyses in ART and other chronic disease services. 
Within the evaluation of ART programs, the treatment of LTFU in analysis varies 
widely. The lack of a standard definition hampers systematic reviews of pooled 
data [37, 38, 99]. Previous work has focused on the optimal duration of loss to 
minimise LTFU misclassification [103, 104] but there is little consensus on other 
aspects of defining LTFU within analyses. 
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Definitions of LTFU used in the analysis of ART programs vary in their application of 
eligibility for inclusion in analysis, the date assigned to the LTFU outcome, and whether 
or not to utilise the outcome LTFU as defined by the site. In light of this heterogeneity, 
it is important to investigate whether and how definitions of LTFU impact on observed 
programme outcomes.  It is plausible that varying analytic definitions give rise to 
spurious observed differences in estimates of LTFU as a programme outcome.  We used 
data from the International Epidemiological Databases to Evaluate AIDS (IeDEA) –
Southern Africa collaboration to explore the impact of varying LTFU definitions on 




IeDEA is an international collaboration comprised of seven data centres that pool large 
HIV datasets [184-186].   The source dataset for this analysis included all adults who 
initiated therapy between 2002 and 2007 at eight public-sector antiretroviral 
programs in South Africa; details of the sites and sample have been reported 
previously [52]. The IeDEA-SA collaboration was approved by the ethics committees of 
the University of Cape Town, South Africa, and University of Bern, Switzerland and the 
ethics committees of each participating site. 
 
Within these data, six different scenarios with varying definitions of LTFU were tested 
to determine how variation in the definition of LTFU may influence programme 
retention outcomes over the first 24 months after ART initiation.  Five definitions 
generated LTFU under varying assumptions, and the sixth used the site-defined 
variable of LTFU. Consistent within the five generated definitions were that individuals 
were defined as LTFU if they had no visit or contact in the previous 6-months.  A 6-
month period was used to accommodate the largest interval between visits within 
contributing cohorts. In addition, this time period has been shown to have the least 
misclassification when defining LTFU [103, 104].  Definitions of LTFU differed in: the 
timing of analysis and database closure, the approach to those who initiated treatment 
and never returned, and the date assigned to the LTFU outcome (Figure 3.1 and Table 
 75 
3.1). Variations in these key factors gave rise to five generated definitions of LTFU 
analysed here.   
3.3.1 Reference approach – Definition A 
In Definition A, the analysis was closed 6 months before database closure.  This 
ensured both sufficient follow-up time among those included as well as a window of 
observation to observe retention in care.   For patients who initiated ART and never 
returned, one day of follow-up was added so that they were included in the time-to-
event analysis.   The last contact date was assigned to the outcome LTFU [56].  
Definition A is the most conservative and likely to result in the highest estimates of 
LTFU.  It is used as the reference to compare with all other scenarios (see bolded 
options in Figure 3.1).   
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Figure 3.1 Decision in defining LTFU in an ART programme cohort analysis 
*Bolded option denotes decision illustrated in Definition A.
Decision 1: Who to include in the analysis 
1.1 Those who initiated treatment and never 
returned: “no follow-up” 
Include, add 1 day follow-up 
Exclude, no follow-up time 
Site-Defined Calculate* 
1.2 When to close the analysis 
Decision 2: Date assigned to LTFU 
Date of last contact 
Date of last contact + 6 months 
No consensus definition of LTFU 
Close analysis at the same time as the 
database  
Close analysis 6-months before the closure of 
the database 
Close analysis at the same time as the 
database, exclude those without 6-months 
potential follow-up 
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Table 3.1 Analytic approaches to defining ART programme loss to follow-
up 
 
 Inclusion of patients 
who started ART  





Date assigned to 
loss to follow-up 
Definition A [56] Yes* Yes Last visit 
Variation A1 [139, 
187] 
Yes* No† Last visit 
Variation A2 [188] No Yes Last visit 
Variation A3 [189] Yes* Yes Last visit plus 6 
months 
Variation A4 No No† Last visit plus 6 
months 
* Patients were included by adding one day of follow-up 
† All patients included, independent of window of observation and duration of follow-up 
Variation A1: the analysis and database closure dates were the same and thus all those who 
initiated treatment in the 6 months preceding the database closure were included in the analysis 
Variation A2: participants who did not return after ART initiation were excluded from analysis 
Variation A3: assigned the date of LTFU as 6-months after the last contact date, allowing patients 
defined as LTFU to contribute additional person-time to the analysis 
Variation A4: combined Variations A1-A3  
 
3.3.2 Variations on the definition of loss to follow-up 
Four variations to generating a definition of LTFU were applied. In Variation A1, 
the analysis and database closure dates were the same and thus all those who 
initiated treatment in the 6 months preceding the database closure were 
included in the analysis [139, 187].  In Variation A2, participants who did not 
return after ART initiation were excluded from analysis [188].  A third scenario, 
Variation A3, assigned the date of LTFU as 6-months after the last contact date, 
allowing patients defined as LTFU to contribute additional person-time to the 
analysis [189]. Variation A4 combined Variations A1-A3: the analysis and 
database closure dates were the same, those who initiated ART and never 
returned were excluded and the date assigned to the outcome LTFU was 6 
months after the last contact date.  The differences between these generated 
definitions are summarised in Table 3.1. A sixth definition of LTFU was based on 
the determination of LTFU by each site. In all of these scenarios above, those who 
were transferred out were censored at the date of transfer; deaths were 
censored on the date of death. 
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3.3.3 Statistical Analysis 
For each of the scenarios, patient characteristics at baseline [age, sex, Cluster of 
Differentiation 4 (CD4) count and year of enrolment] were described with 
appropriate summary statistics.  Kaplan-Meier estimates of LTFU under the six 
different definitions were calculated over 24-months and reported at 6-month 
intervals.  Differences in the proportions LTFU were estimated using Definition A 
as the reference scenario throughout.  Data were analysed using STATA 11.0 




The scenarios included between 43,173 and 45,849 adults with slight variations 
in baseline characteristics based on eligibility for the different analyses. 
Definition A included 44,177 adults with a median age of 35 years and over 60% 
of participants initiating therapy in the last 2 years of enrolment (2006 and 
2007) (Table 3.2).  In Variation A1 with no window between the analysis and 
database closure, an additional 1,655 participants were included. Patient 
characteristics (gender, age, baseline CD4 and year of enrolment) of those LTFU 
were consistent across all scenarios (Table 3.3).   
 
Changes in LTFU by definition  
Under the reference approach (Definition A), estimated LTFU was 9.3%, 14.4%, 
18.8% and 22.4% at 6-, 12, 18- and 24-months post ART initiation, respectively 
(Table 3.4).  Compared to this definition, all other scenarios underestimated 
LTFU in the first year on treatment (Figure 3.2). When the analysis and database 
closure dates were the same (Variation A1), the LTFU underestimation increased 
from 4.3% at 6-months to 12.1% at 24-months compared to Definition A (Table 
3.4). Excluding those who initiate ART and never return (Variation A2) resulted 
in lower estimates of the LTFU proportion compared to Definition A.  At 6-
months the difference was 21.5% decreasing to 7.6% at 24-months.   
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Table 3.2 Patient characteristics at ART initiation in Definition A 
 
Characteristics N (%) 
Adults (≥16 years)  44,177  
Gender  
Female 29,904 (67.7) 
Age,  
Age (years), median (IQR) 35.0 (29.9-41.6) 
Age categories (year)  
16-24 2,306 (5.2) 
25-34 17,654 (40.0) 
35-44 16,177(36.6) 
≥45 8,040 (18.2) 
Baseline CD4 (cells/l), categorical      
<50 9,947 (27.2) 
50-199 22,703 (62.1) 
≥200 3,899 (10.7) 
Year of initiation n(%) 44,177 (100) 
2002 and 2003 1,173 (2.7) 
2004 5,262 (11.9) 
2005 9,909 (22.4) 
2006 13,105 (29.7) 


















Gender          
Male  17.0 15.8 14.6 13.0 10.6 13.7 
Female 14.8 13.8 12.7 10.5 8.5 12.2 
Age (years)       
16-24 22.1 20.2 19.0 15.1 12.2 17.3 
25-34 15.6 14.4 13.6 11.3 9.3 12.4 
35-44 14.6 13.6 12.5 10.9 8.8 12.2 
45+ 15.4 14.3 13.0 11.1 8.6 13.0 
Baseline CD4 (cells/l), categorical           
<50 16.4 15.4 13.2 13.7 11.4 13.7 
50-199 13.8 12.8 12.0 9.7 8.0 11.3 
≥200 17.7 16.0 15.4 12.4 10.2 12.9 
Year of initiation       
2002 & 2003 1.1 1.1 1.1 0.8 0.1 1.0 
2004 9.0 9.0 7.5 6.4 6.0 7.8 
2005 10.8 10.8 9.1 7.8 7.3 8.3 
2006 14.0 13.7 11.8 9.6 8.5 9.9 
2007 26.7 20.7 23.8 21.4 13.3 21.6 
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Variation A3 highlighted the effect of assigning the LTFU date 6-months after the 
date of last contact.  The underestimation of LTFU was 73% at 6-months 
decreasing with time on treatment and at 24-months the LTFU proportion was 
1.8% higher than Definition A (Table 3.4).  Combining variants A1-A3 into 
Variation A4 produced the largest deviations from the reference definition with 
an 86% underestimation of LTFU (1.3% vs. 9.3%) at 6-months decreasing to a 
17% underestimation at 24-months (Table 3.4).    
 
Estimates of LTFU from site-defined LTFU varied appreciably, both in magnitude 
and direction of LTFU, compared to Definition A.  The proportion LTFU at 6-, 12-, 
and 18-months was less than in Definition A (26.9%, 17.4% and 1.6%, 
respectively) and 14.3% higher at 24-months (Table 3.4). 
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Table 3.4 Kaplan-Meier estimates of cumulative mortality and LTFU reported 6 monthly and relative differences of LTFU* 
compared with Definition A 
6-months 12-months 18-months 24-months 
% Mortality % LTFU Difference % Mortality % LTFU Difference % Mortality % LTFU Difference % Mortality % LTFU Difference 
Definition A  4.8 9.3  Ref 6.6 14.4  Ref 7.6 18.8  Ref 8.5 22.4  Ref 
Variation A1 4.7 8.9  4.3 6.4 13.5 6.3 7.3 17.0  9.6 8.0 19.7  12.1 
Variation A2 4.7 7.3  21.5 6.5 12.5  13.2 7.6 17.0  9.6 8.4 20.7  7.6 
Variation A3 4.5 2.5  73.1 6.2 10.7  25.7 7.2 17.2  8.5 8.0 22.8 -1.8 
Variation A4 4.5 1.3  86.0 6.0 8.8  38.9 6.9 14.1  25.0 7.6 18.6  17.0 
Site-Defined 4.6 6.8  26.9 6.3 11.9  17.4 7.2 18.5  1.6 7.9 25.6  -14.3 
* Differences reported are percentage differences compared to Definition A
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3.5 DISCUSSION 
This analysis demonstrates that different definitions of LTFU within an ART cohort 
analysis have an appreciable impact on estimated LTFU over time.  Estimates of LTFU, 
particularly at 12-months, varied in each scenario when compared to the reference 
approach Definition A. If the nature of the analytic approach taken to LTFU varies, 
comparing programs and combining results is not possible.  
There is a growing interest in LTFU and programme retention in ART programs [98].  
Two systematic reviews of ART programme retention have combined the results from 
multiple cohorts despite differences in LTFU definitions [37, 38].  There is strong 
evidence that over time, LTFU is contributing an increasing proportion to those lost to 
care, and may be a more important indicator of programme performance than patient 
mortality [56].  However, it is difficult to assess trends and differences in LTFU 
between and within programs as variations in the definitions of LTFU obstruct 
comparability.   
There are many variations as to how LTFU is defined within the literature.  This 
analysis demonstrates empirically the impact of these variations on estimates of LTFU.   
One approach is to have the analysis and database close at the same time utilizing all of 
the available data [139, 187].  Although it is appealing in its use of all available data, 
this approach, Variation A1, leads to a consistent underestimate of LTFU, as those who 
had recently initiated treatment did not have sufficient potential to be LTFU.   
An alternative approach is to exclude patients who have recently initiated therapy, 
those without sufficient potential to be LTFU, and keep the analysis and database 
closure dates the same [190-192].  The common closure of the analysis and database 
results in an artificial cessation of LTFU in the last 6 calendar months of observation 
because LTFU is impossible among those with a visit in the final 6-months.  Excluding 
those who initiated treatment in the previously 6-months is either non-informative, or 
in context of temporal trends of increasing LTFU, contributes to under ascertainment of 
recent LTFU.  This variation is not utilised here, as it is not recommend given that LTFU 
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is a meaningful event often more likely to occur in the final months of observed patient-
time when the phenomenon is increasing due to service expansion.  
Another approach utilises different dates for database and analysis closure [53, 97, 
139, 193].   As was done in Definition A, restricting the analysis to person time 
observed at least 6-months before the database closure gives a window of observation 
to observe retention in care and ensures sufficient potential observation among those 
who recently initiated therapy.  
Patients who initiate treatment and never return are a group that is often excluded 
from time-to-event analyses.  Excluding this group, as in Variation A2, potentially 
underestimates true LTFU and inflates estimates of programme retention. Alternative 
approaches are to report them as a specific “no follow-up” group [97], or presume a 
small amount of follow-up time (e.g. one day) so that they are included in the analysis 
(Definition A) [56].  The LTFU in Variation A2 was consistently lower than in Definition 
A with the relative difference decreasing over duration of follow-up.  Initiation without 
being confirmed on treatment is debatable, but where data systems are weak, the first 
visit is often preferentially recorded and those individuals with only the initiation visit 
recorded may well have been established on treatment.  
Approaches to the assignment of a date to the outcome LTFU vary as well.  Most 
analyses use the last visit or contact date [139, 194-199] while others choose a date 
somewhere between the date of last contact and the first missed visit date [189, 200].  
Adding 6-months to the follow-up time as in Variation A3, lead to a LTFU estimate of 
1.3% and 8.8% LTFU at 6- and 12-months compared to 9.3% and 14.4% in Definition A, 
respectively.  Presuming follow-up time is working with the unknown whereas the 
differential closure approach (where the analysis closes before the database) has no 
need to make any assumptions.  Given these potential variations in how LTFU is 
defined in analysis, it is unsurprising that few analyses of ART programme outcomes 
employ the same definition of LTFU. 
The LTFU estimates from each of scenarios A1-A3 appeared only modestly different 
from Definition A but when combined in Variation A4, estimates of LTFU were 
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substantially different. This shows that the cumulative impact of small differences in 
defining LTFU can have an appreciable influence on LTFU estimates.    
 
We found that the Site-Defined estimates of LTFU varied greatly when compared to 
Definition A.  This variability around a calculated estimate highlights that sites are 
likely defining outcomes differently and it may be inappropriate to compare or 
combine site-defined outcomes across a number of sites [99].  The variability of site 
definitions suggests that the most efficient approach to standardizing LTFU in 
combined analyses is to generate LTFU from the data at the time of analysis.    
 
To our knowledge, this analysis is the first to examine how defining LTFU in ART 
cohort analyses may produce different estimates of programme outcomes.  This work 
builds on previous methodological research that proposed using 180 days without 
contact since the last clinic encounter as a an optimal period for defining LTFU in order 
to minimise misclassifications [103, 104].  Other research has focussed on determining 
risk factors for being loss to follow-up [183], early and late in the program. Here we 
focus on the analytic definition of LTFU in cohort analyses and the impact that this may 
have on estimates of LTFU.  
 
The objective of the analysis is to demonstrate the impact of LTFU definitions of ART 
programme outcomes and we have focussed on a relatively short duration of 24 
months follow-up.  LTFU is defined in terms of the absence of death and transfers out 
and only at the analysis closure in terms of 6-months of non-attendance.  We did not 
focus on treatment interruptions [92, 145] or distinguishing observed versus actual 
LTFU [103, 104] but acknowledge these are important related issues that require 
additional consideration.  Of note, we have used standard Kaplan-Meier methods, 
which are common in the ART programme literature.  Competing risks methods have 
been proposed as an alternative, but given the relatively low mortality observed in 
these data, the outcomes from the two methodologies are unlikely to differ 
substantively [130, 201].          
 
Concerns around the definition of LTFU are not restricted to ART programme analyses, 
but are likely to emerge in any setting when LTFU may be an outcome of interest. For 
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chronic care programs to be successful, patients need to be adherent and retained in 
treatment services [202].  In order for a patient to be adherent, they must be retained 
within the programme and therefore all patients who are LTFU are by definition not 
adherent. Defining LTFU is therefore relevant in the operational research of all chronic 
care programs where patient retention is an outcome of interest.   
 
In South Africa, the rate of ART programme expansion was so rapid that systems were 
not in place to track and monitor the outcomes of patients after initiation.  There are 
now renewed efforts to determine the outcomes of patients on ART.  To determine the 
number of patients retained in the national programs, accurate estimates of patients 
lost to care are needed.  Linkage with the National Population Register (NPR) has 
improved the accuracy of mortality data [53, 203]. A standardised definition of loss to 
follow-up to improve the accuracy of LTFU estimates is analogous to the linkage with 
the NPR to improve mortality estimates necessary to appropriately assess ART 
programme loss.   
 
These results point to the need for a standardised definition of LTFU for ART service 
evaluation if we are to understand changes within and differences between ART 
programs.  They also highlight the need to consider how LTFU is defined and assessed 
within health systems research involving other long-term therapies. Based on this 
work, we propose a standardised definition to LTFU may facilitate comparisons of 
outcomes within and between ART programs.  Our recommendation is the most 
conservative Definition A, in which the analysis closes 6-months before the database, 
one day of follow-up is added for those who initiate treatment and never return, and 
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Little is known about the evolution of programme outcomes associated with rapid 
expansion of ART in resource-limited settings.  We describe temporal trends and assess 
associations with mortality and loss to follow-up (LTFU) in HIV cohorts from 8 
countries.  
Methods 
Analysis included adults in twenty-five Médecins Sans Frontières supported programs 
initiating ART between 2001 and 2011.  Kaplan-Meier methods were used to describe 
time to death or LTFU, and proportional hazards models to assess associations with 
individual and programme factors.  
Results 
ART programs (n=132,334; median age 35 years; 61% female) expanded rapidly. While 
36-month mortality decreased from 22% to 9% over 5 years (≤2003-2008), LTFU
increased from 11% to 21%. Hazard ratios (HR) of early (0-12 months) and late (12-72 
months) LTFU increased over time, from 1.09 (95% CI 0.83-1.43) and 1.04 (95% CI 
0.84-1.28) in 2004, to 3.29 (95% CI 2.42-4.46) and 6.86 (95%CI 4.94-9.53) in 2011, 
compared to 2001-2003. Rate of programme expansion was strongly associated with 
increased early and late LTFU, adjusted HR (aHR)=2.31 (95%CI 1.78-3.01) and 
HR=2.29 (95%CI 1.76-2.99), respectively, for ≥125 vs. 0-24 patients/month.  Larger 
programme size was associated with decreased early mortality (aHR=0.49, 95% CI 
0.31-0.77 for ≥20,000 vs. <500 patients), and increased early LTFU (aHR=1.77, 95% CI 
1.04-3.04 for ≥20,000 vs. <500 patients). 
Conclusion 
As ART expands in resource-limited settings, challenges remain in improving access to 
ART and preventing programme attrition.  There is an urgent need for novel and 
sustainable models of care to increase long-term retention of patients. 
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4.2 INTRODUCTION 
Over the past decade, there has been rapid expansion of antiretroviral therapy (ART) in 
resource-limited settings.  By 2011, an estimated 9.7 million people in low- and middle-
income countries were receiving ART [24].  During this growth, HIV programs have 
adapted services to cope with the increasing numbers of patients requiring ART. As 
programs mature and increase in size, the need to ensure long-term retention in care of 
patients receiving ART while continuing timely initiation of new patients onto 
treatment presents an ongoing challenge to policy makers and health care providers 
alike.   
 
Over the past decade, the conditions in which ART programs operate in low and 
middle-income countries have changed considerably.  The numbers of patients has 
increased rapidly and often disproportionately to the number of health care workers 
providing care [204]. Guidelines for initiation of ART have been simplified and context 
specific recommendations have been adapted to facilitate improving and expanding 
access to treatment.  Furthermore, eligibility criteria for ART initiation have evolved 
and recommended CD4 cell count thresholds for treatment start have recently been 
increased to improve patient outcomes [28]. 
 
The effectiveness of ART in reducing morbidity and mortality depends on patient 
adherence to therapy and on the ability of HIV programs to retain patients in care.  
Previous analyses examining temporal trends in long-term programme outcomes in 
resource-limited settings have reported conflicting results.  While data from South 
Africa showed increasing loss to follow-up (LTFU) by calendar year of enrolment [56, 
63, 76]; systematic reviews of sub-Saharan African cohorts and findings from a large 
Kenyan cohort reported improvements in patient retention in recent years [38, 85, 
117].  Evaluating programme outcomes, assessing temporal trends in programme 
retention and investigating the factors associated with poor outcomes are essential to 
improve the long-term effectiveness of ART services in low and middle-income 
countries.  Understanding associations between programme expansion and treatment 
outcomes are particularly relevant in the context of the Treatment 2.0 initiative to 
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scale-up HIV treatment through promoting innovation and efficiency gains, and of the 
ambitious goal of expanding ART to fifteen million people by 2015 [24, 205]. 
 
The objective of this study was to describe temporal trends in patient characteristics at 
ART initiation and in ART outcomes using data from resource-limited countries where 
Médecins Sans Frontières (MSF) supports the provision of HIV treatment. We also 
examined associations between individual level risk factors, absolute programme size, 





4.3.1 Study population 
We analysed patient electronic health records from 25 sites in eight countries where 
MSF supports the provision of ART care.  Cohorts were located in Democratic Republic 
of Congo (DRC), India, Kenya, Malawi, Mozambique, Myanmar, Uganda and Zimbabwe. 
Details of these programs have been described previously [206].  All programs 
provided care and treatment free of charge. Criteria for ART initiation followed WHO 
guidelines.  The analysis included all adults aged 16 years or older who initiated ART 
between March 2001 and September 2011 in one of the programs.   
 
4.3.2 Data collection and definitions 
Characteristics at ART initiation including sex, age, CD4 cell counts, WHO clinical stage, 
body mass index (BMI), and date of ART initiation, were prospectively collected with 
the FUCHIA software (Epicentre, Paris).   Throughout, reference to baseline is a 
reference to time of ART initiation.    
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Patient follow-up began at the date of ART initiation and was censored at the earliest 
of: death, transfer out, last clinic visit, or analysis closure.  Sites began initiating 
patients onto ART between 2001 and 2007. Only patients with a minimum of 6-months 
of follow-up were included with analysis closure preceding the database closure date 
by 6-months. The database closure ranged from 30 September 2011 to 20 March 2012.  
Deaths were events recorded before the analysis closure date. Loss to follow-up was 
defined as having no visit in the 6-months before analysis closure. Patients who 
initiated treatment but did not return were given 1-day of follow-up time so that they 
would contribute to survival analysis [207]. Programme retention was defined as being 
in care (i.e., not dead or LTFU) at the time of analysis closure.     
 
To quantify the size of the ART programs two variables, programme size and the rate of 
programme expansion, were defined.  For each patient, programme size was calculated 
as the total number of both pre-ART and ART patients receiving care in the programme 
at the end of the calendar year of patient ART initiation. To define the rate of 
programme expansion, the rank of each patient enrolled by site was divided by the 
duration of ART provision in the site up to the date of enrolment, in months.   For 
example, if the one hundredth patient at the site was enrolled 4 months after the 
programme started, the rate of programme expansion for that patient would be 25 
(100/4).  
 
4.3.3 Statistical methods 
Baseline characteristics were described by year of ART initiation using medians and 
interquartile ranges for continuous variables, and proportions for categorical variables.  
Kaplan-Meier methods were used to describe cumulative probabilities of death, LTFU 
and programme retention after ART initiation and were analysed overall, by calendar 
year of ART start, programme size, and rate of expansion. 
 
Cox’s proportional hazards models were used to assess associations between baseline 
patient characteristics and outcomes. Heterogeneity across sites was accounted for 
using random effects.  To examine differences in risk factors over time, models were 
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stratified by early (0-12 months) and late (12-72 months) follow-up time periods.  
Adjusted models were built first by including all baseline characteristics (model 1), and 
then adding the programme size variable (model 2), or the rate of expansion variable 
(model 3), or both (model 4).  The primary analysis only included patients with 
complete data on baseline characteristics (complete case analysis).   
In sensitivity analyses, models including patients with missing baseline CD4 cell counts, 
clinical stage, and/or BMI as separate categories were used. We also assessed different 
measures of programme size including the number of patients who had previously 
initiated ART by site and the number of ART patients in care at each site at the end of 
the calendar year. Kaplan-Meier survival proportions and hazard ratios (HRs) stratified 
by site were assessed and compared with the primary results. Finally, to account for 
non-differential censoring (e.g. higher risk of death among patients LFTU early after 
ART start), models of time to death and LTFU were calculated using competing risks 
methods [208].     
 
Data was analysed with STATA 12.0 (STATA Corporation, College Station, Texas, USA). 
All FUCHIA sites obtained agreement from health ministries for the prospective 
collection of data.  No patient identifiers were included in datasets.  The International 
Ethics Review Board of MSF reviewed the study and determined it did not require 
formal approval.  The Human Subjects Research Ethics Committee of the Faculty of 
Health Sciences from the University of Cape Town reviewed and approved the data 




4.4.1 Characteristics at ART initiation 
Between 2001 and 2011, 132,334 individuals contributed 299,658 person-years of 
follow-up (median per patient, 1.75 years, interquartile range (IQR), 0.57-3.56).  At 
ART initiation, the median age was 35 years, 61% of patients were female, 69% had 
CD4 cell counts <200 cells/µl and less than 5% had CD4 cell counts >350 cells/µl 
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(Table 4.1).  Twenty-five percent of patients had clinical stage IV disease and a third 
had a BMI below 18.5 kg/m2. More than half of patients received treatment in Malawi 
(n=37,657) or Zimbabwe (n=30,783); Asian cohorts contributed 14% of patients.    
 
4.4.2 Temporal changes in patient baseline characteristics 
and outcomes 
The number of patients initiating ART increased substantially each calendar year 
(Table 4.2), from 4,427 in 2001-2003 to 22,863 in 2010.  Median age was 35 years and 
remained constant over time.  Median CD4 cell count increased over time from 97 in 
2003 or earlier to 184 cells/µl in 2011 (Supplementary Figure 4.1).  However, every 
year approximately 30% of patients initiated ART with a CD4 cell count <100 cells/µl 
(Supplementary Figure 4.2); the range across countries being 22-48%.  The proportion 
of patients with clinical stage IV disease at the time of ART initiation decreased from 
44% to 14%.  
 
Mortality decreased over the study period (Figure 4.1A), from 17% to 5% at 12 
months; and from 22% to 9% at 36 months (Table 4.3). Larger programs (Figure 4.1C) 
and those with greater rate of expansion (Figure 4.1D) had lower rates of mortality 
(Supplementary Table 1).  In contrast, LTFU increased substantially over time, from 6% 
to 15% at 12 months; and from 11% to 21% at 36 months (Figure 4.1B).  LTFU 
increased with programme size up to a number of 7 500 patients (Figure 4.1D). 
Programme retention was highest between 2006 and 2009. Trends in outcomes were 
homogeneous across sites (Supplementary Figure 4.3 and 4.4).  
 
The contribution of LTFU to overall programme attrition increased with duration of 
ART (Supplementary Figure 4.4).  During the first year of treatment, approximately half 
of the programme losses were LTFU (6% of patients had died compared to 8% who 
were LTFU). However, after five years, two thirds of the losses were LTFU patients 
(24% compared to 13% of deaths).  Programme retention decreased from 82% at 12 
months, to 73% at 36 months and 66% at 60 months.  The smallest programs had the 
largest estimates of 12-month mortality: 12%, 11% and 9% in sites with less than 500, 
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500-999 and 1 000-2,499 people, respectively.  However, 12 month LTFU was largest 
in medium size programs.  Similarly, programs with a slow rate of expansion had 
double the risk of 12-month mortality compared to those with the fastest expansion 
(10.0% vs. 5.3%).  LTFU was lowest in programs with a slow rate of expansion 
compared to those with medium or fast expansion (Figure 4.1F).   
 
4.4.3 Risk factors for mortality 
The risk of death decreased with each successive calendar year of enrolment (Table 
4.3).  After adjusting for programme size and rate of expansion this association was 
only seen for the 0-12 month period and up to 2007 (aHR=0.76, 95%CI 0.61-0.95 for 
2007; and aHR=1.00, 95% CI 0.76-1.33, for 0-12 months, and aHR=1.21, 95% CI 0.73-
2.00, for 12-72 months, vs. ≤2003). 
 
Larger programme size was associated with decreased early mortality (aHR=0.49, 95% 
CI 0.31-0.77, for ≥20,000 vs. <500 patients). This association was not significant for late 
mortality (aHR=0.34, 95% CI 0.09-1.27). Fully adjusted models did not show evidence 
of association between rate of expansion and early or late mortality (aHR=1.13, 95%CI 
0.87-1.48, and aHR=0.85, 95%CI 0.55-1.31, respectively, for ≥125 vs. <25 
patients/month). 
 
Increased early and late mortalities were associated with male gender (aHR=1.30, and 
1.57, respectively, for male vs. female), older age (aHR=1.46, and 1.48, respectively, for 
≥45 vs. 16-25 years), and low BMI (aHR=2.59, and 1.56, respectively, for ≤18.5 vs. 18.6-
25.0 kg/m2). Death was also strongly associated with advanced clinical stage and lower 
CD4 cell count level, with the strongest associations observed with early mortality 
(aHR=2.65 for stage IV vs. stages II or II; and aHR=0.29, 0.26-0.32 for 200-349 CD4 
cells/µl vs. <25 CD4 cells/µl).  
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Table 4.1 Patient characteristics at ART initiation 
Characteristics 
No. of patients 
N=132,334 
Sex, n (%) 
Females 80,456 (60.8) 
Age (years), median [IQR] 35.0 [29.4-42.0] 
Age group, n (%) 
16-25 11,840 (9.0) 
25-34 53,332 (40.3) 
35-44 42,894 (32.4) 
45+ 24,268 (18.3) 
CD4 cell count (cell/µL) n=103,197 (78.0) 
Median (IQR) 142 [63-220] 
CD4 categorical, n (%) 
<25 10,890 (10.6) 
25-49 10,054 (9.7) 
50-99 16,826 (16.3) 
100-149 16,220 (15.7) 
150-199 17,253 (16.7) 
200-349 27,484 (26.6) 
350 4,470 (4.3) 
WHO stage, n(%) n=129,859 (98.1) 
I and II 41,105 (31.7) 
III 56,619 (43.6) 
IV 32,135 (24.8) 
BMI group (kg/m2), n (%) n=121,809 (92.0) 
Underweight (18.5) 40,122 (32.9) 
Normal (18.6-25.0) 72,217 (59.3) 
Overweight (25.1-30.0) 7,727 (6.4) 
Obese (>30.0) 1,733 (1.4) 
Country, n (%) 
DRC 4,140 (3.1) 
India 1,526 (1.2) 
Kenya 19,353 (14.6) 
Malawi 37,657 (28.5) 
Mozambique 12,492 (9.4) 
Myanmar 16,784 (12.7) 
Uganda 9,599 (7.3) 
Zimbabwe 30,783 (23.3) 
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Table 4.2 Baseline characteristics and 6-, 12- and 36-month Kaplan-Meier 
cumulative mortality, loss to follow-up and overall programme retention 
stratified by calendar year of ART initiation 
 











Age (years), median [IQR] 34.7 [29.4-41.1] 35.1 [29.4-42.1] 35.0 [29.5-41.9] 34.9 [29.4-41.8] 35.0 [29.8-42.1] 
CD4 cell count  
(cell/µl), median [IQR] 
97 [42-162] 114 [51-178] 116 [50-182] 112 [48-189] 132 [58-205] 
WHO stage IV, n(%)  1 914 (44.4) 3 659 (44.3) 4 276 (40.3) 5 254 (35.0) 5 266 (27.0) 
Underweight, n(%) 1 567 (38.9) 2 672 (27.9) 3 744 (38.5) 5 470 (38 2) 6 254 (33.3) 
Cumulative mortality,  
(95% CI) 
     
6-month 14.1 (13.1-15.2) 9.3 (8.7-9.9) 8.1 (7.6-8.6) 8.0 (7.6-8.5) 5.4 (5.1-5.7) 
12-month 17.3 (16.2-18.5) 11.8 (11.1-12.6) 10.2 (0.6-10.8) 9.9 (9.4-10.4) 6.8 (6.4-7.2) 
36-month 21.5 (20.3-22.8) 15.4 (14.6-16.3) 13.7 (13.0-14.4) 12.8 (12.2-13.3) 9.5 (9.1-10.0) 
Cumulative LTFU,  
(95% CI) 
     
6-month 4.0 (3.4-4.6) 6.9 (6.4-7.5) 6.2 (5.8-6.7) 5.9 (5.5-6.3) 7.6 (7.2-8.0) 
12-month 5.9 (5.2-6.7) 9.3 (8.7-9.9) 8.9 (8.4-9.5) 8.1 (7.7-8.5) 10.3 (9.8-10.7) 
36-month 11.4 (10.4-12.5) 16.3 (15.5-17.2) 14.6 (13.9-15.3) 14.6 (14.0-15.2) 17.1 (16.6-17.7) 
Cumulative programme  
retention in care, (95% CI) 
     
6-month 82.4 (81.3-83.5) 84.5 (83.7-85.2) 86.2 (85.6-86.9) 86.6 (86.0-87.1) 87.4 (87.0-87.9) 
12-month 77.8 (76.6-79.0) 80.0 (79.1-80.8) 81.8 (81.1-82.5) 82.8 (82.2-83.4) 83.6 (83.1-84.2) 
36-month 69.6 (68.2-70.9) 70.8 (69.8-71.7) 73.8 (72.9-74.6) 74.5 (73.8-75.2) 75.0 (74.4-75.6) 
 









Age (years), median [IQR] 35.1 [29.4-42.1] 35.1 [29.3-42.0] 35.0 [29.3-42.0] 35.0 [29.4-42.0] 
CD4 cell count  
(cell/µl), median [IQR] 
150 [72-221] 155 [74-224] 171 [80-248] 184 [77-276] 
WHO stage IV, n(%)  3 814 (20.7) 3 253 (17.0) 3 030 (13.4) 1 669 (14.0) 
Underweight, n(%) 5 594 (31.5) 5 703 (31.3) 5 785 (27.7) 3 333 (30.1) 
,Cumulative mortality,  
(95% CI) 
    
6-month 5.2 (4.9-5.5) 4.5 (4.2-4.8) 4.1 (3.8-4.3) 3.7 (3.3-4.2) 
12-month 6.5 (6.1-6.9) 5.6 (5.2-5.9) 5.1 (4.8-5.4) - 
36-month 8.8 (8.4-9.2) - - - 
Cumulative LTFU,  
(95% CI) 
    
6-month 8.4 (8.0-8.8) 7.3 (7.0-7.7) 9.2 (8.8-9.6) 11.3 (10.4-12.2) 
12-month 11.5 (11.0-11.9) 10.3 (9.9-10.7) 14.6 (14.1-15.2) - 
36-month 21.2 (20.5-21.8) - - - 
Cumulative programme  
retention in care, (95% CI) 
    
6-month 86.8 (86.3-87.3) 88.5 (88.1-89.0) 87.1 (87.7-87.6) 85.5 (84.5-86.4) 
12-month 82.8 (82.2-83.3) 84.7 (84.2-85.2) 81.0 (80.5-81.6) - 







Figure 4.1 Cumulative probability of death and LTFU stratified by year of ART 
initiation, programme size, or rate of expansion 
 
1A) Mortality by year of ART initiation  1B) LTFU by year of ART initiation 
 
1C) Mortality by programme size  1D) LTFU by programme size 
 




4.4.4 Risk factors for lost to follow-up 
Increased risk of early and late LTFU was observed with each successive calendar year 
of ART initiation (Table 4.4).  Adjusted hazard ratios for early LFTU increased from 
1.09 (95%CI 0.83-1.43) in 2004 to 3.29 (95%CI 2.42-4.46) in 2011, compared to the 
2001-2003 period; and adjusted hazard ratio for late LTFU from 1.04 (95%CI 0.84-
1.28) to 6.86 (95%CI 4.94-9.53), respectively. Larger programme size was associated 
with a 7-fold increase in the risk of early  (HR 7.35, 95% CI 5.55-9.73) and late LTFU 
(HR 7.03, 95% CI 4.30-11.48) but the association in final models attenuated for early 
LTFU (aHR 1.77, 95% CI 1.04-3.04) and was not observed for late LTFU (aHR 0.53, 95% 
CI 0.27-1.04).   Rate of programme expansion was strongly associated with an 
increased risk of early and late LTFU (early aHR increased from 1.26 in programs with 
rates of 25-59 patients/month to 2.31 in those with ≥125 patients/month; and late aHR 
from 1.22 to 2.29 compared to programs with rates of 0-24 patients/month 
respectively).  Late LTFU was only higher among patients who received treatment in 
programs with 500-4,999 HIV patients in care (aHR=1.34, 95%CI 1.00-1.80 for 2,500-
4,999 vs. <500 programme size).  
 
Male gender (aHR=1.25 and 1.21, for early and late periods), younger age (aHR=0.58 
and 0.48, respectively, for ≥45 vs. 16-25 years) and advanced clinical stage (aHR=1.56 
and 1.28, respectively, for stage 4 vs. stages 1 or 2) were also associated with an 
increased risk of LTFU.  Patients with a CD4 cell count of less than 25 cells/µl had a 
higher risk of early LTFU (adjusted hazard ratio decreased from 0.89 among patients 
with 25-49 cells/µl to 0.60 among those with 200-349 cells/µl). No association 
between CD4 cell count and late LTFU was observed.    
 
Sensitivity analyses including patients with missing data (Supplementary Tables 4.2 
and 4.3) and stratification by site provided similar results.  Estimates from competing 
risks models were slightly reduced but did not change results appreciably 
(Supplementary Tables 4.4 and 4.5).   
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Table 4.3 Cox proportional hazards estimates of mortality by baseline 
characteristics and year of ART initiation, adjusted by cohort* 
0-12 months 
Univariate 
HR (95% CI) 
Model 1 
(n=94,571) 
HR (95% CI) 
Model 2 
(n=94,571) 
HR (95% CI) 
Model 3 
(n=94,571) 
HR (95% CI) 
Model 4 
(n=94,571) 
HR (95% CI) 
Year of ART initiation  
2003 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2004 0.67 (0.61-0.74) 0.67 (0.58-0.78) 0.74 (0.62-0.88) 0.75 (0.64-0.87) 0.78 (0.65-0.94) 
2005 0.53 (0.48-0.58) 0.62 (0.54-0.71) 0.77 (0.64-0.94) 0.75 (0.64-0.88) 0.82 (0.65-0.94) 
2006 0.51 (0.47-0.56) 0.61 (0.54-0.69) 0.77 (0.64-0.93) 0.76 (0.65-0.89) 0.80 (0.66-0.97) 
2007 0.36 (0.33-0.40) 0.47 (0.42-0.53) 0.71 (0.57-0.88) 0.60 (0.51-0.71) 0.76 (0.61-0.95) 
2008 0.34 (0.31-0.38) 0.55 (0.48-0.62) 0.85 (0.68-1.07)  0.72 (0.60-0.86) 0.91 (0.72-1.14) 
2009 0.29 (0.26-0.32) 0.54 (0.48-0.61) 0.94 (0.74-1.19)  0.71 (0.59-0.85) 0.98 (0.77-1.26) 
2010 0.27 (0.24-0.29) 0.58 (0.51-0.65) 0.95 (0.74-1.21) 0.76 (0.63-0.91) 1.00 (0.78-1.29) 
2011 0.28 (0.24-0.32) 0.60 (0.50-0.71) 0.95 (0.72-1.25) 0.78 (0.63-0.97) 1.00 (0.76-1.33) 
Programme size (patients) 
<500 1.0 (ref) 1.0 (ref) 1.0 (ref) 
500-999 0.90 (0.79-1.03) 1.19 (0.98-1.45) 1.15 (0.94-1.40) 
1,000-2,499 0.64 (0.57-0.72) 1.17 (0.95-1.42) 1.14 (0.94-1.40) 
2,500-4,999 0.51 (0.45-0.57) 0.99 (0.78-1.24) 0.97 (0.77-1.24) 
5,000-7,499 0.31 (0.27-0.35) 0.65 (0.49-0.86) 0.61 (0.45-0.82) 
7,500 – 9,999 0.26 (0.23-0.30) 0.57 (0.42-0.76) 0.48 (0.34-0.68) 
10,000-14,999 0.22 (0.19-0.25) 0.75 (0.54-1.03) 0.61 (0.41-0.90)  
15,000-19,999 0.15 (0.12-0.18) 0.50 (0.34-0.73) 0.41 (0.26-0.63) 
≥20,000 0.18 (0.15-0.22) 0.61 (0.41-0.89) 0.49 (0.31-0.77) 
Rate of expansion (patients/month) 
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-59 0.64 (0.59-0.69) 0.93 (0.83-1.04) 0.93 (0.83-1.05) 
60-89 0.43 (0.40-0.47) 0.75 (0.64-0.87) 0.88 (0.74-1.04) 
90-124 0.37 (0.34-0.41) 0.75 (0.63-0.89) 1.06 (0.86-1.30) 
≥125 0.21 (0.20-0.24) 0.70 (0.58-0.85) 1.13 (0.87-1.48) 
Sex  
Female 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Male 1.61 (1.54-1.68) 1.29 (1.22-1.36) 1.30 (1.23-1.37) 1.29 (1.22-1.37) 1.30 (1.22-1.37) 
Age group (years) 
16-25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-34 1.07 (0.99-1.17) 1.11 (0.99-1.25) 1.10 (0.99-1.23) 1.11 (0.99-1.24) 1.10 (0.99-1.23) 
35-44 1.16 (1.07-1.26) 1.18 (1.05-1.32) 1.16 (1.04-1.31) 1.17 (1.05-1.32) 1.17 (1.04-1.31) 
45+ 1.33 (1.22-1.46) 1.48 (1.31-1.67) 1.46 (1.29-1.65) 1.47 (1.31-1.66) 1.46 (1.29-1.65) 
Body Mass Index  
Underweight 3.65 (3.47-3.83) 2.58 (2.43-2.74) 2.60 (2.45-2.76) 2.58 (2.43-2.74) 2.59 (2.44-2.75) 
Normal 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Overweight 0.59 (0.50-0.69) 0.75 (0.62-0.90) 0.74 (0.61-0.90) 0.75 (0.62-0.90) 0.74 (0.61-0.90) 
Obese 0.88 (0.67-1.17) 1.23 (0.90-1.69) 1.22 (0.88-1.67) 1.24 (0.90-1.71) 1.22 (0.89-1.68) 
CD4 cell count (cells/μl)  
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-49 0.61 (0.57-0.66) 0.71 (0.65-0.78) 0.71 (0.65-0.78) 0.71 (0.65-0.78) 0.71 (0.65-0.78) 
50-99 0.39 (0.36-0.42) 0.52 (0.48-0.56) 0.52 (0.48-0.56) 0.52 (0.48-0.560 0.52 (0.48-0.56) 
100-149 0.26 (0.24-0.28) 0.41 (0.37-0.45) 0.41 (0.37-0.45) 0.41 (0.37-0.45) 0.41 (0.37-0.45) 
150-199 0.19 (0.18-0.21) 0.35 (0.31-0.39) 0.35 (0.31-0.39) 0.35 (0.31-0.39) 0.35 (0.31-0.39) 
200-349 0.15 (0.13-0.16) 0.29 (0.26-0.32) 0.29 (0.26-0.32) 0.29 (0.26-0.32) 0.29 (0.26-0.32) 
≥350 0.24 (0.21-0.28) 0.42 (0.36-0.49) 0.43 (0.36-0.50) 0.42 (0.36-0.49) 0.42 (0.36-0.49) 
Clinical stage  
1 and 2 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
3 2.60 (2.42-2.79 1.65 (1.51-1.80) 1.61 (1.47-1.76) 1.54 (1.50-1.79) 1.61 (1.47-1.76) 
4 5.70 (5.31-6.11) 2.73 (0.48-2.99) 2.65 (2.41-2.91) 2.69 (2.45-2.96) 2.65 (2.41-2.92) 
* All models accounted for site heterogeneity using random effects. Model 1 – demographics and baseline variables, Model 2 - 
Model 1 + programme size, Model 3 – Model 1 + rate of expansion, Model 4 – Model 1 + programme size and rate of expansion 
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Table 4.3 (continued) Cox proportional hazards estimates of mortality by 
baseline characteristics and year of ART initiation, adjusted by cohort. * 
 
 12-72 months 
 Univariate 
 
HR (95% CI) 
Model 1 
(n=62,080) 
HR (95% CI) 
Model 2 
(n=62,080) 
HR (95% CI) 
Model 3 
(n=62,080) 
HR (95% CI) 
Model 4 
(n=62,080) 
HR (95% CI) 
Year of ART initiation     
2003 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2004 0.77 (0.66-0.91) 0.78 (0.63-0.97) 0.85 (0.66-1.09) 0.88 (0.70-1.10) 0.87 (0.68-1.13) 
2005 0.69 (0.59-0.81) 0.72 (0.58-0.88) 0.84 (0.64-1.11) 0.82 (0.65-1.04) 0.85 (0.64-1.11) 
2006 0.58 (0.50-0.68) 0.63 (0.52-0.77) 0.75 (0.57-0.98) 0.74 (0.58-0.94) 0.75 (0.57-0.99) 
2007 0.53 (0.46-0.62) 0.64 (0.53-0.78 0.75 (0.55-1.03) 0.76 (0.59-0.98) 0.76 (0.55-1.04) 
2008 0.46 (0.38-0.54) 0.58 (0.47-0.72) 0.69 (0.49-0.97) 0.71 (0.53-0.99) 0.72 (0.51-1.01) 
2009 0.43 (0.35-0.52) 0.60 (0.47-0.76) 0.73 (0.50-1.06) 0.72 (0.53-0.99) 0.74 (0.51-1.08) 
2010 0.50 (0.35-0.72) 0.83 (0.56-1.23) 1.19 (0.72-1.96) 1.01 (0.65-1.56) 1.21 (0.73-2.00) 
2011 - - - - - 
Programme size (patients)    
<500 1.0 (ref)  1.0 (ref)  1.0 (ref) 
500-999 0.83 (0.69-1.00)  0.99 (0.77-1.27)  0.99 (0.77-1.27) 
1,000-2,499 0.77 (0.65-0.91)  1.07 (0.83-1.39)  1.08 (0.83-1.40) 
2,500-4,999 0.59 (0.49-0.71)  0.84 (0.62-1.14)  0.87 (0.63-1.21) 
5,000-7,499 0.42 (0.34-0.52)  0.75 (0.51-1.11)  0.76 (0.50-1.16) 
7,500 – 9,999 0.38 (0.29-0.51)  0.70 (0.44-1.10)  0.72 (0.42-1.22) 
10,000-14,999 0.42 (0.33-0.54)  0.95 (0.59-1.53)  1.02 (0.59-1.77) 
15,000-19,999 0.35 (0.25-0.50)  0.88 (0.49-1.57)  1.00 (0.51-1.96) 
≥20,000 0.18 (0.06-0.55)  0.29 (0.08-1.06)  0.34 (0.09-1.27) 
Rate of expansion (patients/month)    
<25 1.0 (ref)    1.0 (ref) 1.0 (ref) 
25-59 0.74 (0.65-0.84)   0.89 (0.75-1.05) 0.93 (0.78-1.10) 
60-89 0.56 (0.49-0.65)   0.75 (0.61-0.93) 0.87 (0.68-1.12) 
90-124 0.52 (0.45-0.61)   0.84 (0.65-1.08) 1.02 (0.74-1.40) 
≥125 0.39  (0.32-0.47)   0.74 (0.54-1.02) 0.85 (0.55-1.31) 
Sex      
Female 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Male 1.77  (1.64-1.91) 1.57 (1.42-1.73) 1.57 (1.42-1.73) 1.57 (1.42-1.73) 1.57 (1.42-1.73) 
Age group (years)      
16-25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-34 0.94 (0.81-1.09) 0.85 (0.70-1.03) 0.85 (0.70-1.02) 0.85 (0.70-1.03) 0.85 (0.70-1.02) 
35-44 1.10 (0.92-1.27) 0.99 (0.82-1.20) 0.99 (0.81-1.20) 0.99 (0.81-1.20) 0.99 (0.81-1.20) 
45+ 1.66 (1.42-1.95) 1.49 (1.22-1.82) 1.48 (1.21-1.81) 1.49 (1.22-1.82) 1.48 (1.21-1.82) 
Body Mass Index       
Underweight 1.67 (1.54-1.82) 1.57 (1.42-1.73) 1.57 (1.42-1.74) 1.56 (1.31-1.73) 1.56 (1.41-1.73) 
Normal 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Overweight 0.85 (0.69-1.03) 1.01 (0.80-1.27) 1.01 (0.80-1.27) 1.01 (0.80-1.28) 1.01 (0.80-1.28) 
Obese 0.93 (0.62-1.39) 0.76 (0.43-1.34) 0.76 (0.43-1.34) 0.77 (0.43-1.36) 0.76 (0.43-1.35) 
CD4 cell count (cells/μl)      
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-49 0.93 (0.78-1.10) 0.98 (0.82-1.18) 0.98 (0.81-1.18) 0.98 (0.82-1.18) 0.98 (0.81-1.18) 
50-99 0.86 (0.72-1.00) 1.00 (0.85-1.18) 1.00 (0.85-1.18) 1.00 (0.85-1.18) 1.00 (0.84-1.18) 
100-149 0.63 (0.54-0.75) 0.79 (0.66-0.95) 0.79 (0.66-0.95) 0.80 (0.67-0.95) 0.79 (0.66-0.95) 
150-199 0.65 (0.55-0.76) 0.89 (0.74-1.07) 0.89 (0.74-1.06) 0.90 (0.75-1.07) 0.89 (0.74-1.06) 
200-349 0.52 (0.44-0.61) 0.74 (0.62-0.89) 0.74 (0.62-0.88) 0.75 (0.62-0.89)  0.74 (0.62-0.89) 
≥350 0.78 (0.60-1.03) 0.98 (0.72-1.33) 0.98 (0.72-1.34) 0.98 (0.72-1.33) 0.98 (0.72-1.33) 
WHO stage      
I and II 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
III 1.54 (1.38-1.73) 1.20 (1.05-1.38) 1.19 (1.04-1.37) 1.19 (1.04-1.37) 1.19 (1.03-1.36) 
IV 2.26 (2.01-2.53) 1.54 (1.32-1.79) 1.51 (1.30-1.76) 1.52 (1.31-1.76) 1.51 (1.30-1.75) 
* All models accounted for site heterogeneity using random effects. Model 1 – demographics and baseline variables, Model 2 - 
Model 1 + programme size, Model 3 – Model 1 + rate of expansion, Model 4 – Model 1 + programme size and rate of expansion 
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Table 4.4 Cox proportional hazards estimates of LTFU by baseline characteristics 
and year of ART initiation, adjusted by cohort* 
 
 0-12 months 
 Univariate 
 
HR (95% CI) 
Model 1 
(n=94,571) 
HR (95% CI) 
Model 2 
(n=94,571) 
HR (95% CI) 
Model 3 
(n=94,571) 
HR (95% CI) 
Model 4 
(n=94,571) 
HR (95% CI) 
Year of ART initiation      
2003 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2004 1.62 (1.40-1.88) 1.52 (1.22-1.90) 1.06 (0.81-1.39) 1.36 (1.08-1.72) 1.09 (0.83-1.43) 
2005 1.69 (1.46-1.95) 1.99 (1.61-2.45) 1.34 (1.03-1.76) 1.74 (1.39-2.18) 1.37 (1.04-1.80) 
2006 1.62 (1.41-1.86) 2.18 (1.79-2.66) 1.54 (1.19-1.98) 1.80 (1.43-2.26) 1.43 (1.09-1.88) 
2007 2.04 (1.78-2.34) 3.25 (2.68-3.93) 2.25 (1.71-2.96) 2.60 (2.07-3.26) 2.19 (1.64-2.93) 
2008 2.26 (1.98-2.59) 3.58 (2.95-4.33) 2.43 (1.83-3.21) 2.66 (2.10-3.35) 2.31 (1.72-3.09) 
2009 2.14 (1.87-2.45) 3.58 (2.95-4.34) 2.37 (1.77-3.16) 2.52 (2.00-3.19) 2.14 (1.58-2.89) 
2010 2.99 (2.62-3.42) 5.46 (4.51-6.61) 3.52 (2.62-4.72) 3.74 (2.96-4.73) 3.29 (2.42-4.46) 
2011 3.64 (3.15-4.21) 6.17 (5.03-7.56) 3.61 (2.65-4.92) 4.06 (3.17-5.19) 3.51 (2.55-4.83) 
Programme size (patients)     
<500 1.0 (ref)  1.0 (ref)  1.0 (ref) 
500-999 1.71 (1.29-2.26)  2.01 (1.32-3.06)  1.86 (1.23-2.82) 
1,000-2,499 3.02 (2.33-3.92)  2.66 (1.75-4.05)  2.36 (1.55-3.58) 
2,500-4,999 3.29 (2.54-4.27)  2.80 (1.81-4.32)  2.29 (1.48-3.55) 
5,000-7,499 4.36 (3.36-5.67)  2.54 (1.61-4.00)  1.97 (1.24-3.10) 
7,500 – 9,999 4.60 (3.53-5.99)  2.72 (1.72-4.32)  1.67 (1.04-2.69) 
10,000-14,999 6.17 (4.73-8.04)  4.07 (2.53-6.53)  2.02 (1.22-3.34) 
15,000-19,999 5.97 (4.49-7.93)  4.52 (2.73-7.47)  2.27 (1.34-3.87) 
≥20,000 7.35 (5.55-9.73)  3.66 (2.20-6.10)  1.77 (1.04-3.04) 
Rate of expansion (patients/month)     
<25 1.0 (ref)   1.0 (ref) 1.0 (ref) 
25-59 1.57 (1.41-1.75)   1.36 (1.16-1.60) 1.26 (1.07-1.49) 
60-89 1.94 (1.73-2.18)   1.39 (1.14-1.69) 1.36 (1.10-1.67) 
90-124 2.16 (1.92-2.4)   1.61 (1.31-1.98) 1.70 (1.35-2.14) 
≥125 3.09 (2.74-3.48)   2.21 (1.78-2.75) 2.31 (1.78-3.01) 
Sex      
Female 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Male 1.31 (1.27-1.36) 1.26 (1.20-1.32) 1.26 (1.20-1.32) 1.25 (1.19-1.31) 1.25 (1.2-1.31) 
Age group (years)      
16-25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-34 0.72 (0.69-0.76) 0.72 (0.67-0.77) 0.72 (0.67-0.77) 0.72 (0.67-0.77) 0.72 (0.67-0.77) 
35-44 0.60 (0.57-0.64) 0.60 (0.55-0.64) 0.59 (0.55-0.64) 0.60 (0.55-0.64) 0.59 (0.55-0.64) 
45+ 0.60 (0.56-0.64) 0.58 (0.53-0.63) 0.58 (0.53-0.63) 0.58 (0.53-0.63) 0.58 (0.53-0.63) 
Body Mass Index       
Underweight 1.70 (1.63-1.77) 1.53 (1.45-1.60) 1.52 (1.45-1.59) 1.52 (1.45-1.60) 1.52 (1.45-1.60) 
Normal 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Overweight 0.91 (0.83-0.99) 0.93 (0.84-1.03) 0.93 (0.84-1.03) 0.93 (0.84-1.03) 0.93 (0.83-1.03) 
Obese 1.21 (0.96-1.31) 1.14 (0.94-1.39) 1.14 (0.94-1.39) 1.14 (0.94-1.39) 1.14 (0.93-1.38) 
CD4 cell count (cells/μl)     
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-49 0.81 (0.74-0.87) 0.89 (0.82-0.97) 0.88 (0.81-0.97) 0.89 (0.81-0.97) 0.89 (0.81-0.97) 
50-99 0.61 (0.57-0.66) 0.73 (0.67-0.79) 0.72 (0.66-0.78) 0.72 (0.67-0.78) 0.72 (0.66-0.78) 
100-149 0.56 (0.52-0.60) 0.70 (0.64-0.76) 0.69 (0.66-0.78) 0.69 (0.64-0.75) 0.69 (0.64-0.75) 
150-199 0.47 (0.44-0.51) 0.60 (0.55-0.66) 0.60 (0.64-0.75) 0.60 (0.55-0.65) 0.59 (0.55-0.65) 
200-349 0.51 (0.48-0.55) 0.60 (0.56-0.66) 0.60 (0.55-0.65) 0.60 (0.56-0.65) 0.60 (0.55-0.65) 
≥350 0.78 (0.71-0.87) 0.76 (0.68-086) 0.77 (0.68-0.86) 0.77 (0.68-0.86) 0.77 (0.68-0.86) 
Clinical stage      
1 and 2 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
3 1.10 (1.05-1.14) 1.15 (1.09-1.22) 1.17 (1.11-1.24) 1.17 (1.11-1.24) 1.17 (1.10-1.23) 
4 1.51 (1.44-1.59) 1.52 (1.42-1.62) 1.55 (1.45-1.65) 1.56 (1.46-1.67) 1.56 (1.46-1.66) 
* All models accounted for site heterogeneity using random effects. Model 1 – demographics and baseline variables, Model 2 - 
Model 1 + programme size, Model 3 – Model 1 + rate of expansion, Model 4 – Model 1 + programme size and rate of expansion 
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Table 4.4 (continued) Cox proportional hazards estimates of LTFU by baseline 
characteristics and year of ART initiation, adjusted by cohort* 
 
 12-72 months 
 Univariate 
 
HR (95% CI) 
Model 1 
(n=62 ,080) 
HR (95% CI) 
Model 2 
(n=62,080) 
HR (95% CI) 
Model 3 
(n=62,080) 
HR (95% CI) 
Model 4 
(n=62,080) 
HR (95% CI) 
Year of ART initiation     
2003 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2004 1.31 (1.16-1.49) 1.19 (1.02-1.40) 1.03 (0.84-1.27) 1.09 (0.92-1.29) 1.04 (0.84-1.28) 
2005 1.19 (1.05-1.35) 1.20 (1.03-1.40) 1.03 (0.83-1.28) 1.00 (0.85-1.19) 0.94 (0.76-1.17) 
2006 1.47 (1.31-1.66) 1.67 (1.44-1.93) 1.45 (1.18-1.80) 1.27 (1.07-1.51) 1.17 (0.94-1.46) 
2007 1.82 (1.62-2.05) 2.37 (2.05-2.74) 2.19 (1.72-2.80) 1.76 (1.47-2.11) 1.83 (0.94-1.46) 
2008 2.44 (2.15-2.75) 3.30 (2.83-3.84) 3.02 (2.34-3.89) 2.33 (1.92-2.83) 2.48 (1.91-3.23) 
2009 3.60 (3.16-4.10) 4.71 (4.01-5.53) 4.54 (3.46-5.95) 3.26 (2.65-4.01) 3.58 (2.70-4.75) 
2010 6.50 (5.45-7.76) 8.47 (6.92-10.53) 8.50 (6.18-11.68) 5.94 (4.62-7.46) 6.86 (4.94-9.53) 
2011 - - - - - 
Programme size (patients)    
<500 1.0 (ref)  1.0 (ref)  1.0 (ref) 
500-999 1.64 (1.34-2.00)  1.45 (1.13-1.85)  1.40 (1.09-1.79) 
1,000-2,499 2.35 (1.94-2.86)  1.55 (1.19-2.02)  1.44 (1.10-1.88) 
2,500-4,999 2.66 (2.19-3.22)  1.64 (1.23-2.18)  1.34 (1.00-1.80) 
5,000-7,499 3.80 (3.11-4.65)  1.39 (1.00-1.92)  1.03 (0.74-1.43) 
7,500 – 9,999 5.47 (4.42-6.77)  1.44 (1.02-2.03)  0.83 (0.57-1.20) 
10,000-14,999 4.06 (3.22-5.12)  1.34 (0.90-1.99)  0.83 (0.54-1.27) 
15,000-19,999 4.89 (3.69-6.48)  1.11 (0.71-1.74)  0.74 (0.46-1.19) 
≥20,000 7.03 (4.30-11.48)  0.81 (0.42-1.57)  0.53 (0.27-1.04) 
Rate of expansion (patients/month)    
<25 1.0 (ref)    1.0 (ref) 1.0 (ref) 
25-59 1.48 (1.33-1.64)   1.24 (1.08-1.41) 1.22 (1.06-1.39) 
60-89 1.96 (1.75-2.18)   1.43 (1.21-1.68) 1.56 (1.31-1.85) 
90-124 2.79 (2.48-3.14)   1.86 (1.55-2.23) 2.22 (1.81-2.72) 
≥125 3.72 (3.25-4.27)   1.65 (1.33-2.05) 2.29 (1.76-2.99) 
Sex      
Female 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Male 1.16 (1.11-1.21) 1.21 (1.14-1.28) 1.21 (1.15-1.28) 1.21 (1.14-1.28) 1.21 (1.15-1.29) 
Age group (years)      
16-25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-34 0.63 (0.59-0.67) 0.66 (0.60-0.72) 0.66 (0.60-0.72) 0.66 (0.60-0.72) 0.66 (0.60-0.72) 
35-44 0.50 (0.47-0.54) 0.51 (0.46-0.56) 0.51 (0.46-0.56) 0.51 (0.46-0.56) 0.51 (0.46-0.56) 
45+ 0.51 (0.47-0.56) 0.49 (0.44-0.54) 0.49 (0.44-0.54) 0.49 (0.44-0.54) 0.48 (0.44-0.54) 
Body Mass Index       
Underweight 1.12 (1.07-1.18) 1.06 (1.00-1.13) 1.07 (1.00-1.13) 1.06 (1.00-1.13) 1.07 (1.00-1.13) 
Normal 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Overweight 0.99 (0.90-1.109) 1.08 (0.96-1.20) 1.08 (0.96-1.20) 1.08 (0.97-1.21) 1.08 (0.97-1.21) 
Obese 0.86 (0.70-1.07) 0.98 (0.77-1.25) 0.98 (0.76-1.25) 0.98 (0.76-1.25) 0.97 (0.76-1.25) 
CD4 cell count (cells/μl)      
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-49 0.93 (0.84-1.04) 0.98 (0.8-1.10) 0.99 (0.88-1.11) 0.98 (0.88-1.10) 0.99 (0.88-1.11) 
50-99 0.87 (0.79-0.95) 0.95 (0.85-1.05) 0.95 (0.86-1.05) 0.94 (0.85-1.04) 0.95 (0.85-1.05) 
100-149 0.85 (0.77-0.94) 0.97 (0.88-1.08) 0.98 (0.88-1.08) 0.97 (0.87-1.07) 0.97 (0.88-1.08) 
150-199 0.88 (0.80-0.97) 0.98 (0.88-1.09) 0.98 (0.89-1.09) 0.97 (0.88-1.08) 0.98 (0.88-1.09) 
200-349 0.92 (0.84-1.01) 0.91 (0.82-1.01) 0.92 (0.83-1.02) 0.91 (0.82-1.01) 0.92 (0.83-1.02) 
≥350 1.13 (0.96-1.32) 1.07 (0.91-1.27) 1.09 (0.92-1.29) 1.05 (0.89-1.25) 1.05 (0.89-1.25) 
WHO stage      
I and II 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
III 1.05 (0.99-1.11) 1.21 (1.13-1.30) 1.21 (1.13-1.29) 1.20 (1.12-1.28) 1.18 (1.10-1.27) 
IV 1.11 (1.04-1.18) 1.29 (1.19-1.40) 1.29 (1.19-1.40) 1.29 (1.19-1.40) 1.28 (1.18-1.39) 
* All models accounted for site heterogeneity using random effects. Model 1 – demographics and baseline variables, Model 2 - 





This multicentre cohort study included over 130,000 HIV-infected patients initiated on 
ART in 8 low and middle-income countries where the provision of ART has rapidly 
expanded over the last 10-years.  In this challenging context where programs needed to 
adapt to the growing numbers of patients in need for care, we observed a gradual 
improvement in measures of disease severity at ART initiation and a decrease in 
mortality over time.  Despite these findings, every year 30% of the total number of 
patients who initiated ART had CD4 cell counts less than 100 cells/µl.  Furthermore, 
twelve, 24 and 36-month LTFU rates among patients initiating ART in successive 
calendar years doubled between the periods 2001-2003 and 2008.  
 
Over the 10-year study period, ART provision was rapidly implemented and programs 
expanded to reach a growing number of people infected with HIV.   Expansion rates 
ranged from 0-25 to 125-192 new patients/month, and programme size from <500 to 
20,000-23,995 patients.  Mortality gradually improved with 6-month estimates 
decreasing from 14% in the years before 2004 to less than 4% in 2011, which is 
consistent with reports from South Africa [56].  The observed decreased estimates of 
mortality may result from improved access to ART, as suggested by the increased 
number of patients initiating ART with less severe disease.  The rapid growth of 
programs might have also led to poorer outcome ascertainment, with greater number 
of deaths occurring in recent years misclassified as LTFU [53].  Linkage to national 
population or death registries is not available in these cohorts highlighting the need to 
improve outcome ascertainment for programme evaluation in resource-limited 
countries.  
 
The rapid growth of ART programs is related to a combination of several factors 
including the long-term availability of antiretroviral drugs, the implementation of new 
simplified guidelines for ART, and the widespread availability of CD4 enumeration to 
identify ART-eligible individuals. A third of patients initiated ART with a CD4 cell count 
below 100, placing a substantial strain on the health-care system requiring intensive 
support from clinically trained staff [209, 210].  Our findings do not suggest that 
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increases in treatment guideline thresholds prevent patients with more advanced HIV 
disease from accessing care, but rather that all programs still face challenges in 
timeously seeking, testing, and linking patients to ART care.   
Even with continued challenges to improving access to ART, LTFU appears to present a 
ubiquitous challenge to the long-term effectiveness of ART programs.  After 2-years of 
ART, 15% of the cohort was LTFU and retention was 77% and after 5-years of 
treatment two-thirds of patients remained in care.  This is slightly less than the 
estimate from 23 countries with cohorts of more than 2,000 people which reported 
72% retention after 5-years [24].  A temporal trend of increasing LTFU was observed 
with LTFU contributing an increasing proportion of overall programme attrition [37, 
56].  These findings confirm the urgent need to refocus efforts to improve long-term 
retention and contradict systematic reviews from sub-Saharan Africa suggesting that 
programme outcomes are improving [37, 38].  A novel finding of our study is that the 
rate of programme expansion, more than the size of the HIV program, was associated 
with the high levels of LTFU. This is likely to relate to the need for timely adjustments 
in programs to cope with the increase in activity, independently of financial and human 
resource allocation.  Associations observed between LTFU and male gender, younger 
age, and advanced clinical stage are consistent with previous reports [56, 136, 145, 
147].   
This analysis of long-term outcomes was based on substantial follow-up of a large 
number of patients treated in several resource-limited ART programs.  All sites offered 
care and treatment free of charge, followed WHO recommendations for ART initiation, 
and site heterogeneity was accounted for using random effects in the Cox’s models.  
These data are not likely to be representative of all ART programs since MSF provides 
additional resources and technical support.  For example, quality and completeness of 
routine electronic data are challenging but MSF provides considerable means to 
address these concerns [204].  Without linkage to death registries, estimates of 
programme attrition may misclassify some proportion of deaths as losses to follow-
up [53, 76, 88, 136, 203]. LTFU may be overestimated further due to administrative 
errors, incomplete records of patient decentralisation and unrecorded transfers and 
the contribution of treatment interrupters [92, 145, 204, 211, 212].  Furthermore, we 
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were unable to minimise this bias as we did not have data on tracing for all or a sample 
of those who were LTFU [213]. Our focus was limited to programme outcomes after 
ART initiating acknowledging that a substantial proportion of patients were lost during 
pre-ART care [214-217].  While programme size and the rate of expansion were 
adjusted for, residual confounding may be present if important internal organisational 
aspects were not sufficiently captured and from unmeasured factors.  Sensitivity 
analyses confirmed our results investigating differences by program, including patients 
with missing covariate data, and adjusting for site heterogeneity. A competing risks 
approach led to very similar findings corroborating that the traditional Cox’s 
proportional hazards models are appropriate [130, 201].  
 
Our findings explore the tension and challenges involved in pursuing the ambitious 
goals of expanding ART to 15 million people by 2015 and implementing “Treatment 
2.0” strategies in high prevalence, resource-limited settings [24, 205].  Recent 
Treatment as Prevention models assumed a long-term drop-out rate of 1.5% annually, 
which appears optimistic considering our estimates of long-term retention [218].   
With a high burden of acutely ill patients, ART programs will struggle to expand access 
to patients in earlier stages of HIV disease without additional resources and a change to 
the models of ART delivery.  With new 2013 WHO guidelines to expand ART access to 
an additional 9.2 million people in low- and middle-income countries, we need to fully 
understand the individual and programmatic implications of earlier initiation [24].  
 
Over a decade, ART programs have expanded in high prevalence resource-limited 
settings with a focus to increase access to care and thus patient numbers.  Today, many 
sites hold high numbers of HIV-infected patients, above 20,000 at some sites. The 
quality of ART services and psychosocial counselling at these large sites may be taking 
a back seat as the drive for expansion continues.  The conscious trade-off between 
numbers and quality deserves more discussion and close monitoring as the targets for 
expansion of treatment continue to increase. The findings of our study suggest that, 
potentially, ART sites should be capped at a maximum number of patients and the rate 
of enrolment restricted in favour of balancing growth with quality care. Site human 
resource capacity and programme organisation characteristics are likely to be 
important determinants to consider in achieving this balance and deserve further 
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investigation to provide effective recommendations regarding maximum patient 
volume and expansion rate at programme level.  
 
For the first time, the WHO guidelines acknowledge the challenge of long-term 
retention in ART programs with explicit guidance on operations and service delivery, 
including adherence, retention, decentralisation and task shifting [28].  Additional 
resources are needed to strengthen monitoring systems to ascertain true outcomes of 
children and adults lost to care pre- and post-ART initiation [53, 219]. Identification of 
ART patients disengaged from care is critical as they are at an increased risk of 
developing and transmitting drug resistant strains of HIV [37].  There is an urgent need 
to determine sustainable and optimal models of care for stable patients on lifelong 
ART, especially in large programs in high-prevalence resource-limited settings.  
Decreasing visit frequency by expanding intervals between prescription refills, 
decentralising ART delivery into community-based patient led groups, and introducing 
flexible systems to support mobile populations are all interventions that could be 
considered and assessed on a large-scale [42, 143, 176, 178].   
 
In summary, ART programs in resource-limited settings have grown rapidly over the 
last decade.  However, significant work remains to continue expanding access while 
addressing the growing challenge of programme attrition.  Sustainable models of care 
for long-term retention of patients in large, high-prevalence resource-limited settings 
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To assess the association between higher CD4 cell counts at ART initiation and loss to 
follow-up (LTFU) in public sector antiretroviral therapy (ART) cohorts in South Africa. 
Methods 
We conducted a cohort analysis including all adults initiating ART between 2008-2012 
at 3 public sector sites in South Africa. LTFU was defined as no visit in the 6-months 
before database closure.  The Kaplan-Meier estimator and Cox’s proportional hazards 
models examined the relationship between CD4 cell count at ART initiation and 24-
month LTFU. Final models were adjusted for demographics, year of ART initiation, 
programme expansion and corrected for unascertained mortality.  
Results 
Among 17,038 patients, the median CD4 at initiation increased from 119 (IQR: 54-180) 
in 2008 to 257 (IQR: 175-318) in 2012. In unadjusted models, observed LTFU was 
associated with both CD4 cell counts <100 cells/l and CD4 cell counts 300 cells/l.  
After adjustment, patients with CD4 cell counts 300 cells/l were 1.35 (95% CI: 1.12-
1.63) times as likely to be LTFU after 24 months compared to those with a CD4 150-
199 cells/l. This increased risk for patients with CD4 cell counts 300 cells/l was 
largest in the first 3 months on treatment. Correction for unascertained deaths 
attenuated the association between CD4 cell counts <100 cells/l and LTFU while the 
association between CD4 cell counts 300 cells/l and LTFU persisted. 
Conclusion 
Patients initiating ART at higher CD4 cell counts may be at increased risk for LTFU.  
With programs initiating patients at progressively higher CD4 cell counts, models of 
ART delivery need to be reoriented to support long-term retention. 
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5.2 INTRODUCTION 
Access to antiretroviral therapy (ART) has improved considerably in the past decade.  
By the end of 2013, 12.9 million people globally were receiving ART [26].  Programs 
have increased in size and expanded access with patients initiating ART at higher CD4 
cell counts.  In all regions, median CD4 cell counts at ART initiation are increasing [24].  
 
Increases in CD4 cell counts at ART initiation reflect progressive changes in WHO 
guidelines. Prior to 2010, ART was recommended for adults with CD4 cell counts below 
200 cells/l irrespective of World Health Organization (WHO) clinical stage [220].  The 
CD4 threshold was changed to 350 cells/l in 2010 [221] and raised further in 2013 to 
include all patients with a CD4 cell count of less than 500 cells/l[28].  In some 
countries, ART initiation is recommended irrespective of CD4 cell count [222-224].  
The global trend towards earlier initiation of ART is the result of advances in science, 
improvements in ART drugs and developments in the delivery of HIV care [225].   
 
Despite the potential benefits of earlier ART initiation, its impact on patient behaviour 
and resulting loss to follow-up (LTFU) is not well understood.  LTFU in ART programs 
already represents a considerable challenge and increasing the CD4 threshold at ART 
initiation further increases the number of eligible patients who require treatment in 
resource-constrained health systems [56, 90, 226].   A critical obstacle to assessing 
associations with LTFU is determining whether a patient considered LTFU is truly lost 
or is an unascertained death. Having a valid measure of LTFU is particularly important 
when assessing the association between CD4 and LTFU because lower CD4 cell counts 
are related to mortality [96, 126].  The limited data available on the relationship 
between CD4 cell counts at ART initiation and LTFU is conflicting.  In previous research 
higher CD4 cell counts have been associated with both an increased [134, 136] and 
decreased risk of LTFU [130, 227]. Given this conflicting evidence and the trend 
towards initiation at higher CD4 cell counts, the 2013 WHO guidelines highlight the 
need to assess adherence and retention in people initiating ART at these earlier stages 
of infection [28].  
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We investigated the relationship between CD4 cell counts at ART initiation and the risk 
of LTFU in the first 24 months on treatment among adults initiating ART between 
2008-2012 in the South African cohorts of the International epidemiologic Databases 
to Evaluate AIDS – Southern Africa (IeDEA-SA) collaboration. We hypothesised that 
after adjustment for individual (age, sex, year of ART initiation) and programme 
(cohort size, rate of expansion) factors, patients initiating ART at higher CD4 cell counts 
would have an increased risk of LTFU.   
5.3 METHODS 
Study design, population and eligibility criteria 
We conducted a multicentre, retrospective cohort analysis using data from the IeDEA-
SA collaboration.  The collaboration has been described in detail previously [52, 228].  
Briefly, patients were included in the analysis if they were ART naïve,  were 16 years of 
age or older, were not pregnant at ART initiation, initiated ART in 2008 or later, and 
had a CD4 cell count result available at ART initiation. Analysis was restricted to 
patients who had a minimum of 6-months follow-up and outcomes were restricted to 
the first 24-months of treatment.  For the main analysis, only patients with a recorded 
South African civil identification (ID) number were included and thus the main analysis 
included data from three public sector sites [Hlabisa (Cohort 1), Khayelitsha (Cohort 2), 
Themba Lethu (Cohort 3)] providing ART free of charge to adults in three South African 
provinces (Kwa-Zulu Natal, the Western Cape and Gauteng).  Data from an additional 
two cohorts (Gugulethu and Tygerberg) that did not collect IDs were included in 
sensitivity analyses. 
Variables and definitions 
At ART initiation, individual demographics (sex and age) and measures of disease 
severity (CD4 cell count and WHO stage) were assessed.  Two variables were generated 
to quantify programme expansion: programme size and the rate of programme scale-
up.  For each cohort, the number of ART patients receiving care at the end of the 
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calendar year of ART initiation was defined as a measure of programme size [226]. The 
rate of programme scale-up was estimated as the rank of the patient divided by the 
number of months that the programme had been providing ART.  For example, the 
200th patient enrolling in the tenth month of the programme would have a rate of scale-
up of 20 (200/10) [226].  
Patients were defined as LTFU if they were not known to be dead or transferred out 
and had no visit in the 6 months before the database closure.  The date of LTFU was 
defined as the date of last contact.  For patients who had initiated ART and did not 
return, one day of follow-up was added so that they would be included in the survival 
analysis [207].  Patients who were dead or transferred out were censored at the date of 
death or transfer. 
Corrected estimates of LTFU were made accounting for unascertained deaths through 
linkage by ID within the National Population Register (NPR) of the South African 
Department of Home Affairs. Patients previously defined as LTFU were reclassified as 
dead if they had a date of death in the NPR within 3 months of their date of LTFU [149].  
Corrected estimates therefore reflect incorporating data from the NPR, “corrected 
LTFU”, whereas uncorrected estimates are based on participant attendance, “observed 
LTFU”.   
Data Analysis 
Patient characteristics at ART initiation were compared by CD4 cell count categories at 
ART initiation and reported with appropriate summary statistics (including 
proportions, medians and interquartile ranges [IQR]). The Kaplan-Meier (KM) 
estimator was used to obtain estimates of the proportion of those LTFU (observed or 
corrected) over the first 24-months of treatment and were reported every 6-months. 
KM curves were plotted and presented by CD4 levels at ART initiation.  
To assess the association between CD4 cell count at ART initiation and the risk of LTFU, 
a series of Cox’s proportional hazards regression models were fitted. CD4 cell count at 
ART initiation was modelled as a categorical variable in 50 cells/l increments up to 
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300 cells/l.  The reference category used was a CD4 cell count between 150-199 
cells/l to facilitate examination of possible trends at lower and higher CD4 cell counts.  
All models were stratified by cohort.  Separate models were used to assess observed 
and corrected LTFU.  The proportional hazards of LTFU were modelled overall (0-24 
months) and separately for 0-3 months, 3-12 months and 12-24 months after ART 
initiation. Adjusted models included other variables at ART initiation: year of ART 
initiation, sex, age, cohort size and rate of scale-up.  In the main analysis, WHO status 
was excluded because of the large amount of missing data (36% missing). 
 
A series of sensitivity analyses were conducted to explore the impact of missing data 
and non-differential censoring.  To address missing IDs, inverse probability weighting 
was done whereby patients with IDs who were not alive and in care were weighted to 
represent all patients who were not alive and in care [97, 229-231].  Weighting of 
patients with IDs was determined as the probability of being in a cohort with IDs 
multiplied by the modelled probability of having a recorded ID (based on cohort, year 
of ART initiation, final outcome and CD4 cell count at ART initiation).  Multiple 
imputation using chained equation methods [232] was used to impute missing CD4 cell 
counts at ART initiation.  We multiply imputed CD4 cell counts (5 times) and the 
imputation models included the same variables as the Cox models. Competing risk 
regression was employed to model time to LTFU by taking the competing event of 
death into account [226]. 
 
Data were analysed using STATA 13.0 (STATA Corporation, College Station, Texas, 
USA).  Ethical approval was received from the relevant institutions at each of the sites 
and the University of Cape Town Human Research Ethics Committee provided ethical 




The main analysis included 17,038 adults who initiated ART between January 2008 and 
June 2012 in one of three cohorts (Table 5.1).  Median CD4 at ART initiation increased 
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with each successive calendar year from 119 cells/l in 2008 (IQR: 54-180) to 257 
cells/l in 2012 (IQR: 175-318).  The proportion of patients in WHO stage IV at ART 
initiation was 25%, 17%, 9%, 8% and 17% for patients in CD4 groups <50, 50-99, 100-
199, 200-299 and 300 cells/l, respectively. The median programme size was almost 
10,000 patients (median: 9,846, IQR: 7,588-11,074) with an average of 160 new 
patients initiating treatment every month (median: 167, IQR: 132-192). 
Proportion of LTFU 
A cumulative total of 6%, 10%, 14% and 17% of patients were observed to be LTFU at 
6, 12, 18 and 24 months, respectively.  Observed proportions of LTFU differed by CD4 
cell count at ART initiation (Figure 5.1A).  The highest proportion of observed LTFU 
was seen in patients with CD4 cell counts at ART initiation <100 cells/l or 300 
cells/l and the lowest proportions in patients initiating ART between 100-200 
cells/l. Rates of observed LTFU also varied by cohort with 12-month observed LTFU 
ranging from 7-13% and 24-month observed LTFU from 12-21%.  Consistent across all 
cohorts were high proportions of observed LTFU in patients with CD4 cell counts 
below 50 cells/l.  Proportions of observed LTFU were highest in patients with <50 
cells/l and 300 cells/l CD4 cell counts at ART initiation when stratified by year of 
ART initiation (results not shown).  
After accounting for unascertained deaths, LTFU decreased over time with corrected 
cumulative LTFU estimated at 5%, 8%, 11% and 14% at 6, 12, 18 and 24 months, 
respectively (Figure 5.2).  Correcting for deaths accounted for a relative reduction in 
LTFU of between 16% (24 month) to 30% (6 month) (results not shown).  Corrected 
LTFU differed by CD4 cell count at ART initiation (Figure 5.1B, Figure 5.2). Proportions 
of corrected LTFU appeared similar among all patients initiating ART with CD4 cell 
counts <200 cells/l and were highest in patients initiating ART at a CD4 cell count 
300 cells/l (Figure 5.1B).  This was observed in all cohorts.  As with observed LTFU,
corrected LTFU varied by cohort.  12-month LTFU ranged from 7-10% and 24-month 
LTFU from 12-18% (results not shown). 
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Risk of LTFU 
An increased risk of observed LTFU was seen in patients initiating ART with <100 
cells/l and CD4 cell counts 300 cells/l (Figure 3, Supplementary Table 5.1).  After 
adjusting for demographics, year of ART initiation, programme size and rate of scale-
up, the increased risk of observed LTFU persisted for those with a CD4 cell count <100 
cells/l and 300 cells/l at ART initiation (Table 5.2, Supplementary Table 5.1).  
Patients initiating ART with CD4 cell counts 300 cells/l were at an increased risk of 
being LTFU after 24-months of ART (Table 5.2, Supplementary Table 5.1).  Specifically, 
these patients l were 35% more likely to be LTFU after 24 months of ART compared to 
patients with a CD4 cell count between 150-199 cells/l at ART initiation [adjusted 
Hazard Ratio (aHR): 1.35, 95% CI: 1.12-1.63]. The risk of LTFU was largest in the first 
year on ART (Figure 5.3). After 12-months on treatment, no significant association was 
observed between CD4 cell count at ART initiation and corrected LTFU.  The increased 
risk of LTFU among patients with lower CD4 cell counts at ART initiation was 
attenuated by correcting for unascertained deaths and did not persist in crude or 
adjusted models of corrected LTFU (Figure 5.3, Supplementary Table 5.1, Table 5.2).   
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Table 5.1 Patient characteristics among 17,038 adults initiating public-sector ART by CD4 cell count at ART initiation 
Baseline characteristic CD4 <50 cells/l 
(n=3,145) 
CD4 50-99 cells/l 
(n=2,934) 
CD4 100-199 cells/l 
(n=6,850) 







Hlabisa (1) 1,440 (45.8) 1,437 (49.0) 3,364 (49.1) 1,190 (40.3) 859 (74.4) 8,290 (48.7) 
Khayelitsha (2) 841 (26.7) 925 (31.5) 2,406 (35.1) 1,398 (47.3) 194 (16.8) 5,764 (33.8) 
Themba Lethu (3) 864 (27.5) 572 (19.5) 1,080 (15.8) 366 (12.4) 102 (8.8) 2,984 (17.5) 
Gender 
Female 1,700 (54.1) 1,767 (60.2) 4,696 (68.6) 2 172 (73.5) 908 (78.6) 11,243 (66.0) 
Age 
Median (IQR) 35.2 (30.0-41.7) 35.6 (29.9-42.4) 35.3 (29.8-42.7) 34.5 (28.9-41.3) 35.3 (29.0-43.2) 35.2 (29.6-42.2) 
16-24 197 (6.3) 202 (6.9) 527 (7.7) 263 (8.9) 131 (11.3) 1,320 (7.8) 
25-34 1,351 (43.0) 1,185 (40.4) 2,801 (40.9) 1,282 (43.4) 440 (38.1) 7,059 (41.4) 
35-44 1,072 (34.1) 1,000 (34.1) 2,166 (31.6) 949 (32.1) 344 (29.8) 5,531 (32.5) 
45 535 (16.7) 547 (18.6) 1,356 (19.8) 460 915.6) 240 (20.8) 3,128 (18.4) 
Year of ART initiation 
2008 1,089 (34.6) 918 (31.3) 1,977 (28.9) 601 (20.4) 132 (11.4) 4,717 (27.7) 
2009 1,061 (33.7) 938 (32.0) 2,165 (31.6) 781 (26.4) 199 (17.2) 5,144 (30.2) 
2010 615 (19.6) 663 (22.6) 1,632 (23.8) 808 (27.4) 309 (26.8) 4,027 (23.6) 
2011 358 (11.4) 386 (13.2) 980 (14.3) 615 (20.8) 366 (31.7) 2,705 (15.9) 
2012 22 (0.7) 29 (1.0) 96 (1.4) 149 (5.0) 149 (12.9) 445 (2.6) 
WHO stage 
I and II 342 (18.9) 595 (32.1) 2,260 (50.1) 1,209 (55.6) 321 (49.8) 4,727 (43.0) 
III 1,011 (55.9) 938 (50.6) 1,838 (40.7) 793 (36.5) 217 (33.7) 4,797 (43.6) 
IV 456 (25.2) 321 (17.3) 414 (9.2) 173 (8.0) 106 (16.5) 1,470 (13.4) 
Missing 1 336 (42.3) 1,080 (36.8) 2,338 (34.1) 779 (26.4) 511 (44.2) 6,044 (35.5) 
Cohort size at initiation (patients) 
<7 500 441 (14.0) 467 (15.9) 968 (14.1) 339 (11.5) 233 (20.2) 2,448 (14.4) 
7 500-7 999 595 (19.0) 571 (19.5) 1,453 (21.2) 460 (15.6) 146 (12.6) 3,226 (18.9) 
8 000– 9 899 812 (25.8) 629 (21.4) 1,387 (30.2) 430 (14.6) 218 (18.9) 3,476 (20.4) 
9 900-11 499 781 (24.8) 730 (24.9) 1,639 (23.9) 843 (28.5) 137 (11.9) 4,130 (24.2) 
11 550 515 (16.4) 537 (18.3) 1,403 (20.5) 882 (29.9) 421 (36.5) 3,758 (22.1) 
Rate of scale-up (patients/month) 
<130 735 (23.4) 727 (24.8) 1,573 (23.0) 334 (11.3) 172 (15.0) 3,542 (20.8) 
130-159 557 (17.7) 581 (19.8) 1,395 (20.4) 487 (16.5) 276 (23.9) 3,296 (19.3) 
160-179 525 (16.7) 524 (17.9) 1,438 (21.0) 745 (25.2) 284 (24.6) 3,516 (20.6) 
180-199 464 (14.8) 530 (18.1) 1,364 (19.9) 1,022 (34.6) 320 (27.7) 3,700 (21.7) 
200 864 (27.5) 572 (19.5) 1,080 (15.8) 366 (12.4) 102 (8.8) 2,984 (17.5) 
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Figure 5.1 Kaplan-Meier plots showing observed and corrected 24 month LTFU 
by CD4 cell count at ART initiation 
 
a. Observed LTFU by CD4 cell count at ART initiation 0-24 months follow-up 
 
 
b. Corrected LTFU by CD4 cell count at ART initiation 0-24 months follow-up 
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Figure 5.2 Corrected* loss to follow-up from Kaplan-Meier estimates by CD4 cell 
count at ART initiation 
Corrected loss to follow-up refers to estimates that have been adjusted for unascertained mortality as 
derived through the National Population Register. 
The association between CD4 cell count at ART initiation and LTFU was assessed 
separately for each of the three cohorts (Supplementary Table 5.2). The results in 
Cohorts 1 and 2 were very similar to the overall associations observed between CD4 
cell count and LTFU. For Cohort 3, patients with CD4 cell counts <100 cells/l and 
between 200-249 cells/l had a decreased risk of LTFU compared to patients initiating 
ART between 150-199 cells/l.  In this cohort, a limited number of patients initiated 
treatment at CD4 cell counts above 200 cells/l (n<500) and later than 2009 (n<50).  
Median CD4 cell count in Cohort 3 was 105 compared to 142 and 151 in the other two 
cohorts, respectively (Supplementary Table 5.2).   
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Table 5.2 Hazard ratios of overall, 0-3 month, 3-12 month and 12-24 month 
corrected LTFU by CD4 cell count at ART initiation± 
OVERALL  
(0-24 months) 
0-3 months 3-12 months 12-24 months
n=17 038 n=17 038 n=15 470 n=12 728 
Crude HR 
<50 cells/l 1.13 (0.98-1.30) 1.10 (0.81-1.49) 1.34 (1.07-1.68) 0.95 (0.75-1.20) 
50-99 cells/l 1.01 (0.88-1.17) 1.14 (0.85-1.54) 1.05 (0.83-1.33) 0.92 (0.73-1.15)
100-149 cells/l 1.01 (0.88-1.17) 0.66 (0.47-0.94) 1.14 (0.92-1.43) 1.08 (0.87-1.33)
150-199 cells/l 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
200-249 cells/l 0.95 (0.82-1.11) 0.84 (0.60-1.18) 1.03 (0.81-1.32) 0.94 (0.74-1.19)
250-299 cells/l 1.38 (1.11-1.70) 1.56 (1.01-2.39) 1.39 (0.98-1.96) 1.27 (0.89-1.81)
300 cells/l 1.62 (1.25-1.95) 1.95 (1.35-2.81) 1.70 (1.27-2.27) 1.34 (0.97-1.87)
Adjusted* - aHR 
<50 cells/l 1.08 (0.94-1.24) 1.07 (0.79-1.45) 1.30 (1.04-1.63) 0.89 (0.70-1.12) 
50-99 cells/l 0.98 (0.85-1.13) 1.12 (0.83-1.52) 1.02 (0.81-1.29) 0.88 (0.70-1.11)
100-149 cells/l 1.00 (0.87-1.14) 0.66 (0.47-0.93) 1.12 (0.90-1.40) 1.06 (0.85-1.30)
150-199 cells/l 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
200-249 cells/l 0.89 (0.77-1.04) 0.80 (0.57-1.12) 0.95 (74-1.22) 0.90 (0.71-1.15) 
250-299 cells/l 1.18 (0.95-1.46) 1.40 (0.90-2.16) 1.14 (0.80-1.62) 1.12 (0.89-1.60)
300 cells/l 1.35 (1.12-1.63) 1.68 (1.15-2.45) 1.35 (1.00-1.81) 1.17 (0.84-1.64)
±All estimates are stratified by cohort 
*Adjusted for year of ART initiation, gender, age, programme size and rate of expansion
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Figure 5.3 Adjusted 12-month log hazard ratios of observed and corrected LTFU from 
Cox’s proportional hazards models by CD4 cell count at ART initiation* 
*Adjusted for year of ART initiation, gender, age, programme size and rate of expansion
Sub-group analyses were done to assess the association between CD4 cell count at ART 
initiation and LTFU by year of ART initiation, sex, and age (Supplementary Table 5.3). 
In each year of ART initiation, an increased hazard of LTFU was observed among 
patients initiating ART with a CD4 cell count of 300 cells/l compared to patients 
initiating ART between 150-199 cells/l.  In final models, women were 35% more 
likely (aHR: 1.35, 95% CI: 1.09-1.68) and men were 24% more likely (aHR: 1.24, 95% 
CI: 0.84-1.82) to be LTFU if they initiated ART with a CD4 cell count 300 cells/l 
compared to patients initiating ART between 150-199 cells/l (Supplementary Table 
5.3).  In patients 25-34 years of age, those initiating ART with a CD4 cell count 300 
cells/l were 1.58 times more likely to be LTFU (95% CI: 1.21-2.08) compared to 
patients initiating ART between 150-199 cells/l. In patients 35 years, those with a 
CD4 cell count 300 cells/l at ART initiation were also more likely to be LTFU 
compared to patients initiating ART between 150-199 cells/l (35-44 HR: 1.23, 95% CI 
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0.84-1.80, 45 HR: 1.24, 95% CI 0.69-2.22).  No association between a CD4 cell count 
300 cells/l and LTFU was observed in patients less than 25 years of age (HR: 0.99,
95% CI-0.61-1.58). 
Of the 5 cohorts assessed for eligibility, 2 cohorts did not collect IDs.  There were 
26,466 patients with missing data (CD4 cell counts were missing in 5,457 patients at 
ART initiation, 4,828 did not have a recorded ID, and 16,161 did not have a CD4 cell 
count or recorded ID). In sensitivity analyses accounting for missing data, the 
association between higher CD4 cell count at ART initiation and increased risk of early 
LTFU persisted. Characteristics of patients with and without IDs are summarised in 
Supplementary Table 5.4.  When inverse probability weighting was used to account for 
missing IDs, patients with a CD4 cell count 300 cells/l at ART initiation were 55% 
more likely to be LTFU in the first 3 months of ART (aHR: 1.55, 95% CI 0.94-2.55) 
(Supplementary Table 5.5).  This association was slightly reduced compared to the 
results of the main analysis (aHR:1.68, 95% CI 1.15-2.45) (Table 5.2). Similarly, in 
multiple imputation models including patients with missing CD4 cell counts, a CD4 cell 
count 300 cells/l was associated with a 50% increase in LTFU in the first 3 months 
of ART (95% CI 1.04-2.18) (Supplementary Table 5.6).  The competing risk analysis 
yielded similar conclusions to the main results (Supplementary Table 5.7).  
5.5 DISCUSSION 
Our analyses demonstrate that patients initiating ART at CD4 cell counts 300 cells/l 
are at an increased risk of LTFU in the first 24-months on ART.  The increased risk of 
LTFU among patients with higher CD4 cell counts at ART initiation was observed both 
with and without correction for unascertained deaths and persisted after adjustment 
for individual factors and measures of programme expansion.  The greatest increase in 
risk of LTFU for patients initiating with higher CD4 cell counts was in the first year on 
treatment. While low CD4 cell count at ART initiation was associated with increased 
risk LTFU, correction for unascertained deaths removed this association. 
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Our finding that CD4 cell counts 300 cells/l are associated with higher risk of LTFU is 
aligned with previous findings [134, 136] from smaller, individual studies.  In Uganda, a 
tracing study of patients LTFU found higher rates of LTFU among those with CD4 cell 
counts 250 cells/l. CD4 cell counts 250 cells/l were also associated with treatment 
interruptions [233]. Conversely, other studies have found higher CD4 cell counts were 
associated with reduced LTFU [130, 131]. However, limited data were available on 
patients with CD4 cell counts 300 cells/l and LTFU did not correct for unascertained 
deaths.   
We can speculate as to why patients who initiate ART at higher CD4 cell counts may be 
at an increased risk of being lost to care. ART services have been designed to support 
acutely ill HIV patients with lower CD4 cell counts.  Patients who initiate ART at higher 
CD4 cell counts without an illness experience are not catered for in the services and 
they may not experience any immediate benefits of ART and thus disengage from care 
early [136]. The association between CD4 cell counts of 300 cells/l and risk of LTFU 
was highest in the first year on treatment, especially in the first 3-months. This 
suggests interventions are needed to change how patients with higher CD4 cell counts 
are initiated onto ART. Given the range of CD4 cell counts at which patients are now 
initiating ART, models of ART provision that triage patients at initiation based on CD4 
cell count should be considered to provide more tailored support.  In addition, pre-
therapy counselling should be updated to address the distinct challenges faced by 
patients initiating treatment at higher CD4 cell counts [234].  Beyond ART initiation, 
patients with higher CD4 cell counts at ART initiation may benefit from receiving ART 
outside of traditional facility-based models by accessing ART in community-based 
models of care.   
Our finding that patients initiating ART with higher CD4 cell counts are at greater risk 
of being LTFU is relevant as countries align national ART guidelines with the 2013 
WHO guidelines [28]. With the CD4 threshold in South Africa changing to 500 cells/l 
in 2015 [235], an additional 1.5 million people will be eligible for ART [236].  Given the 
advances in ART drugs and the evidence that earlier ART can benefit both the 
individual and the population, the question is less about when patients should initiate 
ART but how. It is paramount that the change in ART eligibility criteria is accompanied 
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by health system adaptations. We need to adapt where and how patients with higher 
CD4 cell counts are initiated onto ART given the increased risk of LTFU in the first year 
on treatment in this group.  We are reliant on a limited number of service delivery 
models that may not provide the most appropriate care for our evolving ART programs. 
Furthermore, innovative models of care are needed to improve long-term retention of 
patients. It is also apparent that we are going to need a variety of models; models that 
can co-exist and have strong referral mechanisms to meet the different needs of 
increasingly heterogeneous populations accessing ART [237]. Options for populations 
who currently have inequitable access to ART including men, older populations, and 
underserved populations are also needed. 
 
We are uniquely positioned to assess the association between a range of CD4 cell 
counts and LTFU.  With data from multiple cohorts we could look at more patients at 
higher CD4 thresholds than previous research. The challenge faced by many ART 
cohort analyses of differentiating the risk factors for corrected LTFU from the risk 
factors for unascertained deaths is overcome in our case through linkage with the NPR.  
The quality of the NPR data are very high with nearly 90% of adult deaths 
captured [238]. A valuable finding provided through linkage was that no significant 
association between lower CD4 cell counts and corrected LTFU was observed.  This 
suggests that the association in uncorrected models was an artefact of unascertained 
mortality. That fact the association between CD4 cell counts 300 cells/l and LTFU 
remained after linkage gives weight to our findings. Novel to our findings is that the 
association persisted after adjusting for measures of programme expansion. Therefore, 
increases in LTFU are not necessarily the result of deteriorating quality of care as ART 
programs have expanded [239].  Changes to the profile of patients at ART initiation, 
including a greater number of patients at higher CD4 cell counts without an illness 
experience, are related to increased LTFU, a result of the model of ART delivery not 
being appropriate for all patients accessing ART.  
 
Our study should be considered in light of a number of limitations.  Data were missing 
on a number of key variables including CD4 cell counts at ART initiation and South 
African civil ID numbers.  We chose to exclude patients with missing CD4 levels 
postulating that missing data was likely related to administrative and clerical errors 
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and is therefore likely to be missing completely at random (i.e. not related to particular 
covariates). In sensitivity analyses, models with imputed missing CD4 cell counts and 
weighted for missing IDs yielded findings consistent with the main results.  Previous 
analyses also found patients with and without IDs were comparable [230]. Data on 
patients with CD4 cell counts 300 cells/l were limited as the change in South African 
guidelines to initiation of patients with a CD4 cell count <350 cells/l was only 
announced in August 2011 [240].  Therefore, patients with higher CD4 cell counts in 
our analysis may have been initiated for other clinic reasons and not be representative 
of patients initiating ART at higher CD4 cell counts. In this analysis, 17% of patients 
initiating with a CD4 cell count 300 cells/l were in WHO stage IV.  From a 
programmatic perspective, our analysis is limited to reporting on LTFU after ART 
initiation and ignores that a considerable proportion of the patients determined to be 
LTFU may be treatment interrupters who will re-engage with ART services at a later 
date [239]. 
Our study found that patients who initiate ART with a CD4 cell count 300 cells/l are 
at an increased risk of being LTFU after 24-months on treatment compared to patients 
initiating with a CD4 cell count between 150-199 cells/l.  Acknowledging the potential 
benefits of early ART initiation, further research is needed on how to successfully 
support patients who initiate treatment at higher CD4 cell counts.  This is especially 
relevant as ART guidelines expand who is eligible for ART initiation to increasingly 
healthy populations, such as those following Options B+ for the prevention of mother to 
child transmission.  It is widely acknowledged that the greatest threat to the long-term 
success of the rapidly expanding ART programs is ensuring adherence and retention in 
care [77].  Given these challenges, now is the time to innovate our health systems to 
more effectively and efficiently deliver ART.    
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Chapter 6. Outcomes of a nurse-managed 
service for stable HIV-positive patients in a 
large South African public-sector 
antiretroviral therapy programme 
Grimsrud A, Kaplan R, Bekker LG, Myer L. Outcomes of a nurse-managed service 
for stable HIV-positive patients in a large South African public sector 





Models of care utilizing task shifting and decentralisation are needed to support 
growing ART programmes.  We compared patient outcomes between a doctor-
managed clinic and a nurse-managed down-referral site in Cape Town, South Africa.   
Methods 
Analysis included all adults who initiated ART between 2002 and 2011 within a large 
public sector ART service. Stable patients were eligible for down-referral to the Green 
Clinic. Outcomes (mortality, loss to follow-up [LTFU], viral rebound) were compared 
under different models of care using proportional hazards models with time-
dependent covariates. 
Results 
5,746 patients initiated ART and over 5 years 41% (n=2341) were down-referred; the 
median time on ART before down-referral was 1.6 years (interquartile range, 0.9-2.6). 
The Green Clinic (or nurse-managed down-referral site) reported lower crude rates of 
mortality, LTFU and viral rebound compared to the doctor-managed clinic. After 
adjustment, there was no difference in the risk of mortality or viral rebound by model 
of care.  However patients who were down-referred were more likely to be LTFU 
compared to those retained at the doctor-managed site (adjusted hazard ratio, 1.36; 
95% CI, 1.09-1.69). Increased levels of LTFU in the Green Clinic versus doctor-managed 
service were observed in subgroups of male patients, those with advanced disease at 
initiation and those who started ART in the early years of the programme. 
Conclusion 
Reorganisation of ART maintenance by down-referral to nurse-managed services is 
associated with programme outcomes similar to those achieved using doctor-driven 
primary care services. Further research is necessary to identify optimal models of care 
to support long-term retention of patients on ART in resource-limited settings.  
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6.2 INTRODUCTION 
The expansion of antiretroviral therapy in resource-limited settings has been rapid 
over the past decade.  Almost ten million people in low and middle-income countries 
were receiving ART at the end of 2012; approximately 1.6 million of these initiating in 
2011 alone [24].  In many settings the demand for ART services has often outpaced the 
ability of health care services and providers to care for increasing patient 
numbers [204].  As a result of the size and speed of ART expansion, elements of task 
shifting and decentralised provision of ART have been developed and implemented out 
of necessity in parallel to generating evidence of their effectiveness [42].   
Task shifting has been increasingly promoted to address the human resource crisis in 
the health sector exacerbated in many countries by the HIV epidemic [241-243].  Early 
ART programmes in resource-limited settings followed a doctor-driven approach to 
highly individualised care with intensive clinical monitoring.  In response to the limited 
capacity of primary health care systems and human resource constraints, increasing 
levels of responsibility within ART programmes were shifted to other cadres of 
staff [243].  Nurses now initiate and manage ART patients in South Africa and many 
other countries [44] and the expanding responsibilities of counsellors in these 
programmes is increasingly acknowledged [244].  Meanwhile, as treatment 
programmes have expanded, decentralisation of ART services from hospitals to 
primary care sites has been recommended to help facilitate access to care [183, 245, 
246].  With more sites providing ART, the number of patients starting treatment and 
being down-referred to community-based facilities has increased, with favourable 
reports of retention rates [97, 128, 247].  
Continued expansion of ART programmes is needed to reach the target of universal 
coverage by 2015 [248].  In addition, new treatment guidelines recommend earlier ART 
initiation thus increasing the number of patients eligible to start treatment [28]. As 
ART programmes mature, the long-term retention of patients in care is essential to the 
effectiveness of the programme.  Models of care that are sustainable and can support 
life-long adherence to ART are needed.  These models of care will combine elements of 
task shifting, decentralised care and hopefully innovative approaches to address the 
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growing challenge of loss to follow-up (LTFU).  Despite the importance of and interest 
in non-physician led models of ART for ART care and maintenance, there are few data 
on long-term patient outcomes in these programmes Our objective was to evaluate the 
Green Clinic, a nurse-managed, decentralised model of care for stable ART patients, 
compared to a doctor-managed ART clinic, for patients receiving ART in primary care 
in Cape Town, South Africa.  
6.3 METHODS 
6.3.1 Study design 
This was a cohort analysis of prospectively collected clinic data. Ethical approval for 
the use of patient information and the evaluation of models of care were obtained from 
the Faculty of Health Sciences Human Research Ethics Committee at the University of 
Cape Town.  All patients gave written informed consent for their routine care records 
to be included.  
6.3.2 Study setting 
The study took place at a well-characterised, peri-urban community health centre 
(CHC) in Gugulethu, Cape Town [16, 249].  The community surrounding the clinic is of 
low socioeconomic status and the local antenatal HIV seroprevalence was 26% in 2013.  
The general ART service has been described in detail previously [16, 249].  Briefly, 
ambulatory patients who were eligible for ART based on South African national 
guidelines received clinical care, psychosocial counselling, and related services. All 
patients initiated ART at the CHC in the doctor-managed ART clinic (referred to 
hereafter as the treatment-initiation site).  The service was supported by a network of 
peer counsellors [57].  Routine monitoring of CD4 cell count and viral load were done 
every 16 weeks during ART.  
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6.3.3 The down-referral process 
In February 2006 in response to the growing congestion of the treatment-initiation 
site, a down-referral site was opened in a separate building on the grounds of the CHC 
(referred to hereafter as the Green Clinic).  Patients were eligible for down-referral if: 
they had been on ART for at least 16 weeks, their most recent viral load was less than 
50 copies/mL, they had no active opportunistic infections or poorly controlled chronic 
conditions, they were on a first-line ART regimen (comprised of two nucleoside reverse 
transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor) and they 
demonstrated good adherence by pill count. 
For the first two years of the programme, the Green Clinic was staffed with a doctor 
and professional nurse thereafter, transitioning to a nurse-managed, counsellor and 
doctor-supported programme. Green Clinic patients were scheduled to return every 
four4 months to see a nurse for clinical care and a counsellor for adherence support 
and every two months to the pharmacy for ART collection.  Green Clinic patients were 
all dispensed two months of ART compared to one to two months of ART for treatment-
initiation site patients. CD4 cell count and viral loads were monitored every 16 weeks 
at both sites.  Patients could also be up-referred to the treatment-initiation site if they 
developed opportunistic infections requiring more regular clinical care (e.g. active 
tuberculosis), or needed to switch drug regimens.  
6.3.4 Data analysis 
All ART-naïve patients were eligible for analysis and entered on the date of ART 
initiation.  Database closure was June 2012 when referral to a new model of care was 
started and analysis closure was the end of December 2011 [207].  Patients known to 
be down-referred without a referral date were described but excluded from rate and 
time to event analyses.   Deaths referred to all-cause mortality from any source.  
Transfers out were censored at the date of transfer. 
The primary outcomes were death, LTFU, and viral rebound.  Patients were censored at 
the earliest of date of outcome: death, LTFU, transfer out, or analysis closure.  LTFU 
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was defined as no contact between analysis and database closure and the last date of 
contact was assigned as the outcome date [207].  Viral rebound was defined as a single 
viral load >1,000 copies/mL among patients who had a viral load below 1,000 
copies/mL after four months on ART. Time-updated laboratory values for CD4 cell 
count and viral load were available for every four months on treatment, defined as the 
closest laboratory value plus or minus two months.  
 
Pre-ART characteristics of all patients were summarised as proportions for categorical 
variables and medians with inter-quartile ranges (IQRs) for continuous variables, 
stratified by model of care (treatment-initiation site vs. treatment-initiation and Green 
Clinic).  Because of variability in completeness of baseline data, numbers of 
observations are reported for each analysis.  Changes in CD4 cell count and viral load as 
well as the proportion of patients with a CD4 cell count ever above 200 cells/µl and a 
viral load below 1,000 copies/mL at 4-months after ART initiation were presented by 
model of care.  Pearson’s chi-squared and Wilcoxon rank-sum tests were used to assess 
differences by model of care.  Median time to down-referral was calculated by baseline 
characteristics with IQRs and Wilcoxon rank-sum tests used to determine associations 
with baseline characteristics.   
 
We compared unadjusted rates of mortality, LTFU and viral rebound by patient 
characteristics and model of care. Rates of mortality, LTFU and overall attrition were 
calculated overall and by model of care and reported at 6-monthly intervals.  Patients 
who were down-referred contributed analysis time to the treatment-initiation site until 
referral.   
 
Separate Cox’s proportional hazards models with time-varying covariates for model of 
care, CD4 cell count and viral load were used to calculate unadjusted and adjusted 
associations between model of care and outcomes.  Analysis of viral rebound was 
restricted to patients with a viral load below 1,000 copies/mL after four months on 
ART.  Multivariate models were generated adjusting for demographics (age and 
gender), baseline disease characteristics (CD4 cell count, WHO clinical stage, 
haemoglobin), year of initiation, and time-updated laboratory values [178]. Time-
updated CD4 cell count was modelled as a continuous variable per 50-cell change and 
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time-updated viral load as a binary (<1,000 copies/mL vs. ≥1,000 copies/mL). We 
modelled the proportional hazards of virologic suppression from four months after 
ART initiation and 12 months after ART initiation.  The proportional hazards of death 
and LTFU were modelled separately for different time periods (from ART initiation, 
from 4 months after ART initiation and from 12 months after ART initiation). 
Subsidiary analyses used proportional hazards models restricted to levels of baseline 
covariates. Post-estimation survival plots stratified by model of care were generated 
for LTFU following unadjusted and adjusted proportional hazards models.  
All statistical tests were two-sided at an alpha of 0.05. Data were analysed using STATA 
version 12.0 (STATA Corporation, College Station, Texas, USA).   
6.4 RESULTS 
6.4.1 Pre-ART characteristics and changes in viral load and 
CD4 in the first year on ART 
This analysis included 5,746 patients who initiated ART between 2002 and 2011 (67% 
female; median age 34, IQR 29-40) (Table 6.1).  A total of 5,154 patients contributed 13 
744 person-years of observation. Since 2006, 41% of patients were down-referred to 
the Green Clinic (n=2 341). There were no differences in gender (p=0.054), age 
(p=0.936), viral load (p= 0.691) and WHO clinical stage (p-value 0.093) at ART 
initiation between Green Clinic versus those retained in the doctor-managed service.  
After 4 months on ART, a higher proportion of Green Clinic patients had a viral load of 
<1,000 copies/mL (89.8% vs. 62.7%, p<0.001) and had a greater than 100-unit change 
in CD4 cell count from their pre-ART value (56.3% vs. 50.9%, p<0.001) compared to 
patients receiving care at the treatment initiation site only.    
The median time to down-referral was 1.6 years (IQR 0.9-2.6) (Supplementary Table 
6.1).  Patients initiating ART with a CD4 cell count above 200 cells/µl were down-
referred after 1.2 years on ART (IQR 0.7-2.1) compared to 2.1 years (IQR 1.3-3.1) for 
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patients initiating ART with a CD4 cell count less than 50 200 cells/µl. Green Clinic 
patients had better improvements in CD4 cell counts and were more likely to have viral 
loads <1,000 copies/mL compared to patients in the treatment-initiation site in the 
first year on ART (p-values all <0.001) (Table 6.1).   
 
6.4.2 Mortality 
The unadjusted mortality rate on ART was lower in the Green Clinic than in the 
treatment-initiation site (1.2 vs. 4.3/100 person-years, respectively) (Table 6.2). While 
mortality rates were consistently higher for the treatment-initiation site, similar trends 
by baseline characteristics were observed at both sites (Table 6.3). 
 
The unadjusted risk of mortality was 29% lower in the Green Clinic compared to 
patients in the treatment-initiation site (HR 0.71, 95% 0.50-1.00, p=0.047) (Table 6.4). 
However after adjusting for variation in gender, age, pre-ART CD4, WHO stage and 
haemoglobin at baseline, year of ART initiation and time updated CD4 and viral load, 
there was no difference in the risk of mortality between the Green Clinic and 
treatment-initiation site patients (aHR 1.51, 95% CI 0.90-2.55). Mortality was 
associated with male gender, a CD4 cell count below 50 cells/µl at baseline, WHO IV at 
baseline, earlier year of ART initiation, lower time-updated CD4 cell count and not 
being virally suppressed (results not shown).  
 
6.4.3 Loss to follow-up 
The overall LTFU rate was 7.9 per 100 person-years and lower in the Green Clinic than 
in the treatment-initiation site (5.9 vs. 8.9/100 person-years, respectively; Table 6.2). 
Rates of LTFU were highest in the first 6 months after ART initiation and constant over 
24-60 months.  Over 24-48 months LTFU rates were between 6.0 and 6.6 per 100 
person-years in both models of care. The highest rates of LTFU were observed in 
patients initiating ART with a CD4 cell count above 200 cells/µl in the treatment-
initiation site (12.9/100 person-years) and those initiating ART in 2010-2011 both in 
the treatment-initiation site (20.7/100 person-years) and in the Green Clinic (9.9/100 
person-years) (Table 6.3).  
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Table 6.1 Pre-ART characteristics and changes in viral load and CD4 in the first 















2,234 (65.6) 1,593 (68.1) 3,827 (66.6) 0.054 
Age, years 
Median (IQR) 33.9 (28.6-40.6) 33.7 (29.2-39.8) 33.8 (28.9-40.2) 0.936 
CD4 cell count (cells/µl), n(%) 
<50 651 (21.6) 426 (19.3) 1,077 (20.6) <0.001 
50-99 582 (19.3) 494 (22.3) 1,076 (20.6) 
100-199 1,086 (36.1) 950 (43.0) 2,036 (39.0) 
≥200 690 (22.9) 342 (15.5) 1,032 (19.8) 
Median (IQR) 123 (58-193) 118 (62-174) 121 (60-184) 0.005 
Missing, n(%) 396 (11.6) 129 (5.5) 525 (9.1) 
Viral load, log10 copies/mL 
Median (IQR) 4.8 (4.4-5.3) 4.8 (4.4-5.3) 4.8 (4.4-5.3) 0.691 
Missing, n(%) 548 (16.1) 212 (9.1) 760 (13.2) 
Haemoglobin, g/dL 
Median (IQR) 11.0 (9.7-12.4) 11.3 (9.9-12.5) 11.1 (9.8-12.4) 0.002 
Missing, n(%) 638 (18.7) 285 (12.2) 923 (16.6) 
WHO stage, n(%) 
Stage I and II 1,138 (34.4) 739 (31.7) 1,877 (33.3) 0.093 
Stage III 1,557 (47.1) 1131 (48.5) 2,688 (47.7) 
Stage IV 611 (18.5) 460 (19.7) 1,071 (19.0) 
Missing, n(%) 99 (2.9) 11 (0.5) 110 (1.9) 
Year of initiation, n(%) 
2002 - 2003 76 (2.2) 101 (4.3) 177 (3.1) <0.001 
2004 - 2005 364 (10.7) 675 (28.8) 1,039 (18.1) 
2006 – 2007 599 (17.6) 851 (36.4) 1,450 (25.2) 
2008 – 2009 847 (24.9) 502 (21.4) 1,349 (23.5) 
2010 - 2011 1519 (44.6) 212 (9.1) 1,731 (30.1) 
Changes in viral load and CD4 
Supressed (VL<1,000) at 4-months, n(%) 
Supressed  2,136 (62.7) 2,102 (89.8) 4,238 (73.8) <0.001 
4-month CD4, (cells/µl)
Median (IQR) 244 (156-337) 237 (164-323) 241 (160-
330.5) 
0.258 
4-month change in CD4 (4-month - pre-ART), n(%)
<100 1,050 (49.1) 922 (43.7) 1,972 (46.4) <0.001 
≥100 1,087 (50.9) 1,189 (56.3) 2,276 (53.6) 
12-month CD4, (cells/µl)
Median (IQR) 286 (191-391) 297 (213-390) 293 (204-391) 0.001 
12-month change in CD4 (12-month - pre-ART), n(%)
<100 479 (30.7) 440 (21.9) 919 (25.8) <0.001 
≥100 1,079 (69.3) 1571 (78.1) 2,650 (74.3) 
CD4 under 200, 
n(%) 
Always <200 938 (28.2) 72 (3.1) 1,010 (17.8) <0.001 
≥200 2383 (71.8) 2,268 (96.9) 4,651 (82.2) 
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There was no difference in the unadjusted risk of LTFU between the Green Clinic and 
treatment-initiation site patients (HR 0.95, 95% CI 0.80-1.12) (Table 6.4, Figure 6.1A & 
Figure 6.1C). In the multivariate model, Green Clinic patients had a slightly increased of 
risk of LTFU (aHR 1.36, 95% CI 1.09-1.69) compared to treatment-initiation site 
patients (Figure 6.1B).  The increased risk of LTFU in Green Clinic patients after 
adjustment persisted when restricting to patients who survived beyond 4 and 12-
months after ART initiation (Table 6.4, Figure 6.1D). LTFU was also associated with 
male gender, younger age, high CD4 cell count and low haemoglobin at baseline and 
time updated laboratory values (results not shown). An increasing association with 
year of ART initiation and LTFU was also observed; those initiating ART in 2008-2009 
had 5 times the risk of LTFU (aHR 5.22, 95% CI 2.80-9.75) and those initiating ART in 
2010-2011 had 10 times the risk of LTFU (aHR 9.73, 95%CI 5.16-18.37) compared to 
those who initiated ART in 2002-2003.  In unadjusted analysis, Green Clinic patients 
with a high CD4 cell count or in WHO stage I and II had a decreased risk of LTFU 
compared to those at the treatment-initiation site (CD4 ≥200 cells/µl: HR 0.57, 95% CI 
0.36-0.88; WHO Stage I and II: HR 0.66, 95% CI 0.48-0.91) (Supplementary Table 6.2).  
After adjustment, an increased risk of LTFU was observed for Green Clinic patients who 
were men, aged 25-34, initiated ART with a CD4 cell count <50 cells/µl or in WHO 
clinical stage III or stage IV, or initiated ART before 2006 compared to treatment-
initiation site patients.   
6.4.4 Viral rebound 
Rates of viral rebound were defined as a viral load measure >1,000 copies/mL were 
lower in the Green Clinic compared to the treatment-initiation site (8.1 vs. 11.3/100 
person-years) (Table 6.3).  The highest rates of rebound were observed in those less 
than 25 years of age compared to patients 45 years and older in both sites (14.7 vs. 
6.4/100 person-years and 19.5 vs. 7.3/100 person-years, respectively). In unadjusted 
analysis, Green Clinic patients were 23% less likely to experience viral rebound 
compared to patients in the treatment-initiation site (HR 0.77, 95% 0.66-0.91) (Table 
6.4). After adjustment, there was no difference in the risk of viral rebound (HR 0.94, 
95% CI 0.78-1.13).  
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Table 6.2 Incidence rates of mortality and loss to follow-up, at the treatment-initiation site and after down-referral to the 
Green Clinic* 
 
  Mortality Loss to follow-up 
 Person-time (years) Events Rate per 100 PY (95% CI) Events Rate per 100 PY (95% CI) 
Overall incidence rates from ART initiation+(n=5154)    
0-6 months 2,250.6 240 10.7 (9.4-12.1) 325 14.4 (13.0-16.1) 
6-12 months 1,881.9 60 3.2 (2.5-4.1) 158 8.4 (7.2-9.8) 
12-18 months 1,599.5 33 2.1 (1.5-2.9) 129 8.1 (6.8-9.6) 
18-24 months 1,355.6 17 1.3 (0.8-2.0) 77 5.7 (4.5-7.1) 
24-36 months 2,211.1 38 1.7 (1.3-2.4) 132 6.0 (5.0-7.1) 
36-48 months 1,678.2 26 1.6 (1.1-2.3) 97 5.8 (4.7-7.1) 
48-60 months 1,236.4 13 1.1 (0.6-1.8) 74 6.0 (4.8-7.5) 
60+ months 1,531.1 17 1.1 (0.7-1.8) 89 5.8 (4.7-7.2) 
OVERALL 13,744.4 444 3.2 (2.9-3.6) 1081 7.9 (7.4-8.4) 
Treatment-initiation site incidence rates from ART initiation until censoring or down-referral§ (n=5147) 
0-6 months 2,224.4 240 10.8 (9.5-12.2) 323 14.5 (13.0-16.2) 
6-12 months 1,717.2 55 3.2 (2.5-4.2) 145 8.4 (7.2-9.9) 
12-18 months 1,304.7 29 2.2 (1.5-3.2) 104 8.0 (6.6-9.7) 
18-24 months 973.9 14 1.4 (0.8-2.4) 52 5.3 (4.1-7.0) 
24-36 months 1,259.1 24 1.9 (1.3-2.8) 76 6.0 (4.8-7.6) 
36-48 months 693.8 11 1.6 (0.9-2.9) 46 6.6 (5.0-8.9) 
48-60 months 377.4 7 1.9 (0.9-3.9) 27 7.2 (4.9-10.4) 
60+ months 385.6 6 1.6 (0.7-3.5) 24 6.2 (4.2-9.3) 
OVERALL 8,936.0 386 4.3 (3.9-4.8) 797 8.9 (8.3-9.6) 
Green Clinic incidence rates from date of down-referral± (n=1740)   
0-6 months 825.5 11 1.3 (0.7-2.4) 53 6.4 (4.9-8.4) 
6-12 months 726.7 8 1.1 (0.6-2.2) 42 5.8 (4.3-7.8) 
12-18 months 677.6 8 1.2 (0.6-2.4) 28 4.1 (2.9-6.0) 
18-24 months 600.9 6 1.0 (0.5-2.2) 26 4.3 (3.0-6.4) 
24-36 months 943.7 13 1.4 (0.8-2.5) 60 6.4 (4.9-8.2) 
36-48 months 723.8 9 1.2 (0.7-2.4) 47 6.5 (4.9-8.6) 
48-60 months 156.5 3 1.9 (0.6-5.9) 18 11.5 (7.3-18.3) 
60+ months 7.4 0 0 1 13.6 (1.9-96.2) 
OVERALL 4,662.1 58 1.2 (1.0-1.6) 275 5.9 (5.3-6.6) 
*Restricted to patients who have a date of down-referral or who were never down-referred 
+Reports the rates of events among all patients from ART initiation until analysis closure or censoring 
§Reports the rates of events among patients from ART initiation until down-referral, analysis closure, or censoring 
± Reports the rates of event from date of down-referral until analysis closure or censoring 
140 
Table 6.3 Crude rates of progression to death, loss to follow-up and viral rebound by pre-ART characteristics and model of 
care* 
Event rates (per 100 person-years, 95%CI) 
Death Loss to follow-up Viral Rebound± 
Treatment-initiation site Green Clinic§ Treatment-initiation site Green Clinic§ Treatment-initiation site Green Clinicα 
All patients 4.3 (3.9-4.8) 1.2 (1.0-1.6) 8.9 (8.3-9.6) 5.9 (5.2-6.6) 11.3 (10.5-12.3) 8.1 (7.2-9.1) 
Age (years) 
Less than 25 5.1 (3.7-7.0) 0.6 (0.1-2.3) 14.5 (12.0-17.5) 7.3 (4.9-10.8) 19.5 (15.3-24.7) 14.7 (10.5-20.6) 
25-34 3.0 (2.6-3.6) 1.1 (0.8-1.7) 8.9 (8.0-9.8) 6.1 (5.2-7.2) 11.4 (10.1-12.8) 8.6 (7.4-10.1) 
35-45 4.7 (3.9-5.6) 0.6 (0.3-1.2) 8.3 (7.3-9.5) 5.6 (4.5-7.1) 11.3 (9.8-13.2) 6.4 (5.0-8.1) 
45 and above 7.8 (6.3-9.5) 3.6 (2.4-5.6) 7.1 (5.7-8.8) 4.9 (3.3-7.0) 7.3 (5.6-9.5) 6.4 (4.5-9.2) 
Gender 
Males 5.9 (5.1-6.9) 2.1 (1.4-3.0) 10.6 (9.4-11.8) 7.1 (5.8-8.6) 10.9 (9.4-12.7) 8.6 (7.0-10.5) 
Females 3.6 (3.1-4.1) 0.9 (0.6-1.3) 8.2 (7.5-8.9) 5.4 (4.6-6.2) 11.5 (10.5-12.7) 7.8 (6.8-9.0) 
CD4 (cells/µl) 
<50 8.6 (7.3-10.0) 1.4 (0.8-2.5) 8.4 (7.2-9.9) 5.0 (3.7-6.8) 14.4 (12.2-17.0) 9.8 (7.6-12.6) 
50-99 4.2 (3.4-5.3) 1.0 (0.5-1.8) 7.6 (6.4-8.9) 6.5 (5.1-8.2) 11.3 (9.5-13.5) 8.3 (6.5-10.6) 
100-199 2.6 (2.1-3.2) 1.5 (1.0-2.1) 8.3 (7.4-9.3) 6.6 (5.6-7.8) 10.2 (8.9-11.7) 8.0 (6.7-9.6) 
≥200 2.9 (2.1-4.0) 0.9 (0.4-2.1) 12.9 (11.0-15.0) 4.8 (3.3-6.9) 9.1 (7.2-11.5) 6.8 (4.9-9.6) 
WHO stage 
Stage I and II 1.8 (1.4-2.4) 0.8 (0.4-1.4) 10.2 (9.0-11.5) 4.1 (3.1-5.4) 11.2 (9.5-13.1) 7.8 (6.4-9.7) 
Stage III 4.4 (3.8-5.0) 1.4 (1.0-2.0) 8.5 (7.7-9.4) 5.2 (4.3-6.3) 12.0 (10.8-13.5) 8.8 (7.5-10.3) 
Stage IV 7.9 (6.7-9.3) 1.4 (0.9-2.4) 8.0 (6.8-9.5) 4.2 (3.0-5.8) 10.0 (8.2-12.1) 6.9 (5.3-9.1) 
Year of initiation 
2002 - 2003 3.8 (2.6-5.4) 0.6 (0.2-2.5) 1.4 (0.8-2.6) 5.7 (3.6-9.1) 7.2 (5.3-9.8) 3.8 (2.0-7.1) 
2004 - 2005 4.2 (3.5-5.1) 1.5 (1.0-2.2) 3.9 (3.2-4.7) 4.8 (3.9-5.8) 8.9 (7.5-10.6) 7.3 (6.0-9.0) 
2006 – 2007 5.3 (4.5-6.3) 1.4 (0.9-2.0) 8.7 (7.6-10.0) 6.3 (5.3-7.6) 13.5 (11.7-15.7) 9.6 (8.2-11.3) 
2008 – 2009 4.3 (3.5-5.3) 0.4 (0.1-1.6) 11.0 (9.7-12.6) 8.0 (5.9-10.8) 14.2 (12.1-16.6) 7.7 (5.5-10.8) 
2010 - 2011 3.0 (2.2-4.2) - 20.7 (18.3-23.3) 9.9 (4.7-20.9) 11.1 (8.8-14.0) 6.1 (2.3-16.4) 
*Restricted to patients who were never in the down-referral site or have a date of referral. 
§Patients who were down-referred to the Green Clinic contributed analysis time to the treatment-initiation site until referral.
± All patients suppressed (VL<1,000) at 4-months included in this analysis. Viral rebound defined as a viral load ≥1,000 after suppression.
α Restricted to eligible patients who have a down-referral date that precedes their date of failure
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Table 6.4 Relative hazard of mortality, loss to follow-up and viral rebound from Cox's proportional hazards models 
±All patients suppressed (VL<1,000) at 4-months included in this analysis. Virological failure defined as a viral load ≥1,000 after suppression. 
*Multivariate: Includes all demographic (age, sex) and baseline characteristics (CD4, WHO stage, viral load, haemoglobin, year of initiation) + time-updated CD4 and
viral load
§Multivariate: Includes all demographic (age, sex) and baseline characteristics (CD4, WHO stage, viral load, haemoglobin, year of initiation) + time-updated CD4
α Restricted person-time from 4-months after ART initiation
β Restricted person-time from 12-months after ART initiation
Mortality LTFU Viral rebound± 
Univariate Multivariate* Univariate Multivariate*  Univariate Multivariate§  
Model of Care HR (95% CI) aHR (95% CI) 
(n=4 088) 
HR (95% CI) aHR (95% CI) 
(n=4 088) 
HR (95% CI) aHR (95% CI) 
(n=2 981) 
OVERALL 
Treatment-initiation site 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Green Clinic 0.71 (0.50-1.00) 1.51 (0.90-2.55) 0.95 (0.80-1.12) 1.36 (1.09-1.69) 0.77 (0.66-0.91) 0.94 (0.78-1.13) 
FROM 4-MONTHSα 
Treatment-initiation site 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Green Clinic 0.72 (0.51-1.01) 1.41 (0.82-2.41) 0.96 (0.81-1.13) 1.33 (1.06-1.66) 0.77 (0.66-0.91) 0.94 (0.78-1.13) 
FROM 12-MONTHSβ 
Treatment-initiation site 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Green Clinic 0.70 (0.48-1.01) 1.29 (0.72-2.33) 0.95 (0.80-1.13) 1.41 (1.11-1.79) 0.79 (0.66-0.93) 0.97 (0.80-1.18) 
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Figure 6.1 Post-estimation plots of loss to follow-up by site of care, for: (a) 
Unadjusted LTFU, (b) Adjusted LTFU, (c) Unadjusted LTFU restricted to person-
time from 12-months after ART initiation, (d) Adjusted LTFU restricted to 
person-time from 12-months after ART initiation*  
*Adjusted includes demographic (age, sex) and baseline characteristics (CD4, WHO stage, viral load,
haemoglobin, year of initiation) and time-updated CD4 and viral load
6.5 DISCUSSION 
There is a growing need for decentralised models of ART care to deliver services in 
high-burden settings across sub-Saharan Africa. We evaluated a nurse-driven down-
referral service for maintenance of stable patients on ART. Over 5 years, 41% of 
patients were successfully down-referred to the Green Clinic. Overall, we found the risk 
of mortality and viral rebound was similar in patients at the Green Clinic and 
treatment-initiation site. However, LTFU is a significant challenge under both models of 
care, with rates increasing with each successive calendar year of initiation.  The Green 
Clinic was associated with an increased risk of LTFU compared to the treatment-
initiation site among men.  
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We found that mortality rates were highest in older patients, men, and patients with 
advanced HIV disease at ART initiation while LTFU was highest among younger 
patients, men and patients who initiated ART in recent calendar years. Findings are 
consistent with previous research [56, 117].   After adjusting for clinical and 
demographic variability between patients, no difference in mortality or viral rebound 
was observed between patients at the Green Clinic and treatment-initiation site.  Taken 
together, these findings support previous research suggesting that decentralised 
programmes can have comparable outcomes for stable patients [165, 174, 178, 250].  
 
The adjusted risk of LTFU was slightly higher in patients at the Green Clinic compared 
to those attending the treatment-initiation site.  This difference appears to be driven by 
subgroups of male patients, patients 25-34 years of age and those with advanced HIV 
disease.  Patients who initiated ART between 2002-2005 started at the facility when 
the staff to patient ratio had sufficient capacity for individualised counselling and 
support.  It is possible that the change between the level and type of care patients 
received early in the ART programme and the Green Clinic led to increased 
disengagement and the higher risk of LTFU.  
 
Growing evidence highlights LTFU as a ubiquitous challenge facing ART programmes in 
resource-limited settings [56].  Our data support this concern, with the risk of LTFU 
increasing with each calendar year of ART initiation in both models of care.  In adjusted 
models there was a five and ten-fold increase in the risk of LTFU among patients 
initiating ART between 2008-2009 and 2010-2011, respectively, compared to patients 
initiating ART before 2004. Innovative models of care with decentralised ART 
management and task shifting of responsibilities are required to address the challenge 
of growing ART programmes and long-term retention in care [42, 151]. While the 
benefits of such models include offering ART services closer to home, by lower cadres 
of staff, there may be risks involved.  As with the Green Clinic, many of these models 
incorporate less frequent visits, with fewer opportunities for individualised counselling 
and adherence support that could negatively impact long-term retention.  
 
There is some evidence suggesting that patients who initiate ART at higher CD4 cell 
counts may be at greater risk of LTFU and the high rates of LTFU observed in our study 
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among patients at the treatment-initiation site with high baseline CD4 cell counts 
support this [134, 136]. Patients initiating ART with a CD4 cell count above 200 cells/µl 
were 43% less likely to be LTFU at the Green Clinic compared to the treatment-
initiation site.  These results suggest that specialised, doctor-managed clinics may not 
be the most appropriate model of care for patients with high CD4 cell counts at ART 
initiation. Given that the Green Clinic offered shorter and less frequent visits, the model 
may be especially beneficial to patients who initiate with less advanced disease. 
Expanding and accelerating access to decentralised models of care may be especially 
important as ART programmes expand eligibility criteria and initiate patients at 
progressively higher CD4 cell counts. 
This study has several strengths and limitations.  The data come from a large, well-
maintained cohort from a public sector South African ART clinic that is in many ways 
representative of primary care services in the region. There are relatively good 
ascertainment of outcomes, but LTFU may be overestimated through inclusion of 
patients who are dead, transferred out, or otherwise disengaged from care [53, 87, 203, 
211].  However, whether such over-reporting of LTFU could be systematically different 
between the two models of care is unclear.  The early establishment of the down-
referral site allows for substantial follow-up time and the ability to assess the long-
term impact of the model.  The major weakness of this analysis is the potential for 
selection bias in terms of who was eligible and referred for the down-referral model of 
care.  To account for this, we adjusted for pre-ART characteristics and laboratory data.  
Although we cannot rule out the possibility of residual confounding effects, in the 
absence of the ability to randomise patients, data from this operational research 
programme provides valuable evidence on the impact of different models of care on 
patient outcomes.   
The 2013 WHO guidelines include specific recommendations for decentralisation and 
task shifting to assist in expanding ART access and improving retention [28]. These 
data suggest that good outcomes can be achieved in such models of care but that the 
challenge of LTFU requires on-going attention. There is a need for further research to 
determine effective models of care that successfully can deliver ART at a community 
level in high-prevalence, resource-limited settings [42, 151, 176, 183, 245, 247, 251]. In 
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particular, more data are necessary to determine the cost-effectiveness of these 
models, as well as to understand the potential risks and benefits and trade-offs that 
may exist in offering out-of-clinic ART maintenance. Any alternative model of care 
needs to consider that ART programmes are maturing and initiating patients at 
progressively higher CD4 cell counts.   
 
In conclusion, in these data a large proportion of stable ART patients were successfully 
down-referred for treatment maintenance.  While no differences in the risk of mortality 
or virological failure were observed, there was a slight increase in the risk of LTFU at 
the Green Clinic compared to the treatment-initiation site. Overall these data suggest 
relatively good outcomes achieved under this down-referral service. Further research 
is necessary to determine models of care that incorporate task shifting and 
decentralised ART care potentially targeting specific types of patients to effectively 
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Chapter 7. Implementation of community-
based Adherence Clubs for stable 
antiretroviral therapy patients 
Grimsrud A, Sharp J, Kalombo C, Bekker LG, Myer L. Implementation of 
community-based Adherence Clubs for stable antiretroviral therapy patients. 




Community-based models of antiretroviral therapy (ART) delivery have been 
recommended to support ART expansion and retention in resource-limited settings.  
However, the evidence base for community-based models of care is limited. We 
describe the implementation of community-based Adherence Clubs (CACs) at a large, 
public-sector facility in peri-urban Cape Town, South Africa.    
Methods 
Starting in May 2012, stable ART patients were down-referred to CACs. Eligibility was 
based on self-reported adherence, >12 months on ART, and viral suppression.  CACs 
were facilitated by four community health workers (CHWs) and met every eight weeks 
for group counselling, a brief symptom screen and distribution of pre-packed ART.  The 
CACs met in community venues for all visits including annual blood collection and 
clinical consultations. CAC patients could send a patient-nominated treatment 
supporter (“buddy”) to collect their ART at alternate CAC visits.   Patient outcomes 
[mortality, loss to follow-up, and viral rebound (>1,000 copies/mL)] during the first 
18-months of the programme are described using Kaplan-Meier methods.   
Results  
From June 2012 to December 2013, 74 CACs were established, each with 25-30 
patients, providing ART to 2,133 patients. CAC patients were predominantly female 
(71%) and lived within 3km of the facility (70%). During the analysis period, 9 patients 
in a CAC died (<0.1%), 53 were up-referred for clinical complications (0.3%) and 573 
CAC patients sent a “buddy” to at least one CAC visit (27%).  After 12 months in a CAC, 
6% of patients were lost to follow-up and fewer than 2% of patients retained 
experienced viral rebound. 
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Conclusion 
Over a period of 18 months, a community-based model of care was rapidly 
implemented decentralising more than 2,000 patients in a high prevalence, resource-
limited setting. Further research is needed to support down-referral sooner after ART 
initiation and to describe patient experiences of community-based ART delivery.   
7.2 INTRODUCTION 
Models of care for ART delivery have evolved considerably over the last decade of ART 
provision in resource-limited settings.  Services have been decentralised from hospitals 
to primary care facilities and tasks shifted from doctors to nurses and community 
health workers (CHWs) [6].  However, we are dependent on a limited number of 
models of care with 95% of HIV services provided within health facilities [3, 225].  To 
support the ambitious targets and accelerated pace of ART expansion, further 
adaptations are needed [3].    Health system changes are also necessary to improve 
retention in care especially where severe congestion of health facilities is occurring [7].  
To this end, decentralising at least 30% of HIV services into communities has been 
recommended [3].   
Community-based models of care for stable patients present one such model, designed 
to make ART delivery more efficient for the health system and provide appropriate 
support to encourage long-term retention of patients [151].  However, the evidence 
from community-based models of care is limited.  In the recent review on 
decentralisation, the three community-based models of care were limited to programs 
providing home-based ART delivery [153, 167, 168, 171, 174].  While the results 
suggest that community-models can have comparable outcomes to facility-based 
models, the scalability of home-based ART models is debatable and such models do not 
encourage patient self-management, a key level of task shifting required for retention 
in care [41].   
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The adherence club model of care was designed to support ART maintenance for 
groups of stable patients in a CHW-facilitated model with peer-support and increased 
patient self-management [43, 143]. The success of an early pilot project in Cape 
Town [178], led to the model of care being adopted by the City of Cape Town and 
Western Cape Government Department of Health (DOH) [143]. From 2011, facility-
based Adherence Clubs were implemented across Cape Town [43, 143]. The Gugulethu 
adapted the adherence club model to local conditions by shifting the service away from 
health facilities to be community based.  Stable patients were down-referred to 
community-based adherence clubs (CACs) and managed by CHWs.  Adherence clubs 
are expected to have advantages both for patients and the health system [252].  For 
patients, they are trying to reduce costs, both in the time it takes to receive treatment 
and support, and in money reducing transport costs by providing care closer to home 
and taking less time away from work and family commitments. For the health system, 
adherence clubs aim to empower the patient to manage their condition, which thus 
decreases the workload on the health system and improves patient outcomes.  By 
supporting increased patient self-management, the clinically trained staff has more 
time to deal with new and complicated ART patients and facilitates are not crowded by 
patients who do not require clinical care. Here we describe the early outcomes and 
lessons learned from our experience implementing the CACs given the limited evidence 




Adherence clubs were implemented within the Hannan Crusaid Treatment Centre 
(HCTC) at the Gugulethu CHC in Cape Town, South Africa.  The ART programme at the 
HCTC is a well-characterised, large, public-sector service that has been described in 
detail previously [16, 249, 253]. The HCTC receives support from the Desmond Tutu 
HIV Foundation and peer counsellor support from the Sizophila programme [16, 57]. In 
Table 7.1, key features of the standard of ART care at the CHC is compared with the CAC 
model.  Implementation of the CACs is described in detail covering the six core 
components of the WHO health systems framework [254].  
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7.3.1 CAC eligibility and referral 
ART Adherence Clubs were designed to decongest facilities and support stable ART 
patients [43, 143].  Stable patients were voluntarily down-referred to the CACs.  
Patients were considered “stable” if they have been adherent on the same ART regimen 
for >12 months, had two consecutive undetectable (<400 copies/mL) viral loads, and 
did not have any other medical conditions requiring more frequent follow up. 
Individual patient counselling at the time of referral described the benefits of CAC 
model, a description of the visit schedule and how to access clinical care outside of CAC 
visits as necessary.   
Table 7.1 Comparison of Standard of Care and CACs for the management of ART 
patients  
Standard of Care (CHC) Community-based Adherence 
Clubs (CACs) 
Setting Clinic based Community based 
Patient profile All ART patients Stable patients 
Key personnel Doctors/nurses CHW 
Frequency of visits 2 monthly 2 monthly 





Location of clinical 
consultations  
CHC Community-based 
Emphasis of patient 
contacts 
Detecting clinical complications Treatment adherence, patient 
wellness 
Units of care Individual patient Groups of 25-30 
Peer-based support No emphasis Strong emphasis 
Patient self-
management 
Minimal emphasis Strong emphasis 
Frequency of laboratory 
monitoring 
6-12 monthly 12-monthly
Management of clinical 
complications 
On-site Up-referral to CHC 
ART packing and 
dispensing 
Packed at the CHC pharmacy, 
dispensed from pharmacy 
Pre-packed by central dispensing 
unit, dispensed at CAC visit 
Treatment buddy Patients attend the CHC and 
collect ART themselves 
ART can be collected by a 
treatment buddy 
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7.3.2 Community-based Adherence Clubs (CACs) venues 
The adherence club model was adapted to reduce congestion in the CHC deliver care in 
the local community as a result of congestion in the CHC and to provide ART within the 
community.  The first clubs met in a separate building at the CHC.  Starting in May 
2013, Adherence Clubs were transitioned from being facility-based to being located at 
community venues.  From June 2013, the Clubs were all CACs meeting at a community-
based organisation (CBO) facility approximately 300 meters m from the CHC.  From 
April 2014, CACs relocated to a room within the municipal community centre located 
approximately 450 meters m from the CHC. Daily transportation by one of the CHC 
vehicles is provided for the CAC CHWs, the pre-packed ART, the CAC registers and, on a 
phlebotomy or clinical club day, the CAC nurse.  
 
7.3.3 CAC operations 
Recruitment for CACs began in May 2012 and the first club met in June 2012. Initially 
there was one Club per day expanding to two Clubs per day as the programme grew.  
Each club had approximately 25-30 patients who met every two months (eight-weeks).  
At each CAC visit, there was a group counselling session, a brief symptom screening 
and distribution of ART.  The group counselling sessions focused on content relevant to 
stable patients on ART such as safe conception and was facilitated by the CHW.  The 
CHW weighed all patients and asked administered a brief screening questionnaire on 
systemic well-being.  CAC sessions were facilitated by a CHW with a standard Club visit 
lasting approximately 60 minutes.   Annual visits for phlebotomy and clinical 
consultations took longer (maximum three hours) due to the time taken for each 
patient to be seen by the club nurse. At the four-month Club visit monitoring blood 
samples were drawn and this was repeated annually.  A clinical consultation with a 
nurse occurred at the 6-month Club visit and was then repeated annually.  
 
All of the CAC ART was pre-packed off-site at a central pharmacy.  Patients received 2-
months of pre-packed ART at their CAC visit.  During the October/November visit, four-
months of pre-packed ART was distributed to CAC members to support migration over 
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the holiday period [255].  Therefore, most CACs met five times per year.  and 6 monthly 
prescriptions were provided in August/September and February/March.  The group 
counselling session in the October/November CAC visit focused on how to ensure 
adherence to ART when travelling and how to access ART elsewhere should a patient 
not return to Gugulethu for any reason.  
Patients who were late for their CAC visit had a grace period of five working days to 
collect their ART and remain in a club. CAC patients who were late for their CAC would 
return to the CAC CHWs at the CHC for either collection of their ART if they were within 
the grace period or up-referral to the CHC is they were later than five working days. 
Patients were also up-referred if they were no longer stable.  This includedInstability 
included development of a condition that required more frequent clinical consultations 
(e.g. tuberculosis), the need to switch regimens or viral rebound.  
A patient-nominated treatment supporter or “buddy” could be sent to every alternate 
CAC visit to collect the CAC patient’s ART. The buddy would arrive at the CAC with the 
patient’s clinic card, collect their ART and the visit would be recorded in the CAC 
register as a buddy collected visit in place of where the patient’s weight and symptom 
screen would typically be captured.  Patients could nominate more than one buddy and 
the specific details of who the buddy was were not routinely collected.      
7.3.4 CAC Monitoring & Evaluation 
CAC data were recorded in a paper register with one register per CAC.  At each CAC 
visit, the weight of each patient and results of the brief symptom screen were recorded.  
A summary of the CAC data (number of patients attended, number of patients up-
referred, number of patients who sent a buddy) was completed by the CHW following 
each CAC visit and monthly group level reports were compiled for the DOH.  Standard 
individual patient files at the CHC of CAC members were only used at the annual clinical 
visit. When a patient was down-referred to a CAC, the CAC number was placed on the 
CHC patient file so that clinicians could determine where the patient was receiving 
ART.   
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7.3.5  Human resources and management 
CACs were CHW-managed with support from clinical staff at the CHC. The CHWs had 
varying levels of education and experience as part of the Sizophila peer-counselling 
programme [16, 57].  Each of the four CHW’s were responsible for managing between 
12 and 18 CACs.  The specific responsibilities of a CAC CHW included calling all CAC 
patients before their first CAC visit, completing club registers, compiling CAC statistics 
monthly, completing the brief assessment of CAC patients (weighing and symptom 
screening) on their CAC day, facilitating the group counselling session on CAC days, 
checking with the pharmacist that pre-packed ART was ready for each CAC patient, 
tracing any CAC patients who did not arrive, and recording blood results in the CAC 
registers.   
A professional nurse was assigned as the CAC nurse rotating on a monthly basis. The 
CAC nurse was at the community venue for blood and clinical CAC visits approximately 
two days per week.  If a CAC patient needed to see a clinician on their CAC visit date, 
the patient was referred to the CHC and had priority access to the CAC nurse.  
One of the pharmacists at the CHC was responsible for the CACs. The CAC Pharmacist 
ensured that there was a valid script for each CAC patient and that the scripts included 
the CAC number and first visit date for dispensing.  The central pharmacy delivered the 
pre-packed medication parcels to the CHC pharmacy three days before the CAC visit 
date to the CHC pharmacy.  On the day of the CAC, the pharmacist provided all the pre-
packed ART for the CAC to the CAC CHW for distribution to CAC patients.    
Management of the CACs was integrated within the CHC management. The CHC clinical 
manager provided oversight with support from the CHC facility manager.  No 
additional financing was required during the implementation of CACs.  In December 
2013, a clubs manager was appointed from the existing CAC CHW team and a new CHW 
was recruited to join the CAC. This position was created to support the growing 
programme and alleviate the administrative CAC responsibilities previously completed 
by the clinical manager of the CHC.  
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7.3.6 Analysis 
Ethical approval for the collection of routine clinic data and data on adherence clubs 
was obtained from the Human Research Ethics Committee in the Faculty of Health 
Sciences at the University of Cape Town. Data were analysed using STATA 13.0 (STATA 
Corporation, College Station, Texas, USA).   All patients down-referred to an adherence 
club between May 2012 and December 2013 were included in the analysis.  Patients 
entered the analysis on the date of their first club visit.  Patient outcomes were 
assessed at the end of 2013 (analysis closure). The primary outcome of interest was 
loss to follow-up (LTFU) with secondary outcomes of mortality and viral rebound also 
reported.  LTFU was defined as having no contact at a CAC or the CHC in the first 12 
weeks of 2014. For patients defined as LTFU, the date of last contact was the LTFU date.  
Viral rebound was defined as having a single viral load measure of >1,000 copies/mL 
after suppression.  Patients were censored at the date of death, transfer or LTFU.  
The number of new CAC patients and CACs were reported by month. Median year of 
club initiation is reported biannually and described by pre-ART characteristics.  Patient 
characteristics at ART initiation (sex, age, CD4 cell count, viral load and year of 
initiation), CAC initiation (age, CD4 cell count, time on ART) and demographics 
(distance from clinic, employment status) at CAC initiation are described and 
summarised using appropriate summary statistics, continuous variables with medians 
and inter-quartile ranges (IQRs) and categorical variables as proportions. Median time 
to CAC initiation was calculated by pre-ART characteristics with IQRs and Wilcoxon 
rank-sum tests used to investigate associations with pre-ART characteristics.  Time to 
event analysis was conducted using Kaplan-Meier methods.  Kaplan-Meier graphs of 
the outcomes (mortality, LTFU, and viral rebound) are presented and proportions 
reported every three months.   
7.4 RESULTS 
Over an 18-month period, 2,113 patients were decentralised to one of 74 Community-
based Adherence Clubs (Figure 7.1).  During this same period, 2,776 patients were 
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initiated onto ART at the CHC.  By December 2013, approximately one-third of the CHC 
patients were managed in a CAC.  CAC patients were predominantly female (71%), 
lived within three kilometres of the CHC (72%) and unemployed (58%) (Table 7.2).  
The median pre-ART CD4 cell count was 134 cells/l and 32% of CAC patients had been 
on ART for 6 years or longer at the time of joining a CAC. At the time of joining a CAC, 
the median age was 39 years and the median CD4 cell count was 517 cells/l. 
 
Figure 7.1 Implementation of Community-based Adherence Clubs between June 





The median time from ART initiation to CAC uptake was 4.4 years (IQR 2.5-6.6) (Table 
7.3).  For CAC patients who initiated ART in 2011 and 2012 when ACs were available, 
time to CAC initiation was 1.6 (IQR 1.4-1.9) and 1.2 (IQR 1.1-1.3) years, respectively.  
The median year of ART initiation among CAC patients increased from 2007 (IQR: 
2005-2009) among those joining a CAC during 2012, to 2009 (IQR: 2006-2011) in the 
first half of 2013 and 2011 (IQR: 2010-2012) and in the latter half of 2013 (results not 
shown).   
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During the study period, nine patients in a CAC died (<0.1%) (Figure 7.2A), 53 were up-
referred to the CHC for clinical conditions (0.3%) and 573 CAC patients sent a “buddy” 
to at least one club visit (27.1%).  LTFU among CAC patients was 2.6% (95% CI 2.0-
3.4), 3.9% (95% CI 3.1-4.8) and 6.2% (95% CI 5.1-7.4) at months 6, 9 and 12, 
respectively (Figure 7.2B, Table 7.4).  Kaplan-Meier estimates of viral rebound were 
1.4% (95% CI 1.0-2.0) at 6-months and 1.7% (95% CI 1.2-2.4) at 12-months (Figure 
7.2C, Table 7.4). Overall retention on ART was 97.2% (95% CI 95.4-97.8) at 6-months 
and 93.5% at 12-months (95% CI 92.2-94.5).  In Chapter 8, further outcomes from 
CACs are presented.   
Table 7.2 Characteristics and demographics of Community-based Adherence Club 
patients pre-ART and at time of Club start 
Adults (≥16 years) 
n = 2,113 
Gender, n (%) 2,113 (100) 
Female, n(%) 1,489 (70.5) 
Age at Club start (years), median (IQR) 38.8 (34.0-44.5) 
Age categories at Club start (years), n (%) 
16-24 38 (1.8) 
25-34 593 (28.1) 
35-44 974 (46.1) 
≥45 508 (24.0) 
CD4 cell count at Club start (cells/l), n (%) 2,109 (99.8) 
Categorical, n (%) 
<200 49 (2.3) 
200-399 502 (23.8) 
400-599 846 (40.1) 
600-799 439 (20.8) 
≥800 272 (12.9) 
Median (IQR) 517 (396-669) 
Pre-ART Viral load, log10 copies/mL, n (%) 1,588 (75.2) 
Median (IQR) 4.8 (4.3-5.2) 
Years on ART at Club start, median (IQR) 4.6 (2.5-6.6) 
Categorical, n (%) 
<1.5 years 211 (10.0) 
1.5 – 3 years 465  (22.0) 
3 – 4.5 years 407 (19.3) 
4.5 – 6 years 347 (16.4) 
6 – 7.5 years 407 (19.3) 
≥7.5 years 276 (13.1) 
Distance from the CHC, n(%) 1,392 (65.9) 
<1 km 463 (33.2) 
1-3 km 540 (38.9) 
3-5 km 254 (19.0) 
>5 km 12 (9.1) 
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Overall 4.4 (2.5-6.6) 
Gender  
Females 4.5 (2.5-6.7) 0.262 
Males 4.3 (2.4-6.5) 
Age, (years) 
16-24 4.1 (2.5-6.4) 0.013
25-34 4.8 (2.6-6.7)
35-44 4.2 (2.5-6.6)
≥45 3.8 (2.3-6.2) 
CD4, (cells/l) 
<49 5.9 (3.5-7.2) <0.001 
50-99 5.4 (2.3-7.1)
100-199 4.8 (2.9-6.5)
≥200 2.7 (1.7-4.8) 
Missing 3.7 (1.8-6.6) 
Year of initiation 
2002 - 2004 8.6 (8.2-9.2) <0.001 
2005 - 2007 6.4 (5.7-7.1) 
2008 – 2010 3.3 (2.6-4.0) 
2011 – 2012 1.4 (1.2-1.7) 
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Figure 7.2 Kaplan-Meier plots of Community-based Adherence Clubs (a) Morality, 
(b) Loss to follow-up, and (c) Viral rebound
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Table 7.4 Kaplan-Meier estimates of mortality, loss to follow-up and viral 
rebound by duration of follow-up after Community-based Adherence Club 
initiation± 
 
Duration of follow-up n (%) Mortality 
% (95% CI) 
Loss to follow-up 
% (95% CI) 
Viral rebound§ 
% (95% CI) 
3 months 2,078 (98.3) 0.1 (0.1-0.4) 1.0 (0.7-1.6) 0.1 (0.1-0.4) 
6 months 1,925 (91.1) 0.2 (0.1-0.6) 2.6 (2.0-3.4) 1.4 (1.0-2.0) 
9 months 1,602 (75.8) 0.3 (0.1-0.7) 3.9 (3.1-4.8) 1.5 (1.1-2.1) 
12 months 1,170 (55.4) 0.4 (0.2-0.8) 6.2 (5.1-7.4) 1.7 (1.2-2.4) 
15 months 572 (27.1)  0.5 (0.2-1.0) 9.3 (9.9-11.0) 4.4 (3.3-5.8) 
18 months 63 (3.0) 0.9 (0.3-2.2) 12.3 (9.7-15.5) 7.8 (5.2-11.6) 
±Estimates are from time of Community-based Adherence Club initiation 





Over a period of 18 months, more than 2,000 stable ART patients were successfully 
decentralised from a doctor-driven primary health care clinic to a community-based 
model of care where they were managed by four CHWs.  We adapted the adherence 
club model to be community-based with all visits occurring out of the facility.  CAC 
patients accessed ART and received annual clinical consults in the community, thus 
decongesting the primary health care facility. The size and scale-up of the CAC model is 
unprecedented, with implementation occurring more rapidly and the volume of 
patients much larger than previous models of care described [177, 178]. 
 
This model of care exemplifies the substantial paradigm shift in ART delivery over the 
past decade from doctor-led facility-based care towards decentralisation of care and 
task shifting of patient care responsibilities. When ART became publically available in 
2004, programs were largely individualised, hospital-based and doctor-led [42].  In 
South Africa, task shifting has included increasing the number of nurses trained to 
initiate ART from 250 in February 2010 to 23,000 by May 2013 [256].  Concurrently, 
ART services have been increasingly decentralised with the more than 3,500 facilities 
supporting ART provision by mid-2013 [15, 256]. The findings of our study highlight 
that further decentralised community-based models with task shifting to CHWs can 
successfully support ART maintenance and encourage patient self-management.  
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Increasing patient self-management is crucial for ART programs to expand and for HIV 
to be successfully managed as a chronic condition [257]. 
Patients in the CACs had high levels of retention and virologic suppression.  At 12-
months, retention on ART was 94%, LTFU was 6% and 2% of patients had experienced 
viral rebound. These are promising outcomes and demonstrate that the majority of 
patients retained in the community model were adherent and virally suppressed.  
Retention in care was less than the 97% reported from the pilot study of facility-based 
Adherence Clubs [178].  Limited outcome data are available from other community-
based programs with most community-models providing home-based ART 
delivery [154, 155]. The exception is the community adherence group (CAG) model in 
Mozambique with 98% retention in care after 12-months [177].  
Our findings should be considered in light of a number of limitations.  It is difficult to 
determine the generalizability of our findings as the context in which these innovative 
models of care are implemented is of critical importance.  We implemented a novel 
model of care in a high-prevalence site with an existing peer-counselling programme 
with considerable NGO support.  In addition, the site had a well functioning pharmacy 
and logistics system without ART stock-outs during the study period. It is difficult to 
gauge the transferability of our model to other settings, but our results highlight that 
its feasibility should be considered elsewhere.  Furthermore, flexibilities within the 
model allow for adaptations to local contexts. Models of ART delivery are not a one-
size-fits-all solution [151].  Adaptations to local context will therefore be necessary for 
broader implementation.    The focus of this analysis was limited to early outcomes and 
more research is necessary to assess factors associated with retention in this model of 
care delivery with long-term outcomes of decentralized patients.  In addition, the 
impact of decentralizing patients on the workload of the CHC is not assessed.      
We present key factors and challenges that contributed to implementation success 
based on our experiences (Table 7.5).  A cohesive team comprising the CHW, 
pharmacist and clinic management team worked as a collective despite having different 
line managers. It was essential that all clinic staff bought into the benefits of the model 
and trusted that patients could be successfully managed outside of the traditional 
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model of care and clinic facility.  Second, policies allowing ART to be distributed within 
the community were agreed by the provincial, sub-district and facility teams and could 
therefore be used. Furthermore, CACs received a reliable supply of ART. Without a 
reliable drug supply, patients may not trust a community model of care [43].  The 
CHWs involved in CACs were part of a well-established cadre of staff at the CHC and 
played a pivotal role in providing quality treatment support to CAC members.     
 
A fundamental factor to the success of the CACs was that patients receiving ART within 
the community were regarded as an extension of the CHC with the facility continuing to 
assume full responsibility and accountability for AC patients’ care [151].  Since the CHC 
did not routinely see the patients receiving ART in the community-based model, these 
patients could become easily forgotten and dismissed as not the responsibility of the 
CHC. It was difficult to engage staff that were not dedicated CAC staff to support CAC 
patients in CAC activities such as rescripting.  This echoes challenges previously 
described in the literature where health personnel are trained within a hierarchical 
framework of health care delivery and do not provide a supportive environment for 
CHWs [46, 258]. Ongoing and sustained efforts are needed to emphasise that CAC 
patients .    
 
Our experience of implementing community-based ART delivery was not without 
challenges (Table 7.5). The location of the CACs within the community had to shift 
between a CBO facility to a municipal community centre.  A long-term standing 
agreement with the municipal venue is still underway requiring negotiation at the level 
of the city and the community.  While in principal the DOH is supportive of expanding 
community-based ART delivery, in practice there have been significant barriers to 
overcome.  A unique challenge of community-based delivery models is the physical 
location outside of existing health facilities.  Any upgrades or maintenance at 
community venues is not covered within the DOH budgeting and it is unclear if 
extending responsibilities of staff to outside of the CHC is within their contractual 
agreements.  Being located outside of the primary care facility also provides daily 
logistical challenges due to transportation of materials between the community facility 
and the primary care facility.  In addition, with limited resources available at the 
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community facility, CAC CHWs frequently use their personal cell phones to follow-up 
with patients and contact the CHC.  
Table 7.5 Key factors and challenges to implementation success of the CAC model 
Factor for implementation 
success 
Challenge for implementation 
success 
Community-based 
models as an 
extension of the 
facility 
Strong bi-directional referral 
pathways between facility 
and community-based 
models  
Patients in community-based models 
not viewed as the responsibility of the 
facility (i.e. reluctance to assist with 
rescripting of CAC patients)  
Location Stable patients managed 
outside of health care facility 
Ensuring access to a clean and 
appropriate community-based facility 
Staffing Cohesive, multidisciplinary 
team 




ART distribution by CHWs 
supported by the pharmacy 
Policies regarding dispensing and 
distribution 
ART supply Reliable, uninterrupted 
supply 





CHWs using their personal 
cell phones 
Limited resources within the 
community venue and distance to CHC 
for supplies 
Adaptation of the CAC model will be necessary for further implementation.  The 
frequency of CAC visits, the window period for late ART collection by CAC patients and 
the type of symptom screening completed at CAC visits can all be adapted to align with 
local policy.  While we utilised a central pharmacy for the CAC ART, this component of 
the model could be adapted and ART packing done at the facility level.  It is 
recommended that the CAC model be implemented over time, allowing for both 
patients and staff to see the benefits while being reassured that the model can 
adequately support stable patients without undue risk.  It is crucial that the CACs and 
all community-based delivery models be viewed not just as a response to the high 
patient volume but as beneficial and even preferable to patients [151].  Community-
based models of care allow patients to return to normal life and increase their self-
management increasing the effectiveness of ART delivery [42, 134].   
While there is an urgent need for ongoing research to optimise community-based ART 
delivery, our implementation findings support continued expansion of community-
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based ART delivery in high prevalence, resource-limited settings.  The adherence club 
model was successfully adapted, decentralised and implemented to provide 
community-based care, and it is novel that our model supported ART maintenance 
exclusively in the community.  Additional data and shared experiences from innovative 
community-based models of care are needed to support long-term ART retention as 
ART cohorts in resource-limited settings continue to expand and mature.   
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Chapter 8. Community-based Adherence 
Clubs for stable antiretroviral therapy 
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Adherence Clubs for stable antiretroviral therapy patients: Outcomes from 






There are few data on patient outcomes from community-based models of 
antiretroviral therapy (ART) delivery.  We describe outcomes of ART patients 
decentralised to community-based Adherence Clubs (CACs) and compare these to 
patients on ART at the community health centre (CHC). 
Methods 
The analysis included 8,150 adults initiating ART from 2002-2012 at a public sector 
clinic in Gugulethu, South Africa followed until the end of 2013.  From June 2012, stable 
patients (ART >12 months, supressed viral load) were referred to CACs. Kaplan-Meier 
methods estimated time to outcomes stratified by gender and age (youth: 15-24 years 
of age and older patients: >25 years of age). LTFU was compared between CACs and 
facility-based care using proportional hazards models with time-varying covariates and 
inverse probability weights of CAC participation.   
Results 
Of the 2,113 patients (68.8% female, 7.4% youth) decentralised to a CAC, 94% were 
retained on ART after 12-months.  In multivariate models of CAC patients, LTFU 
[(adjusted hazard ratio) aHR: 2.17, 95% CI 1.26-3.73] and viral rebound (aHR 2.24, 
95% CI 1.00-5.04) were twice as likely in youth compared to older patients. Among 
CAC patients, no difference in the risk of LTFU or viral rebound was found by gender 
(p-values 0.613 and 0.278, respectively). CAC participation reduced LTFU by 67% 
(aHR: 0.33, 95% CI 0.27-0.40) compared to facility-based care, and this reduction 
persisted when stratified by patient demographic and clinic characteristics.     
Conclusion 
Community-based Adherence Clubs appear to be associated with a decreased risk of 
LTFU compared to facility-based care.  More research is needed on how to expand the 
role of community-based ART services to support long-term retention. 
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8.2 INTRODUCTION 
The scale-up of antiretroviral therapy (ART) to 13.6 million people in resource-limited 
settings in the past decade has been unprecedented [3]. Despite this, treatment 
coverage in adults is estimated at only 38% [3].  South Africa’s ART programme 
exemplifies these trends of rapid implementation and unmet treatment needs. Between 
2010 and 2013 a third of all new ART patients globally were in South Africa [26] and 
today the programme provides ART to more than 2 million people [4].  However, with 
6.4 million people in the country living with HIV [4], further scale-up of ART is needed.   
In addition to the challenge of accelerating ART expansion, attrition on ART represents 
a substantial hurdle [3, 77].  Loss to follow-up (LTFU) is a considerable threat to the 
success of ART programmes with 20-30% of patients estimated to be lost from the 
programme after 3-years [24, 39, 56].  The risk of LTFU varies across sub-groups with 
higher rates generally higher in men [132, 144-146] and younger patients  [131, 132, 
135, 147].  
Against this background, the 2013 World Health Organization (WHO) guidelines 
recommended earlier ART initiation [28, 29].  To facilitate this expansion and improve 
retention in care, reorientation of ART delivery through decentralisation of services 
into communities and the shifting of specific tasks related to ART provision to different 
cadres of health care workers has been proposed [28].  Recent systematic reviews from 
models with task shifting concluded that patients supported by nurses or community 
health workers (CHWs) have comparable outcomes to those supported by 
doctors [152, 154].  Evidence from models where treatment is decentralised into 
communities is limited with most models providing home-based ART delivery [153, 
155].  
There is burgeoning interest in community-based ART delivery with pilot studies 
reporting favourable outcomes [43, 151, 177].  Community-based Adherence Clubs 
(CACs) facilitated by CHWs were implemented to provide effective ART support to 
stable ART patients.  They were designed both to decongest the local primary health 
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care facility and reduce attrition by decreasing the frequency and intensity of patient 
visits and providing support within the community.  This study describes outcomes 
[LTFU and viral rebound] over the first 18-months of CAC implementation in Cape 
Town, South Africa, and compares patient outcomes under the CAC model of care to 




8.3.1 Study setting 
The Gugulethu Community Health Centre (CHC) is a large primary health care facility, 
typical of urban public sector ART services across the region.  It serves a community of 
predominantly low socioeconomic status with a high HIV seroprevalence. The local 
ART service has been described in detail previously and in Chapters 6 and 7 [57, 63, 
249, 253].  Briefly, the service began providing ART in 2002 based on South African 
national programme criteria for ART initiation and regimens.  CD4 cell count and viral 
load were monitored before ART initiation, after 4 months on ART and then repeated 
annually. At each visit patients had a clinical consultation with either a medical doctor 
or professional nurse followed by adherence support from a counsellor before 
proceeding to the pharmacy to collect their ART.  Each patient was assigned to a peer 
counsellor who conducted pill counts at each clinic visit and provided individual and 
group sessions to promote high levels of adherence. For patients who defaulted, their 
counsellor followed up via phone or home visit. The ratio of counsellors to ART 
patients increased from 2006 onwards from when the total number of counsellors was 
limited to approximately 30 [63].  
 
8.3.2 Community-based Adherence Clubs 
The Adherence Club model of care [43, 143] and details of the implementation of 
community-based Adherence Clubs (hereafter referred to as CACs) in Gugulethu have 
been discussed in Chapter 7.  Briefly, from June 2012, patients classified as stable on 
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ART were recruited from the CHC for down-referral or decentralisation to the CAC 
programme. Specific eligibility criteria were: adherent to ART based on self-report, on 
ART for >12 months, two consecutive suppressed viral loads (<400 copies/ml) and no 
active opportunistic infections. CACs met every 2 months (8 weeks) for group 
counselling, a brief symptom screening and distribution of pre-packed ART.  
Beginning in May 2013, Adherence Clubs were relocated to a community venue where 
all CAC visits, including clinical consultations and blood collection, took place.  A team 
of 4 CHWs supported CACs with a professional nurse available at the community venue 
for annual monitoring bloods (CD4, viral load and creatinine as necessary) and clinical 
consultation. CAC patients could send a patient-nominated treatment supporter or 
“buddy” to collect their ART at alternating CAC visits.   
8.3.3 CAC evaluation 
This analysis focuses on the outcomes of patients referred to CACs and compares these 
to outcomes of patients receiving facility-based care.  Data were obtained from the 
prospectively collected CHC clinical database, the CAC database and the National Health 
Laboratory Service database. Ethical approval for collection of routine clinical data and 
data from CACs was obtained from the Human Research Ethics Committee at the 
University of Cape Town Faculty of Health Sciences. Data were analysed using STATA 
13.0 (STATA Corporation, College Station, Texas, USA).    
8.3.4 Definitions of outcomes 
Patients were eligible for inclusion if they initiated ART before the end of 2012. 
Patients entered the analysis on the date of ART initiation in the CHC, contributing 
person time to the facility-based model of care.  Patients decentralised to the CACs 
contributed person time to the CAC model from their first CAC visit.  Patient outcomes 
were assessed as of the end of 2013 (analysis closure); the database closure was the 
21st of March 2014 [207].    
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As the long-term programmatic goals of ART services are to retain patients in care and 
virologically suppressed over time, the outcomes of interest in this analysis were loss 
to follow-up (LTFU) and viral rebound.  Loss to follow-up was defined as having no 
visit in the first 12-weeks of 2014 and patients were censored at the date of last contact 
with either health care service. Viral rebound was defined as a single viral load 
measurement >1000 copies/ml after previous suppression (<1000 copies/ml).  
 
8.3.5 Statistical analysis 
Pre-ART characteristics of all patients by model of delivery were summarised; 
continuous variables are reported with medians and inter-quartile ranges (IQRs) and 
categorical variables as proportions with 95% confidence intervals (CI). Time-updated 
CD4 and viral load values were available at each patient contact, defined as the closest 
measure within a 2-month window of each patient contact. P-values from Pearson’s 
chi-squared and Wilcoxon rank-sum tests were calculated to investigate differences 
between patients in facility-based care at the CHC versus those attending CACs. 
 
Time to LTFU and viral rebound from first CAC visit were analysed by gender and age 
[youth (16-24 years) and adults (≥25years)] and differences investigated with the log-
rank test. A series of proportional hazards models were used to model relative hazards 
of different patient outcomes adjusting for demographic, programmatic and clinical 
variables including time-updated laboratory values. Results are presented as hazard 
ratios (HR) or adjusted hazard ratios (aHR) with 95% CI. 
  
Since allocation to the CAC model of care was not randomly assigned, a number of 
approaches were undertaken to compare LTFU with the CHC.  In the primary results 
(Approach 1), we used proportional hazards models with the treatment (being in a CAC 
versus CHC) and time-updated laboratory values as time-varying covariates to model 
time to LTFU [253, 259].  In addition, we modelled the probability of CAC participation 
using inverse probability weighting (IPW) [260] and incorporated this weight into the 
proportional hazards models.  To calculate the IPW we used a dataset restricted to 
patients for whom a CAC was available after 12 months on ART (i.e. patients initiating 
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after June 2011).  Stratified hazard ratios by age, gender, year of initiation and CD4 cell 
count at ART initiation were also generated to assess if LTFU differed by subgroup.      
We ran a series of secondary analyses to examine different methods of accounting for 
selection biases when examining the association between model of care and LTFU. In 
Approach 2, proportional hazards models without IPW adjusting for the probability of 
being in a CAC were used.  Further, Cox’s models without (Approach 3) and with the 
IPW (Approach 4) were restricted to patients who were in care 12 months after ART 
initiation.  We also used the IPW with logistic regression to model LTFU (Approach 
5) [178].  Approach 6 generated propensity scores and the average effect of the
treatment on the treated was assessed [165, 261, 262]. 
8.4 RESULTS 
8.4.1 Description of Adherence Club patients 
A total of 2,113 patients were decentralised to a CAC between May 2012 and December 
2013 contributing a total of 2098 years of person-years of follow-up to CACs [median 
1.1 years, interquartile range (IQR) 0.75-1.26].  CAC patients represented a quarter of 
all patients ever initiated onto ART at the site (26%).  The time in the CAC was 6.5% of 
the total person-years of follow-up in the analysis.  Patients referred to CACs had 
similar pre-ART demographic and clinical characteristics to patients retained in 
facility-based care (Table 8.1).  However systematic differences between the two 
groups were apparent following ART initiation: before down-referral, CAC patients 
were more likely to achieve viral suppression (viral load >1000 copies/mL) after 4 and 
12 months on ART compared to patients managed in facility-based care at the CHC (p-
values <0.001).  After 12-months on ART, the median CD4 cell count was higher in CAC 
patients versus CHC patients (320 cells/l vs. 295 cells/l, p-value <0.001)(Table 8.1).   
172 
8.4.2 Outcomes of patients referred to CAC’s 
Loss to follow-up from CACs 
Loss to follow-up among CAC patients was 5.6% and 6.4% at 12-months after the first 
CAC visit, for men and women respectively (Figure 8.1A; p-value 0.961). LTFU was 
higher for youth (ages 16-24) than adults (patients ≥ 25), with 9.1% and 5.9% LTFU at 
12 months after referral to CACs, respectively (Figure 8.1B, p-value 0.022). When 
stratified by gender and age, youth had higher LTFU than adults for both men and 
women (12 month LTFU: 7.7% vs. 5.5% for men and 9.2% vs. 6.1% for women) (results 
not shown). 
In proportional hazards models of patients referred to CACs, the hazard of LTFU was 
higher in youth vs. adults (HR: 1.67, 95% CI 1.00-2.79), and in patients who initiated 
ART in 2002-2004 vs. after 2008 (HR: 1.64, 95% CI 1.00-2.69) (Table 8.2).  In adjusted 
models of CACs, youth were twice as likely to be LTFU compared to adults (aHR: 2.17, 
95% CI 1.26-3.73).  An increased risk of LTFU was also found for patients who initiated 
ART with a CD4 cell count ≥200 cells/l (aHR 2.25, 95% CI 1.36-3.72) and a decreased 
risk in patients with a CD4 cell count <50 cells/l (aHR: 0.52, 95% CI 0.29-0.93) 
compared to patients initiating with a CD4 cell count between 50-199 cells/l in CACs.  
Patients in CACs who initiated ART between 2011-2012 had a 58% decrease in the risk 
of LTFU (aHR: 0.42, 0.22-0.86) compared to those initiating between 2008-2010.  No 
difference in the risk of LTFU was found by gender (aHR: 0.90, 95% CI 0.61-1.34) or in 
patients who sent a buddy to collect medications (aHR 0.89, 95% CI 0.59-1.36).  
Viral rebound in CACs 
No difference in viral rebound was found by gender (Figure 8.2C, p-value 0.173) or age 
(Figure 2D, p-value 0.194).  After 12 months in a CAC, 2.2% (95% CI 1.3-3.9) and 1.5% 
(95% CI 1.0-2.3) of males and females had experienced viral rebound (results not 
shown).  No associations were found between pre-ART characteristics and risk of viral 
rebound in univariate models (Table 8.2).  In final models of CACs, youth were twice as 
likely to experience viral rebound compared to adults (aHR: 2.24, 95% CI 1.00-5.04).  
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Table 8.1 Description of patients by pre-ART characteristics and changes to viral 





Community Health  
Centre only 
(n=6,037) 







Pre-ART characteristic    
Gender     
Females, n(%) 4,091 (68.8) 1,489 (70.5) 5,580 (68.5) 0.021 
Age (years), n(%)    
16-24 728 (12.1) 156 (7.4) 884 (10.9) <0.001 
25-34 2,803 (46.4) 1,026 (48.6) 3,829 (47.0)  
35-44 1,664 (27.6) 656 (31.1) 2,320 (28.5)  
≥45 842 (14.0) 275 (13.0) 1,117 (13.7)  
Median (IQR) 33.2 (28.0-39.8) 33.9 (29.4-39.8) 33.4 (28.4-29.8) <0.001 
CD4 cell count (cells/l), n(%)    
<50 893 (20.3) 275 (16.2) 1,168 (19.2) <0.001 
50-99 837 (10.0) 336 (19.8) 1,173 (19.2)  
100-199 1,589 (36.1) 688 (40.6) 2,227 (37.3)  
≥200 1,083 (24.6) 397 (23.4) 1,480 (24.3)  
Median (IQR) 128 (61-198) 134 (73-195) 130 (64-197) 0.277 
Missing, n(%) 1,635 (27.1) 417 (19.7) 2,052 (25.2)  
Viral load, log10 copies/mL    
Median (IQR) 4.9 (4.4-5.3) 4.8 (4.3-5.2) 4.8 (4.4-5.3) <0.001 
Missing, n(%) 2,405 (39.8) 525 (24.8) 2,930 (36.0)  
Year of initiation, n(%)    
2002 - 2004 372 (6.2) 191 (9.0) 563 (6.9) <0.001 
2005 - 2007 1,818 (30.1) 758 (35.9) 2,576 (31.6)  
2008 – 2010 1,847 (30.6) 803 (38.0) 2,650 (32.5)  
2011 – 2012 2,000 (33.1) 361 (17.1) 2,361 (29.0)  
Changes in viral load and CD4   
Viral suppression at 4-months, n(%)  
Supressed (VL<1,000)  3,595 (59.6) 1,781 (84.3) 5,376 (66.0) <0.001 
Viral suppression at 12-months, n(%)   
Supressed (VL<1,000)  2,677 (44.3) 1,762 (83.4) 4,439 (54.5) <0.001 
4-month CD4, (cells/l)  
Median (IQR) 249 (159-349.5) 254 (180-341) 251 (166-347) 0.045 
4-month change in CD4 (4-month - pre-ART), n(%)  
<100 1,054 (47.9) 529 (44.9) 1,583 (46.8) 0.096 
≥100  1,148 (52.1) 650 (55.1) 1,798 (55.1)  
12-month CD4, (cells/l)  
Median (IQR) 295 (198-411) 319.5 (234-422) 304 (210-416) <0.001 
12-month change in CD4 (12-month - pre-ART), n(%)  
<100  558 (29.8) 236 (20.1) 794 (26.1) <0.001 
≥100  1,316 (70.2) 936 (79.9) 2,252 (73.9)  
CD4 under 200 cells/l, n(%)    
Always <200 1,194 (20.5) 6 (0.3) 1,200 (15.1) <0.001 
≥200  4,623 (79.5) 2,102 (99.7) 6,725 (84.9)  
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Figure 8.1 Kaplan-Meier plots over the first 18-months in a Community-based 
Adherence Club (a) LTFU by gender, (b) LTFU by age, (c) Viral rebound by 




Table 8.2 Relative hazard of loss to follow-up, viral rebound and programme attrition among Community-based Adherence 
Club patients 
 
Characteristic LTFU Viral Rebound Programme attrition  
 Univariate 
HR (95% CI) 
Final Model 
aHR  (95% CI) 
n = 2,083 
Univariate 
HR (95% CI) 
Final Model 
aHR  (95% CI) 
n = 2,088 
Univariate 
HR (95% CI) 
Final Model 
aHR  (95% CI) 
n = 2,083 
Age when starting ART       
Youth - 16-24 years 1.67 (1.00-2.79) 2.17 (1.26-3.73) 1.67 (0.76-3.67) 2.24 (1.00-5.04) 1.75 (1.09-2.83) 2.15 (1.27-3.64) 
Adults - ≥25 years 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Gender       
Male 1.01 (0.71-1.43) 0.90 (0.61-1.34) 1.42 (0.86-2.36) 1.35 (0.79-2.30) 1.08 (0.77-1.52) 0.95 (0.65-1.39) 
Year of ART initiation       
2002-2004 1.64 (1.00-2.69) 1.28 (0.70-2.32) 1.50 (0.67-3.37) 1.88 (0.78-4.51) 1.50 (0.92-2.43) 1.16 (0.65-2.09) 
2005-2007 1.14 (0.79-1.64) 1.19 (0.79-1.79) 1.17 (0.66-2.05) 1.50 (0.83-2.72) 1.07 (0.75-1.53) 1.13 (0.77-1.68) 
2008-2010 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2011-2012 0.77 (0.41-1.45) 0.44 (0.22-0.86) 1.16 (0.49-2.76) 0.66 (0.26-1.69) 0.82 (0.47-1.48) 0.48 (0.26-0.91) 
Ever sent a buddy        
Yes 0.72 (0.49-1.04) 0.89 (0.59-1.36) 0.56 (0.30-1.02) 0.68 (0.37-1.27) 0.67 (0.46-0.96) 0.84 (0.55-1.27) 
CD4 cell count at ART initiation,  
(cells/l) 
    
<50 1.06 (0.62-1.81) 0.52 (0.29-0.93) 0.69 (0.28-1.69) 0.49 (0.19-1.25) 0.96 (0.57-1.62) 0.47 (0.26-0.83) 
50-99 1.19 (0.74-1.93) 0.66 (0.40-1.10) 1.27 (0.64-2.52) 0.95 (0.47-1.94) 1.16 (0.73-1.84) 0.64 (0.40-1.04) 
100-199 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
≥200 1.16 (0.72-1.84) 2.25 (1.3,-3.72) 1.06 (0.52-2.14) 1.56 (0.74-3.27) 1.08 (0.69-1.70) 2.07 (1.26-3.38) 
Missing 1.27 (0.80-2.01) 0.80 (0.35-1.81) 1.03 (0.50-2.12) 1.39 (0.60-3.22) 1.18 (0.76-1.84) 0.73 (0.32-1.65) 
Time-updated CD4,  
(per 50-unit increase) 
0.67 (0.63-0.72) 0.70 (0.63-0.77) 0.84 (0.78-0.90) 0.81 (0.74-0.88) 0.67 (0.63-0.71) 0.70 (0.63-0.76) 
Time-updated viral load,  
(copies/mL)  
      
Suppressed (<1,000) 1.0 (ref) 1.0 (ref) - - 1.0 (ref) 1.0 (ref) 
Not supressed (≥1,000) 19.1 (12.8-28.7) 3.13 (1.82-5.39) - - 20.74 (13.95-30.84) 3.42 (2.02-5.80) 
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8.4.3 Comparison of LTFU in CACs versus CHC 
Patients referred to CACs had a reduced risk of LTFU compared to patients managed in 
facility-based care in all crude and adjusted models (Table 8.3).  We report on 
Approach 1, using inverse probability weights to estimate CAC participation and 
included in proportional hazard models with time-varying covariates.  The inverse 
probability weighting model correctly classified 91% of patients (results not shown).  
In unadjusted models, CAC patients were 62% less likely to be LTFU compared to 
patients managed in facility-based care (HR: 0.38, 95% CI 0.32-0.45) (Table 3). In the 
final model (Model 2) also adjusting for time-updated CD4 and viral load, the CAC 
patients were 67% less likely to be LTFU compared to patients in facility-based care 
(aHR: 0.33, 95% CI 0.27-0.40).  The hazard ratios of covariates in Approach 1 can be 
found in Supplementary Table 8.1. 
In stratified models, LTFU was reduced for all patients managed in a CAC compared to 
facility-based care irrespective of age, gender, year of ART initiation or CD4 cell count 
at ART initiation (Table 8.4). The exception was for youth 16-24 years of age whose 
adjusted hazard of LTFU in a CAC was not significantly different from the hazard of 
LTFU observed under facility-based care (aHR: 0.68, 95% CI 0.37-1.22, p-value 0.197).   
In secondary analyses, CACs decreased in the risk of LTFU (Table 8.3).  Under Approach 
3, the most conservative scenario, models were restricted to patients on ART after 12 
months and the hazard of LTFU in CACs compared to facility-based care was 0.25 (95% 
CI 0.21-0.31) (Table 8.3).  When inverse probability weights to estimate CAC 
participation were incorporated into this model with further restriction (Approach 4) 
the adjusted hazard of LTFU was 0.47 (95% CI 0.39-0.56). Propensity scores were also 
generated adjusting for age, gender, rate of scale-up and programme size.  In all 
matching methods, the average treatment on the treated effect (ATT) was reduced, 
ranging from -0.141 to -0.641 (results not shown).   
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Table 8.3 Risk of LTFU in Community-based Adherence Clubs compared to the Community Health Centre 
Univariate Model 1* Model 2 (Final Model)± 
HR (95% CI) aHR (95% CI) aHR (95% CI) 
Approach 1§ 
Cox's model with IPW** 0.38 (0.32-0.45) 0.21 (0.17-0.25) 0.33 (0.27-0.40) 
Approach 2 
Cox's model 0.38 (0.32-0.45) 0.19 (0.16-0.22) 0.29 (0.24-0.35) 
Approach 3 
Cox's model with further restriction±± 0.50 (0.42-0.60) 0.16 (0.13-0.19) 0.25 (0.21-0.31) 
Approach 4 
Cox's model with IPW** & further restriction±± 0.50 (0.42-0.60) 0.17 (0.14-0.21) 0.29 (0.24-0.36) 
Approach 5  
Logistic regression with IPW** 0.06 (0.05-0.07) 0.08 (0.06-0.09) 0.07 (0.06-0.09) 
* Adjusted for age, gender and year of ART initiation
±Adjusted for age, gender, year of ART initiation, time-updated CD4 and viral load
§Approach 1 is reported as the primary results. Restriction was done in the IPW predicting CAC participation
**IPW denotes inverse probability weighting to predict CAC participation
±±Further restriction limited the models to patients for who were retained in care after 12-months on ART
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Table 8.4 Stratified hazard ratios of LTFU among Community-based Adherence 
Club patients vs. patients at the Community Health Centre 
 
Characteristic Univariate 
HR (95% CI) 
Final Model* 
aHR  (95% CI) 
Age pre-ART   
16-24 0.59 (0.36-0.98) 0.68 (0.37-1.22) 
25-34 0.37 (0.29-0.47) 0.32 (0.24-0.42) 
35-44 0.35 (0.25-0.48) 0.33 (0.23-0.48) 
≥45 0.35 (0.21-0.57) 0.35 (0.23-0.54) 
Gender   
Male 0.38 (0.28-0.52) 0.36 (0.25-0.51) 
Females 0.38 (0.31-0.47) 0.32 (0.25-0.41) 
Year of ART initiation   
2002-2004 0.34 (0.20-0.55) 0.30 (0.16-0.56) 
2005-2007 0.23 (0.17-0.31) 0.42 (0.31-0.59) 
2008-2010 0.14 (0.11-0.19) 0.34 (0.24-0.47) 
2011-2012 0.05 (0.03-0.09) 0.10 (0.05-0.21) 
CD4 cell count pre-ART (cells/l)   
<50 0.35 (0.21-0.58) 0.33 (0.19-0.55) 
50-99 0.41 (0.27-0.63) 0.35 (0.22-0.55) 
100-199 0.34 (0.25-0.47) 0.30 (0.22-0.41) 
≥200 0.34 (0.23-0.51) 0.30 (0.20-0.44) 
* Adjusted for inverse probability weighting of CAC participation, age, year of ART initiation, 





This analysis suggests that the community-based Adherence Club model may achieve 
favourable programmatic outcomes for stable patients on ART in resource-limited 
settings.  For most patient groups, the risk of LTFU was substantially reduced in the 
CAC model compared to facility-based care.  The exception was youth; patients 16-24 
years of age at ART initiation experienced no reduction in the risk of LTFU in CACs 
compared to facility-based care and had an increased risk of LTFU and viral rebound in 
the CACs compared to adults 25 years or older. Within CACs, differences in the risk of 
LTFU were observed by CD4 cell count and year of ART initiation while men and 
women had comparable LTFU, viral rebound and retention.   
 
The CACs appeared to reduce the risk of LTFU compared to facility-based care with a 
two-thirds reduction in the hazard of LTFU. The hazard ratio in the final adjusted 
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model of 0.33 is similar to that from facility-based Adherence Clubs reporting 0.43 in 
modelling the hazard of LTFU or death [178].  These are novel data as previous results 
for models of care labelled as “community-based” are actually models of home-based 
care for individual patients. [167, 168, 171-175].  
There is a particular concern about how to effectively provide ART to men who 
represent more than 40% of the HIV epidemic in South Africa [4] but have inequitable 
access to ART [149, 263-265]. Community-based models of ART delivery may be 
uniquely positioned to support men on ART [151].  Among CAC patients, outcomes did 
not differ by gender; a promising finding given that men consistently have worse 
outcomes on ART in primary care facilities [56, 226, 266].  Recent evidence from 
community-based drug dispensing programmes also found no difference in retention 
between men and women [267].  By contrast, men in the community-based adherence 
group model in Mozambique had twice the risk of attrition compared to women [177]. 
Further research into what components of community models of care can support the 
retention of men, whether it is being out of the health care facilities, decreasing visit 
frequency or some other factor, is warranted.    
Youth were the only sub-set of patients that did not have a decreased risk of LTFU in 
CACs compared to the CHC. This finding is crucial since 40% of new infections occur in 
this age group [268] and adds to the current discussion of the need for managed health 
care transition from adolescent to adult type services [269, 270].  A renewed focus on 
strategies to successfully retain youth in care, both for their own health and given the 
potential benefits of ART as prevention in this age group, is required.   
CAC patients initiating ART with higher CD4 cell counts ≥200 cells/l had an increased 
risk of LTFU compared to patients with CD4 cell counts between 100-199 cells/l at 
ART initiation.  However, rates of LTFU in CACs among patients with CD4 cell counts 
≥200 cells/l at initiation were less than a third of those observed under facility-based 
care.  These findings highlight that retention of patients initiating ART at higher CD4 
cells is a challenge in both models of care. As the guidelines encourage healthier 
patients to be initiated onto ART, there must be a concurrent shift away from the 
common perception that ART is for sick patients [271].  Our findings of decreased LTFU 
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in CACs regardless of CD4 cell count at baseline and year of ART initiation calls for 
community-based models of care to be expanded towards achieving optimistic 
treatment targets and supporting long-term retention in care [3, 151]. 
A number of strengths and limitations must be considered in the interpretation of our 
findings.  Our data are from a large cohort that decentralised a previously described 
model into the community.  Data was available for comparing the CAC with facility-
based care including data on time-varying laboratory values [132].  We were limited to 
reporting short-term outcomes over the first year of the programme.  We acknowledge 
that the outcome LTFU represents all patients with an unknown outcome: including 
unascertained deaths and transfers [211], administrative LTFU and those currently 
interrupting treatment [239].  Further, our data are from a cohort with considerable 
research support and an established counsellor programme that may impact the 
generalizability of our findings. To assess data quality during the recent scale-up at the 
CHC, a random sample of patients identified to be LTFU among those initiating ART in 
2011 and 2012 were selected for a folder review.  Of the patients classified as LTFU, 
two thirds were confirmed to be LTFU, while approximately 20% were administrative 
LTFU and 15% were unascertained transfers.  The effect of CACs on reducing LTFU is 
therefore likely overestimated but not entirely explained by issues of data quality.  
These observational data do not provide a direct comparison of outcomes between the 
CACs and facility-based models of care. The major limitation is selection bias into the 
intervention (CACs).  We used different methods to adjust for this bias [165, 178, 253, 
262].  Our main results incorporated the probability of being in a CAC into models of 
time to LTFU thereby adjusting for this confounding. In the absence of trial data, we are 
dependent on the methods of observational epidemiology, which are limited by the 
quality of the data and measurement of factors that determine entry into a CAC and 
outcomes; we cannot rule out residual confounding that was unmeasured or measured 
with imprecision.  This is a fundamental challenge of observational evaluations of 
models of health service delivery. In this light, it may be more appropriate to compare 
novel models of care such as CACs to predetermined targets for outcomes as opposed 
to attempting to overcome the methodological challenges of comparing them to 
increasingly heterogeneous patients in facility-based care. LTFU from CACs at 12 
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months was 6% and 98% of these patients were virally suppressed.  These figures, 
even without comparison to other programmes, represent successful ART provision 
and support the CAC model of care.   
Our findings on the benefits of CACs are relevant as countries look to expand ART 
eligibility in line with the 2013 WHO guidelines [28].  Nevertheless, questions remain 
about how community-based models of ART delivery can best support service 
expansion and retention in care.  Patients were only eligible to join the programme 
after a year on ART, but the model is of potential benefit to patients sooner after 
treatment initiation especially as healthier patients access ART.  Expansion of the 
model to include patients who previously have had inequitable access and outcomes on 
ART, such as women who initiate ART in pregnancy, should be considered. Since 
sending a buddy reduced the visit frequency for the patient and we found no difference 
in the outcomes for patients who sent a buddy and those who did not, further reducing 
the visit frequency could be desirable to patients without negatively impacting 
outcomes [255].  More data are needed to determine the long-term outcomes of CACs.  
In addition, documenting patient experiences and preferences and conducting cost-
effectiveness analyses would be beneficial to scaling up the model.  Further 
investigation into how community-based programmes could support ART at different 
stages of the treatment cascade, such as testing and ART initiation, are also needed.   
From a policy perspective, community-based models raise questions about how to 
integrate ART provision allowing for patients to return to normal life and minimise the 
disruptions from ART delivery  [42, 134].  In the context of increased availability of 
fixed-dose combination therapy and point of care viral load testing, policies regarding 
who can distribute ART and the frequency of rescripting and clinical consultations need 
to be reconsidered.   
In summary, we found that stable patients were successfully managed by CHWs within 
a community-based model of ART delivery.  Higher rates of retention and viral 
suppression were maintained in both men and women.  More long-term data are 
needed to understand how best community-based models of care can improve 
retention in care with particular attention given to supporting youth. Given that ART 
 183 
cohorts in high-prevalence, resource limited settings are continuing to expand and 
mature, community-based models of care represent a promising alternative to promote 
patient self-management and community involvement within ART delivery.  
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Chapter 9. Discussion and recommendations  
 
This chapter provides a synopsis of key findings in relation to the thesis aim and 
objectives. Three underlying themes are presented, summarising what we know as we 
enter the second decade of ART delivery in resource-limited settings.  
Recommendations for research, policy, programmes and services are made based on 
the thesis results as a combined body of work.   
 
9.1 SYNOPSIS OF KEY FINDINGS 
9.1.1 Definitions of LTFU impact estimates of outcomes  
In Chapter 3, a series of different analytic approaches of LTFU were used to estimate 
programme outcomes addressing the first objective of this thesis.  This thesis found 
that variations in the definition of LTFU can have an appreciable impact on estimates of 
outcomes.  For conclusions to be drawn about ART programme effectiveness, 
standardisation of an approach and definition of LTFU is needed.  Chapters 4-8 adopted 
the recommended definition of LTFU from Chapter 3.  
 
9.1.2 Increasing LTFU observed by calendar year of ART 
initiation 
Data from MSF cohorts in eight resource-limited countries was analysed in Chapter 4.  
The risk of LTFU increased with each calendar year of ART initiation, addressing 
objective 2a, and confirming the association previously found in South African 
cohorts [56].  Year of ART initiation was associated both with early LTFU in the first 12 
months of ART and late LTFU over 12-72 months of follow-up.  The strength of the 
association persisted in final models adjusted for pre-ART characteristics and 
programme expansion. Year of ART initiation was included in multivariate analyses in 
Chapters 5-8.    
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9.1.3 Pace of scale-up more important the programme size in 
relation to LTFU 
To address objective 2b, two variables were used to quantify programme expansion. 
Programme size and rate of expansion were both related to increased risk of early (0-
12 month) and late LTFU (12-72 month) among the MSF cohorts in Chapter 4.  After 
adjusting for baseline characteristics and year of initiation, the association between 
programme size and LTFU was attenuated.  However, the association between rate of 
expansion and LTFU persisted in final multivariate models. This suggests that it is not 
simply cohort size that is related to programme outcomes, but the pace of scale-up.   
9.1.4 Higher CD4 cell counts associated with increased risk 
of early LTFU 
The focus of Chapter 5 was on objective 2c to determine if patients initiating ART at 
higher CD4 cell counts had a greater risk of LTFU.  Using the South African adult 
cohorts contributing to the IeDEA-SA collaboration with linkage to the National 
Population Register, corrected estimates of LTFU were higher among patients initiating 
ART at CD4 cell counts above 300 cells/l compared to those with CD4 cell counts 
between 150-199 cells/l at ART initiation.  This increased risk of LTFU among 
patients initiating ART at CD4 cell counts above 300 cells/l persisted after 
adjustment for programme size and rate of scale-up, as well as pre-ART characteristics 
and year of ART initiation.  The relationship between CD4 cell counts above 300 
cells/l and LTFU was highest in the first three months on treatment.  Given that 
countries are implementing the 2013 WHO guidelines and increasing the CD4 
threshold for initiation to 500 cells/l, programmes must acknowledge that patients 
with higher CD4 cell counts at initiation may need different models of care and support 
to be successfully retained on treatment [272].  
9.1.5 Models of care delivery to support ART retention for 
stable patients 
Stable patients were down-referred to the nurse-managed Green Clinic in Chapter 6 
and community-based Adherence Clubs (CACs) in Chapters 7 and 8 and outcomes 
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compared to patients at the community health centre (CHC).  Assessing the outcomes of 
these models was in line with objective 3a.  Green Clinic patients had no difference in 
their risk of mortality or viral rebound, but LTFU was slightly higher compared to 
patients in the CHC, in final models.  CACs were successfully implemented, down-
referring more than 2,000 patients over 18 months to the decentralised model of care.  
The CACs reduced the risk of LTFU significantly and in final models patients in a CAC 
were 0.33 times as likely to be LTFU compared to the CHC. 
 
9.1.6 Models of care offer risk and benefits to different sub-
groups of patients 
To address objective 3b, outcomes in the models of care were assessed in different sub-
groups of patients. In both the Green Clinic and the CACs, lower rates of LTFU were 
observed for patients who recently initiated ART and who initiated ART at CD4 cell 
counts ≥200 cells/l compared to the CHC. In the Green Clinic, the increased risk of 
LTFU was driven by higher LTFU among men, younger patients (25-34 years old) and 
those who initiated ART with advanced HIV disease or early years of the programme.  
CAC patients had preferable outcomes with all sub-groups having reduced risk of LTFU. 
The exception was youth, patients 16-24 at ART initiation, for whom the CACs offered 
no improvement in risk of LTFU.  Men and women in CACs had similar rates of 
retention, a promising finding given that men consistently have worse ART outcomes 
than women in previous analyses focusing on facility-based models of care.   
 
9.1.7 Strengths and limitations 
While study-specific limitations are presented within the discussion section of each 
results chapter, there are overarching limitations that should be stated in advance of 
making recommendations.  First and foremost, the generalisability of our findings must 
be considered in light of all data coming from cohorts with considerable research 
support. This support enables improvements in data quality and outcome 
ascertainment.  Furthermore, contributing cohorts likely have greater resources than 
other sites in resource-limited settings.  Previous research has found that programmes 
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with adherence support and tracing programmes have improved patient outcomes and 
hypothesised these improvements are the result of greater resources [87, 102]. Despite 
the data coming from research sites, we did not have access to data on human 
resources and other resources that may affect capacity for increasing scale-up.  These 
resources may be related to LTFU and retention and without data on their availability 
there may be residual confounding in how scale-up and year of ART association are 
related to outcomes.   
Moreover, the contributing cohorts were from well-established programmes that 
began providing ART relatively early in the treatment efforts in resource-limited 
settings.  They are therefore not representative of the newer programmes in recent 
years, when there has been a proliferation of new ART sites and the rate of ART scale-
up has been most dramatic [3].  The analyses in Chapters 4 and 5 were restricted to 
patients who started treatment in and before 2011 and 2012, respectively, and 
therefore may not accurately represent the current rate of scale-up.  
Our findings and insights on models of ART delivery are also limited in that data was 
from a single ART site and with limited duration of follow-up (Chapter 6-8).  This site 
has previous experience with innovating care for HIV patients [16, 57] and therefore, 
the successes and challenges that were observed may be different to challenges 
elsewhere.  While the nurse-managed Green Clinic programme described in Chapter 6 
was started in 2007 and had follow-up data through 2012, the community-based 
Adherence Clubs in Chapters 7 and 8 were limited to a maximum of 18 months of 
follow-up, with very small patient numbers beyond one year.  Further follow-up time 
will be required to understand the long-term outcomes of novel models of care. 
All our data were from observational cohorts by sites providing ART within the public 
sector.  The value of using this observational data are that it will reflect some of the 
realties on the ground.  In Chapters 6-8, the data are limited by the fundamental 
difference of observational compared to experimental research designs.  The central 
challenge is one of selection bias to the intervention compared to the control group.  
Allocation into the novel models of care was not at random, but informed by subjective 
measures of adherence as defined by clinicians and factors associated with improved 
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LTFU and retention.  These analyses adjusted for this confounding, but were limited by 
the type and quality of data available.   
 
There are outstanding questions regarding LTFU and models of care to support 
retention that were beyond the scope of this thesis.  As outlined in Section 2.1, this 
thesis only addressed one step in the treatment cascade, losses after ART initiation. 
This thesis did not address losses along other stages of the cascade such as after a 
positive HIV test (linkage to care) or from eligibility for treatment and initiation.  
Beyond the cascade, this thesis did not endeavour to document the patient and health 
care provider experiences.  The analyses of models of care delivery did not extend to 
measure cost-effectiveness or efficiency [250].  This thesis was limited to adult ART 
programmes. However, LTFU is a considerable challenge for other populations such as 
those with inequitable access to ART including paediatric, adolescent and key 
populations. 
 
The thesis utilised the most conservative approach to defining LTFU as per the 
recommendations from Chapter 3.  However, patients classified as LTFU are indeed 
patients with three distinct outcomes as drawn out in Section 2.2, including 
unascertained deaths, unascertained transfers and patients currently disengaged from 
care.  With the exception of Chapter 5, where LTFU was adjusted for unascertained 
deaths through linkage with the National Population Register, we did not trace patients 
to disaggregate those classified as LTFU into the three discrete groups.  As highlighted 
in a recent systematic review of tracing studies, rates of unascertained transfers or self-
transfers are increasing with scale-up [91]. Given that the data did not link to data from 
other ART facilities, estimates of LTFU are likely overestimates of programme loss, 
with a considerable proportion of patients being in care elsewhere [211].  The 
classification of LTFU also included a considerable proportion of patients who were in 
a treatment interruption and will re-engage with care at a later stage.  Potentially, 
treatment interruptions occur at different rates across the treatment lifetime, with 
patients who have more recently initiated ART more likely to be in an interruption and 
therefore classified as LTFU [239].  This thesis also did not assess risk factors for 
patients in an interruption compared to those who are permanently LTFU.   
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The importance of context when assessing risk factors for LTFU and the outcomes of 
models of care delivery for ART cannot be overstated.  The thesis findings come from a 
specific a geographical context, as well as a temporal context.  Chapter 7 focussed 
specifically on the implementation of CACs providing the detailed context necessary for 
programme managers and policy makers to understand, before extending the model to 
their setting.  Given the pace of change over the first decade of ART provision in 
resource-limited settings, factors associated with LTFU and models of care to support 
retention are placed within a specific time context as well.  Effective community 
interventions in one context may not work in all contexts and detailed compendium of 
heuristics is necessary to tailoring the model to the setting [19, 273].  The 
recommendations that follow are presented with an overall caveat that 
implementation must be contextualised and consider the local resources, size of the 
ART programme and targets for scaling up access to ART [43, 151].   
 
 
9.2 WHAT WE KNOW GOING INTO THE SECOND 
DEACDE OF ART DELIVERY IN RESOURCE-LIMITED 
SETTINGS  
Acknowledging the transitional context over the first decade of ART provision in 
resource-limited settings, as represented in Figure 1.1 and re-presented below, is 
important ahead of making recommendations for the next decade.  Further adaptations 
are necessary, given the ambitious treatment targets and call for quickening the pace of 
ART scale-up [3].  Before presenting recommendations, three underlying themes 
summarising what we know about the HIV response and ART programmes to date are 
given to provide the current context: LTFU is a significant and pervasive challenge, the 
composition of the ART cohort will be increasingly heterogeneous and the focus should 
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9.2.1 LTFU is a significant and pervasive challenge  
LTFU is a significant and pervasive challenge threatening the effectiveness of ART 
programmes.  Data from Chapter 4 suggested that while estimates of mortality 
decreased, 36-month LTFU nearly doubled from 11% to 21% between patients 
initiating in 2003 or earlier and those initiating in 2008.  As a result, the contribution of 
LTFU to overall programme losses increased dramatically.  Further, rates of LTFU 
increased with each successive year of ART initiation (Objective 2a). An increase in 
LTFU by year of ART initiation was also observed in Chapters 5-7.   
 
Figure 9.1 is a frequently cited graph representing the impressive rate of ART scale in 
resource-limited settings over the past decade [24]. The slope of the curve representing 
the rate of scale-up and the number of patients accessing ART is striking, but we know 
very little about the outcomes of patients starting ART during the most rapid scale-up 
period over the last five years.  Outcome data available from cohorts is largely from 
observations in 2008 and earlier [56, 90, 139, 195, 274].  The last systematic review on 
retention on ART in sub-Saharan Africa was published in 2010 with a meta-analysis of 
outcomes from cohorts under observation in 2008 and earlier [38].  The dotted line in 
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Figure 9.1 highlights the end of the observation time of contributing cohorts in this 
review, drawing attention to how estimates of programme outcomes is limited to 
before the majority of patients initiated ART (2009 onwards).  
Figure 9.1 Actual and projected numbers of people receiving ART in low- and 
middle -income countries, and by WHO region, 2003-2015.  
Reprinted from Global update on HIV treatment 2013: Results, impact and opportunities [24] 
In addition to having limited data on outcomes among patients initiating ART in recent 
years, many of the cohorts providing data for previous estimates of outcomes were 
large, established research cohorts supported by academic and non-governmental 
partners and not likely to be representative of the national cohorts.  Further, patients 
initiating ART in recent years have done so at new, decentralised and nurse-managed 
sites.  In South Africa, more than 3,500 sites were providing ART by mid-2013 and the 
number of nurses trained to initiate ART had increased from 250 in February 2010 to 
23,000 [15, 256].  Given the trend of increasing LTFU that we observed in Chapters 4, 6 
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and 7, it is likely that recent estimates of LTFU presumed from earlier cohorts may be 
overestimating the proportion of ART patients retained in care.  LTFU is therefore a 
significant and pervasive challenge, given that conservative estimates from Chapter 4 
have only two thirds of patients retained in care after five years on treatment.   
9.2.2 The composition of the ART cohort will be 
heterogeneous  
UNAIDS recently redefined the narrative around HIV treatment targets calling for 
acceleration of ART to ensure 90% of HIV patients know their status, 90% of patients 
have access to ART and that 90% of patients are achieving viral suppression by 2030 or 
“90-90-90” [3]. Efforts to meet these ambitious treatment targets combined with 
implementation of the 2013 WHO guidelines, will see both an increase in the volume of 
patients, as well as a change in the composition of the cohort [237].  The 2013 
Guidelines support earlier initiation, expanding the CD4 cell count thresholds from 
<350 cells/l to <500 cells/l and thus increasing the number of patients eligible for 
ART who do not have an illness experience from their HIV. In addition, healthier 
patients, including women who initiate in pregnancy regardless of CD4 cell count and 
HIV-positive patients in serodiscordant relationships, are also recommended to initiate 
ART.  At the same time, the current ART cohort is aging and there will be an increase in 
the number of complex patients on ART.  These complex patients will include patients 
with chronic conditions associated with aging, comorbidities more likely in those with 
HIV co-infection, ART complications due to long-term exposure and toxicities, and 
more patients on second- and third-line regimens [47, 275].    
In contrast to the healthier patients accessing ART, there will still be a significant and 
continued number of patients who are initiating with low CD4 cell counts, less than 100 
cells/l, who require substantial clinical resources [210, 216, 276, 277].  As shown in 
Chapter 4, despite a rise in the median CD4 cell count at ART initiation, a consistent 
30% of patients are starting ART with a CD4 cell count <100 cells/l.  The high burden 
of low CD4 cell count patients was also observed in Chapter 5.  This dichotomy of a 
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rising median CD4 cell count of the cohort combined with a substantial burden of low 
CD4 cell count patients has been observed in many regions [277]. 
9.2.3 The focus should be on how to support effective ART 
delivery 
In the past decade, determining when to start ART in the course of HIV disease or the 
optimal CD4 threshold for ART initiation has been the centre of a number of large trials, 
analyses of observational cohorts and considerable debate [29, 236, 278-285].  The 
current discourse on ART delivery needs to be reframed from when to start ART to how 
to efficiently and effectively provide ART.  At present, the focus remains on scale-up, as 
reflected in the UNAIDS document Fast-track: Ending the AIDS epidemic by 2030 [3].  
While Fast-track outlines the benefits of accelerated scale-up of ART and presents the 
ambitious targets for “90-90-90” by 2030, there is no mention of how to support 
retention or decrease LTFU, despite the reality that retaining patients in care will be 
essential to reaching the targets.  Given the threat of LTFU to ART programme 
effectiveness, it is high time that some of the focus on when to start be shifted to how to 
provide ART.   
 
The substantial resources leveraged to provide ART to millions of patients worldwide 
and the size and scale of the response has been one of exceptionalism [25, 286, 287].  
Shifting attention to support the effective delivery of ART would be in line with this 
exceptionalism. Exceptionalism is reflected in the human rights approach to the 
disease, whereby patients are autonomous.  It is further affirmed in how adaptations to 
the provision of ART were implemented in parallel with research to support their 
effectiveness [42].  
 
An underlying tenet of the public health approach to HIV is that HIV-positive patients 
on ART can to return to normal life and that models of care for accessing ART should 
cause as little disruption as possible [42, 134].  This tenant is held by the findings of 
this thesis, where models of care delivery outside of the traditional in-facility model 
provided effective provision of ART (Chapters 6-8).  Community-based models of care 
are not just as a response to the need to expand ART and overburdened facilities, but 
also as preferable models providing ART closer to patients’ homes [288, 289].  
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It is the opportune time to leverage some of the resources from when to start ART to 
investigate how to effectively support ART provision.  Following on from 
decentralisation to community health centres and task shifting to nurses, community-
based models of care with provision of ART by CHWs and increased patient self-
management are needed [290]. More gravitas is needed in the discussions on how to 
support effective ART provision if we are to achieve the grand targets of “90-90-90”.      
 
 
9.3 RECOMMENDATIONS   
This section outlines recommendations for research and policy, and programmes and 
services based on the findings of the thesis.  An overarching recommendation is made 
for the expansion of community-based models of care to support retention [57-61].   
 
The primary model of care for delivery of ART has shifted from being within specialised 
and hospital facilities to primary care facilities.   Figure 9.2 depicts the delivery of ART 
within South Africa in 2004, 2012 and a hypothetical scenario for 2020.  At each time-
point, the HIV-positive population is represented and those accessing ART are depicted 
within different boxes, representing where they receive treatment.  In 2004, when 
public sector roll-out of ART began, access was restricted to within specialised and 
district hospitals to only 55,000 patients [291].  By 2012, the ART cohort had grown 
dramatically, with more than 2 million patients on treatment [4] and the majority of 
patients were accessing ART in primary care facilities.  While this scenario represents 
the ART cohort in South Africa, it is likely representative of the situation in other 
resource-limited settings where it estimated that at present, 95% of ART delivery is 
facility-based [3].    
 
In 2020, the size of the on-ART population will expand; treatment coverage will 
increase will the total number of patients living with HIV (bottom box, Figure 9.2).  This 
is a hypothetical scenario whereby the majority of patients are accessing ART within 
community-based models of care.  The size of the community-based cohort is higher 
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than the 30% of the treatment cohort that has been recommended by UNAIDS and 
others [3, 143]. Given that healthier patients accessing ART earlier may benefit from 
earlier engagement with community-based models, at least 50% of patients should 
access treatment in community-based models of care.  We are currently dependent on 
a limited number of models of care, most of which are dependent on doctors and 
nurses [25, 237, 292].   Given the changes in the treatment cohort, the human resource 
constraints and challenges with retention innovations are required in service delivery 
to maximise efficiency [225]. Further decentralisation into communities is needed and 
support by the findings of community-based Adherence Clubs in Chapters 7 and 8.  For 
millions of HIV patient to be managed in sustainable, chronic disease care [7], we need 
to extend ART delivery into communities. 
 
 
In Figure 9.2, the black arrows between boxes represent the bi-directional referral 
pathways between models of care delivery. Just as patients moved between hospitals 
and primary care facilities, it is envisioned that patients will move between 
community-based and facility based models as their needs change throughout their 
treatment lifetime.   
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Figure 9.2 Models of care delivery within the South African primary health care 
system: 2004 [291], 2012 and 2020 
The number of PLWHIV are represented by the grey box and this number increases from 2004 to 2012 
and to 2020 as the HIV-positive population increases.  Patients on ART are represented within the blue 
boxes proportional to the number of patients on ART at each time point.  The black arrows between each 
ART service point represent referral patterns between the models of care.    
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9.3.1 Expansion of community-based models of care 
Expansion of community-based models of ART delivery follows on logically from 
previous evolutions over the first decade of ART in resource-limited settings (Figure 
1.1).  Community-based models of care are an extension of the Alma Ata definition of 
primary health care, by providing health care as close as possible to where people 
live [293].  They also importantly employ decentralisation and patient and community 
participation, as recommended by the public health approach to ART delivery in 
resource-limited settings [237].  The premise is that community-based models of care 
are an extension of, and not a replacement for, the health care system. As evidenced in 
community-based approaches for reducing childhood mortality, community 
interventions need well-functioning local health facilities and are not stand alone 
services [294]. 
A key to community-based models being an extension of the formal health services is 
the acknowledgement of the role of the staff within the community-based model.  As 
highlighted in Chapter 7, a key factor to the implementation of CACs was the CHC 
viewing the CAC patients and staff as part of the health service, despite being based in 
the community.  Removing the hierarchy from traditional facility-based models is 
necessary to engage the multidisciplinary staff required for successful community-
based provision of services [295].  There are examples of this in ART programmes in 
resource-poor areas in developed countries [40] and from community-based models 
with CHWs to address childhood diseases [294]. 
9.3.2 Recommendations for research and policy 
Questions remain about how to support long-term retention in care while facilitating 
expansion of ART provision.  The research agenda therefore focuses on gaps in our 
understanding revealed from the results of this thesis.  
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More research on LTFU and programme retention 
A primary recommendation is that the programme outcomes of LTFU and retention 
need continual research with updated estimates published regularly.  As highlighted in 
Section 9.2, LTFU represents a substantial challenge to ART effectiveness and cohort 
data on outcomes from the last five years are limited. It is also critical that the 
assessment of LTFU and programme outcomes utilise a standardised definition of LTFU 
(Chapter 3, Objective 1).  Furthermore, given the relationship between LTFU and 
temporal factors of year of ART initiation (Chapter 4, Objective 2a), programme 
expansion (Chapter 4, Objective 2a) and CD4 cell count (Chapter 5, Objective 2b), there 
is a need for continual updates to our estimates of LTFU. Analyses of programme 
outcomes thus need to include multivariate models that adjust for temporal and 
individual factors.   
Neglecting to present updated estimates of programme outcomes may lead to 
overstating the success of ART programmes.  If we continue to focus on simply the 
number of people ever initiated onto ART we will not have an understanding of who is 
presently on treatment, what proportion of the HIV-positive population is suppressed 
and therefore the community viral load.  The ability of ART to act as prevention will be 
exaggerated. There will also be no systems in place to support transitions within and 
between HIV programmes to have accurate numbers of patients retained in care.     
As delivery of ART services adapts and novel models of care are utilised (Chapter 6-8, 
Objective 3), published programme outcomes should include a description of the 
delivery model.  This description should include staffing patterns, details of the 
community health worker cadre in regards to their role and training, the counselling 
and support provided at the time of ART initiation, the protocol around pre-ART 
support and how patients who are late or miss visits are followed up.  A standardized 
tool to collect this information would be beneficial to ensure consistency between sites.  
In addition to describing the model of ART delivery, additional data surrounding the 
process of design and implementation should be encouraged.  One such tool that could 
be utilized is the Consolidated Framework For Implementation Research, which 
defines specific constructs related to process and supports building the knowledge 
base for broader implementation in multiple contexts [296].   
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Further research on models of care delivery is needed, especially on long-term 
outcomes [25, 251, 297-300].   While the notion that community-based models of care 
delivery can support retention is not new, there is a pressing need for more 
evidence [12, 107]. In addition, research into patients’ experiences within models of 
care is necessary to support expansion of novel models.  It will also be advantageous to 
engage with health care workers around their experiences of models of delivery 
including community health workers as well as facility-based staff.   The cost-
effectiveness of different community-based models of care provision also warrants 
further research [301].   
 
What study design should be used to investigate models of care presents an interesting 
dilemma.  As mentioned within the strengths and limitations section, the data in this 
thesis was limited to observational studies with selection bias of patients into the novel 
models of care.  It may be necessary for randomized control trial methodology to be 
used to generate sufficient quality of evidence to change policy, despite a growing 
evidence base from observational studies.  This would parallel the generation of 
evidence for changing the policy around doctors versus nurses for ART initiation.  
While many programmes had moved to nurse-led models as the result of resource 
constraints, it was the evidence generated from the CIPRA-SA randomized trial that 
facilitated the policy shift to nurse initiated management of antiretroviral treatment 
(NIMART).    
Further research is needed for a model of care delivery that provides 
ART effectively to youth  
Youth represent a significant and growing challenge to our ART programmes given 
their poor treatment outcomes [146, 147, 267, 302-305] and that the numbers of youth 
in our cohorts is likely to increase. In this thesis, youth had an increased risk of LTFU in 
community-based Adherence Clubs (Chapter 8, Objective 3b) and in the MSF cohorts in 
Chapter 4.  They also had higher rates of viral rebound than other age groups in all 
three models of care, the CHC, Green Clinic and CACs (Chapters 6 and 8). The higher 
rates of LTFU and viral rebound we observed are similar to findings from a recent 
analysis of ART cohorts from Kenya, Mozambique, Tanzania and Rwanda [306].  
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Delivering ART to young people also represents a particular opportunity, given that 
early treatment in this age group has the most potential for reducing transmission.  The 
youth included in this thesis were most likely to be behaviourally infected as opposed 
to perinatally infected since they were initiating ART in young adulthood. While 
considerable resources and interventions have been targeted to perinatally infected 
children who are maturing into adolescents, the behaviourally infected youth are less 
acknowledged.  Youth are a blind spot within our ART service delivery most commonly 
grouped into the adult cohort without tailored support or interventions that recognise 
their unique challenges [269].  This age group is in a critical developmental stage 
transitioning from childhood to adulthood.  
Youth pose a substantial challenge to our programmes given their high rates of LTFU. 
However, our systems are failing them and our approaches not working, evidenced by 
their high rates of LTFU and viral rebound.  Further research is needed to elucidate 
what models of care can effectively support ART provision for youth. 
Optimal implementation of community-based models of ART delivery 
Community-based ART should not be just for stable ART patients 
A paradigm shift underscoring the utility of community-based models beyond only 
stable patients is needed. At present, most community-based models for ART are 
focused on delivery and support for stable patients but the definition of “stable” is not 
standardised. It is unknown what proportion of the global ART cohort is stable and 
therefore eligible for existing stable models of care [151].  Community-based models of 
care should also be considered for patients who are struggling with adherence and may 
currently not qualify [54].  Such adherence problems may be caused by limited time 
available to attend the clinic and may benefit the peer-support in out-of-facility models.  
However, these non-stable patients may require closer and more regular clinical 
oversight.  Another area of future research is how community-based models of care can 
support patients who default from treatment while in the community-based models.  At 
present, defaulting patients would be up-referred to the CHC.  Depending on why the 
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patient is defaulting, an increase in counselling support within the community-based 
model of care may be preferable to up-referring the patient.    
Earlier transition to community-based models 
Further research is warranted to investigate if patients can be transitioned to 
community-based models of care sooner after ART initiation.  With patients initiating 
treatment at higher CD4 cell counts, viral suppression can be achieved within a few 
months of initiating ART, and therefore waiting a year (as in the case of CACs) until 
decentralisation may be unnecessary.  Support for earlier transition to community-
based models was found in Chapters 4-7.  In Chapter 4, patients with recent ART 
initiation had the highest rates of LTFU and in Chapter 6 and 8 patients with recent 
ART initiation had an increased risk of LTFU in the traditional in-facility model and 
benefitted most from down-referral. The question of how soon patients can be 
effectively down-referred to community-based models of ART warrants further 
research.   
Supporting HIV testing and pre-ART patients 
Community-based models may also have benefits at other stages in the HIV “treatment 
cascade”.  This thesis was limited to assessing their effectiveness in supporting ART 
provision after a year or more on treatment, but they may also be effective in initiating 
patients onto treatment. With the challenges in retaining patients along the “treatment 
cascade” [76], community-based models may also support linkage between HIV testing 
and treatment.  Community-based models could be equipped to provide HIV testing as 
well as CD4 and viral load monitoring for patients not yet eligible to start ART. Point-
of-care (POC) viral load and CD4 cell count testing within community-based models 
could provide further innovation [307].  
The frequency of viral load monitoring for ART patients is changing.  Potentially, if viral 
load monitoring was done using POC technology or with pooled viral loads in dried 
blood spots, different frequencies may be cost-effective for community models, 
especially if community models are restricted to stable patients. 
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The need to adapt the ART supply chain 
Adaptations of the ART supply chain are also needed to support community-based 
models.  In the CACs in Chapter 7, pre-packaged ART was transported daily from the 
CHC to the community venue. Direct delivery of ART to the community venues should 
be considered as should direct delivery from pharmaceuticals.  Simplification of 
regimens will assist in expanding opportunities for community-based models of 
delivery [237].  Another option or model that requires further investigation is that of 
community pharmacies or community distribution points [43].  Research into what 
components of community-based models support retention in care, whether it is 
decreased visit frequency, shorter visits, peer support or some other factor, is 
necessary [308]. This work will help to inform how community distribution points 
compared with Adherence Clubs may support ART provision.  
 
Strengthening referral pathways  
The pathways between models of care are bi-directional, supporting movement both in 
and out of primary care (Figure 9.2).  While acutely ill patients need to be timeously up-
referred to ensure appropriate disease management, the systems and transition of 
down-referral into community models also requires attention.  In both the Green Clinic 
in Chapter 6 and the Community-based Adherence Clubs in Chapter 8, patients who 
initiated ART in the early years of the programme had a higher risk of being LTFU in 
the down-referred models compared to patients who initiated treatment more 
recently. Furthermore, patients in the Green Clinic who had advanced HIV disease had 
an increased risk of LTFU compared to the CHC.  This suggests that patients who 
initiated treatment in the early years of the programme and those who had an illness 
experience may value the CHC model of care and require a more active transition when 
they are down-referred.  Potentially increasing the counselling and support is needed 
for these patient groups so that they understand the rationale for the decentralisation.  
It is important that they not only have the right to choose to stay at the primary care 
facility, but also that with being down-referred they do not feel as though they are 
being pushed out of the health care system.  Appropriate support of referrals both into 
and out of the primary care setting are therefore needed to ensure retention across 
models of care.   
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Policies can impede community-based models of care 
A key policy in the ability of programmes to decentralise ART delivery is around ART 
dispensing versus ART distribution.  Dispensing and distributing are not synonymous, 
and there must be balance between oversight and provision of ART while allowing 
reasonable distribution by CHWs.   
The amount of ART that can be collected at one time affects the number of patient visits 
within a year.  Decreased visit frequency offers huge potential benefits both to the 
patient and the health system.  At the Gugulethu CHC, the amount of ART that is 
dispensed per visit ranges from 4 weeks to 16 weeks.  National policy in South Africa is 
for 8 weeks, or a maximum of 2 months of ART to be distributed.  However, data from 
Community-based Adherence Clubs found no difference in retention or viral rebound 
among patients who were given four months vs. two months of ART [255].  While 
dispensing of four months of ART is against policy, the policy should be reconsidered 
and revised to be evidence-based. 
In South Africa, patients are rescripted every six months by a nurse or a doctor.  With 
the ART programme providing treatment to more than 2 million South Africans, this 
equates to high volume of administration due to prescriptions.  In addition, with 
simplified regimens, the majority of stable patients are on the same regimen.  With 
decentralisation of ART into communities, patients in the Community-based Adherence 
Clubs are rescripted blindly; the patient does not sit with the clinician while the script 
is written.  Therefore, the frequency of this process should be reconsidered and if 
possible amended.  Electronic scripting or other ways of reducing the administrative 
burden should be considered.  
Beyond ART towards integration 
A large component of the research agenda for community-based models of ART 
delivery revolves around how to integrate with other services.  While originally 
implemented as an emergency response, ART programmes in resource-limited settings 
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have adapted and been transformed towards supporting sustainable chronic care [40, 
309]. In recent years, there have been moves to combine ART programmes with one 
other programme, often tuberculosis (TB) or maternal health, creating integrated 
diagonal programmes [25, 310, 311].  The dominant paradigms are shifting away from 
horizontal and vertical approaches and treatment versus prevention [273] towards full 
integration and the Integrated Management of Adult Illnesses (IMAI) [312].  This in 
part is due to the successes of Integrated Management of Childhood Illnesses (IMCI), 
where the move is towards full integration.   
 
There is a renewed interest in operational models of primary care delivery following 
the thirtieth anniversary of the Alma Ata Deceleration of “health for all” [25, 293, 312-
315].  This approach is very much aligned with the public health approach of ART 
programmes in resource-limited settings.  In addition, there has been a simultaneous 
shift away from communicable and non-communicable diseases, towards health 
systems for acute and chronic diseases and HIV care exemplifies this shift [312]. Health 
systems research regarding ART originally focussed on whether or not ART 
programmes were beneficial or detrimental to other services [309].  Today, it is 
recognised that ART programmes in many resource-limited settings were the first 
successful, large-scale chronic care programmes [46].  Therefore, there are many 
lessons that can be learned and further research into how systems that can be 
leveraged for wider improvement of the health system [35, 40, 46, 47, 49, 289, 316, 
317].  In line with the revitalisation of Alma Ata and the public health approach, calls 
have been made to capitalise on the systems implemented for ART provision and 
expand them to other services [41].  
 
There is a unique opportunity for strengthening links between community-based 
models of ART delivery and existing programmes for IMAI and IMCI [310].  IMAI and 
IMCI were a response to fragmented vertical programmes, the result of disease-specific 
programming, such as HIV-specific programmes, that were focussed on achieving 
short-term measurable targets [318].  Utilising existing ART programmes to build IMAI 
echoes how systems of outreach that were implemented for immunisation were the 
foundation for IMCI [294, 310].  However, in contrast to IMCI, there has been very little 
uptake of IMAI and resultantly limited evidence of its effectiveness [310].  Lessons from 
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IMCI can therefore lend insight into how to expand implementation of IMAI and define 
the research agenda.  Within the campaigns for IMCI expansion, the importance of 
extending the health systems out of facilities and into health spaces was identified as a 
key factor for uptake [319].  To date, the guidelines and policies for IMAI have mirrored 
those for IMCI and been integrated with HIV services.  A noteworthy difference is the 
paucity of guidance around community level delivery of services for IMAI [310].  
Therefore, to support the broader implementation of IMAI necessary for research on its 
effectiveness, increasing the guidelines regarding community-based programmes is 
recommended.   
In summary, there is a large and exciting future research agenda into how community-
based models of care utilised for ART delivery can be expanded to other services [309].  
In order to support expanding IMAI, further guidelines in regards to community 
delivery are needed [49].  Despite the sizable interest in global health and focus on 
health systems strengthening, limited data on actual delivering health services in 
resource-limited settings has received little academic interest [273].   
9.3.3 Recommendations for programmes and services 
Programmes and services need to adapt to the current challenge of LTFU and the 
growing and changing cohort as new initiation guidelines are implemented. Based on 
findings of this thesis, recommendations are for triaging of patients at ART initiation, 
an overhaul of the approach and delivery of ART for healthier ART patients and 
simplification of monitoring and evaluation (M&E) systems.   
Improving ART effectiveness may mean revisiting the public heath 
approach to ART provision  
To date, a public health approach to the provision of ART in resource-limited settings 
has supported the rapid scale-up of ART.  However, with the increase in the 
heterogeneity of ART patients and the challenge of LTFU, it may be time to reconsider 
some elements of the “one-size-fits-all” approach [41]. While the principles of 
simplification, decentralisation, equity and patient and community participation are 
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still very relevant, the increased heterogeneity of the ART cohort demands that the 
standardisation principle is revisited.  Our findings that the ART cohort consists of a 
considerable group of acutely ill patients, as well an increasing number of patients who 
are healthy and without an illness experience, leads to a recommendation of triaging 
patients at the time of ART initiation.  This recommendation is based on the findings of 
the thesis and supports many of the public health principles while highlighting that we 
need to do better to improve ART effectiveness and support retention in care.        
Designating resources for those in need of clinical support 
As outlined above and evidenced in Chapter 4, a large proportion and absolute number 
of patients are still initiating ART with a low CD4 cell count, <100 cells/l. This group 
of patients requires substantial clinical resources and timely initiation onto ART to 
prevent mortality.  Counselling of this group should be specific to their needs, focussing 
on how ART can reduce mortality and addressing underlying reasons for late initiation. 
The model of care more appropriate to this group of patients may be the traditional in-
facility model given its ability to provide significant clinical support.  While it is 
discouraging that such a large number of patients are still accessing ART so late in their 
disease progression, it is also promising that increasing the treatment threshold is not 
squeezing these patients out of care [19].  WHO guidelines specify that provision to this 
group remain a priority and this can be achieved within parallel innovative models of 
care to be implemented for other patient groups [283].  Given that timely ART is 
necessary to prevent mortality in this patient population, it is essential that there is a 
model of care for them to access with appropriate resources.  The model of care is also 
needed for the complex patients (aging cohort, chronic co-morbidities, patients with 
treatment failure, etc.) as described in Section 9.2.  Designating resources for patients 
accessing ART with low CD4 cell counts can be supported by triaging healthier patients 
at ART initiation and stable patients out of facilities and into community-based models 
of care [237].  
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Appropriate services for healthier ART patients 
As highlighted in Section 9.2, implementation of the 2013 WHO guidelines will lead to a 
healthier group of patients accessing treatment. These healthy patients are unlikely to 
be acutely ill or feel as though they have a chronic condition.  Put another way, they are 
HIV patients without an illness experience.  It is crucial to therefore consider how best 
services can support their initiation and retention on ART.  As a first step, the healthier 
patients must be separated from the <100 cells/l patients.   
 
Separate healthier patients at ART initiation 
In Chapter 5, patients accessing ART at higher CD4 cell counts had an increased risk of 
LTFU (Objective 2c).  The primary care facilities we analysed in Gugulethu, the IeDEA-
SA collaboration and the MSF sites were designed for acutely ill patients but are 
increasingly utilised by this healthier group of patients. The facilities are congested, 
have long queues in waiting areas and increasingly have patients wearing masks to 
prevent transmission of TB.  The exposure of the HIV patient without an illness 
experience to this clinic experience may be detrimental to their motivation to be 
retained in care.  Patients without an illness experience may feel “too healthy” to be on 
ART and could be deterred by long queues for medication for a disease for which they 
have yet to experience [271].  Continuing to offer services in the same physical space 
for patients with low CD4 cell counts <100 cells/l and those without an illness 
experience may be reinforcing the common perception that ART is treatment for sick 
patients [63].  We observed that rates of LTFU were higher in the CHC for patients 
initiating at higher CD4 cell counts (Chapters 6 and 8) compared to down-referred 
models.   
 
Change ART initiation counselling for healthier patients 
How to initiate patients with higher CD4 cell counts onto ART is also of critical 
importance.  In Chapter 5, the highest risk of LTFU was in the first year on ART and 
peaked in the first three months for patients initiating at high CD4 cell counts.  The 
counselling support and information provided to patients around initiation is therefore 
critical.  ART needs to be rebranded as something not just for sick patients [271].  
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Initiation materials are out-dated and require an overhaul to reflect the changes in first 
line regimens, the scientific advances on the role of ART as prevention and the benefits 
of earlier initiation.  The focus needs to be on the benefits of life long viral suppression, 
how ART can be prevention and why daily adherence is crucial. Without an overhaul to 
the messaging provided to patients without an illness experience at initiation, we risk 
them disengaging from care early and a perpetuation of the out-dated view that ART is 
just for treatment.   
Move healthier patients at ART initiation into community models of care sooner 
The timing of decentralisation into communities was raised as a key area for further 
research in Section 9.3.1.  However, given that historically with ART provision changes 
to operational models have been made concurrently with research to evaluate their 
effectiveness [42], our findings support that programmes should proceed with earlier 
decentralisation into communities. When patients with high CD4 cell counts accessed 
either the nurse-managed Green Clinic (Chapter 6) or community-based Adherence 
Clubs (Chapter 8), they had substantially reduced LTFU compared to the traditional 
community health centre. With increases to the CD4 cell count threshold for ART 
initiation, programmes should consider fast-tracking patients without an illness 
experience who are healthy to community-models of care delivery that may more 
effectively support retention.  We acknowledge that retention in care is not the same as 
adherent on treatment and being virally supressed [48].  However, data from the CACs 
did support that retained patients were adherent.  Viral rebound at 6-months and 12-
months was less than 2%, evidence that patients retained in care were adherent.   
There are risks to transitioning patients to out of facility-models earlier in their 
treatment cycle.  Decentralisation may be viewed as being pushed out of the health care 
system and not give patients sufficient time to develop a relationships with CHC staff.  
It may also give the impression that their HIV is not a serious condition, as it does not 
warrant frequent clinical consultations.  To address these concerns, the messaging 
around decentralisation and when and how to access primary care as necessary, is 
critical.   
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Simplified and modernised monitoring and evaluation 
LTFU appears to be increasing with each calendar year as concluded Chapter 4, 
observed in the IeDEA-SA cohort in Chapter 5 and suggested in the Gugulethu ART 
cohort in Chapters 7 and 8.  As discussed in the strengths and limitations section in 9.1, 
all of these cohorts were research cohorts, with support and resources provided by 
academic or non-governmental partners. Significant external resources are provided to 
ensure high levels of data quality.  However, even in these well-resourced sites, 
retention in care appears to be deteriorating and the volume and rate of scale-up 
presents challenges to obtaining good quality monitoring data.  If LTFU is increasing at 
these sites, it is likely that the situation is even worse elsewhere and that efforts are 
necessary to support simplified monitoring of patients.   
One reason for the poor outcomes in existing ART programmes is high rates of 
administrative LTFU, whereby monitoring and evaluation systems are overwhelmed by 
patient volume and unable to accurately record basic patient-level data.  The number of 
key variables at the individual level that need to be collected should be limited in 
favour of quality [237].  As we saw in Chapter 3, the analytic approach to defining LTFU 
can affect estimates of patient outcomes. Therefore, it is essential for the approach to 
be harmonised across programmes, including standardisation of the type and methods 
of data collected.  
Setting targets for evaluating innovative models of care 
For programmes, one solution is to change the way in which innovative models of care 
are evaluated.  While conventionally new interventions are judged against the standard 
of care, this may be increasingly difficult and irrelevant for ART models of care. 
Outcomes from pre-existing services providing ART or the standard of care are 
deteriorating, as evidenced by the increasing rates of LTFU and challenges due to poor 
data quality. If the outcomes from the standard of care models are below a level that 
would be recommended, comparing novel models to existing models is futile. Further, 
given that patients are selected into new models of care based on factors related to 
better outcomes, it is a substantial methodological challenge to find comparable patient 
populations as a reference group.  Potentially, targets for retention and sustained viral 
 211 
suppression should be set and used as benchmarks for comparing the outcomes from 
innovative models of care.  This would serve to simplify analysis and expedite evidence 
of ways in which health services could adapt to support expanding ART access and 
retaining patients on care. 
 
A growing need to track patients across programmes and between models of care 
Higher rates of transfers between programmes are documented as the number of sites 
providing ART continues to grow [91].  With the expansion of the number of ART sites 
and moves afoot for greater decentralisation, the ability to track patients between and 
across programmes is increasingly important to accurately assess patient 
outcomes [211, 289]. To account for patient mobility, systems need to consider unique 
identifiers, the sharing of information between facilities and more modern biometric 
identifiers [91, 212, 251, 320].  The potential impact of improved systems for tracing 
patients between sites is huge; both to patients and health systems.  Patients are given 
flexibility to move between and across models ensuring they have an uninterrupted 
ART supply and that at the time of ART collection the person dispensing can see the 
patients most recent viral load measure and regimen.  For the system, patient 
outcomes are accurately and timeously collected allowing for effective programme 
monitoring, the ability to accurately forecast ART needs and identification of patients 
who are in need of support to re-engage with care [237].   Considerable and ongoing 
efforts to improve the monitoring of ART patients highlight that in resource-limited 
settings where health systems are severely constrained in financial and human 
resources as well as technical infrastructure, the substantial challenge of making 




This thesis has addressed the challenge of LTFU from ART programmes in South Africa 
and other high prevalence resource-limited settings.  It investigated the impact of the 
definition of LTFU on programme outcomes before describing temporal factors, 
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including year of ART initiation, programme expansion and increasing CD4 cell count at 
ART initiation, and their impact on LTFU.  Lastly, it assessed models of care for 
improving retention among stable ART patients.   
The first contribution of this thesis was demonstrating that how the definition and 
analytic approach to LTFU can have an appreciable impact on programme outcomes.  
Given that LTFU is a reflection of programme effectiveness, having a standardised 
definition will be necessary to compare outcomes within and between programmes. 
The second novel finding of this thesis was confirmation of the increasing trend of 
LTFU with calendar year of ART initiation.  Looking at data from twenty-five cohorts 
from 8 low and middle-income countries, calendar year of ART initiation was 
persistently associated with an increased risk of LTFU, with adjustment for individual 
level factors and measures of programme expansion.  This finding corroborated a 
concerning trend that LTFU is a growing challenge.  Our research also suggests that it is 
the pace of scale-up and not programme size that may be associated with increases in 
LTFU.  
Thirdly, we provided evidence that healthier patients initiating ART at higher CD4 cell 
counts, above 300 cells/l, were at an increased risk of LTFU in the first year on ART.  
Given the trend towards earlier ART initiation, we must acknowledge that patients 
initiating ART without an illness experience may require different support and systems 
to effectively delivery ART.   
The final contribution of this thesis was in the assessment of models of care for ART 
delivery to stable patients.  The implementation experience and early outcomes from 
the community-based Adherence Clubs support continued decentralisation and task 
shifting for effective ART provision.  Investigating patient sub-groups and their 
outcomes in novel models of care confirmed that not all patients benefit equally.  
Patients who initiated ART in the early years of the programme or with advanced 
disease need increased support during down-referral.  Patients who have recently 
initiated ART had large improvements in outcomes with down-referral, suggesting 
earlier decentralisation may lead to additional risk reduction.   
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The findings of this thesis draw attention to the growing challenge of LTFU in a time 
when ART programmes are encouraged to increase the pace of scale-up.  Globally, 
millions of HIV patients require ART for effective management of their chronic 
condition.  However, ART expansion must be accompanied by changes to the health 
system to support retention of patients in care.  Based on the results of this thesis, the 
recommendation for expanding community-based models of care is presented as a 
strategy to provide ART more efficiently and to alleviate clinical capacity to assist late 
presenters and complex ART patients.  While the challenges and context of ART 
provision in resource-limited settings have evolved over the past decade, new 
challenges have arisen.  ART was first provided in resource-limited settings without 
evidence of its effectiveness in this context and no implementation experience.  Now, 
we must once again proceed with limited data, as it is our responsibility to expand 
access and encourage retention.   
 
Health systems adaptions with approaches that support patient self-management and 
ART delivery closer to home need to be expanded.  Recommendations include 
expanding community-based models of ART delivery and further research into how 
community-based models can be integrated to support management of other adult 
illnesses. With the knowledge that ART can provide benefits beyond the individual it is 
our collective imperative to improve how ART is provided in support of an AIDS free 
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Objective Criteria for included studies 
Study design, date range, 
region 
Description of included 
studies 
# of publications, programs, 
countries, patients 
Key findings related to improving 
LTFU/retention/adherence  








models of care in 
sub-Saharan Africa 
Quantitative and qualitative, 
Sub-Saharan Africa 
18 studies [168, 170-176, 
323-329], 6 programs, 3 
countries 
Programs were for home-based ART delivery in 
Uganda & Kenya, and the CAGs in Mozambique 
No key findings related to LTFU 






Assess the effects 
of models of 
decentralised ART 
treatment and 
care for initiating 
and maintaining 
ART 
Quantitative, 1996-31 March 
2013 
16 studies (2 RCTs, 14 
cohorts; 6 partial 
decentralisation [163-165, 
246, 330, 331], 7 full 
decentralisation [36, 204, 
332-336], 3 CBART [168, 
171, 174]), 1 from outside 
of Africa 
Partial decentralisation led to less LTFU after 12-
months (RR: 0.55, 95% CI 0.45-0.69), full 
decentralisation led to less LTFU after 12-months 











reviews of ART 
decentralisation 
(one of four 
objectives)  
Quantitative 10 studies (4 partial 
decentralisation [163, 165, 
171, 174, 246, 330], 4 full 
decentralisation [36, 204, 
332, 334], 2 CBART [168, 
174]) 
Partial decentralisation had improved retention 
(RR: 1.05, 95% CI 1.01-1.09), full decentralisation 
had improved retention (RR: 1.12, 95% CI 1.01-
1.17), comparable retention in CBART to hospital 
based (RR: 1.01, 95% CI 0.99-1.03) 
Models of care - Task shifting 
Callaghan 
et al 




of task shifting in 
HIV care in Africa 
Quantitative and qualitative 
and grey literature, until 2009, 
Africa 
84 articles, 51 on outcomes 
(25 original articles), 15 
reviews, 12 opinion pieces, 
13 describing models, 6 
policy analysis studies  









Objective Criteria for included studies 
Study design, date range, 
region 
Description of included 
studies 
# of publications, programs, 
countries, patients 
Key findings related to improving 
LTFU/retention/adherence  















RCTs, non-randomized control 
trials, cohorts, and case-
control studies, excluding lay 
workers and CHWs, including 
conference abstracts 
12 studies (3 qualitative 
only, 9 for meta-
analysis [44, 45, 164, 165, 
332, 334, 337-339] 
including 5 non-physician 
initiated ART and 4 non-
physician ART 
maintenance)) 
No difference in LTFU in non-physician ART 
maintenance (HR 0.98, 95%CI 0.59-1.66), less 
LTFU in non-physician ART initiation (HR 0.63, 
95% CI 0.45-0.87), Overall in non-physician 
models, LTFU was reduced (HR 0.72, 95% CI 0.56-
0.94) 







quality of ART 
initiation and 
maintenance in 
models that task 
shift care from 
doctors to non-
doctors 
Quantitative 10 studies (4 RCTs, 6 
cohorts) [44, 45, 164, 165, 
168, 173, 332, 334, 339, 
340], all sub-Saharan Africa 
Assessed nurse initiated 
and maintenance model, 
doctor initiated nurse 
maintenance model, and 
community maintenance 
model – looked at outcomes 
as 12-months by study 
design 
In nurse initiated and maintenance model vs. 
doctor, lower LTFU from RCTs (RR 0.73, 95% CI 
0.55-0.97) and no difference in cohorts; in doctor 
initiated and nurse maintenance model, no 
difference in LTFU from RCTs or cohorts; in 
community maintenance model, no difference in 








impact on cost of 
task shifting 
RCTs, quasi-experimental 
studies and modelling studies 
for costing 
8 studies, 6 on effectiveness 
(4 on clinicians to 
CHWs [168, 171, 174, 341], 
2 on doctors to nurses [44, 
45]) and 3 evaluating cost 
impact 
Task shifting from clinicians to CHWs led to 
comparable adherence and LTFU, task shifting 
from doctors to nurses led to comparable LTFU.  




Describe the role 
and outcomes of 
CHWs 
Quantitative and qualitative, 
until Dec 2012, sub-Saharan 
Africa 
23 studies, 21 programs (5 
qualitative, 7 cohort, 6 
mixed methods, 3 RCTs), 9 
countries 
CHWs provided adherence support, improved 




Supplementary Table 2.2 Models of care included in systematic reviews of task 
shifting and decentralisation 
 

















































































































































Assefa et al. 2012 [332] ✔  ✔  ✔  ✖ ✔  ✖ ✖ ✖ 
Balcha et al. 2010 [333] ✔  ✖ ✖ ✖ ✖ ✖ ✖ ✖ 
Bedelu et al. 2007 [334] ✔  ✔  ✔  ✔  ✔  ✖ ✖ ✖ 
Brennan et al. 2011 [165] ✔  ✔  ✖ ✖ ✔  ✖ ✖ ✖ 
Chan et al. 2010 [163] ✔  ✖ ✔  ✖ ✖ ✖ ✖ ✖ 
Decroo et al. 2014 [177] ✖ ✖ ✖ ✖ ✖ ✖ ✖ ✔  
Fairall et al. 2012 [45] ✖ ✔  ✖ ✖ ✔  ✔  ✖ ✖ 
Fatti et al. 2010 [246] ✔  ✖ ✔  ✖ ✖ ✖ ✖ ✖ 
Humphreys et al. 2010 [164] ✔  ✔  ✖ ✖ ✔  ✖ ✖ ✖ 
Jaffar et al. 2009 [168] ✔  ✔  ✔  ✔  ✖ ✔  ✔  ✔  
Kipp et al. 2012 [172] ✔  ✔  ✖ ✖ ✖ ✔  ✔  ✔  
Luque-Fernandez et al. 
2013 [178] 
✖ ✖ ✖ ✖ ✖ ✖ ✖ ✖ 
Massaquoi et al. 2009 [36] ✔  ✖ ✔  ✖ ✖ ✖ ✖ ✖ 
McGuire et al. 2012 [204] ✔  ✖ ✔  ✔  ✖ ✖ ✖ ✖ 
Sanne et al. 2010 [44] ✖ ✔  ✖ ✖ ✔  ✔  ✖ ✖ 
Selke et al. 2010 [174] ✔  ✖ ✔  ✖ ✖ ✔  ✔  ✔  
Sherr et al. 2010 [339] ✖ ✔  ✖ ✖ ✔  ✖ ✖ ✖ 
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Supplementary Table 4.1 Kaplan–Meier estimates of mortality, loss to follow-up 
and programme retention in care by duration of follow-up, programme size and 






% (95% CI) 
LTFU 
 
% (95% CI) 
Retention in 
care 
% (95% CI) 
Duration of  
follow-up     
6 months 102,289 (77.3) 6.0 (5.9-6.2) 7.7 (7.6-7.9) 86.7 (86.6-86.9) 
12 months 85,249 (64.4) 7.6 (7.5-7.8) 10.8 (10.6-11.0) 82.4 (82.2-82.7) 
24 months 61,005 (46.1) 9.3 (9.2-9.5) 15.1 (14.9-15.4) 76.9 (76.7-77.2) 
36 months 41,801 (31.6) 10.5 (10.3-10.7) 18.6 (18.4-18.9) 72.8 (72.5-73.1) 
48 months 25,835 (19.5) 11.6 (11.3-11.8) 21.7 (21.4-22.0) 69.2 (68.9-69.6) 
60 months 14,747 (11.1) 12.5 (12.3-12.8) 24.4 (24.1-24.8) 66.1 (65.8-66.5) 
Programme size 












% (95% CI) 
<500 3,512 (2.7) 12.1 (11.1-13.3) 2.7 (2.2-3.3) 85.5 (84.3-86.6) 
500-999 7,398 (5.6) 10.6 (9.9-11.3) 5.3 (4.8-5.8) 84.7 (83.9-85.5) 
1,000-2,499 25,348 (19.2) 9.4 (9.0-9.7) 7.8 (7.5-8.2) 83.5 (83.1-84.0) 
2,500-4,999 37,001 (28.0) 8.1 (7.8-8.4) 10.3 (10.0-10.7) 82.4 (92.0-82.8) 
5,000-7,499 22,153 (16.7) 5.5 (5.2-5.9) 14.7 (14.2-15.2) 80.6 (80.1-81.2) 
7,500 – 9,999 14,530 (11.0) 5.8 (5.4-6.2) 12.7 (12.1-13.3) 82.3 (81.6-82.9) 
10,000-14,999 13,314 (10.1) 6.3 (5.8-6.7) 13.9 (13.3-14.5) 80.7 (80.0-81.4) 
15,000-19,999 3,885 (2.9) 4.7 (4.1-5.5) 10.6 (9.7-11.7) 85.2 (84.0-86.3) 
≥20,000 5,193 (3.9) 5.6 (4.9-6.4) 12.2 (11.2-13.3) 82.9 (81.6-84.0) 
Rate of expansion 












% (95% CI) 
<25 23,445 (17.7) 10.0 (9.6-10.4) 5.6 (5.3-6.0) 84.9 (84.5-85.4) 
25-60 23,214 (17.5) 9.3 (8.9-9.7) 9.6 (9.2-10.0) 82.0 (81.5-82.5) 
60-90 27,009 (20.4) 7.3 (7.0-7.6) 12.6 (12.2-13.1) 81.0 (80.5-81.5) 
90-125 27,375 (20.7) 6.7 (6.4-7.1) 11.6 (11.2-12.0) 82.5 (82.0-82.9) 
≥125 31,291 (23.7) 5.3 (5.0-5.6) 13.3 (12.9-13.7) 82.1 (81.6-82.6) 
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Supplementary Table 4.2 Sensitivity analysis: Cox proportional hazards 
estimates of mortality including patients with missing data* 
0-12 months  (n=132,334) 
Univariate 
HR (95% CI) 
Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Model 3 
HR (95% CI) 
Model 4 
HR (95% CI) 
Year of ART initiation  
2003 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2004 0.67 (0.61-0.74) 0.69 (0.63-0.76) 0.82 (0.72-0.93) 0.81 (0.73-0.91) 0.89 (0.78-1.01) 
2005 0.53 (0.48-0.58) 0.60 (0.54-0.66) 0.74 (0.65-0.85) 0.76 (0.68-0.86) 0.82 (0.70-0.95) 
2006 0.51 (0.47-0.56) 0.65 (0.59-0.71) 0.85 (0.74-0.98) 0.87 (0.77-0.99) 0.96 (0.82-1.12) 
2007 0.36 (0.33-0.40) 0.53 (0.48-0.59) 0.82 (0.69-0.96) 0.74 (0.65-0.84) 0.92 (0.77-1.10) 
2008 0.34 (0.31-0.38) 0.57 (0.51-0.62) 0.94 (0.79-1.11) 0.84 (0.73-0.97) 1.09 (0.91-1.31) 
2009 0.29 (0.26-0.32) 0.50 (0.45-0.55) 0.87 (0.73-1.05) 0.76 (0.65-0.88) 1.03 (0.84-1.24) 
2010 0.27 (0.24-0.29) 0.47 (0.43-0.52) 0.79 (0.66-0.96) 0.72 (0.63-0.84) 0.93 (0.76-1.14) 
2011 0.28 (0.24-0.32) 0.49 (0.43-0.57) 0.81 (0.65-1.00) 0.75 (0.63-0.90) 0.93 (0.74-1.16) 
Programme size (patients) 
<500 1.0 (ref) 1.0 (ref) 1.0 (ref) 
500-999 0.90 (0.79-1.03) 0.95 (0.83-1.09) 0.94 (0.82-1.08) 
1,000-2,499 0.64 (0.57-0.72) 0.87 (0.75-1.00) 0.87 (0.75-1.00) 
2,500-4,999 0.51 (0.45-0.57) 0.77 (0.65-0.91) 0.81 (0.68-0.96) 
5,000-7,499 0.31 (0.27-0.35) 0.55 (0.44-0.67) 0.58 (0.47-0.72) 
7,500 – 9,999 0.26 (0.23-0.30) 0.43 (0.35-0.54) 0.50 (0.39-0.63) 
10,000-14,999 0.22 (0.19-0.25) 0.54 (0.43-0.69) 0.66 (0.50-0.86) 
15,000-19,999 0.15 (0.12-0.18) 0.43 (0.32-0.57) 0.53 (0.38-0.73) 
≥20,000 0.18 (0.15-0.22) 0.56 (0.42-0.75) 0.70 (0.50-0.96) 
Rate of expansion (patients/month) 
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-59 0.64 (0.59-0.69) 0.86 (0.79-0.94) 0.85 (0.78-0.93) 
60-89 0.43 (0.40-0.47) 0.69 (0.62-0.78) 0.74 (0.65-0.83) 
90-124 0.37 (0.34-0.41) 0.67 (0.59-0.77) 0.79 (0.68-0.91) 
≥125 0.21 (0.20-0.24) 0.54 (0.47-0.63) 0.63 (0.52-0.77) 
Sex  Sex  
Female 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref 1.0 (ref) 
Male 1.61 (1.54-1.68) 1.30 (1.25-1.36) 1.31 (1.25-1.37) 1.31(1.25-1.37) 1.31 (1.25-1.37) 
Age group (years) 
16-25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-34 1.07 (0.99-1.17) 1.13 (1.05-1.24) 1.14 (1.05-1.24) 1.14 (1.05-1.24) 1.14 (1.05-1.24) 
35-44 1.16 (1.07-1.26) 1.23 (1.13-1.34) 1.22 (1.12-1.33) 1.23 (1.13-1.34) 1.22 (1.12-1.33) 
45+ 1.33 (1.22-1.46) 1.49 (1.36-1.63) 1.48 (1.35-1.62) 1.49 (1.36-1.62) 1.48 (1.35-1.62) 
Body Mass Index  
Underweight 3.58 (3.40-3.76) 2.57 (2.44-2.70) 2.58 (2.45-2.71) 2.57 (2.44-2.70) 2.57 (2.44-2.70) 
Normal 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Overweight 0.59 (0.50-0.70) 0.74 (0.62-0.87) 0.73 (0.62-0.86) 0.74 (0.62-0.87) 0.73 (0.62-0.86) 
Obese 0.91 (0.69-1.20) 1.20 (0.90-1.58) 1.18 (0.89-1.56) 1.20 (0.90-1.59) 1.18 (0.89-1.57) 
Missing 7.21 (6.75-7.70) 6.18 (5.78-6.60) 6.39 (5.98-6.83) 6.24 (5.84-6.67) 6.45 (6.04-6.90) 
CD4 cell count (cells/μl)  
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-49 0.60 (0.56-0.65) 0.70 (0.65-0.75) 0.70 (0.65-0.76) 0.70 (0.65-0.76) 0.70 (0.65-0.76) 
50-99 0.38 (0.36-0.41) 0.50 (0.47-0.54) 0.51 (0.47-0.55) 0.51 (0.47-0.55) 0.51 (0.47-0.55) 
100-149 0.26 (0.24-0.28) 0.39 (0.36-0.43) 0.40 (0.36-0.43) 0.40 (0.37-0.43) 0.40 (0.37-0.43) 
150-199 0.19 (0.17-0.21) 0.34 (0.31-0.37) 0.34 (0.31-0.37) 0.34 (0.31-0.37) 0.34 (0.31-0.37) 
200-349 0.14 (0.13-0.16) 0.28 (0.25-0.30) 0.28 (0.26-0.31) 0.28 (0.26-0.31) 0.28 (0.26-0.31) 
≥350 0.24 (0.21-0.28) 0.38 (0.32-0.44) 0.38 (0.33-0.44) 0.38 (0.33-0.44) 0.38 (0.33-0.44) 
Missing 0.45 (0.42-0.48) 0.51 (0.48-0.54) 0.52 (0.48-0.55) 0.52 (0.49-0.56) 0.52 (0.49-0.56) 
WHO stage  
I and II 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
III 2.60 (2.42-2.79) 1.79 (1.66-1.93) 1.74 (1.61-1.87) 1.75 (1.62-1.88) 1.72 (1.60-1.86) 
IV 5.70 (5.31-6.11) 3.09 (2.87-3.33) 3.00 (2.78-3.23) 3.01 (2.79-3.24) 2.96 (2.74-3.19) 
Missing 2.04 (1.72-2.43) 1.53 (1.28-1.82) 1.49 (1.25-1.77) 1.51 (1.26-1.79) 1.48 (1.24-1.76) 
* All models accounted for site heterogeneity using random effects.  Model 1 – demographics and baseline variables, Model 2 - 
Model 1 + programme size, Model 3 – Model 1 + rate of expansion, Model 4 – Model 1 + programme size and rate of expansion 
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Supplementary Table 4.2(continued) Sensitivity analysis: Cox proportional 
hazards estimates of mortality including patients with missing data* 
12-72 months (n=85,171) 
Univariate 
HR (95% CI) 
Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Model 3 
HR (95% CI) 
Model 4 
HR (95% CI) 
Year of ART initiation  
2003 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2004 0.77 (0.66-0.91) 0.77 (0.65-0.90) 0.88 (0.72-1.08) 0.88 (0.74-1.05) 0.91 (0.74-1.12) 
2005 0.69 (0.59-0.81) 0.72 (0.61-0.84) 0.88 (0.71-1.09) 0.85 (0.71-1.03) 0.88 (0.71-1.11) 
2006 0.58 (0.50-0.68) 0.63 (0.54-0.74) 0.78 (0.63-0.98) 0.78 (0.64-0.95) 0.81 (0.64-1.02) 
2007 0.53 (0.46-0.62) 0.63 (0.53-0.74) 0.80 (0.62-1.04) 0.78 (0.64-0.97) 0.83 (0.63-1.09) 
2008 0.46 (0.38-0.54) 0.56 (0.47-0.66) 0.74 (0.56-0.98) 0.72 (0.57-0.92) 0.78 (0.58-1.04) 
2009 0.43 (0.35-0.52) 0.52 (0.42-0.63) 0.70 (0.51-0.96) 0.68 (0.52-0.88) 0.73 (0.53-1.00) 
2010 0.50 (0.35-0.72) 0.61 (0.42-0.87) 0.93 (0.60-1.45) 0.79 (0.53-1.17) 0.97 (0.62-1.52) 
2011 - - - - - 
Programme size (patients) 
<500 1.0 (ref) 1.0 (ref) 1.0 (ref) 
500-999 0.83 (0.69-1.00) 0.97 (0.80-1.19) 0.98 (0.80-1.19) 
1,000-2,499 0.77 (0.65-0.91) 1.03 (0.84-1.27) 1.05 (0.96-1.29) 
2,500-4,999 0.59 (0.49-0.71) 0.83 (0.65-1.06) 0.89 (0.69-1.14) 
5,000-7,499 0.42 (0.34-0.52) 0.65 (0.48-0.90) 0.69 (0.50-0.96) 
7,500 – 9,999 0.38 (0.29-0.51) 0.58 (0.40-0.85) 0.63 (0.41-0.96) 
10,000-14,999 0.42 (0.33-0.54) 0.81 (0.55-1.19) 0.88 (0.57-1.34) 
15,000-19,999 0.35 (0.25-0.50) 0.80 (0.49-1.32) 0.93 (0.531.61) 
≥20,000 0.18 (0.06-0.55) 0.29 (0.08-1.02) 0.34 (0.10-1.19) 
Rate of expansion (patients/month) 
<25 1.0 (ref)  1.0 (ref) 1.0 (ref) 
25-59 0.74 (0.65-0.84) 0.84 (0.73-0.97) 0.87 (0.75-1.00) 
60-89 0.56 (0.49-0.65) 0.72 (0.60-0.86) 0.81 (0.67-0.99) 
90-124 0.52 (0.45-0.61) 0.75 (0.61-0.92) 0.92 (0.72-1.17) 
≥125 0.39  (0.32-0.47) 0.66 (0.50-0.86) 0.79 (0.56-1.12) 
Sex  
Female 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Male 1.77  (1.64-1.91) 1.59 (1.47-1.72) 1.59 (1.47-1.72) 1.59 (1.47-1.72) 1.59 (1.47-1.72) 
Age group (years) 
16-25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-34 0.94 (0.81-1.09) 0.95 (0.82-1.10) 0.95 (0.81-1.10) 0.95 (0.82-1.10) 0.95 (0.81-1.10) 
35-44 1.10 (0.92-1.27) 1.07 (0.91-1.24) 1.06 (0.91-1.24) 1.07 (0.91-1.24) 1.06 (0.91-1.24) 
45+ 1.66 (1.42-1.95) 1.60 (1.37-1.88) 1.60 (1.36-1.87) 1.61 (1.37-1.88) 1.60 (1.37-1.88) 
Body Mass Index  
Underweight 1.64 (1.51-1.78) 1.46 (1.34-1.58) 1.46 (1.35-1.59) 1.45 (1.34-1.58) 1.46 (1.34-1.59) 
Normal 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Overweight 0.85 (0.70-1.04) 0.96 (0.79-1.18) 0.96 (0.78-1.17) 0.97 (0.79-1.18) 0.96 (0.79-1.17) 
Obese 0.95 (0.64-1.43) 1.11 (0.74-1.66) 1.10 (0.73-1.64) 1.11 (0.74-1.67) 1.10 (0.73-1.65) 
Missing 3.83 (3.31-4.43) 3.68 (3.18-4.27) 3.80 (3.28-3.41) 3.70 (3.19-4.29) 3.84 (3.31-4.45) 
CD4 cell count (cells/μl)  
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-49 0.92 (0.78-1.09) 0.96 (0.81-1.14) 0.96 (0.81-1.14) 0.96 (0.81-1.14) 0.96 (0.81-1.14) 
50-99 0.86 (0.73-1.00) 0.95 (0.81-1.11) 0.95 (0.81-1.11) 0.95 (0.82-1.11) 0.95 (0.81-1.11) 
100-149 0.63 (0.54-0.75) 0.75 (0.63-0.89) 0.75 (0.64-0.89) 0.75 (0.64-0.89) 0.75 (0.64-0.89) 
150-199 0.64 (0.44-0.61) 0.82 (0.70-0.97) 0.82 (0.70-0.97) 0.83 (0.70-0.98) 0.82 (0.70-0.97) 
200-349 0.52 (0.44-0.61) 0.69 (0.58-0.81) 0.69 (0.58-0.81) 0.70 (0.59-0.82) 0.69 (0.59-0.82) 
≥350 0.79 (0.60-1.05) 0.95 (0.72-1.26) 0.96 (0.72-1.27) 0.85 (0.72-1.26) 0.95 (0.72-1.26) 
Missing 0.90 (0.78-1.03) 0.95 (0.82-1.09) 0.97 (0.83-1.12) 0.96 (0.83-1.11) 0.97 (0.84-1.12) 
WHO stage  
I and II 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
III 1.54 (1.38-1.72) 1.27 (1.13-1.43) 1.26 (1.12-1.42) 1.26 (1.12-1.42) 1.25 (1.12-1.41) 
IV 2.26 (2.01-2.53) 1.68 (1.49-1.90) 1.65 (1.46-1.87) 1.66 (1.46-1.87) 1.64 (1.45-1.85) 
Missing 1.43 (1.10-1.86) 1.29 (0.99-1.68) 1.28 (0.98-1.68)  1.28 (0.98-1.67) 1.27 (0.97-1.66) 
* All models accounted for site heterogeneity using random effects.  Model 1 – demographics and baseline variables, Model 2 - 
Model 1 + programme size, Model 3 – Model 1 + rate of expansion, Model 4 – Model 1 + programme size and rate of expansion
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Supplementary Table 4.3 Sensitivity analysis: Cox proportional hazards 
estimates of LTFU including patients with missing data* 
 
 0-12 months  (n=132,334) 
 Univariate 
HR (95% CI) 
Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Model 3 
HR (95% CI) 
Model 4 
HR (95% CI) 
Year of ART initiation      
2003 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2004 1.62 (1.40-1.88) 1.59 (1.37-1.84) 1.06 (0.88-1.27) 1.42 (1.21-1.66) 1.04 (0.87-1.25) 
2005 1.69 (1.46-1.95) 1.76 (1.52-2.03) 1.16 (0.97-1.39) 1.55 (1.32-1.82) 1.12 (0.92-1.35) 
2006 1.62 (1.41-1.86) 1.86 (1.62-2.14) 1.21 (1.01-1.45) 1.58 (1.34-1.87) 1.12 (0.92-1.35) 
2007 2.04 (1.78-2.34) 2.55 (2.22-2.92) 1.48 (1.23-1.80) 2.12 (1.80-2.50) 1.40 (1.14-1.71) 
2008 2.26 (1.98-2.59) 2.83 (2.47-3.24) 1.70 (1.40-2.06) 2.25 (1.90-2.66) 1.46 (1.27-1.92) 
2009 2.14 (1.87-2.45) 2.72 (2.37-3.12) 1.56 (1.27-1.90) 2.07 (1.75-2.46) 1.35 (1.09-1.67) 
2010 2.99 (2.62-3.42) 3.84 (3.35-4.40) 2.15 (1.75-2.63) 2.86 (2.41-3.39) 1.90 (1.53-2.36) 
2011 3.64 (3.15-4.21) 4.77 (4.12-5.53) 2.63 (2.12-3.27) 3.51 (2.93-4.20) 2.44 (1.94-3.06) 
Programme size (patients)     
<500 1.0 (ref)  1.0 (ref)  1.0 (ref) 
500-999 1.71 (1.29-2.26)  1.93 (1.45-2.56)  1.80 (1.35-2.39) 
1,000-2,499 3.02 (2.33-3.92)  2.81 (2.13-3.72)  2.60 (1.97-3.44) 
2,500-4,999 3.29 (2.54-4.27)  2.90 (2.16-3.88)  2.54 (1.89-3.41) 
5,000-7,499 4.36 (3.36-5.67)  3.29 (2.42-4.48)  2.86 (2.10-3.90) 
7,500 – 9,999 4.60 (3.53-5.99)  2.92 (2.13-4.00)  2.13 (1.54-2.95) 
10,000-14,999 6.17 (4.73-8.04)  3.95 (2.79-5.32)  2.34 (1.67-3.30) 
15,000-19,999 5.97 (4.49-7.93)  4.50 (3.18-6.38)  2.79 (1.94-4.01) 
≥20,000 7.35 (5.55-9.73)  3.78 (2.66-3.67)  2.26 (1.56-3.27) 
Rate of expansion (patients/month)     
<25 1.0 (ref)   1.0 (ref) 1.0 (ref) 
25-59 1.57 (1.41-1.75)   1.32 (1.17-1.49) 1.27 (1.12-1.44) 
60-89 1.94 (1.73-2.18)   1.34 (1.16-1.54) 1.30 (1.12-1.51) 
90-124 2.16 (1.92-2.4)   1.40 (1.20-1.63) 1.46 (1.24-1.73) 
≥125 3.09 (2.74-3.48)   1.79 (1.52-2.10) 2.04 (1.68-2.46) 
Sex      
Female 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Male 1.31 (1.27-1.36) 1.29 (1.24-1.33) 1.28 (1.24-1.33) 1.28 (1.23-1.33) 1.28 (1.23-1.33) 
Age group (years)      
16-25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-34 0.72 (0.69-0.76) 0.76 (0.72-0.80) 0.76 (0.72-0.80) 0.76 (0.72-0.80) 0.76 (0.72-0.80) 
35-44 0.60 (0.57-0.64) 0.62 (0.59-0.66) 0.62 (0.59-0.66) 0.62 (0.58-0.66) 0.62 (0.59-0.66) 
45+ 0.60 (0.56-0.64) 0.61 (0.57-0.65) 0.61 (0.57-0.65) 0.61 (0.57-0.65) 0.61 (0.57-0.65) 
Body Mass Index       
Underweight 1.69 (1.63-1.76) 1.50 (1.44-1.57) 1.50 (1.44-1.56) 1.50 (1.44-1.57) 1.50 (1.44-1.56) 
Normal 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Overweight 0.91 (0.83-0.99) 1.00 (0.91-1.09) 1.00 (0.91-1.08) 1.00 (0.91-1.09) 0.99 (0.91-1.09) 
Obese 1.13 (0.96-1.32) 1.28 (1.10-1.50) 1.28 (1.09-1.50) 1.29 (1.10-1.51) 1.28 (1.09-1.50) 
Missing 2.91 (2.76-3.07) 2.70 (2.55-2.85) 2.72 (2.57-2.88) 2.69 (2.54-2.84) 2.73 (2.58-2.88) 
CD4 cell count (cells/μl)     
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-49 0.81 (0.75-0.88) 0.89 (0.82-0.96) 0.88 (0.81-0.96) 0.88 (0.81-0.96) 0.88 (0.81-0.96) 
50-99 0.62 (0.58-0.67) 0.73 (0.68-0.79) 0.72 (0.67-0.78) 0.72 (0.67-0.78) 0.72 (0.67-0.78) 
100-149 0.57 (0.53-0.61) 0.70 (0.65-0.75) 0.69 (0.64-0.75) 0.69 (0.64-0.75) 0.69 (0.64-0.75) 
150-199 0.48 (0.44-0.51) 0.60 (0.56-0.65) 0.60 (0.55-0.65) 0.60 (0.55-0.65) 0.60 (0.55-0.65) 
200-349 0.52 (0.48-0.55) 0.60 (0.56-0.65) 0.59 (0.55-0.63) 0.60 (0.55-0.63) 0.59 (0.55-0.63) 
≥350 0.79 (0.71-0.87) 0.75 (0.67-0.83) 0.75 (0.67-0.83) 0.75 (0.68-0.84) 0.75 (0.68-0.84) 
Missing 0.83 (0.78-0.89) 0.92 (0.86-0.98) 0.93 (0.87-0.99) 0.92 (0.86-0.98) 0.92 (0.86-0.98) 
WHO stage      
I and II 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
III 1.10 (1.05-1.14) 1.17 (0.11-1.22) 1.17 (1.12-1.23) 1.18 (1.13-1.24) 1.18 (1.12-1.23) 
IV 1.51 (1.44-1.59) 1.54 (1.46-1.62) 1.55 (1.48-1.64) 1.57 (1.49-1.65) 1.57 (1.49-1.65) 
Missing 1.01 (0.88-1.17) 1.05 (0.91-1.21) 1.04 (0.90-1.20) 1.05 (0.91-1.21) 1.03 (0.89-1.18) 
* All models accounted for site heterogeneity using random effects.  Model 1 – demographics and baseline variables, Model 2 - 
Model 1 + programme size, Model 3 – Model 1 + rate of expansion, Model 4 – Model 1 + programme size and rate of expansion 
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Supplementary Table 4.3 (continued) Sensitivity analysis: Cox proportional 
hazards estimates of LTFU including patients with missing data* 
12-72 months (n=85,171) 
Univariate 
HR (95% CI) 
Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Model 3 
HR (95% CI) 
Model 4 
HR (95% CI) 
Year of ART initiation  
2003 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2004 1.31 (1.16-1.49) 1.30 (1.15-1.47) 1.07 (0.90-1.26) 1.15  (1.00-1.31) 1.02 (0.87-1.21) 
2005 1.19 (1.05-1.35) 1.21 (1.07-1.37) 0.99 (0.83-1.18) 0.96 (0.84-1.11) 0.84 (0.70-1.00) 
2006 1.47 (1.31-1.66) 1.56 (1.39-1.76) 1.30 (1.10-1.54) 1.16 (1.00-1.34) 1.00 (0.84-1.20) 
2007 1.82 (1.62-2.05) 2.00 (1.77-2.26) 1.74 (1.43-2.11) 1.46 (1.26-1.70) 1.37 (1.11-1.69) 
2008 2.44 (2.15-2.75) 2.68  (2.37-2.04)  2.33 (1.89-2.86) 1.86 (1.58-2.19) 1.80 (1.45-2.24) 
2009 3.60 (3.16-4.10) 3.96 (2.47-4.51) 3.59 (2.88-4.46) 2.67 (2.25-3.18) 2.61 (2.06-3.29) 
2010 6.50 (5.45-7.76) 7.07 (5.92-8.46) 6.61 (5.11-8.55) 4.87 (3.95-6.00) 4.94 (3.77-6.47) 
2011 - - - - - 
Programme size (patients) 
<500 1.0 (ref) 1.0 (ref) 1.0 (ref) 
500-999 1.64 (1.34-2.00) 1.60 (1.31-1.96) 1.55 (1.27-1.89) 
1,000-2,499 2.35 (1.94-2.86) 1.75 (1.41-2.16) 1.69 (1.27-2.10) 
2,500-4,999 2.66 (2.19-3.22) 1.87 (1.48-2.36) 1.64 (1.29-2.08) 
5,000-7,499 3.80 (3.11-4.65) 1.65 (1.26-2.15) 1.37 (1.3-1.79) 
7,500 – 9,999 5.47 (4.42-6.77) 1.67 (1.26-2.21) 1.07 (0.79-1.45) 
10,000-14,999 4.06 (3.22-5.12) 1.49 (1.09-2.04) 1.02 (0.74-1.43) 
15,000-19,999 4.89 (3.69-6.48) 1.16 (0.80-1.67) 0.84 (0.57-1.23) 
≥20,000 7.03 (4.30-11.48) 0.95 (0.54-1.67) 0.67 (0.38-1.20) 
Rate of expansion (patients/month) 
<25 1.0 (ref)  1.0 (ref) 1.0 (ref) 
25-59 1.48 (1.33-1.64) 1.27 (1.14-1.42) 1.21 (1.08-1.35) 
60-89 1.96 (1.75-2.18) 1.47 (1.28-1.68) 1.49 (1.29-1.72) 
90-124 2.79 (2.48-3.14) 1.81 (1.56-2.11) 1.98 (1.68-2.34) 
≥125 3.72 (3.25-4.27) 1.69 (1.41-2.03) 2.28 (1.84-2.82) 
Sex  
Female 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Male 1.16 (1.11-1.21) 1.21 (1.16-1.27) 1.21 (1.16-1.27) 1.21 (1.15-1.27) 1.21 (1.16-1.27) 
Age group (years) 
16-25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-34 0.63 (0.59-0.67) 0.64 (0.60-0.69) 0.64 (0.60-0.69) 0.64 (0.60-0.69) 0.64 (0.60-0.69) 
35-44 0.50 (0.47-0.54) 0.51 (0.47-0.55) 0.50 (0.47-0.54) 0.51 (0.47-0.55) 0.50 (0.47-0.54) 
45+ 0.51 (0.47-0.56) 0.50 (0.46-0.55) 0.50 (0.46-0.55) 0.51 (0.47-0.55) 0.50 (0.46-0.55) 
Body Mass Index  
Underweight 1.12 (1.06-1.17) 1.05 (1.00-1.11) 1.06 (1.00-1.11) 1.05 (1.00-1.11) 1.05 (1.00-1.11) 
Normal 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Overweight 0.99 (0.90-1.09) 1.07 (0.97-1.17) 1.06 (0.97-1.17) 1.07 (0.97-1.18) 1.07 (0.97-1.17) 
Obese 0.87 (0.70-1.07) 0.98 (0.79-1.121) 0.97 (0.79-1.20) 0.98 (0.79-1.21) 0.97 (0.79-1.20) 
Missing 2.00 (1.84-2.18) 1.97 (1.81-2.14) 2.00 (1.84-2.18) 1.99 (1.83-2.17) 2.07 (1.90-2.25) 
CD4 cell count (cells/μl)  
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-49 0.93 (0.84-1.04) 1.00 (0.90-1.11) 1.00 (0.90-1.12) 0.99 (0.89-1.11) 1.00 (0.90-1.12) 
50-99 0.86 (0.78-0.95) 0.95 (0.86-1.05) 0.96 (0.87-1.05) 0.94 (0.86-1.04) 0.95 (0.86-1.05) 
100-149 0.84 (0.77-0.93) 0.94 (0.85-1.03) 0.95 (0.86-1.04) 0.93 (0.84-1.02) 0.94 (0.85-1.03) 
150-199 0.87 (0.79-0.96) 0.96 (0.87-1.06) 0.97 (0.88-1.07) 0.95 (0.86-1.05) 0.96 (0.87-1.06) 
200-349 0.91 (0.83-1.00) 0.91 (0.82-1.00) 0.92 (0.84-1.01) 0.90 (0.82-0.99) 0.92 (0.83-1.01) 
≥350 1.15 (0.98-1.34) 1.04 (0.89-1.23) 1.06 (0.90-1.24) 1.02 (0.87-1.20) 1.03 (0.88-1.21) 
Missing 1.02 (0.94-1.12) 1.08 (0.99-1.18) 1.08 (0.98-1.18) 1.04 (0.96-1.14) 1.05 (0.96-1.14) 
WHO stage  
I and II 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
III 1.05 (0.99-1.11) 1.19 (1.12-1.26) 1.18 (1.11-1.25) 1.18 (1.11-1.25) 1.16 (1.10-1.23) 
IV 1.11 (1.04-1.18) 1.29 (1.20-1.38) 1.28 (1.20-1.37) 1.29 (1.21-1.38) 1.29 (1.20-1.37) 
Missing 1.06 (0.89-1.25) 1.14 (0.96-1.35) 1.12 (0.94-1.33) 1.11 (0.94-1.32) 1.08 (0.91-1.29) 
* All models accounted for site heterogeneity using random effects.  Model 1 – demographics and baseline variables, Model 2 - 
Model 1 + programme size, Model 3 – Model 1 + rate of expansion, Model 4 – Model 1 + programme size and rate of expansion
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Supplementary Table 4.4 Sensitivity analysis: Competing risks estimates of 
mortality* 
 
 0-12 months 
 Univariate 
 
HR (95% CI) 
Model 1 
(n=94,571) 
HR (95% CI) 
Model 2 
(n=94,571) 
HR (95% CI) 
Model 3 
(n=94,571) 
HR (95% CI) 
Model 4 
(n=94,571) 
HR (95% CI) 
Year of ART initiation      
2003 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2004 0.65 (0.59-0.71) 0.66 (0.57-0.76) 0.53 (0.46-0.62) 0.64 (0.56-0.74) 0.54 (0.46-0.63) 
2005 0.56 (0.51-0.61) 0.60 (0.53-0.69) 0.51 (0.44-0.59) 0.61 (0.53-0.69) 0.53 (0.46-0.62) 
2006 0.54 (0.49-0.59) 0.55 (0.49-0.61) 0.47 (0.29-0.38) 0.55 (0.49-0.62) 0.48 (0.42-0.55) 
2007 0.36 (0.33-0.40) 0.41 (0.36-0.46) 0.33 (0.29-0.38) 0.40 (0.35-0.45) 0.34 (0.29-0.39) 
2008 0.34 (0.31-0.38) 0.48 (0.43-0.55) 0.38 (0.33-0.44) 0.45 (0.39-0.51) 0.39 (0.34-0.45) 
2009 0.29 (0.27-0.32) 0.47 (0.42-0.53) 0.39 (0.34-0.45) 0.43 (0.38-0.49) 0.39 (0.33-0.45) 
2010 0.26 (0.24-0.29) 0.48 (0.43-0.54) 0.36 (0.31-0.42) 0.43 (0.38-0.49) 0.37 (0.32-0.43) 
2011 0.25 (0.21-0.28) 0.44 (0.38-0.52) 0.32 (0.26-0.38) 0.39 (0.33-0.47) 0.32 (0.27-0.39) 
Programme size (patients)     
<500 1.0 (ref)  1.0 (ref)  1.0 (ref) 
500-999 0.85 (0.76-0.96)  1.10 (0.92-1.31)  1.10 (0.92-1.31) 
1,000-2,499 0.74 (0.67-0.82)  1.53 (1.29-1.80)  1.49 (1.26-1.77) 
2,500-4,999 0.64 (0.58-0.71)  1.47 (1.24-1.73)  1.35 (1.10-1.64) 
5,000-7,499 0.44 (0.39-0.49)  1.35 (1.12-1.62)  1.23 (0.98-154) 
7,500 – 9,999 0.41 (0.36-0.46)  1.32 (1.08-1.61)  1.00 (0.77-1.29) 
10,000-14,999 0.43 (0.38-0.48)  1.97 (1.62-2.39)  1.33 (0.99-1.77) 
15,000-19,999 0.36 (0.30-0.43)  1.61 (1.26-2.07)  1.08 (0.78-1.49) 
≥20,000 0.43 (0.36-0.50)  2.13 (1.69-2.69)  1.39 (1.01-1.92) 
Rate of expansion (patients/month)     
<25 1.0 (ref)   1.0 (ref) 1.0 (ref) 
25-59 0.91 (0.86-0.97)   1.14 (1.05-1.24) 1.09 (0.99-1.20) 
60-89 0.69 (0.65-0.73)   1.02 (0.94-1.12) 1.05 (0.91-1.21) 
90-124 0.64 (0.60-0.690   1.09 (1.00-1.20) 1.16 (1.01-1.34) 
≥125 0.49 (0.46-0.53)   1.41 (1.28-1.56) 1.55 (1.25-1.92) 
Sex      
Female 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Male 1.56 (1.50-1.63) 1.21 (1.14-1.28) 1.22 (1.15-1.29) 1.21 (1.15-1.28) 1.22 (1.15-1.29) 
Age group (years)      
16-25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-34 1.10 (1.01-1.19) 1.11 (0.99-1.24) 1.10 (0.98-1.23) 1.11 (0.99-1.24) 1.10 (0.98-1.23) 
35-44 1.19 (1.09-1.29) 1.23 (1.10-1.38) 1.22 (1.08-1.36) 1.22 (1.09-1.37) 1.21 (1.08-1.36) 
45+ 1.37 (1.26-1.50) 1.60 (1.42-1.80) 1.56 (1.39-1.76) 1.57 (1.39-1.77) 1.56 (1.38-1.76) 
Body Mass Index       
Underweight 3.49 (3.32-3.66) 2.47 (2.33-2.63) 2.49 (2.34-2.65) 2.48 (2.33-2.64) 2.49 (2.34-2.65) 
Normal 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Overweight 0.58 (0.49-0.68) 0.72 (0.60-0.87) 0.72 (0.60-0.87) 0.73 (0.60-0.88) 0.72 (0.60-0.87) 
Obese 0.86 (0.65-1.13) 1.13 (0.83-1.55) 1.15 (0.84-1.57) 1.16 (0.85-1.58) 1.14 (0.84-1.56) 
CD4 cell count (cells/μl)     
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-49 0.64 (0.59-0.69) 0.73 (0.67-0.80) 0.73 (0.66-0.79) 0.73 (0.67-0.79) 0.73 (0.67-0.79) 
50-99 0.43 (0.40-0.46) 0.57 (0.53-0.62) 0.57 (0.52-0.62) 0.57 (0.52-0.62) 0.57 (0.52-0.62) 
100-149 0.29 (0.27-0.32) 0.46 (0.42-0.51) 0.46 (0.42-0.50) 0.46 (0.42-0.50) 0.46 (0.42-0.50) 
150-199 0.21 (0.20-0.23)  0.39 (0.35-0.43) 0.38 (0.35-0.43) 0.39 (0.35-0.43) 0.38 (0.35-0.43) 
200-349 0.17 (0.15-0.18) 0.35 (0.31-0.38) 0.34 (0.31-0.37) 0.34 (0.31-0.38) 0.34 (0.31-0.37) 
≥350 0.28 (0.24-0.32) 0.53 (0.45-0.62) 0.52 (0.45-0.61) 0.52 (0.44-0.61) 0.52 (0.45-0.61) 
WHO stage      
I and II 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
III 2.43 (2.27-2.61) 1.50 (1.37-1.63) 1.55 (1.42-1.69) 1.58 (1.43-1.71) 1.58 (1.45-1.73) 
IV 5.41 (5.05-5.79) 2.45 (2.23-2.69) 2.55 (2.32-2.81) 2.61 (2.37-2.87) 2.61 (2.37-2.87) 
* All models accounted for site heterogeneity using random effects.  Model 1 – demographics and baseline variables, Model 2 - 
Model 1 + programme size, Model 3 – Model 1 + rate of expansion, Model 4 – Model 1 + programme size and rate of expansion 
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Supplementary Table 4.4 (continued) Sensitivity analysis: Competing risks 
estimates of mortality* 
 
 12-72 months 
 Univariate 
 
HR (95% CI) 
Model 1 
(n=62,080) 
HR (95% CI) 
Model 2 
(n=62,080) 
HR (95% CI) 
Model 3 
(n=62,080) 
HR (95% CI) 
Model 4 
(n=62,080) 
HR (95% CI) 
Year of ART initiation      
2003 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2004 0.82 (0.70-0.96) 0.80 (0.65-0.99) 0.89 (0.71-1.11) 0.95 (0.77-1.18) 0.91 (0.73-1.14) 
2005 0.82 (0.71-0.96) 0.79 (0.65-0.96) 0.97 (0.78-1.19) 0.90 (0.74-1.10) 0.92 (0.74-1.15) 
2006 0.69 (0.60-0.80) 0.69 (0.58-0.83) 0.82 (0.67-0.99) 0.78 (0.65-0.95) 0.78 (0.64-0.95) 
2007 0.60 (0.51-0.69) 0.69 (0.57-0.83) 0.80 (0.65-0.98) 0.80 (0.66-0.97) 0.75 (0.61-0.93) 
2008 0.48 (0.40-0.56) 0.61 (0.50-0.75) 0.73 (0.57-0.92) 0.71 (0.57-0.89) 0.71 (0.56-0.90) 
2009 0.43 (0.35-0.51) 0.60 (0.48-0.75) 0.72 (0.55-0.95) 0.67 (0.53-0.86) 0.68 (0.51-0.89) 
2010 0.46 (0.32-0.66) 0.76 (0.52-1.12) 1.02 (0.67-1.55) 0.86 (0.58-1.28) 0.97 (0.64-1.47) 
2011 - - - - - 
Programme size (patients)     
<500 1.0 (ref)  1.0 (ref)  1.0 (ref) 
500-999 0.86 (0.73-1.02)  1.01 (0.80-1.26)  1.04 (0.83-1.30) 
1,000-2,499 0.82 (0.70-0.95)  1.13 (0.91-1.39)  1.23 (0.99-1.52) 
2,500-4,999 0.57 (0.49-0.67)  0.74 (0.60-0.92)  0.91 (0.70-1.19) 
5,000-7,499 0.39 (0.32-0.46)  0.64 (0.49-0.84)  0.80 (0.59-1.11) 
7,500 – 9,999 0.35 (0.27-0.44)  0.63 (0.45-0.89)  0.78 (0.51-1.18) 
10,000-14,999 0.57 (0.47-0.70)  1.09 (0.83-1.44)  1.38 (0.94-2.02) 
15,000-19,999 0.46 (0.34-0.64)  1.02 (0.67-1.55)  1.43 (0.84-2.43) 
≥20,000 0.22 (0.07-0.70)  0.38 (0.11-1.27)  0.52 (0.15-1.82) 
Rate of expansion (patients/month)     
<25 1.0 (ref)    1.0 (ref) 1.0 (ref) 
25-59 0.69 (0.63-0.77)    0.76 (0.66-0.86) 0.80 (0.69-0.93) 
60-89 0.52 (0.47-0.58)   0.58 (0.50-0.67) 0.73 (0.58-0.90) 
90-124 0.57 (0.51-0.64)   0.75 (0.64-0.87) 0.91 (0.72-1.16) 
≥125 0.45 (0.39-0.53)   0.76 (0.62-0.93) 0.72 (0.51-1.03) 
Sex      
Female 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Male 1.80 (1.67-1.94) 1.56 (1.42-1.72) 1.51 (1.37-1.67) 1.50 (1.36-1.66) 1.50 (1.36-1.66) 
Age group (years)      
16-25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-34 0.98 (0.84-1.14) 0.87 (0.72-1.05) 0.88 (0.73-1.06) 0.88 (0.73-1.07) 0.88 (0.73-1.06) 
35-44 1.13 (0.98-1.32) 1.03 (0.85-1.25) 1.06 (0.87-1.28) 1.07 (0.88-1.29) 1.06 (0.88-1.29) 
45+ 1.66 (1.42-1.94) 1.54 (1.27-1.88) 1.62 (1.33-1.98) 1.64 (1.35-2.00) 1.64 (1.34-2.00) 
Body Mass Index       
Underweight 1.67 (1.54-1.81) 1.54 (1.39-1.71) 1.51 (1.36-1.67) 1.50 (1.35-1.66) 1.50 (1.36-1.66) 
Normal 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Overweight 0.85 (0.69-1.03) 1.01 (0.80-1.27) 1.01 (0.80-1.28) 1.01 (0.80-1.28) 1.01 (0.80-1.28) 
Obese 0.95 (0.64-1.43) 0.75 (0.42-1.33) 0.76 (0.43-1.35) 0.77 (0.43-1.36) 0.77 (0.43-1.36) 
CD4 cell count (cells/μl)     
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-49 0.95 (0.80-1.12) 1.01 (0.84-1.21) 0.98 (0.82-1.18) 0.99 (0.83-1.19) 0.98 (0.82-1.18) 
50-99 0.87 (0.74-1.01) 1.04 (0.88-1.22) 1.02 (0.86-1.21) 1.04 (0.88-1.23) 1.03 (0.87-1.21) 
100-149 0.64 (0.54-0.75) 0.82 (0.68-0.98) 0.82 (0.68-0.98) 0.83 (0.69-1.00) 0.82 (0.69-0.99) 
150-199 0.64 (0.55-0.76) 0.92 (0.77-1.10) 0.91 (0.76-1.08) 0.93 (0.78-1.12) 0.91 (0.76-1.10) 
200-349 0.53 (0.45-0.62) 0.79 (0.66-0.94) 0.76 (0.64-0.92) 0.79 (0.66-0.95) 0.77 (0.64-0.93) 
≥350 0.78 (0.59-1.03) 1.01 (0.74-1.37) 1.02 (0.75-1.39) 1.02 (0.75-1.39) 1.02 (0.75-1.39) 
WHO stage      
I and II 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
III  1.49 (1.33-1.66) 1.14 (0.99-1.31) 1.11 (0.97-1.27) 1.13 (0.99-1.30) 
IV  2.28 (2.04-2.55) 1.46 (1.26-1.69) 1.43 (1.24-1.66) 1.45 (1.25-1.68) 
*All models accounted for site heterogeneity using random effects.  Model 1 – demographics and baseline variables, Model 2 - 
Model 1 + programme size, Model 3 – Model 1 + rate of expansion, Model 4 – Model 1 + programme size and rate of expansion
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HR (95% CI) 
Model 1 
(n=94,571) 
HR (95% CI) 
Model 2 
(n=94 ,571) 
HR (95% CI) 
Model 3 
(n=94,571) 
HR (95% CI) 
Model 4 
(n=94,571) 
HR (95% CI) 
Year of ART initiation  
2003 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2004 1.66 (1.44-1.93) 1.45 (1.16-1.82) 0.89 (0.70-1.12) 1.02 (0.81-1.28) 0.91 (0.72-1.15) 
2005 1.59 (1.38-1.83) 1.75 (1.43-2.16) 0.99 (0.79-1.23) 1.24 (1.00-1.53) 1.11 (0.89-1.40) 
2006 1.45 (1.26-1.66) 1.72 (1.42-2.10) 0.95 (0.77-1.16) 1.20 (0.98-1.47) 1.02 (0.83-1.26) 
2007 1.89 (1.65-2.16) 2.57 (2.12-3.10) 1.15 (0.94-1.41) 1.69 (1.40-2.06) 1.34 (1.09-1.65) 
2008 2.13 (1.86-2.44) 2.94 (2.43-3.55) 1.31 (1.07-1.61) 1.82 (1.50-2.21) 1.50 (1.22-1.85) 
2009 1.90 (1.66-2.17) 2.71 (2.24-3.28) 1.23 (1.00-1.51) 1.77 (1.46-2.15) 1.44 (1.16-1.78) 
2010 2.66 (2.33-3.04) 4.00 (3.32-4.82) 1.79 (1.47-2.20) 2.56 (2.11-3.10) 2.15 (1.74-2.65) 
2011 2.90 (2.51-3.35 3.90 (3.19-4.76) 1.76 (1.42-2.19) 2.50 (2.04-3.06) 2.14 (1.71-2.67) 
Programme size (patients) 
<500 1.0 (ref) 1.0 (ref) 1.0 (ref) 
500-999 1.99 (1.58-2.52) 2.52 (1.82-3.50) 2.39 (1.72-3.32) 
1,000-2,499 3.03 (1.58-2.52) 3.22 (2.36-4.39) 2.54 (1.89-3.48) 
2,500-4,999 4.21 (3.40-5.20) 5.21 (3.83-7.07) 2.67 (1.93-3.70) 
5,000-7,499 6.09 (4.86-7.44) 7.13 (5.23-9.74) 3.21 (2.29-4.49) 
7,500 – 9,999 5.21 (4.20-6.46) 5.84 (4.26-7.99) 2.36 (1.67-3.33) 
10,000-14,999 5.55 (4.47-6.88) 6.88 (5.03-9.42) 2.51 (1.77-3.57) 
15,000-19,999 4.35 (3.45-5.48) 6.28 (4.50-8.77) 2.25 (1.56-3.26) 
≥20,000 5.25 (4.19-6.59) 5.14 (3.72-7.13) 1.79 (1.24-2.48) 
Rate of expansion (patients/month) 
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-59 1.76 (1.64-1.89) 1.91 (1.75-2.10) 1.71 (1.53-1.91) 
60-89 2.40 (2.25-2.57) 2.88 (2.64-3.15) 2.32 (2.03-2.66) 
90-124 2.18 (2.04-2.33) 2.41 (2.21-2.64) 2.12 (1.84-2.43) 
≥125 2.57 (2.41-2.75) 2.74 (2.50-3.00) 2.86 (2.39-3.34) 
Sex  
Female 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Male 1.17 (1.13-1.21) 1.11 (1.06-1.16) 1.18 (1.12-1.23) 1.18 (1.12-1.23) 1.18 (1.13-1.24) 
Age group (years) 
16-25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-34 0.70 (0.66-0.74) 0.70 (0.65-0.75) 0.70 (0.65-0.75) 0.70 (0.65-0.75) 0.70 (0.65-0.75) 
35-44 0.60 (0.56-0.63) 0.61 (0.56-0.66) 0.59 (0.55-0.64) 0.59 (0.55-0.64) 0.59 (0.55-0.64) 
45+ 0.62 (0.58-0.66) 0.63 (0.58-0.69) 0.59 (0.54-0.64) 0.59 (0.54-0.64) 0.59 (0.54-0.64) 
Body Mass Index  
Underweight 1.46 (1.40-1.52) 1.36 (1.30-1.43) 1.40 (1.33-1.47) 1.41 (1.34-1.48) 1.40 (1.34-1.47) 
Normal 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Overweight 0.96 (0.83-0.99) 0.93 (0.84-1.03) 0.94 (0.85-1.05) 0.94 (0.85-1.04) 0.94 (0.84-1.04) 
Obese 1.20 (0.88-1.04) 1.14 (0.94-1.39) 1.15 (0.95-1.39) 1.14 (0.94-1.38) 1.13 (0.93-1.37) 
CD4 cell count (cells/μl)  
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-49 0.81 (0.75-0.88) 0.85 (0.78-0.93) 0.87 (0.80-0.95) 0.87 (0.80-0.96) 0.88 (0.81-0.96) 
50-99 0.62 (0.58-0.67) 0.76 (0.70-0.83) 0.75 (0.69-0.81) 0.76 (0.70-0.82) 0.76 (0.70-0.82) 
100-149 0.57 (0.53-0.61) 0.76 (0.70-0.83) 0.74 (0.68-0.81) 0.75 (0.69-0.81) 0.75 (0.69-0.81) 
150-199 0.48 (0.44-0.51) 0.65 (0.60-0.71) 0.64 (0.58-0.70) 0.64 (0.59-0.70) 0.64 (0.59-0.70) 
200-349 0.52 (0.48-0.55) 0.66 (0.61-0.72) 0.64 (0.59-0.70) 0.65 (0.60-0.70) 0.65 (0.60-0.70) 
≥350 0.79 (0.71-0.87) 0.92 (0.82-1.03) 0.86 (0.77-0.96) 0.87 (0.77-0.97) 0.86 (0.77-0.97) 
WHO stage  
I and II 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
III 1.10 (1.05-1.14) 1.04 (0.98-1.10) 1.09 (1.03-1.16) 1.12 (1.06-1.19) 1.12 (1.05-1.18) 
IV 1.51 (1.44-1.59) 1.22 (1.14-1.31) 1.37 (1.28-1.46) 1.39 (1.30-1.49) 1.40 (1.31-1.50) 
* All models accounted for site heterogeneity using random effects.  Model 1 – demographics and baseline variables, Model 2 - 
Model 1 + programme size, Model 3 – Model 1 + rate of expansion, Model 4 – Model 1 + programme size and rate of expansion 
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Supplementary Table 4.5 (continued) Sensitivity analysis: Competing risks 
estimates of LTFU* 
 
 12-72 months 
 Univariate 
 
HR (95% CI) 
Model 1 
(n=62,080) 
HR (95% CI) 
Model 2 
(n=62 ,80) 
HR (95% CI) 
Model 3 
(n=62,080) 
HR (95% CI) 
Model 4 
(n=62,080) 
HR (95% CI) 
Year of ART initiation      
2003 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2004 1.44 (1.27-1.63) 1.30 (1.11-1.53) 0.81 (0.68-0.97) 0.98 (0.84-1.16) 0.94 (0.78-1.12) 
2005 1.17 (1.04-1.32) 1.23 (1.06-1.44) 0.71 (0.60-0.84) 0.95 (0.81-1.11) 0.85 (0.71-1.02) 
2006 1.41 (1.26-1.59) 1.58 (1.37-1.83) 0.96 (0.82-1.12) 1.14 (0.98-1.32) 1.03 (0.87-1.21) 
2007 1.73 (1.54-1.94) 2.17 (1.88-2.51) 1.48 (1.27-1.74) 1.55 (1.34-1.80) 1.65 (1.40-1.95) 
2008 2.20 (1.95-2.49) 2.85 (2.46-3.31) 1.83 (1.55-2.17) 2.21 (1.89-2.58) 2.13 (1.78-2.54) 
2009 2.95 (2.60-2.25) 3.76 (3.21-4.40) 2.50 (2.10-2.98) 3.06 (2.60-3.60) 2.91 (2.42-3.50) 
2010 4.72 (3.97-5.61) 5.70 (4.61-7.04) 3.91 (3.11-4.92) 4.67 (3.78-5.77) 4.85 (3.80-6.15) 
2011 - - - - - 
Programme size (patients)     
<500 1.0 (ref)  1.0 (ref)  1.0 (ref) 
500-999 1.93 (1.62-2.30)  1.88 (1.51-2.33)  1.83 (1.47-2.27) 
1,000-2,499 2.03 (1.73-2.39)  1.78 (1.44-2.19)  1.45 (1.16-1.81) 
2,500-4,999 3.26 (2.79-3.83)  3.55 (2.89-4.36)  1.82 (1.43-2.31) 
5,000-7,499 3.84 (3.26-4.52)  3.10 (2.50-3.85)  1.52 (1.18-1.95) 
7,500 – 9,999 5.33 (4.49-6.33(  3.38 (2.68-4.25)  1.52 (1.16-1.01) 
10,000-14,999 1.96 (1.63-2.35)  1.54 (1.21-1.95)  0.72 (0.54-0.95) 
15,000-19,999 2.19 (1.72-2.78)  1.34 (1.00-1.80)  0.66 (0.46-0.93) 
≥20,000 3.11 (1.95-4.97)  1.15 (0.66-2.01)  0.53 (0.29-0.97) 
Rate of expansion (patients/month)     
<25 1.0 (ref)    1.0 (ref) 1.0 (ref) 
25-59 1.58 (1.46-1.70)   1.71 (1.56-1.88) 1.59 (1.42-1.78) 
60-89 2.09 (1.95-2.25)   2.76 (2.08-2.49) 2.04 (1.77-2.34) 
90-124 2.42 (2.25-2.60)   2.63 (2.40-2.88) 2.58 (2.22-2.99) 
≥125 1.85 (1.69-2.03)   1.33 (1.18-1.49) 2.12 (1.74-2.56) 
Sex      
Female 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Male 1.06 (1.01-1.10) 1.05 (0.99-1.11) 1.11 (1.05-1.18) 1.13 (1.07-1.19) 1.12 (1.06-1.19) 
Age group (years)      
16-25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-34 0.65 (0.61-0.70) 0.70 (0.64-0.77) 0.68 (0.63-0.75) 0.69 (0.63-0.75) 0.68 (0.62-0.74) 
35-44 0.55 (0.52-0.60) 0.59 (0.53-0.64) 0.55 (0.50-0.61) 0.55 (0.50-0.61) 0.55 (0.50-0.60) 
45+ 0.60 (0.55-0.65) 0.61 (0.55-0.68) 0.56 (0.50-0.62) 0.55 (0.49-0.61) 0.55 (0.49-0.61) 
Body Mass Index       
Underweight 0.98 (0.94-1.03) 0.93 (0.87-0.99) 0.98 (0.92-1.04) 0.98 (0.92-1.04) 0.99 (0.93-1.05) 
Normal 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Overweight 1.09 (0.99-1.20) 1.16 (1.04-1.29) 1.12 (1.01-1.25) 1.14 (1.02-1.27) 1.12 (1.00-1.25) 
Obese 1.00 (0.81-1.23) 1.12 (0.87-1.43) 1.05 (0.82-1.35) 1.06 (0.83-1.36) 1.02 (0.80-1.31) 
CD4 cell count (cells/μl)     
<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
25-49 0.86 (0.77-0.96) 0.87 (0.78-0.98) 0.93 (0.83-1.04) 0.92 (0.81-1.03) 0.94 (0.84-1.06) 
50-99 0.83 (0.75-0.91) 0.86 (0.77-0.95) 0.90 (0.81-0.99) 0.88 (0.79-0.97) 0.91 (0.82-1.00) 
100-149 0.83 (0.76-0.92) 0.90 (0.81-1.00) 0.93 (0.84-1.03) 0.90 (0.81-1.000 0.94 (0.84-1.04) 
150-199 0.85 (0.77-0.93) 0.88 (0.79-0.97) 0.92 (0.83-1.02) 0.89 (0.80-0.98) 0.93 (0.84-1.03) 
200-349 0.81 (0.74-0.89) 0.76 (0.68-0.84) 0.83 (0.75-0.92) 0.78 (0.71-0.86) 0.84 (0.76-0.93) 
≥350 1.00 (0.86-1.18) 0.92 (0.77-1.09) 0.95 (0.80-1.13) 0.88 (0.75-1.05) 0.92 (0.77-1.09) 
WHO stage      
I and II 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
III 1.02 (0.96-1.07) 1.23 (1.15-1.32) 1.15 (1.07-1.24) 1.20 (1.11-1.28) 1.15 (1.07-1.24) 
IV 0.99 (0.93-1.05) 1.22 (1.12-1.32) 1.21 (1.12-1.32) 1.26 (1.16-1.37) 1.23 (1.13-1.33) 
* All models accounted for site heterogeneity using random effects.  Model 1 – demographics and baseline variables, Model 2 - 




Supplementary Table 5.1 Hazard ratios of overall, 0-3 month, 3-12 month and 
12-24 month observed LTFU by CD4 cell count at ART initiation± 
 
 OVERALL  
(0-24 months) 
0-3 months 3-12 months 12-24 months 
 n=17,038 n=17,038 n=15,470 n=12,728 
 Observed LTFU 
Crude HR     
<50 cells/l 1.62 (1.44-1.83) 2.35 (1.87-2.95) 1.64 (1.35-2.00) 1.15 (0.93-1.42) 
50-99 cells/l 1.25 (1.10-1.41) 1.75 (1.38-2.23) 1.18 (0.96-1.46) 1.00 (0.81-1.24) 
100-149 cells/l 1.11 (0.98-1.26) 0.98 (0.75-1.28) 1.22 (0.99-1.49) 1.10 (0.90-1.34) 
150-199 cells/l 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
200-249 cells/l 0.96 (0.83-1.10) 0.88 (0.65-1.18) 1.03 (0.81-1.29) 0.94 (0.75-1.18) 
250-299 cells/l 1.29 (1.06-1.58) 1.29 (0.87-1.92) 1.36 (0.99-1.87) 1.25 (0.89-1.75) 
300 cells/l 1.45 (1.22-1.73) 1.57 (1.13-2.19) 1.58 (1.20-2.07) 1.28 (0.93-1.76) 
Adjusted* - aHR     
<50 cells/l 1.55 (1.37-1.75) 2.24 (1.78-2.81) 1.60 (1.32-1.95) 1.08 (0.87-1.33) 
50-99 cells/l 1.21 (1.06-1.37) 1.70 (1.34-2.17) 1.15 (0.94-1.42) 0.96 (0.77-1.19) 
100-149 cells/l 1.09 (0.96-1.24) 0.96 (0.73-1.26) 1.20 (0.98-1.46) 1.07 (0.88-1.31) 
150-199 cells/l 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
200-249 cells/l 0.92 (0.80-1.06) 0.87 (0.64-1.17) 0.96 (0.77-1.22) 0.92 (0.73-1.16) 
250-299 cells/l 1.18 (0.97-1.45) 1.31 (0.88-1.96) 1.17 (0.85-1.62) 1.15 (0.82-1.61) 
300 cells/l 1.33 (1.12-1.59) 1.61 (1.15-2.25) 1.34 (1.02-1.76) 1.18 (0.85-1.62) 
±All estimates are stratified by cohort  
*Adjusted for year of ART initiation, gender, age, programme size and rate of expansion
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Supplementary Table 5.2 Description of patients at baseline and hazard ratios of 
overall corrected LTFU by CD4 cell count at ART initiation by cohort 
 






CD4 cell count at ART initiation    
Median (IQR) 142 (72-199) 151 (82-205) 105 (40-176) 
Year of ART initiation, n(%)    
2008 2,003 (24.2) 1,354 (23.5) 1,360 (45.6) 
2009 1,872 (22.6) 1,695 (29.4) 1,577 (52.9) 
2010 2,116 (25.5) 1,902 (33.3) 9 (0.3) 
2011 1,856 (22.4) 813 (14.1) 36 (1.2) 
2012 443 (5.3) 0 (0) 2 (0.1) 
 Hazard ratio of overall corrected LTFU 
Crude HR, HR (95% CI)    
<50 cells/l 1.39 (1.12-1.75) 1.22 (0.99-1.52) 0.60 (0.43-0.83) 
50-99 cells/l 1.02 (0.80-1.29) 1.16 (0.94-1.44) 0.67 (0.48-0.95) 
100-149 cells/l 0.89 (0.70-1.13) 1.19 (0.98-1.45) 0.82 (0.58-1.14) 
150-199 cells/l 1.0 (ref) 1.0 (ref) 1.0 (ref) 
200-249 cells/l 0.99 (0.72-1.35) 1.05 (0.86-1.28) 0.64 (0.43-0.97) 
250-299 cells/l 1.45 (1.03-2.03) 1.46 (1.09-1.97) 1.10 (0.51-2.39) 
300 cells/l 1.66 (1.28-2.16) 1.89 (1.38-2.57) 0.93 (0.51-1.70) 
Adjusted*, aHR (95% CI)    
<50 cells/l 1.28 (1.02-1.61) 1.17 (0.94-1.45) 0.60 (0.43-0.82) 
50-99 cells/l 0.99 (0.78-1.25) 1.12 (0.90-1.38) 0.65 (0.46-0.92) 
100-149 cells/l 0.89 (0.70-1.13) 1.14 (0.93-1.39) 0.82 (0.58-1.15) 
150-199 cells/l 1.0 (ref) 1.0 (ref) 1.0 (ref) 
200-249 cells/l 0.88 (0.64-1.21) 1.00 (0.82-1.22) 0.59 (0.39-0.89) 
250-299 cells/l 1.20 (0.85-1.69) 1.27 (0.94-1.71) 1.07 (0.49-2.34) 
300 cells/l 1.41 (1.08-1.83) 1.59 (1.16-2.17) 0.84 (0.45-1.57) 
*Adjusted for year of ART initiation, gender, age, programme size and rate of expansion 
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Supplementary Table 5.3 Sub-group analyses, stratified hazard ratios of corrected LTFU by covariates from multivariate 
models 
Baseline characteristic <50 cells/l 50-99 cells/l 100-149 cells/l 150-199 cells/l 200-249 cells/l 250-299 cells/l 300 cells/l
Year of ART initiation± 
2008 1.00 (0.74-1.34) 0.91 (0.67-1.25) 0.97 (0.72-1.32) 1.0 (ref) 0.88 (0.61-1.28) 0.43 (0.16-1.18) 1.70 (1.01-2.85) 
2009 0.95 (0.74-1.21) 0.88 (0.69-1.14) 0.94 (0.74-1.20) 1.0 (ref) 0.80 (0.61-1.06) 0.85 (0.46-1.58) 1.23 (0.81-1.87) 
2010 1.12 (0.85-1.49) 1.16 (0.89-1.52) 1.08 (0.83-1.40) 1.0 (ref) 0.97 (0.73-1.29) 1.48 (1.07-2.05) 1.68 (1.23-2.28) 
2011 1.42 (1.02-1.99) 0.96 (0.68-1.36) 0.97 (0.69-1.36) 1.0 (ref) 0.89 (0.63-1.24) 1.35 (0.90-2.03) 1.16 (0.78-1.71) 
2012 - 1.0 (ref) 
Gender§ 
Female 1.04 (0.86-1.26) 0.92 (0.76-1.12) 0.94 (0.78-1.12) 1.0 (ref) 0.86 (0.71-1.04) 1.24 (0.97-1.59) 1.35 (1.09-1.68) 
Male 1.15 (0.92-1.42) 1.07 (0.96-1.34) 1.10 (0.88-1.38) 1.0 (ref) 0.97 (0.75-1.26) 0.92 (0.58-1.48) 1.24 (0.84-1.82) 
Age* 
16-24 0.80 (0.51-1.24) 0.62 (0.39-0.99) 0.63 (0.41-0.97) 1.0 (ref) 1.02 (0.68-1.54) 1.49 (0.95-2.36) 0.99 (0.61-1.58) 
25-34 1.02 (0.83-1.26) 1.04 (0.84-1.29) 0.99 (0.80-1.22) 1.0 (ref) 0.92 (0.74-1.15) 1.20 (0.87-1.65) 1.38 (1.21-2.08) 
35-44 1.17 (0.90-1.52) 1.07 (0.83-1.39) 1.14 (0.88-1.46) 1.0 (ref) 0.74 (0.55-1.00) 0.96 (0.61-1.50) 1.23 (0.84-1.80) 
45 1.40 (0.95-2.08) 0.92 (0.61-1.41) 1.10 (0.76-1.60) 1.0 (ref) 1.08 (0.70-1.67) 0.70 (0.30-1.63) 1.24 (0.69-2.22) 
± Adjusted for gender, age, programme size and rate of expansion 
§ Adjusted for year of ART initiation, age, programme size and rate of expansion
* Adjusted for year of ART initiation, gender, programme size and rate of expansion
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Supplementary Table 5.4. Patient characteristics among those with and without 
South African civil ID numbers 
 







Cohort    
Gugulethu 2,377 (13.2) 0 (0) 2,377 (7.2) 
Hlabisa (1) 2,715 (15.1) 8,290 (47.0) 11,005 (33.2) 
Khayelitsha (2) 1,676 (9.3) 5,764 (32.7) 7,440 (22.4) 
Themba Lethu (3) 8,157 (45.4) 2,984 (16.9) 11,141 (33.6) 
Tygerberg 1,236 (6.9) 0 (0) 1,236 (3.7) 
Gender    
Female 9,846 (60.9) 11,243 (66.0) 21,089 (63.6) 
Age    




16-24 1,313 (8.1) 1,320 (7.8) 2,633 (7.9) 
25-34 6,152 (38.1) 7,059 (41.4) 13,211 (39.8) 
35-44 5,426 (33.6) 5,531 (32.5) 10,957 (33.0) 
45 3,270 (20.2) 3,128 (18.4) 6,398 (19.3) 
Year of ART initiation    
2008 2,173 (13.5) 4,717 (27.7) 6,890 (20.8) 
2009 2,672 (16.5) 5,144 (30.2) 7,816 (23.5) 
2010 4,511 (27.9) 4,027 (23.6) 8,538 (25.7) 
2011 4,025 (24.9) 2,705 (15.9) 6,730 (20.3) 
2012 2,780(17.2) 445 (2.6) 3,225 (9.7) 
WHO stage    
I and II 2,748 (39.3) 4,727 (43.0) 7,475 (41.5) 
III 3,021 (43.1) 4,797 (43.6) 7,818 (43.4) 
IV 1,233 (17.6) 1,470 (13.4) 2,703 (15.0) 
Missing 9,159 (56.7) 6,044 (35.5)  15,203 (45.8) 
Cohort size at initiation (patients)   
<7,500 6,585 (40.6) 2,448 (14.4) 9,033 (27.2) 
7,500-7,999 610 (3.8) 3,226 (18.9) 3,836 (11.6) 
8,000– 9,899 947 (5.9) 3,476 (20.4) 4,423 (13.3) 
9,900-11,499 6,685 (41.4) 4,130 (24.2) 10,815 (32.6) 
11,550 1,334 (8.3) 3,758 (22.1) 5,092 (15.3) 
Rate of scale-up (patients/month)   
<130 2,943 (24.4) 3,542 (20.8) 7,485 (22.6) 
130-159 589 (3.6) 3,296 (19.3) 3,885 (11.7) 
160-179 1,407 (8.7) 3,516 (20.6) 4,923 (14.8) 
180-199 2,065 (12.8) 3,700 (21.7) 5,765 (17.4) 
200 8,157 (50.5) 2,984 (17.5) 11,141 (33.6) 
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Supplementary Table 5.5 Sensitivity analysis of weighted hazard ratios of overall, 




0-3 months 3-12 months 12-24 months
n=26,955 n=26,955 n=24,244 n=18,551 
Crude HR 
<50 cells/l 1.11 (0.96-1.29) 1.11 (0.81-1.53) 1.28 (1.01-1.63) 0.96 (0.75-1.22) 
50-99 cells/l 1.04 (0.89-1.22) 1.37 (0.95-1.99) 1.02 (0.79-1.30) 0.89 (0.70-1.13)
100-149 cells/l 1.03 (0.89-1.20) 0.64 (0.45-0.92) 1.22 (0.94-1.58) 1.06 (0.85-1.32)
150-199 cells/l 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
200-249 cells/l 1.00 (0.83-1.20) 1.21 (0.75-1.97) 1.01 (0.77-1.32) 0.87 (0.68-1.11)
250-299 cells/l 1.27 (1.00-1.61) 1.35 (0.79-2.29) 1.31 (0.88-1.95) 1.18 (0.83-1.68)
300 cells/l 1.40 (1.13-1.75) 1.83 (1.15-2.92) 1.35 (1.00-1.83) 1.12 (0.80-1.57)
Adjusted* - aHR Adjusted* - aHR 
<50 cells/l 1.03 (0.89-1.20) 1.02 (0.74-1.41) 1.21 (0.95-1.54) 0.88 (0.69-1.13) 
50-99 cells/l 1.01 (0.86-1.18) 1.32 (0.93-1.87) 0.99 (0.78-1.27) 0.86 (0.68-1.09)
100-149 cells/l 1.01 (0.87-1.18) 0.63 (0.44-0.90) 1.20 (0.93-1.55) 1.05 (0.85-1.31)
150-199 cells/l 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
200-249 cells/l 0.94 (0.79-1.12) 1.11 (0.71-1.72) 0.93 (0.71-1.22) 0.85 (0.67-1.09)
250-299 cells/l 1.07 (0.84-1.37) 1.18 (0.69-2.02) 1.09 (0.73-1.63) 1.05 (0.74-1.48)
300 cells/l 1.17 (0.93-1.47) 1.55 (0.94-2.55) 1.10 (0.80-1.51) 1.00 (0.71-1.40)
±All estimates are stratified by cohort 
§Weighted to represent all patients regardless of SA civil ID number availability
*Adjusted for year of ART initiation, gender, age, programme size and rate of expansion
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Supplementary 5.6 Sensitivity analysis with imputed CD4 cell counts at ART 
initiation.  Corrected hazard ratios of overall, 0-3 month, 3-12 month and 12-24 
month corrected LTFU by CD4 cell count at ART initiation±§ 
OVERALL  
(0-24 months) 
0-3 months 3-12 months 12-24 months
n=22,495 n=22,495 n=20,374 n=16,599 
Crude HR 
<50 cells/l 1.05 (0.91-1.20) 1.01 (0.77-1.32) 1.16 (0.91-1.47) 0.96 (0.79-1.18) 
50-99 cells/l 0.98 (0.85-1.14) 1.07 (0.82-1.40) 0.99 (0.74-1.32) 0.93 (0.76-1.13)
100-149 cells/l 1.00 (0.88-1.14) 0.73 (0.52-1.02) 1.08 (0.88-1.34) 1.05 (0.85-1.31)
150-199 cells/l 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
200-249 cells/l 1.01 (0.83-1.21) 0.95 (0.68-1.33) 1.06 (0.74-1.52) 0.98 (0.79-1.22)
250-299 cells/l 1.22 (1.01-1.48) 1.25 (0.82-1.92) 1.26 (0.88-1.79) 1.16 (0.84-1.58)
300 cells/l 1.32 (1.09-1.59) 1.34 (0.92-1.93) 1.35 (1.03-1.78) 1.26 (0.90-1.77)
Adjusted* - aHR 
<50 cells/l 1.08 (0.94-1.24) 1.02 (0.78-1.34) 1.21 (0.95-1.54) 0.98 (0.80-1.20) 
50-99 cells/l 0.97 (0.84-1.14) 1.07 (0.81-1.40) 0.98 (0.73-1.32) 0.92 (0.76-1.12)
100-149 cells/l 0.99 (0.87-1.13) 0.72 (0.51-1.01) 1.08 (0.87-1.33) 1.04 (0.84-1.30)
150-199 cells/l 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
200-249 cells/l 0.87 (0.72-1.06) 0.81 (0.58-1.14) 0.92 (0.64-1.30) 0.86 (0.69-1.07)
250-299 cells/l 1.05 (0.86-1.28) 1.22 (0.78-1.90) 1.02 (0.70-1.49) 0.99 (0.73-1.35)
300 cells/l 1.24 (1.04-1.49) 1.50 (1.04-2.18) 1.18 (0.90-1.56) 1.19 (0.86-1.65)
±All estimates are stratified by cohort 
§Weighted to represent all patients regardless of SA civil ID number availability
*Adjusted for year of ART initiation, gender, age, programme size and rate of expansion
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Supplementary Table 5.7 Sensitivity analysis of competing risks hazard ratios of 
overall, 0-3 month, 3-12 month and 12-24 month corrected LTFU by CD4 cell 
count at ART initiation§ 
 
 OVERALL  
(0-24 months) 
0-3 months 3-12 months 12-24 months 
 n=17,038 n=17,038 n=15,431 n=12,697 
Crude HR    
<50 cells/l 0.98 (0.85-1.13) 1.05 (0.78-1.42) 1.25 (1.00-1.56) 0.89 (0.71-1.13) 
50-99 cells/l 0.06 (0.83-1.11) 1.11 (0.82-1.50) 1.02 (0.80-1.29) 0.89 (0.71-1.11) 
100-149 cells/l 0.99 (0.86-1.14) 0.66 (0.47-0.93) 1.13 (0.91-1.41) 1.07 (0.86-1.32) 
150-199 cells/l 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
200-249 cells/l 1.05 (0.90-1.22) 0.97 (0.69-1.36) 1.12 (0.87-1.43) 1.03 (0.81-1.30) 
250-299 cells/l 1.38 (1.12-1.71) 1.48 (0.96-2.27) 1.40 (0.99-1.98) 1.31 (0.92-1.86) 
300 cells/l 1.45 (1.20-1.74) 1.56 (1.09-2.25) 1.57 (1.17-2.10) 1.26 (0.90-1.75) 
Adjusted* - aHR    
<50 cells/l 0.99 (0.86-1.14) 1.05 (0.77-1.42) 1.27 (1.01-1.60) 0.88 (0.70-1.11) 
50-99 cells/l 0.96 (0.83-1.10) 1.11 (0.82-1.50) 1.01 (0.80-1.29) 0.87 (0.69-1.10) 
100-149 cells/l 0.98 (0.85-1.12) 0.65 (0.46-0.92) 1.12 (0.89-1.39) 1.05 (0.85-1.30) 
150-199 cells/l 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
200-249 cells/l 0.89 (0.76-1.03) 0.79 (0.56-1.12) 0.95 (0.74-1.21) 0.90 (0.71-1.14) 
250-299 cells/l 1.17 (0.94-1.45) 1.40 (0.91-2.16) 1.13 (0.80-1.60) 1.11 (0.78-1.57) 
300 cells/l 1.34 (1.11-1.63) 1.69 (1.16-2.48) 1.34 (0.99-1.80) 1.17 (0.84-1.65) 
§Weighted to represent all patients regardless of SA civil ID number availability 







Supplementary Table 6.1 Median time to down-referral by baseline 
characteristics 
Baseline characteristic 




Overall 1.6 (0.9-2.6) 
Gender 
Females 1.7 (0.9-2.6) 0.643 
Males 1.6 (1.0-2.5) 
Age 
16-24 1.5 (0.9-2.2) 0.030 
25-34 1.7 (1.0-2.7)
35-44 1.7 (1.0-2.7)
45+ 1.5 (0.8-2.4) 
CD4 (cells/µl) 
<50 2.1 (1.3-3.1) <0.001 
50-99 2.0 (1.1-2.8)
100-199 1.5 (0.9-2.5)
≥200 1.2 (0.7-2.1) 
Missing 1.8 (1.0-2.4) 
Viral load, log10 copies/mL 
Supressed (≤ 200) 1.3 (1.0-3.2) 0.008 
201-24,999 1.5 (0.9-2.5)
25,000-99,999 1.9 (1.0-2.7) 
100,000+ 1.6 (0.9-2.7) 
Missing 1.5 (0.8-2.2) 
Haemoglobin, g/dL 
<10 1.6 (1.0-2.7) 0.463 
10-12 1.6 (0.9-2.7)
12+ 1.5 (0.9-2.6) 
Missing 1.9 (1.0-2.2) 
WHO stage 
Stage I and II 1.3 (0.7-2.2) <0.001 
Stage III 1.8 (1.1-2.6) 
Stage IV 2.0 (1.1-3.1) 
Missing 0.8 (0.6-1.1) 
Year of initiation 
2002 - 2003 4.4 (4.2-4.8) <0.001 
2004 - 2005 2.5 (2.1-3.1) 
2006 – 2007 1.3 (0.9-1.7) 
2008 – 2009 1.0 (0.6-1.7) 
2010 - 2011 0.8 (0.5-1.1) 
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Supplementary Table 6.2 Stratified hazard ratios of LTFU among down-referred 
patients versus patients at the treatment-initiation site 
LTFU 
Univariate Multivariate* 
HR (95% CI) aHR (95% CI) 
Gender 
Males 1.03 (0.78-1.37) 1.80 (1.22-2.66) 
Females 0.90 (0.73-1.11) 1.19 (0.91-1.56) 
Age - categorical 
16-24 0.81 (0.49-1.35) 1.11 (0.60-2.05)
25-34 0.98 (0.77-1.24) 1.67 (1.22-2.29)
35-44 1.07 (0.78-1.48) 1.10 (0.71-1.69)
≥45 0.68 (0.40-1.15) 0.84 (0.41-1.76) 
CD4 (cells/µl) 
<50 1.02 (0.67-1.58) 1.76 (1.02-3.03) 
50-99 1.18 (0.82-1.70) 1.49 (0.92-2.40)
100-199 0.98 (0.76-1.26) 1.32 (0.95-1.82)
≥200 0.57 (0.36-0.88) 0.75 (0.40-1.41) 
WHO stage 
Stage I & II 0.66 (0.48-0.91) 1.04 (0.69-1.56) 
Stage III 1.11 (0.88-1.40) 1.40 (1.04-1.88) 
Stage IV 1.05 (0.70-1.57) 1.88 (1.05-3.37) 
Year of ART initiation 
2002 - 2003 1.58 (0.62-4.02) 4.04 (1.03-15.78) 
2004 - 2005 1.06 (0.73-1.55) 2.20 (1.29-3.78) 
2006 – 2007 0.77 (0.59-1.01) 1.08 (0.77-1.51) 
2008 – 2009 0.71 (0.50-1.00) 1.27 (0.80-2.00) 
2010 - 2011 0.73 (0.38-1.39) 1.27 (0.55-2.95) 
*Multivariate: Includes Model of Care, all demographic (age, sex) and baseline characteristics (CD4, WHO
stage, viral load, haemoglobin, year of initiation) + time-updated CD4 and viral load
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Supplementary Table 8.1 Approach 1 (Primary results) - Relative hazards of loss 




HR (95% CI) 
Model 1 




aHR (95% CI) 
n=5 753 
Model 3 
aHR  (95% CI) 
n = 5 753 
Model of Care     
CHC 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
CAC 0.38 (0.32-0.45) 0.21 (0.17-0.25) 0.33 (0.27-0.40) 0.32 (0.26-0.39) 
Age when starting ART     
16-24 1.41 (1.27-1.56) 1.38 (1.21-1.57) 1.19 (1.05-1.36) 1.26 (1.10-1.43) 
25-34 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
35-44 0.94 (0.87-1.01) 0.87 (0.79-0.95) 0.92 (0.83-1.01) 0.92 (0.83-1.02) 
≥45 0.94 (0.85-1.04) 0.75 (0.66-0.85) 0.88 (0.77-1.00) 0.81 (0.71-0.93) 
Gender     
Male 1.09 (1.02-1.17) 1.12 (1.06-1.26) 0.95 (0.87-1.04) 1.01 (0.92-1.10) 
Year of ART initiation     
2002-2004 0.13 (0.11-0.16) 0.12 (0.10-0.16) 0.18 (0.14-0.23) 0.22 (0.17-0.28) 
2005-2007 0.40 (0.36-0.44) 0.44 (0.39-0.50) 0.41 (0.36-0.46) 0.43 (0.39-0.49) 
2008-2010 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
2011-2012 3.39 (3.10-3.71) 3.22 (2.87-3.60) 3.21 (2.87-3.58) 2.83 (2.53-3.17) 
CD4 at ART initiation,  
(cells/l) 
    
<50 0.90 (0.80-1.01) - - 0.50 (0.45-0.57) 
50-99 0.94 (0.84-1.04) - - 0.68 (0.60-0.76) 
100-199 1.0 (ref) - - 1.0 (ref) 
≥200 1.55 (1.41-1.71) - - 2.06 (1.85-2.30) 
Time-updated CD4  
(per 50-unit increase) 
0.74 (0.73-0.75) - 0.79 (0.78-0.81) 0.72 (0.71-0.74) 
Time-updated viral load, 
(copies/mL)  
    
Suppressed (<1,000) 1.0 (ref) - 1.0 (ref) 1.0 (ref) 











Appendix 3: Supplemental figures  
 





Supplementary Figure 4.2 Baseline CD4 cell count level by year of ART initiation 
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Supplementary Figure 4.4 Kaplan-Meier cumulative estimates of LTFU by country and year of ART initiation 
 
